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Abstract 
Lentiviral  vectors  used  in  clinical  trials  are  currently  produced  by  transient  transfection  of 
adherent human embryonic kidney (HEK)293(T) cells.  However, this approach is not scalable 
and  for  commercialisation  the  development  of  alternative  strategies  based  on  suspension-
adapted  producer  cell  lines,  that  have  all  genes  for  vector  production  stably  integrated,  is 
desired.  To assist progress in this area, the aim of this thesis was to establish a microscale cell 
culture  platform  that  enables  key  bioprocess  design  data  to  be  acquired  rapidly  and  cost-
effectively.    ProSavin
®,  an  equine  infectious  anaemia  virus  (EIAV)-derived  lentiviral  vector 
developed for the treatment of Parkinson’s disease (Palfi et al., 2014) was used as a model 
system.  First, the suitability of a shaken 24-well plate system for the suspension culture of 
HEK293T-derived  producer  cells  was  established.    This  system  was  shown  to  support 
equivalent  cell  growth  and  ProSavin
®  titres  to  conventional  shake  flasks  while  providing 
substantially greater opportunity for parallelisation.  Second, the utility of the microscale platform 
when combined with statistical Design of Experiments (DoE) techniques for optimising titres and 
informing the design of a scale-up strategy was demonstrated.  An initial screening experiment 
identified three parameters as having a critical influence on ProSavin
® titres, which were post-
induction  period,  liquid  fill  volume  and  concentration  of  doxycycline  (inducer  compound).  
Subsequent optimisation experiments defined operating ranges for these parameters.  Third, 
the insights obtained during the microwell investigations were shown to aid successful scale-up 
of the ProSavin
® process to a single-use 2 L WAVE bioreactor.  Fourth, with a view to informing 
further  improvements  in  process  design,  the  half-life  of  ProSavin
®  and  other  EIAV-based 
lentiviral  vectors  was  determined,  and  approaches  to  moderate  the  rate  of  decay  during 
upstream  processing  trialled.    Overall,  it  was  concluded  that  the  microwell  platform may  be 
viewed as an effective tool for future use in the development of lentiviral vector bioprocesses.   
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1  Introduction 
1.1  Thesis rationale and overview 
In November 2012, a significant milestone was reached: Glybera
 became the first human gene 
therapy to receive marketing approval in the Western world (uniQure, 2012; Kastelein et al., 
2013).  Other gene therapies are soon expected to follow suit, offering exciting prospects for the 
treatment  of  various  diseases.  Gene  therapies  that  use  lentiviral  vectors  to  mediate  gene 
delivery  have  shown  particular  promise,  with  lentiviral  vectors  being  employed  in  over  sixty 
clinical trials to date (Segura et al., 2013).  However, as these clinical programmes advance 
towards commercialisation, a primary concern is whether existing manufacturing practices are 
capable  of  generating  sufficient  quantities  of  material  to  meet  the  expected  demands.  The 
majority of lentiviral vectors used in clinical trials are currently produced by transient transfection 
of adherent human embryonic kidney (HEK)293(T) cells, however this method is problematic to 
scale-up (Schweizer and Merten, 2010).  The development of a simple, scalable manufacturing 
route based on the suspension culture of stable producer cell lines is highly desirable.  Despite 
this, few studies have explored large-scale suspension-based production strategies for lentiviral 
vectors (Segura et al., 2007; Broussau et al., 2008; Ansorge et al., 2009; Witting et al., 2012). 
To  aid  the  development  of  industrially  viable  bioprocesses  for  lentiviral  vectors,  a  better 
understanding  of  the  factors  influencing  yields  from  suspension  cultures  of  HEK-derived 
producer  cells  is  required.    As  a  variety  of  parameters  may  impact  on  titres,  numerous 
experiments are necessary to characterise their various effects.  A rational approach combining 
microscale  bioprocessing  and  Design  of  Experiments  (DoE)  techniques  could  simplify  this 
process.    Microscale  bioprocessing  facilitates  numerous  culture  conditions  to  be  evaluated 
quickly and simultaneously, and at low-cost (Kumar et al., 2004; Micheletti and Lye, 2006; Lye 
et  al.,  2009;  Marques  et  al.,  2010;  Neubauer  et  al.,  2013),  while  DoE  enables  efficient 
characterisation of the effects of multiple parameters through a limited number of logically linked 
experiments (Czitrom, 1999; Tye, 2004; Anderson and Whitcomb, 2007; Eriksson et al., 2008).  
The  value  of  such  an  approach  has  been  demonstrated  for  the  optimisation  of  protein 
expression from microbial cultures (Islam et al., 2007; Holmes et al., 2009).  It was recently 
proposed  that  DoE  techniques  could  aid  the  development  of  lentiviral  vector  production 27 
 
 
systems, leading to more efficient bioprocesses and better characterised products (Segura et 
al., 2013).  However, there are no published studies that have employed this methodology, or 
tested  the  value  of  a  suspension-based  microscale  system,  for  lentiviral  vector  process 
development  to  date.    Thus,  the  aim  of  this  work  is  to  establish  a  microwell  experimental 
platform for the suspension culture of lentiviral vector producer cells, which can be utilised in 
conjunction with DoE techniques for the rapid, early generation of critical bioprocess design 
data.  The approach will be demonstrated and published on using ProSavin
®, a lentiviral vector 
engineered for treatment of Parkinson’s disease that has successfully completed a Phase I/II 
clinical trial (Mitrophanous et al., 1999; Azzouz et al., 2002; Jarraya et al., 2009; Stewart et al., 
2009; Stewart et al., 2011; Palfi et al., 2014).   
1.2  Introduction to gene therapy  
This section  provides  a  brief  introduction  to  gene  therapy,  through  (i)  outlining  some  of  the 
major milestones  and  setbacks  that  have  defined  progress  in  the  field,  (ii)  summarising  the 
current status of ongoing gene therapy clinical trials, and (iii) considering some of the remaining 
challenges.   
1.2.1  An overview of gene therapy  
‘Gene therapy’ may be broadly defined as the introduction of therapeutic genes into target cells 
in order to treat disease (Escors and Breckpot, 2010).  However, it is important to note that 
applications of gene therapy are far-reaching, and the Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) have published more lengthy definitions (see FDA, 2006; 
EMA, 2009)  that strive to capture recent innovations within this field.  Importantly, a distinction 
exists between somatic gene therapy, in which the genetic change is restricted to the individual 
patient, and germ line gene therapy, in which the genetic change is heritable and thus passed 
on to the patient’s offspring; the latter is not permitted by current legislation (Wirth et al., 2013).   
From the 1960s to the 1990s gene therapy progressed from conception to clinical evaluation; an 
evolution largely catalysed by the advent of recombinant DNA techniques and the development 
of virus-based gene delivery vectors (for an overview see Friedmann, 1992).  In 1989, the first 
Federally approved  gene  transfer study  using human patients took place (Rosenberg et al., 28 
 
 
1990).    A  marker  gene  (conferring  neomycin  resistance)  was  introduced  into  autologous 
tumour-infiltrating lymphocytes in vitro using a retroviral vector; the modified lymphocytes were 
then reintroduced into patients with advanced melanoma and their distribution monitored over 
time (Rosenberg et al., 1990).  Although this study did not have a therapeutic aim, it critically 
demonstrated the potential of retroviral vectors for gene transfer (Edelstein et al., 2004).  In 
1990, the first Federally approved clinical trial using a therapeutic gene commenced, in which 
two children with severe combined immunodeficiency (SCID) caused by adenosine deaminase 
(ADA)-deficiency (ADAˉ SCID) received autologous T cells that had been transduced in vitro by 
a retroviral vector carrying a functional ADA gene (Blaese and Anderson, 1990; Blaese et al., 
1995).  Although this early attempt at gene therapy for treatment of ADAˉ SCID did not correct 
the  immunodeficiency,  the  viability  and  safety  of  the  procedure  was  demonstrated  and 
transduced T cells persisted up to 15 - 20 years later (Fischer et al., 2010).  In the decade 
succeeding these pioneering studies (1989 - 1999) close to 500 gene therapy clinical trials were 
approved worldwide, including an unprecedented 116 trials in the year 1999 alone (Ginn et al., 
2013).  These figures are indicative of a rapidly expanding, thriving field.  Unfortunately, the 
advances  made  during  this  period  were  cast  into  shadow  when,  in  1999,  Jesse  Gelsinger 
became the first clinical trial patient to die as a direct consequence of gene therapy (Hollon, 
2000).  Gelsinger, a teenager with partial ornithine transcarbamylase (OTC) deficiency,  died 
from vector-related toxicity shortly after receiving an adenoviral vector carrying the OTC gene 
(Hollon,  2000;  Check,  2005).  A  five-year  investigation  by  the  US  Department  of  Justice 
revealed that several mistakes had been made during the study, including failure to inform the 
Recombinant DNA Advisory Committee of an alteration in the protocol and failure to report a 
serious  adverse  reaction  to  therapy  (Hollon,  2000;  Check,  2005;  Couzin  and  Kaiser,  2005; 
Sheridan,  2011).  The  Gelsinger  case  was  significant,  as  it  illuminated  widespread 
underreporting  of  adverse  events  in  gene  therapy  trials  in  general  (Teichler  Zallen,  2000; 
Sheridan,  2011);  the  FDA  and  National  Institutes  of  Health  responded  by  launching  new 
initiatives  to  provide  greater  protection  for  patients  enrolled  in  gene  therapy  trials  and  to 
reinstate  public  trust  in  gene  therapy  research  (McCarthy,  2000).    In  the  years  during  and 
succeeding the Gelsinger case, the field of gene therapy suffered a further blow as several 
instances of insertional mutagenesis following (gamma)retroviral mediated gene therapy were 
reported.    In  two  trials  for  X-linked  SCID  (SCID-X1),  autologous  haematopoietic  cells  were 29 
 
 
transduced in vitro using a vector encoding the interleukin 2 receptor-γ (IL2RG) gene and re-
introduced into patients (twenty in total by the end of the study), however five patients went on 
to  develop  a  T  cell  leukemic  disease  due  to  the  activation  of  proto-oncogenes  as  a 
consequence of provirus integration (Hacein-Bey-Abina et al., 2008; Howe et al., 2008; Fischer 
et  al.,  2010;  Hacein-Bey-Abina  et  al.,  2010).  Insertional  mutagenesis  also  led  to  the 
development of T cell leukaemia in one out of ten patients in trials targeting  Wiskott-Aldrich 
Syndrome  (WAS)  (Galy  and  Thrasher,  2011)  and  to  the  development  of  clonal 
myeloproliferation in three out of twelve patients in  clinical trials addressing X-linked chronic 
granulomatous disease (X-CGD) (Grez et al., 2011).  The toxicity observed in the Gelsinger 
case and instances of insertional mutagenesis observed in the SCID-X1, WAS and X-CGD trials 
highlighted serious safety concerns associated with the use of early generation adenoviral and 
retroviral vectors.   This has led to the development of better investigative and analytical tools, 
such as animal models of insertional mutagenesis (Montini et al., 2009) and high throughput 
insertion site analysis techniques (Schmidt et al., 2007) that have been the basis for the more 
recent successes in gene therapy.     
1.2.2  The current status of gene therapy 
By  June  2012,  1843  gene  therapy  clinical  trials  had  been  approved  worldwide  (Ginn  et  al., 
2013).  Using the data presented in Ginn et al. (2013), the geographical distribution, disease 
targets, gene types, delivery methods, and clinical phase of these trials are summarised here.  
Note that the data presented by Ginn et al. (2013) is also available as a searchable database 
that  is  updated  periodically  on  The  Journal  of  Gene  Medicine  Gene  Therapy  Clinical  Trials 
Worldwide website (http://www.wiley.co.uk/genmed/clinical/). 
The majority of gene therapy trials (63.7 %) have been performed in the US, followed by the UK 
(11 %), Germany (4.4 %), France (2.9 %) and Switzerland (2.7 %) (Ginn et al., 2013).  Cancer is 
the second leading cause of death in the West (Ortiz et al., 2012), and around two thirds of 
gene therapy trials worldwide have targeted cancer diseases (Table 1.1; Ginn et al. (2013)). 
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Table 1.1  Indications addressed in gene therapy clinical trials from 1989 to June 2012.  
Data was derived from Ginn et al. (2013). 
Indications 
Gene therapy clinical trials 
%  Number 
Cancer diseases  64.4  1186 
Monogenic diseases  8.7  161 
Cardiovascular diseases  8.4  155 
Infectious diseases  8.0  147 
Neurological diseases  2.0  36 
Ocular diseases  1.5  28 
Inflammatory diseases  0.7  13 
Other diseases  1.4  25 
Gene marking  2.7  50 
Healthy volunteers  2.3  42 
Total    1843 
The  gene  types  most  commonly  transferred  in  gene  therapy  trials  were  antigens  (e.g.  viral 
vector-mediated  transfer  of  tumour  antigens  to  intensify  the  immune  response  in  a  tumour-
bearing patient (Edelstein et al., 2007)), cytokines, tumour suppressors and suicide enzymes, 
which are principally employed to tackle cancer (the category most targeted by gene therapy), 
and together comprised 55.3 % of all trials (Ginn et al., 2013).  The majority of trials employed 
modified  viruses  (‘viral  vectors’)  to  deliver  the  genetic  material  into  target  cells  (Table  1.2).  
Viruses  have  naturally  evolved  effective  mechanisms  for  infecting  various  cell  types,  thus 
delivery vectors exploiting this capacity are more efficient than alternative non-viral techniques 
(Warnock et al., 2006).  Adenoviral and retroviral vectors have been most commonly utilised 
(Table 1.2), although since the Gelsinger case and the incidences of leukaemia in SCID-X1 
patients  (see  Section  1.2.1)  there  has  been  a  movement  away  from  these  vector  types 
(Sheridan, 2011).  To January 2004, 26 % of all trials employed adenoviral vectors and 28 % 
used retroviral vectors (Edelstein et al., 2004), but by June 2012, these values had decreased 
to 23.3 % and 19.7 %, respectively  (Ginn et al., 2013).  However, adenoviral and retroviral 
vectors continue to be utilised today, and published data indicates that between July 2007 and 
June 2012, 107 adenovirus-based trials and 65 retrovirus-based trials were approved (Edelstein 
et al., 2007; Ginn et al., 2013).  Adenoviral and retroviral vectors with improved safety profiles 
are in development (Vetrini and Ng, 2010; Sadelain et al., 2012), and alternative viral and non-
viral delivery methods are increasingly being explored (Table 1.2).  31 
 
 
Table 1.2  Gene delivery methods employed in gene therapy clinical trials from 1989 to 
June 2012.  Data was derived from Ginn et al. (2013). 
Gene delivery method 
Gene therapy clinical trials 
%  Number 
Adenovirus  23.3  438 
Retrovirus  19.7  370 
Naked/Plasmid DNA  18.3  345 
Vaccinia virus  7.9  148 
Lipofection  5.9  111 
Poxvirus  5.0  95 
Adeno-associated virus  4.9  92 
Herpes simples virus  3.1  59 
Lentivirus  2.9  55 
Other categories  5.6  105 
Unknown  3.4  64 
Total    1882 
The majority (78.6 %) of approved gene therapy clinical trials are in Phase I or I/II, less (16.7 %) 
are in Phase II, and very few (4.5 %) are in Phase II/III or III (Ginn et al., 2013).  This pattern is 
not  unexpected,  as  attrition  rates  are  generally  high  within  the  pharmaceutical  sector-  on 
average just 11 % of new therapies tested in humans ever reach registration (Kola and Landis, 
2004).  For cancer, the leading indication being addressed by gene therapy (Table 1.1), the 
success rate is even lower, with just 5 % of new treatments achieving registration (Kola and 
Landis,  2004).  Added  to  this  is  the  fact  that  gene  therapy  is  an  emerging  field,  with  the 
regulatory framework, and also the scientific tools to measure safety and efficacy, still being 
developed.  Nonetheless, to date, two  gene therapy products have been granted marketing 
authorisation.  In October 2003, Shenzhen SiBiono GenTech (China) received a license from 
the State Food and Drug Administration of China for Gendicine, an adenoviral vector carrying 
the p53 tumour suppressor gene used for treatment of patients with head and neck squamous 
cell carcinoma (Pearson et al., 2004).  The only gene therapy currently licensed in the West is 
Glybera  (or  alipogene  tiparvovec),  for  which  uniQure  (The  Netherlands)  received  EMA 
marketing approval in November 2012 (Bryant et al., 2013; Kastelein et al., 2013).  Gybera is an 
adeno-associated  viral  vector  containing  a  functional  human  lipoprotein  lipase  (LPL)  gene, 
engineered for treatment of patients with LPL deficiency (LPLD) (Bryant et al., 2013; Kastelein 
et al., 2013).  As other gene therapies approach marketing authorisation, fresh challenges are 
emerging within the sector as discussed below.  
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1.2.3  Future challenges for gene therapy  
Work to improve the safety of gene therapy and refinements to existing vector delivery systems 
are  ongoing.  For  example,  to  diminish  the  incidence  and  severity  of  immune  reactions  to 
adenoviral  vectors,  helper-dependent  adenoviral  vectors,  that  are  devoid  of  viral  coding 
sequences,  are  in  development  (Vetrini  and  Ng,  2010).    In  addition,  to  reduce  the  risk  of 
insertional  mutagenesis,  self-inactivating  (SIN)  retroviral  vectors,  in  which  all  enhancer  and 
promoter elements have been deleted from the U3 region of the long terminal repeat (LTR), 
have  been  described  (Modlich  et  al.,  2006).    However,  although  for  some  gene  therapies 
ongoing improvement of the vector delivery system is essential, for others, adequate evidence 
of safety and therapeutic efficacy has been gathered and soon marketing authorisation will be 
sought.  The approval granted by the EMA for Glybera was a landmark case, and has opened 
the  door  to  other  organisations  seeking  to  register  gene  therapies  in  the  West.  As  these 
therapies  approach  commercialisation,  however,  an  immediate  concern  is  whether  current 
manufacturing  practices  are  suitable  for  large-scale  industrial  applications.    It  is  a  concern 
experts  agree  has  received  inadequate  attention  and  investment  to  date  (Sheridan,  2011; 
Dolgin, 2012). 
The development of a scalable bioprocess that is compliant with Good Manufacturing Practice 
(GMP) standards is recognised as major a hurdle to gene therapy commercialisation (Denèfle, 
2011).  James  Wilson  (Perelman  School  of  Medicine,  University  of  Pennsylvania),  recently 
acknowledged “the rate-limiting step in most of these [gene therapy] programmes is a scalable, 
commercial-grade process”, while Fulvio Mavilio, scientific director of Généthon (a not-for-profit 
gene therapy organisation based in France), described the state-of-the-art as “primitive” and 
stated “we’re not talking about robust processes that can be scaled up for manufacturing.  Not 
at all” (Dolgin, 2012).  A fundamental problem is that production systems are typically based on 
adherent cell culture, for example adenoviral (Dormond and Kamen, 2011), retroviral (Cruz et 
al.,  2011), adeno-associated  viral  (Chen, 2011)  and lentiviral  (Schweizer  and  Merten, 2010) 
vectors  are  all  commonly  generated  from  human-derived  cell  lines  grown  in  monolayers.  
Sander  van  Deventer,  speaking  as  Chief  Scientific  Officer  (CSO)  of  Amsterdam  Molecular 
Therapeutics in The Netherlands (which developed Glybera but has since been renamed as 
uniQure) commented “you need to have a soluble cell system” as adherent cell systems cannot 33 
 
 
be scaled-up (Sheridan, 2011).  This point was echoed by Stuart Naylor, CSO of gene therapy 
company Oxford BioMedica (UK), who noted that scale-up by the addition of extra cell culture 
vessels (i.e. a ‘scale-out’ approach) is not feasible, as this leads to a disproportionately large 
quantity  of  the  final  product  being  consumed  by  quality  testing  (Sheridan,  2011).  Using 
suspension-grown  cells  to  produce  gene  therapy  vectors  mitigates  this  problem,  as  three 
dimensional  scale-up  into  multi-litre  bioreactors  is  then  feasible.    Interestingly,  Glybera  is 
manufactured using suspension-cultured insect cells (Dolgin, 2012; Bryant et al., 2013) even 
though,  for  this  particular  gene  therapy,  process  scalability  was  never  a  major  hurdle  to 
commercialisation as LPLD affects fewer than 1,000 people across Europe (Dolgin, 2012).  The 
use of insect cells was possible in this case because a non-enveloped adeno-associated viral 
vector  was  employed  -  for  enveloped  vectors,  such  as  those  based  on  retroviruses  or 
lentiviruses, this approach is more problematic (Fernandes et al., 2013).  Thus, for other gene 
therapies approaching registration, which target more prevalent indications, the development of 
scalable GMP-compliant industrial processes remains a crucial challenge. 
Further recognised obstacles to gene therapy commercialisation relate to the purification and 
final  formulation  of  the  product  (Denèfle,  2011).  In  particular,  impurities  left  over  from  the 
upstream  process,  such  as  animal  serum,  contaminating  DNA  and  host  cell  proteins  can 
present a concern (Segura et al., 2006; Jolly and Aguilar-Cordova, 2008).  Where possible, the 
best solution is to avoid the introduction of such components in the first place.  For example, 
switching to chemically-defined media and stable producer cell lines would eliminate anxieties 
relating to the presence of animal serum and plasmid DNA originating from cell transfections.  
Host cell-derived contaminants, however, must be removed later in the process, and this can 
prove  problematic.    For  example,  John  Gray,  director  of  the  Vector  Development  and 
Production  Shared  Resource  at  St  Jude  Children’s  Research  Hospital  (Tennessee)  recently 
commented that fragments of host cell DNA commonly end up inside viral vectors, meaning 
they cannot be eradicated from the final product (Dolgin, 2012).  It is possible some of these 
fragments may  be necessary for the proper formation and functioning of viral vectors.   It is 
currently  unknown  whether  such  genetic  impurities  are  harmless  or  if  they  have  in  fact 
contributed to the  inflammatory side effects observed in gene therapy trials to date (Dolgin, 
2012).  Another difficulty of virus-based gene delivery systems is that transduction-competent 34 
 
 
particles typically comprise a small proportion of total particles in a given preparation (Kay et al., 
2001).  For example, preparations of lentiviral and adeno-associated viral vectors can contain 
around  10,000  non-functional  particles  for  each  single  functional  particle  (Jolly  and  Aguilar-
Cordova, 2008; Stewart et al., 2009).  Of particular concern are ‘empty’ particles, which do not 
contain vector RNA, as they compete with functional particles for entry to target cells and also 
may provoke unwanted immune reactions (Zhao et al., 2008; Sheridan, 2011).  Removal of 
empty particles downstream is thus highly desirable, however they are particularly troublesome 
to  quantitate  and  isolate  due  to  their  inherent  similarity  in  size  and  protein  composition  to 
complete particles, although some success has been achieved using anion exchange or size 
exclusion chromatography techniques (Qu et al., 2007; Zhao et al., 2008).  Lastly, in addition to 
purification,  significant  concentration  of  gene  therapy  products  is  typically  required  to  attain 
clinical efficacy.  Routine doses of gene therapy products are forecast to be within the range of 
10
8 to 10
15 viral particles per kg of bodyweight (Denèfle, 2011).  For Glybera, the dose is 1 x 
10
12 genome copies per kg of bodyweight, which is achievable as the finished product contains 
3 x 10
12 genome copies per mL; a 60 kg patient, for example, would therefore receive 20 mL of 
finished product (EMA, 2012).  When concentrating gene therapies for clinical administration, 
minimising the co-concentration of unwanted contaminants while maintaining product integrity 
remains a common challenge (Morenweiser, 2005).  To sum-up, defining robust, commercially-
viable manufacturing routes for gene therapy products is an area requiring significant attention.    
1.3  Gene therapy using lentiviral vectors 
Having provided a broad introduction to gene therapy in Section 1.2, the specific application of 
lentiviral vectors is examined here.   To June 2012,  lentiviral  vectors had been employed  in 
around 2.9 % (n = 55) of gene therapy clinical trials (Ginn et al., 2013).  In addition, recent 
research  has  demonstrated  a  more  favourable  integration  pattern  for  lentiviral  vectors  as 
compared  to  conventional  retroviral  vectors  (Dropulić  (2011),  and  references  therein),  thus 
lentiviral vectors are becoming of increasing interest (Sheridan, 2011).  Briefly outlined below is 
the general biology of lentiviruses, followed by an overview of lentivirus-based gene delivery 
systems.  The section concludes by introducing  ProSavin
®, the lentiviral vector utilised as a 
model system throughout this work. 35 
 
 
1.3.1  General characteristics of lentiviruses 
Lentiviridae form a subfamily within the Retroviridae family of viruses, which also includes the 
Oncornaviridae and Spumaviridae; the groupings broadly reflect the nature of the pathogenesis 
experienced  by  the  host  (Wagner  et  al.,  2008).  It  is  thus  important  to  clarify  that  the  term 
‘retroviral  vectors’  used  within  this  thesis  refers  exclusively  to  vectors  derived  from 
oncornaviruses (‘lentiviral vectors’ obviously relates only to lentivirus-based vectors).  Although 
several gene therapy vectors based on spumaviruses are in development (e.g., Horino et al., 
2013 and references therein), none have yet progressed to human clinical trials and this group 
will not be discussed further in this thesis.  
Lentiviruses  are  pathogens  of  humans  and  animals  (Table  1.3),  causing  diseases  that  are 
characterised by a long incubation period (lenti meaning ‘slow’ in Latin), are persistent despite 
strong  immune  responses,  affect  multiple  organs  and  invariably  prove  fatal  (Haase,  1986; 
Clements  and  Zink,  1996).  Although  equine  infectious  anaemia  virus  (EIAV)  was  the  first 
lentivirus to be discovered (Table 1.3), human immunodeficiency virus (HIV)-1 has been most 
studied  due  to  its  critical  impact  on  human  health.    Transmission  of  lentiviruses  between 
individuals occurs solely by the exchange of bodily fluid, and EIAV is the only known lentivirus 
to  be  spread  via  an  insect  vector  (Narayan  and  Clements,  1989).    Most  lentiviruses  infect 
macrophages, and all lentiviruses can infect non-dividing cells (Wagner et al., 2008), a feature 
that  spurred  the  development  of  lentivirus-based  vectors  for  gene  therapy,  as  conventional 
oncornavirus-based vectors lack this capacity (Naldini et al., 1996b). 
Table 1.3  Common  lentiviruses  and  their  hosts,  with  a  reference  to  their  discovery  or 
isolation.  Information derived from Coffin et al. (1997) and Wagner et al. (2008). 
Lentivirus  Host  Discovery/Isolation 
Equine infectious anaemia virus (EIAV)  Horse  (Vallée and Carré, 1904) 
Ovine maedi-visna virus (MMV)  Sheep  (Sigurdsson, 1954) 
Bovine immunodeficiency virus (BIV)  Cattle  (Van der Maaten et al., 1972) 
Caprine arthritis-encephalitis virus (CAEV)  Goat  (Cork et al., 1974) 
Human immunodeficiency virus 1 (HIV-1)  Human  (Barré-Sinoussi et al., 1983) 
Simian immunodeficiency virus (SIV)  Monkey  (Letvin et al., 1985) 
Human immunodeficiency virus 2 (HIV-2)  Human  (Clavel et al., 1986) 
Feline immunodeficiency virus (FIV)  Cat  (Pedersen et al., 1987) 36 
 
 
Lentiviral  particles  contain  two  copies  of  positive-sense  strand  RNA  genome,  which  are 
complexed  with  nucleocapsid  (NC)  proteins  and  enclosed  within  a  capsid  (CA)  that  also 
contains the protease (PR), integrase (IN) and reverse transcriptase (RT) enzymes that play 
fundamental roles in the lentiviral life cycle (Rodrigues et al., 2011; Wagner et al., 2008; Figures 
1.1 and 1.2).  A layer of matrix proteins (MA) outside the CA interacts with the envelope (a lipid 
bilayer derived from the host cell) (Rodrigues et al., 2011).  Viral envelope (Env) proteins are 
anchored within the lipid membrane by a transmembrane (TM) subunit, while the surface (SU) 
subunit interacts with cellular receptors (Rodrigues et al., 2011).   
 
Figure 1.1  Schematic representation of lentivirus particle.  Gag (group specific antigen), 
Pol  (polymerase)  and  Env  (envelope)  proteins  are  indicated.    Note:  actual  diameter  of  a 
lentivirus  particle  is  approximately  119  nm  (Wagner  et  al.,  2008).  Figure  is  adapted  from 
illustrations presented in Segura et al. (2006) and Wagner et al. (2008). 
 
     
Diploid RNA genome 
Lipid membrane 
Host protein 
Nucleocapsid (NC) 
Capsid (CA) 
Matrix (MA) 
Protease (PR) 
Integrase (IN) 
Reverse transcriptase (RT)  Transmembrane subunit (TM) 
Surface subunit (SU) 
Env 
proteins 
Gag 
proteins 
Pol 
proteins 37 
 
 
 
Figure 1.2  Schematic  representation  of  the  lentivirus  life  cycle.    Note  that  the  reverse 
transcriptase (RT) enzyme mediates reverse transcription of lentiviral RNA into DNA (step 3.); 
integrase  (IN)  facilitates  the  integration  of  proviral  DNA  into  the  cell  genome  (step  4.);  and 
protease  (PR)  cleaves  Gag  and  Gag-Pol  during  the  assembly,  budding  and  maturation  of 
particles (steps 7. and 8.) (Wagner et al., 2008; Rodrigues et al., 2011). Figure is adapted from 
illustrations presented in Leroux et al. (2004) and Wagner et al. (2008). 
The basic genetic organisation of lentiviruses is largely analogous to that of oncornaviruses.  R 
(repeated) regions that contain transcriptional signals utilised in proviral DNA are located at both 
ends of the genome (Wagner et al., 2008).  Following the R sequence at the 5’ end of genomic 
DNA  is  (i)  a  U5  non-coding  cis-acting  regulatory  sequence  (ii)  a  primer  binding  site  where 
cellular transfer (t)RNA binds and acts as a primer for initiation of reverse transcription, and (iii) 
a leader sequence that comprises the genome packaging signals used in virus maturation and 
also splice donor signals that are important in creating spliced lentiviral messenger (m)RNAs 
(Wagner et al., 2008).  The 3’ end of genomic DNA contains a polypurine tract that is essential 
for the generation of DNA from RNA, a U3 non-coding sequence and a second copy of the R 
sequence (Wagner et al., 2008).  Similar to oncornaviruses (‘simple’ retroviruses), lentiviruses 
encode the structural genes gag, pol and env; however, lentiviruses (‘complex’ retroviruses) 
 
 
 
 
 
 
 
 
   
1. Receptor-mediated viral 
attachment 
2. Membrane fusion 
and partial uncoating 
Pre-integration 
complex (PIC) 
3. Reverse 
transcription 
of RNA into 
DNA within 
the PIC 
RNA 
DNA 
4. Nuclear import 
and integration of 
viral DNA into cell 
genome 
Cellular 
genomic 
DNA 
5. Transcription 
and splicing  
Progeny RNA 
6. Translation of 
viral proteins  
7. Encapsidation 
of viral RNA  
8. Budding and 
maturation of viral 
particle  
Nucleus 
Cytoplasm 38 
 
 
additionally express several accessory proteins that confer the unique life cycle presented in 
Figure 1.2 (Wagner et al., 2008).  An overview of lentiviral proteins and their functions is given 
in Table 1.4. 
Table 1.4  Lentiviral proteins and their functions.  Only proteins common to all lentiviruses 
and those that are primate-related are listed, as these have been best-studied.  Lentiviruses 
known to express each given protein are indicated (for non-abbreviated names refer to Table 
1.3).  Information was derived from Federico (2003). 
Protein    Function  Lentiviruses 
Structural     
Group specific antigen (Gag)  Gag precursor proteins are cleaved 
to form the nucleocapsid, capsid 
and matrix of the viral particle. 
All 
Polymerase (Pol)  Gag-Pol precursor proteins are 
cleaved to generate viral protease, 
integrase and reverse transcriptase 
enzymes. 
All 
Envelope (Env)  The Env precursor protein is 
cleaved to create the viral surface 
and transmembrane envelope 
proteins. 
All 
Accessory     
Trans-activator of transcription (Tat)  Mediates elongation of viral 
transcripts. 
All 
Regulatory viral protein (Rev)  Facilitates the export of unspliced 
and partially spliced viral RNA from 
the cell nucleus into the cytoplasm. 
All 
Negative factor (Nef)  Promotes viral infectivity by 
mechanisms not yet fully 
understood. 
HIV-1, HIV-2, SIV 
Viral infectivity factor (Vif)  Counteracts a cellular inhibitor of 
viral replication. 
All except EIAV 
Viral protein r (Vpr)  Arrests cell cycle in G2 phase.  Aids 
migration of viral pre-integration 
complex towards cell nucleus. 
HIV-1, HIV-2, SIV 
Viral protein u (Vpu)  Forms ion channels in cell 
membrane to aid viral release. 
HIV-1 
Viral protein x (Vpx)  Aids migration of viral pre-
integration complex towards cell 
nucleus. 
HIV-2, SIV 
1.3.2  The development of lentiviral vectors for gene therapy 
As noted in Section 1.3.1, the capacity of lentiviruses to transduce non-diving cells provided 
impetus for their application as gene therapy vectors.  Further successful attributes of lentiviral 
vectors, in common with conventional retroviral vectors, include their ability to integrate within 
the cellular genome and an absence of pre-existing immunity in the recipient (Ansorge et al., 39 
 
 
2010).  Lentiviral vector development culminated in 1996 in the first description of a practical 
system by Naldini et al. (1996a), who achieved successful in vivo transduction of rat neurons 
using a HIV-1-derived vector system.  Since this landmark study numerous lentiviral vectors 
have been developed, though the majority are still based on HIV-1, and the biosafety of these 
systems  has  improved  over  time  with  regard  to  minimising  the  risk  of  replication-competent 
lentivirus  (RCL)  formation  (Binder  and  Dropulic,  2008;  Ansorge  et  al.,  2010).    The  ‘first-
generation’ vector system developed by Naldini et al. (1996a) expressed seven out of the nine 
wild-type HIV-1 genes (vpu and env were rendered defective), and vectors were generated by 
three-plasmid transient transfections.  All HIV-1 trans-acting sequences (i.e those encoding viral 
proteins) were contained on one plasmid (the ‘packaging plasmid’), while regulatory cis-acting 
elements were confined to a separate ‘transfer plasmid’, which also comprised the transgene 
(encoding  a  fluorescent  marker);  the  third  ‘envelope’  plasmid  encoded  either  the  murine 
leukaemia virus (MLV) amphotrophic envelope protein or the vesicular stomatitis virus envelope 
protein  (VSV-G),  for  a  broad  tissue  tropism  (Naldini  et  al.,  1996b).  Separation  of  vector 
constructs on to three plasmids is an important technique for the prevention of recombination 
events leading to RCL, however further steps to improve the biosafety of lentiviral vectors were 
necessary (Binder and Dropulic, 2008).  Thus, second-generation vectors were developed, in 
which the virulence genes env, nef, vif, vpr and vpu were deleted (Zufferey et al., 1997), and 
soon after third-generation vectors were established, in which the tat gene was also removed 
(offset by the insertion of a constitutive promoter upstream of the vector transgene) (Kim et al., 
1998) and rev was confined to a separate expression plasmid to that encoding gag and pol (Dull 
et al., 1998).  The latest generations of lentiviral vectors are also ‘self-inactivating’ (SIN), as they 
include a deletion in the U3 region of the LTR that is transferred to the 5’ LTR during reverse 
transcription, preventing the generation of full-length vector RNA in target cells (Zufferey et al., 
1998).  Finally, the discovery that inclusion of the woodchuck hepatitis virus posttranscriptional 
regulatory element (WPRE) could significantly enhance transgene expression (Zufferey et al., 
1999) was a critical development that helped advance lentiviral vectors to clinical application. 
In the first clinical trial to utilise lentiviral vectors, initiated in 2003, patients with chronic HIV 
infection received autologous CD4
+ T cells that had been modified ex vivo by a HIV-1-derived 
vector encoding an antisense gene against the HIV envelope (VRX496
TM) (Manilla et al., 2005; 40 
 
 
Levine et al., 2006).  Up to January 2013, 62 lentiviral vector-based clinical trials had been 
undertaken (Segura et al. (2013); Table 1.5).  Although gene therapy trials overall have mostly 
addressed  cancer  (Section  1.2.2),  trials  based  on  lentiviral  vectors  have  largely  targeted 
monogenic diseases (Table 1.5).  This may be explained by the fact that, unlike non-integrating 
vectors (e.g. those derived from adenoviruses and adeno-associated viruses), lentiviral vectors 
can permanently integrate therapeutic genes within host cell DNA (Thomas et al., 2003), thus 
they  hold  the  potential  to  confer  life-long  disease  correction.  Since  trials  employing  the 
VRX496
TM vector were initiated more than 10 years ago 65 HIV-positive patients have been 
treated and, encouragingly, no adverse events have been reported (McGarrity et al., 2013).  
Trials targeting X-linked adrenoleukodystrophy (ALD) are also relatively advanced, with a Phase 
II/III  trial  currently  underway  (http://clinicaltrials.gov/show/NCT01896102  accessed  08.10.13).  
ALD  is  a  fatal  demyelinating  disease  caused  by  mutations  in  the  ABCD1  (adenosine 
triphosphate  (ATP)-binding  cassette,  sub-family  D,  member  1)  gene,  for  which  allogeneic 
haematopoietic  cell  transplantation  from  a  matched  donor  is  presently  the  only  effective 
treatment (Cartier et al., 2009).  In the recently opened (August 2013) Phase II/III trial, boys with 
childhood cerebral ALD will receive autologous CD4
+ haematopoietic stem cells that have been 
modified ex vivo by a HIV-1-derived vector encoding the ABCD1 gene (Cartier et al. (2009); 
http://clinicaltrials.gov/show/NCT01896102 accessed 08.10.13).  As for gene therapies overall 
(Section 1.2.3), while lentiviral vectors make good progress in the clinic, developing scalable, 
GMP-compliant  manufacturing  processes  remains  a  major  challenge  (Ansorge  et  al.,  2010; 
Schweizer  and  Merten,  2010;  Segura  et  al.,  2013).    This  topic  will  be  covered  in  depth  in 
Section 1.4; first, however, an introduction to the lentiviral vector utilised as a model system 
throughout this research is required.   
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Table 1.5  Indications addressed in lentiviral vector-based clinical trials performed up to 
January  2013.    The  number  of  clinical  trials  in  each  Phase  is  also  given.    Information  was 
derived from Segura et al. (2013); note that this source listed details of 52 trials only. 
Indications  Phases 
  I  I/II  II  II/III  III  All 
Monogenic diseases            22 
Adrenoleukodystrophy (ALD)    1    1  1   
Thalassemia  3           
Wiskott-Aldrich syndrome (WAS)  2  1         
ADAˉ SCID    2         
Fanconi anaemia  2           
SCID-X1  2           
Haemophilia A  1           
Metachromatic leukodystrophy    1         
Mucopolysaccharidosis Type VII (MPS VII)  1           
Netherton syndrome  1           
Sickle cell anaemia  1           
Sickle cell anaemia, thalassemia    1         
X-linked chronic granulomatous disease (X-CGD)    1         
Cancer diseases            15 
Leukaemia / lymphoma   4  2         
Melanoma  3           
Ovarian cancer  2           
Advanced myeloma  1           
Glioma  1           
Paediatric patients with high risk brain tumours  1           
Synovial sarcoma  1           
Infectious diseases            9 
HIV infection  4  4  1       
Ocular diseases            4 
Stargardt macular degeneration (SMD)    2         
Age-related macular degeneration (AMD)  1           
Usher Syndrome    1         
Neurological diseases            2 
Parkinson’s disease    2         
1.3.3  ProSavin
®: a lentiviral vector for treatment of Parkinson’s disease 
The  research  presented  in  this  thesis  was  predominantly  conducted  using  ProSavin
®  as  a 
model system.  ProSavin
® is an EIAV-derived lentiviral vector developed for the treatment of 
Parkinson’s  disease,  which  encodes  the  enzymes  necessary  for  dopamine  synthesis 
(Mitrophanous  et  al.,  1999;  Azzouz  et  al.,  2002;  Jarraya  et  al.,  2009;  Stewart  et  al.,  2009; 
Stewart et al., 2011; Palfi et al., 2014).  Most EIAV sequences have been removed, leaving a 
minimal vector system as illustrated in Figure 1.3.  
Wild-type EIAV has the simplest genome of any lentivirus (8.2 kb in length), encoding only the 
genes gag, pol, env, tat, rev and S2 (Leroux et al., 2004).  S2 encodes a protein unique to EIAV 
(Rohll et al., 2002), not required for in vitro replication (Li et al., 1998), but of importance for in 42 
 
 
vivo replication and pathogenicity (Li et al., 2000).  It has been suggested that S2 may function 
in the cytoplasm by organising Gag proteins during particle assembly, and is unlikely to play a 
role in the early stages of the life cycle (Yoon et al., 2000).  Another important difference to HIV-
1, is that EIAV, along with all other non-primate lentiviruses, expresses a dUTPase (DU) from a 
domain within the pol gene (Elder et al., 1992), which serves to minimise the misincorporation of 
uracil into DNA (Chen et al., 2002).  It has been demonstrated that S2 and DU are dispensable 
when creating EIAV-based vectors (Mitrophanous et al., 1999).   
 
Figure 1.3  Schematic  representation  of  the  genetic  organisation  of  (a)  wild-type  equine 
infectious anaemia virus (EIAV), (b) lentiviral vector platform, and (c) the ProSavin
® genome 
construct (pONYK1).  The following terms have been abbreviated: long terminal repeat (LTR), 
packaging signal (Ψ), central polypurine tract (cPPT), Rev response element (RRE), polypurine 
tract (PPu), polyadenylation signal (pA), Cytomegalovirus promoter (CMVp), codon optimised 
(CO), vesicular stomatitis virus glycoprotein (VSV-G), neomycin resistance gene (neo), tyrosine 
hydroxylase  type  2  gene  (TH*),  aromatic  amino  acid  decarboxylase  gene  (AADC),  GTP-
cyclohydrolase 1 gene (CH1), internal ribosome entry site (IRES) from encephalomyocarditis 
(EMCV), IRES from polio virus (PV), woodchuck hepatitis virus post transcriptional regulatory 
element (WPRE).  Image kindly provided by Oxford BioMedica.  Permission to reproduce this 
image has been granted by Oxford BioMedica. 
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The EIAV lentiviral vector system developed by Oxford BioMedica and illustrated in Figure 1.3, 
comprises three components: the packaging construct, envelope construct, and vector genome 
construct.  In order from 5’ to 3’ the packaging construct contains a cytomegalovirus promoter 
(CMVp),  a codon-optimised open reading frame (ORF) for Gag-Pol, linked by  a non-codon-
optimised ribosome shift frame (essential for maintaining the correct balance of Gag and Gag-
Pol  proteins),  and  a  heterologous  polyadenylation  (pA)  signal.  pA  signals  promote 
polyadenylation  (important  for  the  nuclear  export  and  stability  of  eukaryotic  mRNAs)  and 
terminate  transcription  of  genomic  lentiviral  RNA  (Tolmachov  et  al.,  2011).    The  envelope 
component contains (from 5’ to 3’) a CMVp, an ORF for VSV-G, and a heterologous pA signal.  
The  ProSavin
®  vector  genome  construct  pONYK1  contains  just  861  nucleotides  of  EIAV 
sequence and does not express any functional viral proteins.  This construct comprises (from 5’ 
to 3’) a CMVp-R-U5 region, a packaging signal (Ψ), a neomycin resistance gene (neo) ORF 
(which, by inclusion, abolishes the requirement for rev (Miskin et al., 2008)), an internal CMVp, 
a codon-optimised ORF for truncated tyrosine hydroxylase (TH), an internal ribosome entry site 
(IRES), a codon-optimised ORF for aromatic amino acid decarboxylase (AADC), another IRES, 
a codon-optimised ORF for GTP-cyclohydrolase 1 (CH1), a WPRE, and a SIN LTR.  TH, AADC 
and CH1 are the three critical enzymes required for dopamine synthesis (Azzouz et al., 2002).  
By incorporating IRES units within the transgene cassette, translation of mRNA may be initiated 
from more than one site (Hellen and Sarnow, 2001). 
As ProSavin
® is the lentiviral vector predominantly employed in the studies presented in this 
thesis, a brief introduction to  Parkinson’s disease and current treatment options is included; 
however,  it is  important to  note that several  products have been generated  using the  EIAV 
lentiviral vector platform (Table 1.6).  ProSavin
® was chosen as a model system as it is the most 
clinically advanced (Phase I/II trials have been completed, see Palfi et al. (2014)), and it is 
anticipated that large amounts of material will be required for Phase III trials and commercial 
manufacture, thus the speedy development of a scalable bioprocess is highly desirable (Stewart 
et al., 2011).  Parkinson’s disease is the second most prevalent progressive neurodegenerative 
disorder after Alzheimer’s disease (Nanou and Azzouz, 2009).  The average age at onset is 60 
years (Ishihara et al., 2007) and in age groups greater than 60 years prevalence was reported 
to  be  1.28  -  1.5  %  in  European  countries  (von  Campenhausen  et  al.,  2005).    For Western 44 
 
 
Europe’s five most and the world’s ten most populous nations Dorsey et al. (2007) estimated 
the total number of individuals greater than 50 years with Parkinson’s disease to be 4.1 - 4.6 
million in 2005 and forecasted that this figure would double to 8.7 - 9.3 million by 2030.  The 
precise  aetiology  of  Parkinson’s  disease  is  unknown  (Olanow  and  Tatton,  1999)  and  a 
consequent lack of reliable predictive risk markers has hindered the development of effective 
preventative treatments (Poewe, 2009).  However, the pathogenesis of Parkinson’s disease has 
been well described.  Parkinson’s disease is chiefly characterised by a loss of dopaminergic 
neurons in the substantia nigra pars compacta region of the brain, which leads to a depletion of 
dopamine  in the striatum (Nanou  and  Azzouz, 2009).  Archetypal clinical symptoms include 
rigidity, resting tremor, bradykinesia and postural instability; although a multitude of motor and 
non-motor symptoms can accompany the disease (Jankovic, 2008).  
Table 1.6  Pipeline  of  products  developed  by  Oxford  BioMedica  that  are  based  on  the 
equine infectious anaemia virus (EIAV) lentiviral vector platform. Information was derived from 
Oxford BioMedica (2013). 
Indication  Product   Partner / funding  Development stage 
Neurological        
Parkinson’s disease  ProSavin
®  -  Phase I/II trial completed 
Motor neuron disease  MoNuDin
® 
UK Motor 
Neurone Disease 
Association 
Research 
Ocular       
Stargardt disease  StarGen
TM   Sanofi  Phase I/IIa trial ongoing 
Usher syndrome type 1B  UshStat
®  Sanofi  Phase I/IIa trial ongoing 
Corneal graft rejection  EncorStat
®  Sanofi  Phase I/II trial preparation 
“Wet” age-related macular 
degeneration  RetinoStat
®  Sanofi  Phase I trial ongoing 
Chronic glaucoma  Glaucoma-GT  Mayo Clinic, USA  Pre-clinical 
For over 40 years, levodopa has been the gold standard treatment for controlling the symptoms 
of Parkinson’s disease  (Poewe,  2009).  Levodopa  is the amino acid precursor to dopamine 
which, unlike dopamine, can cross the blood-brain barrier (Pezzoli and Zini, 2010).  Chronic use 
of  levodopa  is  associated  with  disabling  motor  complications,  however,  which  emerge  after 
approximately  five  years  of  therapy  (Yokochi,  2009).    These  complications  arise  due  to  the 
discontinuous delivery of levodopa to the brain (a function of the oral dosage regimen), which 45 
 
 
leads to the pulsatile stimulation of dopamine receptors (Olanow  et al., 2006).  Attempts to 
define alternative delivery routes for levodopa have produced limited success, and a decrease 
in  the  efficacy  of  levodopa  therapy  over  time  remains  inevitable  due  to  a  continuing 
degeneration  of  dopaminergic  neurons  with  disease  progression,  thus  cell  replacement 
therapies and gene therapies are being evaluated as alternatives (Goole and Amighi, 2009).   
At present, cell replacement approaches appear to have been delayed, as early clinical studies 
failed to demonstrate efficacy and, worryingly, caused graft-induced dyskinesia in some patients 
(Lindvall, 2013).  Gene therapy has shown more promise, with four approaches having recently 
undergone  clinical  evaluation.    Three  of  these  employed  adeno-associated  serotype  2  virus 
vectors to deliver genes encoding either (i) glutamic acid dehydroxylase (GAD), which catalyses 
production of the neurotransmitter γ-aminobutyric acid (GABA) (Kaplitt et al., 2007; LeWitt et al., 
2011),  (ii)  the  neurotropic  factor  neurturin  (Marks  et  al.,  2010),  or  (iii)  the  AADC  enzyme 
(evaluated by two groups) (Muramatsu et al., 2010; Valles et al., 2010).  The fourth approach - 
based  on  the  lentiviral  vector  ProSavin
®  -  is  the  only  strategy  to  deliver  all  three  enzymes 
required  for  dopamine  synthesis  (AADC,  CH1,  TH)  to  the  striatum  (Jarraya  et  al.,  2009).  
Promising data pertaining to the safety and efficacy of ProSavin
® was generated in a Phase I/II 
study (Palfi et al., 2014) and Oxford BioMedica are presently evaluating a more potent vector 
construct  to  maximise  the  likelihood  of  success  in  future  Phase  II  trials  (Oxford  BioMedica, 
2012).    A further challenge is the development of a bioprocess that is capable of generating 
sufficient material to satisfy future Phase III and commercial requirements (Stewart et al., 2011), 
and methods for the manufacture of lentiviral vectors are discussed in depth below. 
1.4  Manufacturing lentiviral vectors 
The establishment of large-scale clinical GMP-compliant bioprocesses for lentiviral vector-based 
gene therapies is a pressing challenge (Ansorge et al., 2010; Schweizer and Merten, 2010; 
Segura  et  al.,  2013).  This  section  considers  current  and  upcoming  lentiviral  vector 
manufacturing  approaches,  and  their  suitability  for  commercial  application.  Pertinent  issues 
were highlighted in Section 1.2.3 for gene therapies in general and, as these issues are wholly 
relevant for lentiviral vector-derived therapies, they shall be reiterated here in brief: (i) the use of 
adherent cell expression systems is not scalable, (ii) elimination of contaminants arising from 46 
 
 
the upstream process, such as medium components (e.g. serum), those derived from transient 
transfections (including plasmid DNA), and those derived from host cells is problematic, and 
impossible  if  they  have  been  incorporated  into  viral  particles,  (iii)  removal  of  non-functional 
vector  is  difficult  as  it  often  co-purifies  with  functional  vector,  and  (iv)  concentration  to  the 
degree required for therapeutic purposes without co-concentration of impurities is challenging.  
It  is  with  these  concerns  in  mind  that  recent  progress  in  the  area  of  lentiviral  vector 
manufacturing is presented.  This section covers cell expression systems, culture technologies, 
downstream processing methodologies and assays for evaluation of the quantity and quality of 
lentiviral  vector  yields.    The  section  concludes  by  considering  the  development  of  future 
manufacturing approaches for ProSavin
®, in terms of progress made and challenges remaining. 
1.4.1  Cell expression systems 
For the large-scale manufacture of lentiviral vectors, adherently cultured HEK293 cells or their 
derivatives are most commonly employed (Ansorge et al., 2010; Schweizer and Merten, 2010; 
Segura et al., 2013).  Exposure of human embryonic kidney cells to sheared Adenovirus Type 5 
fragments yielded the immortalised HEK293 cell line (Graham et al., 1977), which contains the 
adenoviral transcription units early region (E)1a and E1b (Louis et al., 1997).  HEK293 cells are 
preferentially employed for lentiviral production as they are of human derivation, have a proven 
safety record for production of retroviral vectors (Ansorge et al., 2010), and are easy to transfect 
(Segura et al., 2007).  As multi-plasmid transient transfection is the method most commonly 
employed for generating research and clinical-grade lentiviral vectors, HEK293T is the most 
commonly used cell derivative (Cockrell and Kafri, 2007; Schweizer and Merten, 2010; Gama-
Norton et al., 2011).  HEK293T cells express the Simian vacuolating virus 40 (SV40) large T 
antigen,  which  promotes  the  replication  of  plasmids  carrying  the  SV40  origin  of  replication 
(DuBridge  et  al.,  1987).  Use  of  HEK293T  as  compared  to  HEK293  has  been  reported  to 
improve titres by around 4- to 10-fold (Merten et al., 2011; Ausubel et al., 2012).  
HIV-1  based  lentiviral  vectors  have  several  proteins  reported  to  be  cytotoxic  or  cytostatic, 
including: protease (Kaplan and Swanstrom, 1991), Rev (Miyazaki et al., 1995), Tat (Li et al., 
1995), Vpr (Planelles et al., 1995; Rogel et al., 1995) and Env (Sodroski et al., 1986).  Although 
Tat, Vpr and Env are not expressed in third generation lentiviral vectors (Kim et al., 1998), the 47 
 
 
problem is not necessarily reduced as, for example, the VSV-G envelope commonly used as a 
replacement for viral Env is also highly cytotoxic (Burns et al., 1993; Yee et al., 1994; Yang et 
al., 1995; Ory et al., 1996).  As constitutive expression of lentiviral vectors is thus not possible, 
transient transfection of cells with plasmid DNA has been the method most utilised to generate 
lentiviral vectors to date (Cockrell and Kafri, 2007; Schweizer and Merten, 2010; Gama-Norton 
et al., 2011; Segura et al., 2013).  Using this technique, transfected DNA remains in the cell 
nucleus in an episomal state until cell death occurs, presumably due to the accumulation of 
cytotoxic  vector  proteins  (Al-Dosari  and  Gao,  2009).    GMP  clinical  productions  have  been 
performed using two (Slepushkin et al., 2003), three (Stewart et al., 2009), four (Merten et al., 
2011)  or  five  plasmids  (Negré  et  al.,  2008);  multiple  plasmids  are  used  to  minimise  the 
likelihood  of  recombination  leading  to  RCL,  as  noted  earlier  (Section  1.3.2).    Published 
protocols for the production of GMP clinical grade material are summarised in Table 1.7.  As 
naked DNA molecules cannot efficiently traverse cell membranes due to their large size and 
hydrophilic nature, delivery of DNA into the cytoplasm is accomplished using either chemical 
compounds or physical force (Al-Dosari and Gao, 2009).  Once in the cytoplasm, nuclear entry 
of  DNA  is  best  achieved  in  dividing  cells,  where  the  nuclear  envelope  disassembles  during 
mitosis, removing the barrier (Dean et al., 2005).  To gain cellular entry, co-precipitation of DNA 
molecules  with  calcium  phosphate  is  the  technique  most  often  employed  for  clinical  GMP 
lentiviral vector production (Slepushkin et al., 2003; Negré et al., 2008; Merten et al., 2011; 
Ausubel  et  al.,  2012).  Interestingly,  ProSavin
®  for  Phase  I/II  trials  was  generated  using  a 
cationic liposome-mediated transfection (lipofection) method (Stewart et al., 2011), although the 
cost  of  the  commercial  reagent  is  thought  to  preclude  use  of  this  method  for  large-scale 
productions (Segura et al., 2013).  Partly due to this concern stable producer cell lines are in 
development for the manufacture of ProSavin
® for Phase III trials and beyond (Stewart et al., 
2009; 2011).  Alternative transfection methods that have shown recent potential, but to the best 
of  my  knowledge  have  not  yet  been  applied  in  clinical  setting,  include  the  use  of 
polyethylenimine  (PEI)  (Kuroda  et  al.,  2009;  Toledo  et  al.,  2009;  Segura  et  al.,  2010)  and 
electroporation (Witting et al., 2012).  
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Table 1.7  Published upstream processing protocols employed for large-scale production 
of Good Manufacturing Practice (GMP)-compliant clinical-grade lentiviral vectors.  VIRxSYS’s 
(Gaithersburg, MD, USA) protocol relates to the first clinical lentiviral vector, VRX496
TM, used 
for  treatment  of  HIV;  Oxford  BioMedica’s  protocol  relates  to  ProSavin
®  used  for  treatment 
Parkinson’s disease; Généthon’s (Evry, France) protocol relates to a lentiviral vector used for 
treatment  of  Wiskott-Aldrich  Syndrome  (WAS);  Beckman  Research  Institute’s  (Duarte,  CA, 
USA) protocol relates to a lentiviral vector used for treatment of HIV.  TU is an abbreviation for 
‘transducing units’ and IG is an abbreviation for ‘infectious genomes’. 
Institute / 
company  VIRxSYS  Oxford BioMedica  Généthon  Beckman 
Research Institute 
Reference  Slepushkin 
et al. (2003) 
Schweizer and 
Merten (2010); 
Stewart et al. (2011) 
Merten et al. 
(2011) 
Ausubel et al. 
(2012) 
Lentiviral 
vector  HIV-1  EIAV  HIV-1  HIV-1 
Cell line  HEK293  HEK293T  HEK293T  HEK293T 
Number of 
plasmids  2  3  4  4 
Transfection 
reagent 
Calcium 
phosphate 
Lipofectamine
TM 
2000 CD 
Calcium 
phosphate 
Calcium 
phosphate 
Vessel 
10-layer 
Cell 
Factory
TM 
10-layer Cell 
Factory
TM 
10-layer Cell 
Factory
TM 
10-layer Cell 
Factory
TM 
Production 
scale (L)  36-52  72 (24 per campaign)  52  20-120 
Crude titre  1.1-3.2 x 
10
7 TU mL
-1  0.2-2.0 x 10
6 TU mL
-1  3.1-5.0 x 10
7 IG 
mL
-1  ~1 x 10
6 TU mL
-1 
Transient transfection methods offer f lexibility and  are  fast to develop , thus are suited to 
producing lentiviral vectors for early Phase clinical trials (Ansorge et al., 2010; Rodrigues et al., 
2011; Segura et al., 2013).  However, for generating licensed product, use of this technique is 
unfeasible for the following reasons: (i) it is costly and technically challenging to scale-up (ii) 
batch-to-batch  variability  is  common  due  to  variability  in  plasmid  uptake  and  expression 
efficiencies (iii) a transfection step  complicates the  upstream process and the elimination  of 
plasmid DNA downstream is difficult, (iv) the presence of large quantities of transfected plasmid 
DNA may increase the risk of a recombination event leading to formation of a RCL (Cockrell 
and  Kafri,  2007;  Stewart  et  al.,  2009;  Ansorge  et  al.,  2010;  Schweizer  and  Merten,  2010; 
Rodrigues et al., 2011; Segura et al., 2013).  As a result, stable packaging and producer cell 
lines are in development (Table 1.8) which, although initially time consuming to create (Cockrell 
and Kafri, 2007; Ansorge et al., 2010; Rodrigues et al., 2011), should ultimately address these 
concerns.  Packaging cell lines express all lentiviral vector components apart from the genome 49 
 
 
construct,  thus  still  require  one-plasmid  transient  transfection;  producer  cell  lines,  however, 
express  all  necessary  lentiviral  vector  components  (Ansorge  et  al.,  2010).  Controlled  gene 
expression is essential for overcoming the cytotoxic/cytostatic effects of certain lentiviral vector 
components,  and  for  this  purpose  a  tetracycline(tet)-OFF  regulatory  system  has  been  most 
commonly employed (Table 1.8).  However, as total removal of doxycycline (dox; an analogue 
of tet used to maintain cells in the OFF state) is only practical with adherent cells, these systems 
are  not  considered  amenable  to  large-scale  production  (Ansorge  et  al.,  2010).  As  a 
consequence  packaging  and  producer  cells  incorporating  a  tet-ON  regulatory  system  have 
recently been developed (Broussau et al., 2008; Stewart et al., 2009).  Encouragingly, titres 
from  these  systems  were  in-line  with  those  attained  using  current  clinical  GMP  transient 
transfection protocols (Table 1.7), and the producer clones (encoding green fluorescent protein 
[GFP]  or  ProSavin
®,  respectively)  were  stable  during  extended  cultures  (≥  83  days)  in  the 
absence  of  antibiotic  selection  (Broussau  et  al.,  2008;  Stewart  et  al.,  2011).  The  cell  lines 
developed by Broussau et al. (2008) were grown in serum-free suspension conditions, thus this 
study represents the most promising advance towards a scalable upstream process for lentiviral 
vectors  to  date.  Large-scale  culture  systems  that  have  been  utilised  for  the  production  of 
clinical-grade lentiviral vectors, and studies evaluating alternative vessels for future applications 
are outlined below.   
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1.4.2  Large-scale cell culture systems 
GMP-compliant  lentiviral  vector  productions  are  currently  based  on  transient  transfection  of 
adherent HEK293-derived cell lines (Section 1.4.1), and to generate sufficient material for early 
Phase clinical trials the Nunc
TM Cell Factory
TM (Thermo Fisher Scientific, Wilmington, DE, USA) 
is the only system reported to have been employed to date (Slepushkin et al., 2003; Schweizer 
and  Merten,  2010;  Merten  et  al.,  2011;  Stewart  et  al.,  2011;  Ausubel  et  al.,  2012).  Cell 
Factory
TM systems are simply multi-layered tissue culture trays, each tray has a culture area of 
632 cm
2, and usually the trays are utilised as 10-layer stacks (Table 1.7).  Alternative large-
scale culture vessels that have been evaluated for lentiviral vector production, but have not yet 
been utilised to generate clinical-grade material are given in Table 1.9. 
Table 1.9  Comparison  of  large-scale  culture  methods  that  have  been  evaluated  for 
lentiviral vector production.  Alternatives to the Cell Factory
TM system conventionally used for 
clinical-grade manufacturing are listed.  The maximum titre from a single harvest is reported.  
TU, IU and IVP are abbreviations of ‘transducing units’, ‘infectious units’ and ‘infectious viral 
particles’, respectively. 
Vessel  Scale  Growth mode  Process  Titre  Reference 
HYPERFlask
TM 
1720 cm
2 
(single 
flask) 
Adherent 
monolayer 
3 plasmid transient 
transfection using 
calcium phosphate 
2.3 x 10
8 
TU mL
-1 
Kutner et 
al. (2009) 
HYPERFlask
TM 
1720 cm
2 
(single 
flask) 
Adherent 
monolayer 
3 plasmid transient 
transfection using 
polyamine 
1.3 x 10
7 
TU mL
-1 
Cooper et 
al. (2011) 
WAVE 
bioreactor  25 L 
Adherent 
attached to 
microcarriers 
Tet-OFF producer 
cell line 
2 x 10
7 
TU mL
-1 
Throm et 
al. (2009); 
Greene et 
al. (2012) 
WAVE 
bioreactor  2.3 L  Serum-free 
suspension 
4 plasmid transient 
transfection using 
flow electroporation 
1.3 x 10
7 
IU mL
-1 
Witting et 
al. (2012) 
Stirred tank 
bioreactor  3 L  Serum-free 
suspension 
4 plasmid transient 
transfection using 
PEI 
1.1 x 10
6 
IVP mL
-1 
Segura et 
al. (2007) 
 
Stirred tank 
bioreactor  2.8 L  Serum-free 
suspension 
Tet-ON (+ cumate) 
packaging cell line, 
single plasmid 
transient 
transfection using 
PEI 
2 x 10
6 
TU mL
-1 
Broussau 
et al. 
(2008) 
 
Stirred tank 
bioreactor  2.7 L 
Serum-free 
suspension 
supplemented 
with bovine 
serum albumin 
4 plasmid transient 
transfection using 
PEI 
8 x 10
7 
TU mL
-1 
Ansorge et 
al. (2009) 
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Use of the Corning
® HYPERFlask
TM cell culture vessel (Sigma-Aldrich, Poole, UK) for lentiviral 
vector production has been reported (Kutner et al., 2009; Cooper et al., 2011).  HYPERFlask
TM 
vessels comprise ten growth areas (totalling 1720 cm
2) that are each interconnected by a gas 
permeable membrane, and provide the benefit of a small footprint (similar to a conventional 175 
cm
2 tissue culture flask).  Kutner et al. (2009) reported approximately 10-fold higher productivity 
when  generating  lentiviral  vectors  by  calcium  phosphate  transient  transfection  in  a 
HYPERFlask
TM as compared to a 150 cm
2 dish (which is analogous to a Cell Factory
TM in terms 
of  the  culture  environment)  that  the  authors  hypothesised  could  be  due  to  superior  gas 
exchange.  Further work is necessary to confirm whether this improvement holds true for other 
lentiviral  vector  expression  systems.    However,  despite  potential  advantages  over  the  Cell 
Factory
TM system in terms of equipment footprint and attainable titres, neither vessel is suitable 
for  commercial  scale  manufacture,  as  production  capacity  can  only  be  increased  by  linear 
scale-out, i.e. by multiplying the number of production vessels (Schweizer and Merten, 2010).   
Growth of adherent cells on microcarrier disks, as opposed as to monolayers, overcomes the 
issue of linear scale-out.  It was recently reported that stable producer cells that were adhered 
to Fibra-Cel
® microcarrier disks (New Brunswick, Enfield, CT, USA) could be cultured at 25 L 
scale and generated lentiviral vectors at clinically relevant titres (Throm et al., 2009; Greene et 
al., 2012).  A drawback of the reported process, however, was the use of a tet-OFF regulatory 
system, as multiple wash steps and a full medium exchange was thus required for cell induction 
(Throm et al., 2009; Greene et al., 2012).  These studies employed a WAVE bioreactor system 
(GE  Healthcare,  Buckinghamshire,  UK), in  which  cells  are  cultured  within  a  disposable  bag 
chamber and are mechanically rocked to facilitate fluid mixing and oxygen transfer.  It is likely 
this form of bioreactor was chosen as bubble-free aeration and minimal mechanical stress is 
required  for  the  efficient  growth  of  microcarrier  cultures  (Ansorge  et  al.,  2010).    An  added 
benefit of the WAVE system is that, along with the Cell Factory
TM and HYPERFlask
TM vessels, it 
is single-use.  For the production of lentiviral vectors, disposable technologies are preferable to 
re-usable systems as lentiviral vectors cannot be subjected to traditional virus inactivation or 
removal  steps  (such  as  those  used  for  recombinant  proteins),  thus  contamination  by 
adventitious agents must be avoided during their manufacture (Segura et al., 2013).  The pre-
sterility  of  the  cultivation  vessel  also  affords  cost  and  time  savings  and  allows  flexible 53 
 
 
application of the bioreactor base unit with a minimal chance of cross-contamination (Eibl et al., 
2010b).  A potential drawback with both single-use technologies and microcarrier disks is the 
risk  of  generating  extractables  and  leachables.  The  use  of  WAVE  bioreactors  is  more 
commonplace, and the ‘Cellbag’ cultivation chamber meets US Pharmacopeia Class VI testing 
for leachables (Mikola et al., 2007), however the use of microcarriers can generate fine debris 
and contaminants that are difficult to remove downstream, and are of particular concern when 
seeking to develop a GMP-compliant process.       
Despite  the  recent  advances  made  using  microcarriers  (Throm  et  al.,  2009;  Greene  et  al., 
2012), scale-up is most cost-effectively and easily achieved using suspension-adapted cell lines 
(Peshwa et al., 1993; Ansorge et al., 2010), thus this remains the best option for future industrial 
productions of lentiviral vectors.  However, HEK293 cells and their derivatives display a high 
propensity for aggregation when cultured in suspension (Wurm and Bernard, 1999; Liu et al., 
2006; Zhao et al., 2007), an undesirable trait as cells in the centre of clumps gradually become 
non-viable, possibly due to diffusional limitations (Peshwa et al., 1993), likely limiting the overall 
productivity  of  the  culture.  Cell  density,  extent  of  agitation,  magnesium  and  calcium 
concentrations have all been reported to affect the degree of HEK293 aggregation observed in 
suspension cultures (Peshwa et al., 1993; Liu et al., 2006; Zhao et al., 2007; Liu et al., 2009).  
Lowering  the  calcium  content  of  culture  media  has  been  the  main  strategy  employed  to 
minimise the formation of HEK293 aggregates, and the creation of specialist suspension media, 
such as the low-calcium serum-free medium (LC SFM) developed by Côté et al. (1998), has 
enabled suspension-based lentiviral vector production strategies to be developed (Table 1.9). 
Witting et al. (2012) presented a large-scale process for lentiviral vector production that was 
based  on  the  culture  of  suspension-adapted  HEK293-derived  cells  in  a  WAVE  bioreactor 
system.  However, the complexity of the protocol would likely preclude its industrial application.  
Although cells were initially expanded in the WAVE bioreactor (to 5 L), they were then removed, 
pelleted, washed, re-suspended in 10 - 100 mL and transfected in an electroporation chamber 
using four plasmids, following which the suspension was transferred into multiple tissue culture 
flasks and DNase treated, before finally being returned to the WAVE bioreactor (fill volume 2.1 - 
2.3 L) for two days, after which lentiviral vector could be harvested (Witting et al., 2012).  The 
number  of  manipulations  involved  makes  this  process  vulnerable  to  contamination  and, 54 
 
 
although the authors acknowledge that improvements to the liquid handling steps are required 
(Witting et al., 2012), overall the use transient transfection makes the process unattractive for 
commercial applications. 
Conventional stirred bioreactors have also been explored for the production of lentiviral vectors 
from suspension cultures (Segura et al., 2007; Broussau et al., 2008; Ansorge et al., 2009).  An 
advantage  of  stirred  bioreactors,  as  compared  to  WAVE  systems,  is  that  they  have  long 
standing  use  in  the  biotechnology  sector,  thus  the  culture  environment  has  been  highly 
characterised.  Segura  et  al.  (2007)  produced  lentiviral  vectors  from  suspension  cultures  of 
HEK293-derived cells in a 3 L bioreactor by PEI-mediated transient transfection.  Titres were in-
line with those attained using standard adherent protocols however, to realise most benefit from 
the system, three full media exchanges were performed (Segura et al., 2007), complicating the 
procedure.  Again,  the  use  of  transient  transfection  renders  this  process  unrealistic  for 
commercial applications.  A significant breakthrough was made by Broussau et al. (2008), who 
generated lentiviral vectors in a 2.8 L stirred bioreactor using a batch suspension culture of 
HEK293-derived  packaging  cells.  To  date,  no  other  study  has  reported  the  successful 
development of a lentiviral vector packaging or producer cell line that is capable of growth in 
suspension  (Table  1.8),  likely  as  changes  in  cell  morphology  brought  about  by  suspension 
adaption can diminish the capacity of these cells to generate high titres (Ansorge et al., 2010).  
The success achieved by  Broussau et al. (2008) could be owing to the fact packaging and 
producer clones were generated from cells that had previously been adapted to suspension, 
thus  subsequent  to  stable  transfection  no  further  adaption  was  required.  Reasonable  titres 
were generated from the packaging cells in the 2.8 L bioreactor (Table 1.9), although these 
were more than three-fold lower than those attained from 25 mL shake flask cultures, which the 
authors suggested may have been because transfection efficiency is generally poorer at larger 
scales (Broussau et al., 2008).  It should be noted that producer clones were also developed, 
which it is conceivable might therefore outperform the packaging cells in the stirred bioreactor, 
however this was not tested (Broussau et al., 2008).  Finally, Ansorge et al. (2009) generated 
lentiviral  vectors  in  a  2.7  L  stirred  bioreactor  by  PEI-mediated  transfection  of  suspension-
adapted HEK293.  This process was thus analogous to that reported earlier by Segura et al. 
(2007),  and  suffers  the  same  drawback  of  still  relying  on  transient  transfection,  limiting  its 55 
 
 
applicability primarily to early Phase clinical trials.  However, an important advance  was the 
development of a perfused system, which is more industrially viable than discontinuous media 
exchanges, such as were performed by Segura et al. (2007).  Lentiviral vectors rapidly decay at 
37 °C, the temperature at which they are produced (Higashikawa and Chang, 2001; Carmo et 
al.,  2009a;  Carmo  et  al.,  2009b),  thus  perfusion  enables  their  continual  removal  to  low 
temperature storage (preserving their activity), while also preventing the accumulation of toxic 
by-products within the cell media and introducing new nutrients to extend the productivity of the 
culture.    Overall,  the  perfused  system  generated  good  titres  (Table  1.9)  although  similar  to 
Broussau et al. (2008), the authors found that titres were lower in the bioreactor than those 
generated using small-scale cultures, which they also suggested was a result of less efficient 
transfection,  but  went  further  to  hypothesise  that  perhaps  this  was  due  to  increased  cell 
aggregation caused by the acoustic cell filter used (Ansorge et al., 2009).  Overall, the potential 
of stirred bioreactors for lentiviral vector production has been demonstrated and, although non-
disposable vessels were used in these particular studies (Segura et al., 2007; Broussau et al., 
2008; Ansorge et al., 2009), several disposable stirred bioreactors have been developed (Eibl et 
al., 2010a) which may prove superior for future industrial applications. 
It is clear from the paucity of available data regarding scalable bioprocesses for lentiviral vector 
production (Table 1.9) that this topic is in its infancy.  This is probably because, so far, lentiviral 
vectors  have  mostly  been  employed  in  early  Phase  clinical  trials  (Table  1.5)  that  require  a 
relatively  small  volume  of  material,  thus  methods  based  on  the  transient  transfection  of 
adherent monolayers of HEK293-derived cells have proved adequate.  However, it is now more 
than 10 years since the first gene therapy trial using lentiviral vectors commenced, and lentiviral 
vectors have since made good progress in the clinic (Section 1.3.2), as such the apparent lack 
of scalable, GMP-compliant manufacturing processes is of mounting concern (Ansorge et al., 
2010; Schweizer and Merten, 2010; Segura et al., 2013).  An ideal upstream process would be 
based  on  serum-free  suspension  cultures  of  ON-inducible  stable  producer  cells,  and  would 
generate high-quality (i.e. containing a low proportion of defective particles) high-titre lentiviral 
vectors  within  a  disposable  closed  system.  To  date,  no  single  published  process  has 
successfully combined all of these elements, although several studies have reported progress in 
one or more of these areas (Segura et al., 2007; Broussau et al., 2008; Ansorge et al., 2009; 56 
 
 
Stewart et al., 2009; Throm et al., 2009; Stewart et al., 2011; Greene et al., 2012; Witting et al., 
2012).  The development of industrially viable upstream processes for lentiviral vectors is thus 
an area warranting significant attention. 
1.4.3  Scalable downstream processing methodologies 
Although lentiviral vector downstream processing strategies are not explored in this research, in 
order to design efficient upstream processes that do not overburden subsequent purification 
and  concentration  stages  an  understanding  of  this  topic  is  critical,  thus  a  brief  overview  of 
current practices is here presented.  The primary goal of downstream processing specific to 
gene  therapy  is  to  remove  impurities  while  retaining  vector  activity  (Segura  et  al.,  2013).  
Impurities may be product-related, e.g. non-functional vector particles; or process-related, such 
as those derived from the culture medium, production process (e.g. transfection reagents) and 
host  cells,  or  extractables  and  leachables  derived  from  the  application  of  single-use 
technologies  during  either  upstream  or  downstream  processing  steps  (Segura  et  al.,  2013).  
Published protocols that have been utilised to prepare material for early Phase clinical trials are 
presented in Table 1.10.  The unit operations employed varied slightly in each instance, as did 
the order in which they were performed; however the overall approach was not dissimilar. 
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Table 1.10  Published  downstream  processing  protocols  used  for  the  large-scale 
preparation of GMP-compliant clinical-grade lentiviral vectors.  The specific product to which 
each protocol relates was outlined earlier (Table 1.7).  Both original (left column) and improved 
(right  column)  downstream  approaches  reported  by  VIRxSYS  (Slepushkin  et  al.,  2003)  are 
given.  TU is an abbreviation for ‘transducing units’ and  IG is an abbreviation for ‘infectious 
genomes’. 
Institute / 
company  VIRxSYS  Oxford 
BioMedica  Généthon 
Beckman 
Research 
Institute 
Reference  Slepushkin et al. (2003); Lu et al. 
(2004); Schweizer and Merten (2010) 
Schweizer and 
Merten (2010); 
Stewart et al. 
(2011) 
Merten et al. 
(2011) 
Ausubel et al. 
(2012) 
Process steps 
Clarification 
(filtration using 
decreasing pore 
size to 0.22 µm) 
Clarification 
(filtration using 
decreasing pore 
size to 0.22 µm) 
Clarification (1.2 
µm to 0.45 µm 
filtration) 
Clarification (0.8 
µm to 0.45 µm 
filtration) 
Clarification 
(0.45 µm or 0.5 
µm filtration) 
Concentration 
(ultrafiltration) + 
buffer exchange 
(diafiltration) 
Purification 
(anion exchange 
chromatography) 
Nucleic acid 
digestion 
(Benzonase
®) 
Nucleic acid 
digestion 
(Benzonase
®) 
Nucleic acid 
digestion 
(Benzonase
®) 
Nucleic acid 
digestion 
(Benzonase
®) 
Concentration 
(ultrafiltration) + 
buffer exchange 
(diafiltration) 
Purification 
(anion exchange 
chromatography) 
Purification 
(anion exchange 
chromatography) 
Concentration 
(ultrafiltration) + 
buffer 
exchange 
(diafiltration) 
Polishing (size 
exclusion 
chromatography) 
Nucleic acid 
digestion 
(Benzonase
®) 
Concentration 
(ultrafiltration) + 
buffer exchange 
(diafiltration) 
Concentration 
(ultrafiltration) 
Concentration 
(centrifugation) 
Sterilisation 
(0.22 µm 
filtration) 
Buffer exchange 
(diafiltration) 
Sterilisation (0.2 
µm filtration) 
Polishing (size 
exclusion 
chromatography) 
+ buffer 
exchange  
 
 
Sterilisation 
(0.22 µm 
filtration) 
Concentration 
(ultrafiltration) 
Sterilisation 
(0.22 µm 
filtration) 
 
Concentration 
factor (x)  30-40  20  2000  200  209-357 
Recovery (%)  30  30  30-40  13  31 
Final titre  3.3 x 10
8 TU mL
-1  2.2 x 10
8 TU mL
-1  0.1-2.0 x 10
9 TU 
mL
-1  ≥ 1 x 10
9 IG mL
-1  0.5-3.0 x 10
8 
TU mL
-1 
Clarification of crude harvests to eliminate cells and cellular debris is achieved at large-scale by 
microfiltration, where the supernatant is commonly passed through several filters of decreasing 
pore size to minimise membrane fouling.  The smallest pore size typically used at this stage is 
0.45 µm (Merten et al., 2011; Stewart et al., 2011; Ausubel et al., 2012; Bandeira et al., 2012; 
Yang et al., 2012), or 0.2/0.22 µm (Slepushkin et al., 2003; Lu et al., 2004).  Material for early 
Phase clinical trials is subjected to Benzonase
® (Sigma-Aldrich) treatment to digest unwanted 
nucleic  acids  (Slepushkin  et  al.,  2003;  Ansorge  et  al.,  2010;  Schweizer  and  Merten,  2010; 
Merten et al., 2011; Stewart et al., 2011; Ausubel et al., 2012).   58 
 
 
After initial harvest and clarification of the vector using membrane filtration, further purification 
has  been  most  commonly  achieved  by  anion  exchange  chromatography,  which  exploits  the 
negative charge of lentiviral vectors (Slepushkin et al., 2003; Ansorge et al., 2010; Schweizer 
and Merten, 2010; Lesch et al., 2011; Merten et al., 2011; Stewart et al., 2011; Zimmermann et 
al., 2011), while their large size has also supported the use size exclusion chromatography as a 
polishing step (Slepushkin et al., 2003; Merten et al., 2011).  For the preparation of early clinical 
material,  purification  by  anion  exchange  chromatography  has  generally  preceded  vector 
concentration (Table 1.10), perhaps so that co-concentration of impurities may be minimised, 
however when moving to commercial scale the practicability and cost of purifying such large 
feed volumes requires consideration.  To concentrate lentiviral vectors, centrifugation has been 
used to prepare early clinical material (Ausubel et al., 2012), although this method is generally 
not considered scalable (Segura et al., 2006; Ansorge et al., 2010; Segura et al., 2013).  At 
large-scale,  ultrafiltration  is  more  commonly  used,  with  tangential  flow  filtration  being  the 
preferred method (Slepushkin et al., 2003; Geraerts et al., 2005; Schweizer and Merten, 2010; 
Cooper et al., 2011; Merten et al., 2011; Stewart et al., 2011).  Ultrafiltration may be combined 
with diafiltration for buffer exchange (Slepushkin et al., 2003; Lu et al., 2004; Cooper et al., 
2011; Stewart et al., 2011; Ausubel et al., 2012).  Finally, downstream processing of clinical 
material usually concludes with sterile filtration, using a pore size of 0.2 or 0.22 µm (Slepushkin 
et al., 2003; Merten et al., 2011; Stewart et al., 2011), although one group has reported omitting 
this step (Ausubel et al., 2012), presumably to mitigate losses of functional vector.  One protocol 
included  an  ultrafiltration  step  after  sterile  filtration,  for  the  further  concentration  of  lentiviral 
vectors (Stewart et al., 2011).   
Little data has been published regarding the final formulation of lentiviral vectors.  For clinical 
material, this has been described in two instances, in one case a protein-containing medium 
required for ex vivo delivery of the lentiviral vector was used (Merten et al., 2011) while in the 
other phosphate buffered saline (PBS) supplemented with lactose was utilised (Ausubel et al., 
2012).   Lentiviral vectors are usually stored at -80 °C to prevent thermal inactivation (Schweizer 
and Merten, 2010; Segura et al., 2013).  Following downstream processing of clinical-grade 
material, recoveries were typically only 13 - 40 %, although 20 to 2000-fold concentration was 
achieved and final yields of at least 1 x 10
8 TU mL
-1 attained (Table 1.10). 59 
 
 
1.4.4  Assays to quantify lentiviral vectors 
At  various stages of the  manufacturing process, it  is desirable to  evaluate the quantity and 
quality of lentiviral vector stocks.  To achieve this various assays have been developed, which 
have been reviewed in depth by Delenda and Gaillard (2005), and more recently in brief by 
Ansorge et al. (2010).  Those techniques most commonly employed are outlined here.  Methods 
that directly measure vector components within supernatants are typically the fastest to perform.  
Such  assays  typically  quantify  either:  (i)  viral  RNA  by  one-step  reverse  transcriptase  (RT) 
quantitative PCR (RT qPCR) (Rohll et al., 2002; Sastry et al., 2002; Lizée et al., 2003; Geraerts 
et al., 2006), (ii) RT activity using the product enhanced reverse transcriptase (PERT) method 
(Rohll et al., 2002), or (iii) the p24 CA protein of HIV-1 using an enzyme-linked immunosorbent 
assay (ELISA) (Geraerts et al., 2006).  These techniques do not discriminate between functional 
(active) and non-functional (inactive) lentiviral particles, but are used to assess total particle 
numbers.  They are primarily employed during early process development studies or are utilised 
in conjunction with functional titre assays to assess the overall quality of lentiviral vector stocks 
(Segura et al., 2006; Ansorge et al., 2010). 
Functional  titre  assays  are  conducted  after  the  transduction  of  target  cells.    Transduction 
efficiency is cell line dependent (Ikeda et al., 2002).  For example, HEK293 were found to be 
superior  to  HeLa  (human  cervical  carcinoma)  and  Mus  dunni  (murine  fibroblast)  cell  lines 
(Sastry et al., 2002), but inferior to NIH 3T3 (murine embryonic fibroblast), HEK293T and FRL 
19 (rat liver carcinoma) cell lines (Zhang et al., 2004).  Zhang et al. (2004) also reported that the 
number  of  target  cells,  volume  of  vector,  vector  stability  and  adsorption  period  impacts  on 
transduction efficiencies, and varying these parameters (as well as the cell type) caused more 
than 50-fold differences in titre.  Using controlled transduction conditions is clearly important if 
results  from  different  assays  are  to  be  meaningfully  compared.    Unfortunately  no  single 
procedure,  or  even  assay  standard,  is  widely  used,  making  it  difficult  to  compare  results 
published  by  different  groups.  Following  the  transduction  of  target  cells,  the  following 
parameters are commonly quantified (i) proviral DNA by qPCR (Rohll et al., 2002; Sastry et al., 
2002;  Lizée  et  al.,  2003),  (ii)  cellular  mRNA  using  one-step  RT  qPCR  (Lizée  et  al.,  2003; 
Geraerts  et  al.,  2006),  or  (iii)  expression  of  a  target  protein  or  reporter  gene,  e.g.  cells 60 
 
 
expressing GFP are enumerated using flow cytometry (Sastry et al., 2002; Lizée et al., 2003; 
Geraerts et al., 2006). 
Assays other than those described here may be used to qualify the safety of lentiviral vector 
batches for clinical release (e.g. to demonstrate a lack of RCL, minimal levels of endotoxin etc.).  
These assays are not commonly performed during bioprocess development studies, and will not 
be covered here.  Up-to-date information on this topic maybe found in the recent review by 
Segura et al. (2013).   
1.4.5  Challenges in the development of an industrially viable bioprocess for ProSavin
® 
ProSavin
® is a lentiviral vector engineered for treatment of Parkinson’s disease, for which Phase 
I/II  clinical  trials  have  been  successfully  completed  (Section  1.3.3).    These  trials  required 
relatively  small  amounts  of  vector  material,  which  was  generated  by  transiently  transfecting 
adherent monolayers of HEK293T with three plasmids (an overview of the process is provided 
in Table 1.7).  However, for Phase III clinical trials and beyond, the use of stable producer cells 
that are amenable to growth in suspension is highly desirable (Sections 1.4.1 and 1.4.2).  As a 
first step towards this goal, two tet-ON inducible stable ProSavin
® producer cell lines that yield 
comparable titres to the standard HEK293T transfection protocol have been developed (Stewart 
et al., 2009; 2011).  One of these cell lines, termed PS46.2, was successfully adapted to growth 
in suspension (Stevenson et al., 2009).  However, while PS46.2 yields titres of 4.4 x 10
5 TU mL
-
1 when cultured adherently (Stewart et al., 2009), in suspension mode titres were diminished 5- 
to 20- fold (K. Mitrophanous, pers. comm.).  The reason for this drop in titre is unknown: cell 
aggregation  in  suspension  cultures  (Merten  et  al.,  2001),  changes  in  the  morphology  and 
membrane properties of producer cells during suspension adaption (Ansorge et al., 2010), and 
non-optimised culture conditions (Segura et al., 2013) may all play a role in reducing titres.  For 
clinical applications, crude titres of at least 2 x 10
5 TU mL
-1, equalling those attained using the 
current  HEK293T  transfection  protocol  (Schweizer  and  Merten,  2010),  are  required.  
Compensating  for  lower  crude  titres  by  altering  the  downstream  process  is  both  unfeasible 
(supernatants are already concentrated 2000-fold in two ultrafiltration steps, see Table 1.10) 
and undesirable, as the final product would comprise a greater proportion of impurities.  Thus at 
present, use of suspension-adapted PS46.2 is not a viable option for the future manufacture of 61 
 
 
ProSavin
®.  Lack  of  a  scalable  upstream  process  for  ProSavin
®  could  impede  its  future 
commercialisation.  It is therefore vital that this issue is addressed.  As a first step, a better 
understanding of the factors influencing lentiviral vector yields from suspension cultures of HEK-
derived producer cells is required.  As outlined below, this can most rapidly be achieved using a 
combination  of  microscale  experimentation  and  statistical  Design  of  Experiments  (DoE) 
techniques.  
1.5  Approaches to upstream process development  
A wide range of parameters may affect lentiviral vector production from suspension-adapted 
producer  cells.    In  order  to  characterise  their  various  effects,  numerous  experiments  are 
required.  A rational approach combining microscale bioprocessing and DoE techniques can 
simplify this process by enabling rapid, low-cost, parallel, multi-parameter experimentation.  The 
utility of such an approach has been demonstrated for the optimisation of protein expression 
from microbial cultures (Islam et al., 2007; Holmes et al., 2009).  It was recently hypothesised 
that application of DoE to lentiviral vector systems would yield more efficient bioprocesses and 
better characterised products (Segura et al., 2013) however, to the best of my knowledge no 
studies have employed this methodology, or tested the value of a microscale platform, to date.  
This section provides an overview of currently available small-scale culture systems and gives 
an introduction to DoE techniques, with a view to their application for the characterisation of 
lentiviral vector production from suspension-adapted producer cells.  As these tools are only 
useful  if  they  generate  data  that  is  relevant  upon  scale-up  to  larger  vessels,  the  section 
concludes by considering which criteria may be appropriate for scale translation.     
1.5.1  Small-scale culture systems 
Microscale bioprocessing enables numerous parameters to be characterised rapidly in parallel 
and at low cost (Kumar et al., 2004; Micheletti and Lye, 2006; Lye et al., 2009; Marques et al., 
2010; Neubauer et al., 2013).  Shake flasks, with fill volumes of  10 - 500 mL, are the classic 
small-scale culture vessel, having been employed in process development studies for over fifty 
years (Betts and Baganz, 2006).  Shake flasks are cheap and simple to use, requiring only an 
orbital  shaking  platform  for  their  operation  (Büchs,  2001a;  Kumar  et  al.,  2004).    Oxygen 
limitation is the most commonly cited problem when using shake flasks for microbial cultures 62 
 
 
(Büchs, 2001a), however this is not generally a concern for mammalian cell cultures, whose 
oxygen demands are considerably lower (Micheletti et al., 2006).  Shake flasks are not typically 
instrumented (Kumar et al., 2004), thus fermentation parameters are not monitored or controlled 
as they would be at large-scale leading to an absence of quantitative data (Neubauer et al., 
2013).  Another drawback of shake flasks is their bulkiness, for example just twelve 250 mL 
flasks (50 mL typical working volume) will fit on a standard IKA KS 260 (Sigma-Aldrich) shaking 
platform (own observations).  Their geometry also makes them unsuited to automation (Lye et 
al., 2003), thus overall their utility for high throughput experimentation is somewhat limited.   
Like shake flasks, orbitally shaken microwell plates are also low-cost and easy to use, however 
they  require  less  space  and  culture  materials,  and  are  amenable  to  automation;  thus  they 
facilitate a greater degree of parallelisation (Kumar et al., 2004; Neubauer et al., 2013).  Plates 
with 6, 12, 24 or 96 wells operating with a fill volume of 20 - 2000 µL are most commonly 
employed  (Lye  et  al.,  2003;  Micheletti  and  Lye,  2006).    A  range  of  well  geometries  and 
construction materials are available (Lye et al., 2003; Betts and Baganz, 2006).  Although plates 
are generally produced in plastic (thus are single-use), glass and metal formats also exist (Lye 
et  al.,  2003; Betts  and  Baganz,  2006).  Like  shake  flasks,  microwell  plates  rely  on  surface 
aeration therefore have a limited oxygen transfer capacity (Betts and Baganz, 2006).  However, 
the highest oxygen mass transfer coefficient (kLa) value reported for shaken plates is 792 hr
-1 
(Micheletti and Lye, 2006), which should support most microbial cultures, including yeast and 
Escherichia coli for example, whose typical kLa requirements are reported as 200 - 400 hr
-1 
(Bareither and Pollard, 2011).  For mammalian cells, a kLa of just 1 hr
-1 is generally thought 
sufficient to support the oxygen demand of 10
6 - 10
7 cells mL
-1 (Barrett et al., 2010; Bareither 
and Pollard, 2011).  Consequently, oxygen limitation is unlikely to be a concern when using 
shaken  microwells  to  culture  mammalian  cells.    Perhaps  not  surprisingly  therefore,  shaken 
microwells have so far been successfully applied to the cultivation of HEK293, Chinese hamster 
ovary (CHO), and murine hybridoma cell lines  (Girard et al., 2001; Deshpande et al., 2004; 
Davies et al., 2005; Micheletti et al., 2006; Barrett et al., 2010; Silk et al., 2010).  Like shake 
flasks,  microwell  plates  are  not  commonly  instrumented,  although  versions  with  integrated 
sensors for pH measurements (Weiss et al., 2002; Elmahdi et al., 2003) and dissolved oxygen 
readings (Stitt et al., 2002; John et al., 2003; Deshpande et al., 2004) have been developed.  63 
 
 
PreSens Precision Sensing GmBH have also created a set of non-invasive optical sensor spots 
for  pH,  oxygen  and  carbon  dioxide  monitoring  which  can  be  applied  to  most  microwell 
geometries.  A  drawback  of  using  microwell  plates  is  the  risk  of  cross-contamination  from 
aerosols formed at fast shaking speeds (Kumar et al., 2004), however this is more of an issue 
for microbial systems that require high agitation rates to maintain  adequate oxygen transfer.  
For mammalian cells, which are relatively much slower growing, cultures can last for several 
days and evaporation instead becomes a concern (Girard et al., 2001; Deshpande et al., 2004).  
However,  this  can  largely  be  overcome  by  using  a  humidified  incubator  (Deshpande  et  al., 
2004) and a suitable plate cover (Micheletti et al., 2006; Barrett et al., 2010; Silk et al., 2010), by 
filling  the  intersections  of  wells  with  sterile  water  (Girard  et  al.,  2001),  and  by  feeding  the 
cultures with additional water (Deshpande et al., 2004) or medium (Silk et al., 2010).   
Minibioreactors, which are essentially small replicas of conventional stirred bioreactors, have 
been developed as an alternative to shaken systems for early bioprocess development studies 
(Kumar et al., 2004; Betts and Baganz, 2006; Bareither and Pollard, 2011).  These systems 
typically have a capacity of 50 - 300 mL, and allow temperature, pH, and dissolved oxygen to be 
monitored and controlled (Kumar et al., 2004).  As they are similar to stirred bioreactors in terms 
of  their  geometry  and  means  of  aeration  and  agitation,  scale-up  should  be  relatively 
straightforward (Kim et al., 2012).  Minibioreactors were initially developed for microbial cultures 
(Kostov  et  al.,  2001;  Lamping  et  al.,  2003;  Zanzotto  et  al.,  2004),  and  applications  to 
mammalian  cell  culture  are  somewhat  lagging  (Ge  et  al.,  2006).  Although  several 
commercialised  platforms  are  available,  for  example  the  ambr
TM  micro  bioreactor  from  TAP 
Biosystems and the Micro-24 MicroReactor from Pall Corporation, the exorbitantly high cost of 
these systems, and their lack of utility for high-throughput experimentation (Kumar et al., 2004), 
has likely limited uptake in this area. 
1.5.2  Design of Experiments (DoE) 
One-factor-at-a-time (OFAT) experiments, in which a single factor is varied while all others are 
fixed, are all too commonly employed when developing and optimising manufacturing processes 
(Czitrom,  1999).  An  OFAT  approach  entails  numerous  experiments,  but  generates  little 
information about the system under investigation (Tye, 2004). The approach assumes that all 64 
 
 
factors independently influence the measured response, thus the optimal setting for one factor 
stays constant regardless of variations in the other factor settings (Islam et al., 2007).  With 
regards to complex biological systems, this presumption is likely over-simplistic, and as a result 
the  true  optimal  operating  conditions  may  fail  to  be  identified  (Islam  et  al.,  2007).  Multi-
parameter  experimentation  using  a  structured  DoE  approach,  on  the  other  hand,  generates 
more precise information from a smaller set of experiments that are linked in a rational manner 
(Tye, 2004).  The fundamental advantages of undertaking a DoE approach, as compared to 
OFAT experimentation, are that it: (i) is less resource-intensive, (ii) more precisely estimates the 
impact of each factor, (iii) accounts for factor interactions, and (iv) generates experimental data 
for a larger region of the design space (Czitrom, 1999).   
The first stage in implementing DoE is to define the experimental objective (Figure 1.4; Eriksson 
et al. (2008)).  For early stage bioprocess development studies  this will likely be screening, 
initially, to identify the key parameters impacting on product quality, followed by optimisation to 
further characterise the precise effect of those parameters and ascertain their optimum levels - 
the  outcome  of  which  should  inform  subsequent  scale-up.  Decisions  made  throughout  the 
succeeding steps of the DoE process (outlined in Figure 1.5) are largely governed by the choice 
of experimental objective.  Once the objective has been defined the factors to be investigated 
should be specified and given an experimental range, and responses chosen (e.g. for lentiviral 
vectors this would likely include titre).  A regression model, based on either a linear, interaction 
or quadratic polynomial model, is next selected and a design generated according to the choice 
of  model.    Most  commonly,  regularly  arranged  factorial  or  central  composite  designs  are 
employed (Eriksson et al., 2008).  Factorial designs comprise two levels per factor, thus can 
only  support  linear  and  interaction  models,  limiting  their  application  to  screening;  central 
composite designs, on the other hand, can support quadratic models as each factor is explored 
over three or five levels, making them suitable for optimisation (Eriksson et al., 2008).  The final 
step prior to data collection is the generation of a worksheet that details the specific factor levels 
to be employed during individual experimental runs.  
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Figure 1.4  Experimental  objectives  used  to  direct  Design  of  Experiments  (DoE).    A 
familiarisation study is usually only performed if researchers are confronted with an entirely new 
experimental system - minimal resources are expended to determine what is experimentally 
feasible.  Screening experiments examine many factors in little depth, the objective being to 
discover which factors are most influential and their approximate optimum ranges. Occasionally 
this is followed by a second experiment to locate the optimal region, if the optimum did not 
seem to be contained within the experimental region explored during screening.  Optimisation 
experiments are conducted to gain detailed information about the relationship between a few 
critical factors and the measured response, and to identify optimum settings for these factors.  
Robustness testing is commonly only carried out before a product or process is released, the 
aim being to uncover all parameters that may influence the result and regulate them such that 
the  outcome  remains  within  specifications.    Mechanistic  modelling  is  only  relevant  if  a 
theoretical model is to be established.  Information derived from Eriksson et al. (2008).   
 
Figure 1.5  Common stages of DoE.  Information derived from Eriksson et al. (2008). 
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Once the raw data has been collected, it should be evaluated to determine its suitability for 
regression  analysis-  a  range  of  plots  are  available  to  help  at  this  stage  (Anderson  and 
Whitcomb, 2007; Eriksson et al., 2008).  Of particular utility are the ‘Normal’ plot and ‘Box-Cox’ 
plot,  which  reveal  if  response  data  is  approximately  normally  distributed  and,  if  not,  which 
transformation should be applied (Anderson and Whitcomb, 2007).  Once satisfied that the data 
is suitable for further analysis, regression analysis can be carried out.  The ‘goodness of fit’ and 
ANOVA statistics should subsequently be scrutinised.  The ‘goodness of fit’ statistics comprise 
the adjusted R
2 (adjR
2) and predicted R
2 (predR
2) values, which together indicate how well the 
regression model fits the experimental data (Eriksson et al., 2008).  The adjR
2 (which has a 
value between zero and one) and the predR
2 (which may be any value from minus infinity to 
one) indicate the proportion of the response variation explained and predicted by the model, 
respectively  (Islam  et  al.,  2007;  Eriksson  et  al.,  2008).  The  model  fit  is  generally  thought 
adequate if both values are high (for predR
2 ≥ 0.5 is good, while ≥ 0.9 is excellent) and ideally 
not separated by a value of more than 0.3, although the limits deemed acceptable will obviously 
vary depending on the application (Eriksson et al., 2008).  The ANOVA statistics are used to 
determine if a given model is significant, and whether it is valid based on a comparison between 
the calculated replicate error and model error - low model error is desired and is denoted by a 
‘lack of fit’ p value that is above 0.05 (Anderson and Whitcomb, 2007; Eriksson et al., 2008).  If 
a model contains irrelevant terms, i.e. terms which do not significantly impact on the response, it 
is logical to explore the consequence of removing these, as refining the model in this way can 
improve the ‘goodness of fit’ (Eriksson et al., 2008).  The final step is to use the model.  If the 
objective was screening, plotting the regression coefficients (with  95 % confidence intervals) 
can  aid  quick  identification  of  those  factors  exerting  the  greatest  impact  on  the  measured 
response; if the objective was optimisation, a response surface plot can be useful for locating 
the optimal operating region (Islam et al., 2007).  The DoE approach specifically employed in 
this research project is described further in Chapter 2. 
Finally, it is worth recognising the difficulties in applying DoE techniques to complex biological 
systems. The presence of uncontrolled factors or mechanisms can lead to high model error 
(Islam et al., 2007), while variability between replicate response measurements can cause high 
experimental  error,  both  of  which  can  contribute  to  a  poor  fitting  model.  Indeed,  reducing 67 
 
 
variability (rather than increasing yield) may in fact be  the main goal of optimisation studies 
when using biological systems (Tye, 2004).  The occurrence of interactions between controlled 
factors can also compromise the accuracy of a model if not accounted for due to limitations in 
the chosen design (fractional factorial designs, for example, do not support the analysis of factor 
interactions). 
1.5.3  Criteria for scale translation  
Microscale cell culture systems can only support the rapid  development and  optimisation  of 
bioprocesses if the data they generate is reliably scalable (Micheletti et al., 2006; Marques et 
al.,  2010).   Although scale-up studies  are therefore critical if a microscale platform is to be 
considered of any worth, surprisingly little has been published on the subject (Micheletti et al., 
2006).  This is probably because no straightforward or universal strategy exists for tackling the 
matter (Betts and Baganz, 2006; Marques et al., 2010).  For every new system, key process 
parameters likely to affect product quality need timely identification and characterisation (Betts 
and Baganz, 2006; Marques et al., 2010).  Those conditions producing optimum results in the 
small-scale  vessel  should  be  maintained  as  far  as  possible  during  scale-up  (Doran,  1995; 
Marques et al., 2010).  Biological and chemical parameters (such as cell density, concentration 
of inducer compounds etc.) are often relatively straightforward to preserve at constant levels.  
Replicating the physical culture environment presents a much greater challenge, however, and 
to achieve successful scale-up an understanding the mass transfer and fluid mixing properties 
of both the small- and large-scale vessels is critical.  To date, scale-up from flasks, microwells 
or  minibioreactors  has  been  most  often  performed  on  the  basis  of  matched  oxygen  mass 
transfer coefficient (kLa) values for microbial systems (Marques et al., 2010), while mean energy 
dissipation rates (power per unit volume; P/V) or mixing times have been used as scale-up 
criteria for mammalian cell cultures (Micheletti et al., 2006; Barrett et al., 2010; Gill et al., 2011).  
Early scale translation studies have focused on shifting  bacterial processes into stirred tank 
bioreactors.  For this application, kLa has proven to be the most appropriate scaling criterion 
(Kostov et al., 2001; Micheletti et al., 2006; Gill et al., 2008; Islam et al., 2008; Zhang et al., 
2008; Marques et al., 2009).  Broadly, kLa describes the capacity of a culture vessel to deliver 
oxygen to cells (Doran, 1995).  Specifically, it characterises the transfer of oxygen from gas to 68 
 
 
liquid, the driving force being the gradient between the oxygen concentration at the gas-liquid 
interface and the average oxygen concentration in the bulk liquid (Garcia-Ochoa and Gomez, 
2009).    kLa  is  affected  by  both  gas  solubility  (which  in  turn  is  influenced  by  temperature, 
pressure, media composition, and chemical reactions) and the metabolic activity of the cells, 
and  may be determined experimentally or estimated using empirical correlations - the former 
method being generally deemed the most accurate (Garcia-Ochoa and Gomez, 2009).  kLa is 
likely the most useful scaling criterion for bacterial processes because the oxygen uptake rate 
for bacterial cells is extremely high – around 0.46 - 2.33 x 10
-3 g cell
-1 hr
-1 (Micheletti et al., 
2006) – and maintaining a ready supply of dissolved oxygen is therefore crucial to avoid sub-
optimal oxygen limited conditions (Marques et al., 2010).   
Unlike bacteria, the oxygen uptake rate for mammalian cells  is several orders of magnitude 
lower  –  approximately  1  -  10  x  10
-12  g  cell
-1  hr
-1  –  thus  oxygen  transfer  is  not  commonly 
considered a limiting factor for cell growth (Micheletti et al., 2006).  Use of kLa as a scaling 
factor for mammalian cell cultures is therefore less appropriate.  As mammalian cells lack a cell 
wall and are consequently more sensitive to shear forces than bacteria (Kretzmer and Schügerl, 
1991),  the  hydrodynamic  forces  within  the  culture  vessel  instead  require  important 
consideration.  Shear sensitivity is governed by cell type, the extent of vorticity around the cell, 
the proximity of the cell to solid-liquid and gas-liquid interfaces (bubbles rising through the liquid 
and  bursting  at  the  surface  can  contribute  to  cell  damage),  and  local  hydrodynamic  energy 
dissipation (Doran, 1995; Heath and Kiss, 2007).  Owing to its direct relation to shear rate, 
energy  dissipation  rate,  or  P/V,  has  been  evaluated  as  a  criterion  for  scale-up  of  antibody 
production processes based on murine hybridoma cell cultures (Micheletti et al., 2006; Barrett et 
al., 2010).  The average P/V in this instance was determined for microwells using computational 
fluid dynamics (CFD) simulations, for shake flasks using the correlation of Büchs et al. (2000a), 
and for a stirred bioreactor by direct measurement of the impeller power number (Barrett et al., 
2010).  Microwell and shake flask fermentations were subsequently performed based on an 
average P/V value of 40 W m
-3, however a lower average P/V value of 3.64 or 8 W m
-3 had to 
be accepted for stirred bioreactor fermentations (Micheletti et al., 2006; Barrett et al., 2010).  
Although operation of the stirred bioreactor at matched P/V was desired, it was unfeasible due 
to the  high  impeller speed required to  attain the  average  value  of 40 W m
-3 - when trialled 69 
 
 
excessive  foaming  had  resulted  (Barrett  et  al.,  2010).  Nevertheless,  despite  the  lower  P/V 
values  in  the  stirred  bioreactor,  similar  cell  growth  and  antibody  production  kinetics  were 
observed for all three vessel types (Micheletti et al., 2006; Barrett et al., 2010).  However, as the 
P/V  in  the  stirred  bioreactor  could  not  be  matched  to  that  of  the  microwell  or  shake  flask, 
Micheletti et al. (2006) concluded that P/V was useful as a basis of scale translation between 
shaken vessels only.  It is worth noting that most cell damage in stirred bioreactors is highly 
localised around the impeller zone, therefore an impeller zone P/V (rather than average P/V) 
may be useful in the future for scale-up between stirred vessels. 
Scale-up from shaken vessels to a WAVE bioreactor based on matched P/V could be feasible, 
although this has not been trialled.  The average P/V for a 2 L WAVE bioreactor, calculated 
from film sequences that had been analysed using Computer Aided Design (CAD), was recently 
reported to be between 8 and 561 W m
-3, depending on the fill volume and rocking conditions 
used  (Eibl  et  al.,  2010b).    It  is  therefore  conceivable  that  the  average  P/V  associated  with 
optimal  culture  conditions  in  small  shaken  vessels  may  be  replicated  in  a  WAVE  system, 
although  the  same  degree  of  hydrodynamic  stress,  or  cell  culture  performance  would  not 
necessarily be guaranteed.  The mode of mixing differs markedly between small shaken vessels 
and wave-mixed systems, leading to different local and temporal energy dissipation rates.  For 
example, Barrett et al. (2010) reported a maximum local P/V of 2 kW m
-3 (observed at the gas-
liquid  interface)  for  microwells  operating  under  standard  cell  culture  conditions.    For  a  2  L 
WAVE bioreactor (with 1 L fill volume), CFD simulations revealed that during a single rock the 
average  P/V  value  peaks  and  drops  two  or  four  times,  fluctuating  between  zero  and 
approximately double the overall average (Eibl et al., 2009).  Knowledge of the maximum P/V 
likely to be encountered within a vessel is important, as high values may compromise culture 
performance.    For  example,  a  value  of  1  kW  m
-3  was  found  to  detach  CHO  cells  from 
microcarriers, while values in the range of 1000 kW m
-3 produced a cessation in cell growth and 
gradual  decline in cell  viability (Heath and  Kiss, 2007).   Cell types  obviously  differ in their 
susceptibility to shear damage, however, but of note is the fact that clusters of cells, along with 
cells attached to microcarriers, are likely to be most vulnerable (Mollet et al., 2004).    
Interestingly, although the feasibility of P/V as a basis for scale-up into WAVE bioreactors has 
not been tested, scale-up from microwells to a WAVE system has been successfully performed 70 
 
 
on the basis of mixing time (Gill et al., 2011).  Mixing time may be defined as: “the time required 
to  achieve  a  given  degree  of  homogeneity  starting  from  the  completely  segregated  state” 
(Doran, 1995, p. 147).  Mixing time may be considered a function of P/V, as to decrease mixing 
time an increase in P/V is usually required.  It is often measured by the addition of sodium 
thiosulphate to an iodine solution under standard vessel fill volume and agitation conditions - the 
time taken for complete (or near complete) decolourisation to occur is then recorded (Nienow et 
al., 1996).  Mixing time may thus be assessed relatively simply regardless of the geometry or 
instrumentation  capabilities  of  a  particular  vessel.    In  this  sense  it  is  therefore  an  attractive 
scaling  parameter,  however  it  has  rarely  been  employed  as  such  for  stirred  bioreactors,  as 
maintaining  a  constant  mixing  time  when  transferring  the  process  to  larger  vessels  would 
demand a considerable increase in P/V, which could not feasibly be realised with most stirring 
equipment (Doran, 1995).  In the study by Gill et al. (2011), an antibody production process 
based  on  CHO  cell  culture  was  successfully  scaled  from  a  shaken  microwell  to  a  WAVE 
bioreactor using a relatively fast mixing time of around 5 s.  Mixing time could therefore be a 
useful basis of scale translation between small shaken vessels and wave-mixed systems. 
Dimensionless numbers, although not useable as scaling parameters in themselves, can also 
provide insight into the mixing environment within small scale culture vessels, which in turn can 
inform the choice of operating conditions during scale-up.  Particularly useful are the Reynolds 
number  (Re),  Froude  number  (Fr)  and  Phase  number  (Ph).  Re  is  a  parameter  that 
characterises  the  relative  importance  of  inertial  and  viscous  effects,  and  can  be  used  to 
determine whether fluid flow is laminar, creating a non-homogenous environment, or turbulent, 
creating  a  well-mixed  environment  (Happel  and  Brenner,  1983;  Doran,  1995).    Re  can  be 
calculated for shaken systems using the equation of Büchs et al. (2000b), although only one 
study has attempted to link calculated values to observed flow regimes - in this instance for a 
24-well plate culture format (Barrett et al., 2010).  Fr is a ratio of inertial and gravitational forces 
(Doig  et  al.,  2005)  that  is  used  to  establish  the  relative  influence  of  gravity  on  fluid 
hydrodynamics.    Thus,  Fr  could  be  used  to  ascertain  whether  the  culture  environment 
encourages the settling of cells due to the influence of gravity.  When considered in conjunction 
with the Fr, Ph can be used to describe whether the bulk of a liquid in a shaken vessel is 
circulating “in-phase” with the shaking platform, or whether so-called “out-of-phase” conditions 71 
 
 
are present such that the majority of the liquid remains stationary in the centre of the vessel and 
only a minor fraction is actually rotating along the vessel wall (Büchs et al., 2001b; Barrett et al., 
2010).  Fr may be calculated for shaken systems using the equation of Büchs et al. (2000b), 
while Ph may be calculated using the equation of Büchs et al. (2001b).  Only for conditions 
where the Fr > 0.4 and the Ph > 1.26 can the influence of gravity be disregarded and “in-phase” 
operation be assumed (Büchs et al., 2000b; Barrett et al., 2010).  “In-phase” conditions are 
associated with better mixing and gas transfer.    
With regard to  lentiviral  vector process development, it is  acknowledged  that  bioreactor cell 
culture conditions may profoundly impact on titres, and optimal conditions are generally cell line 
and lentiviral vector-specific (Segura et al., 2013).  It is evident that the field would benefit from 
the development of a generic microscale platform that is suitable for the culture of suspension-
adapted HEK293-derived cell lines,  and that can be employed for the generation of  reliably 
scalable bioprocess design data.  
1.6  Thesis aims and objectives 
Despite  concerns  that  current  lentiviral  vector  manufacturing  practices,  based  on  transient 
transfection of adherent HEK293(T) cells, cannot be easily scaled to meet future commercial 
requirements, alternative production strategies based on suspension cell culture appear to have 
been little explored (Segura et al., 2007; Broussau et al., 2008; Ansorge et al., 2009; Witting et 
al., 2012).  To support the design of a simple, scalable manufacturing route for lentiviral vectors, 
the overall aim of this thesis is to establish a microwell experimental platform based on the 
suspension  culture  of  stable  producer  cell  lines  that  can  be  employed  for  the  rapid,  early 
generation  of  relevant  bioprocess  design  data.    The  approach  will  be  illustrated  using 
ProSavin
®, a lentiviral vector for treatment of Parkinson’s disease that has recently completed a 
Phase I/II clinical trial (Mitrophanous et al., 1999; Azzouz  et al., 2002; Jarraya et al., 2009; 
Stewart et al., 2009; Stewart et al., 2011; Palfi et al., 2014).  The specific objectives of this 
thesis are: 
  To  establish  microwell  methods  for  the  suspension  culture  of  HEK293T-derived 
producer cells, and to evaluate the utility of the microscale platform (in conjunction with 
statistical DoE techniques) for the rapid screening of several operating parameters to 72 
 
 
ascertain their relative impact on lentiviral vector titre.  This work is described in Chapter 
3. 
  To determine whether a DoE-guided microwell approach is efficient in optimising the 
yield and quality of lentiviral vector preparations.  This work is described in Chapter 4. 
  To  discover  whether  the  insights  gained  during  microwell  experiments  can  inform 
laboratory  scale  operation  of  a  single-use  WAVE  bioreactor  system.    This  work  is 
described in Chapter 5. 
  To  ascertain  the  half-life  of  lentiviral  vectors  under  process-relevant  conditions  and 
consider  how  this  knowledge  may  be  applied  to  further  improve  bioprocess  design.  
This work is described in Chapter 6. 
In addition, Appendix A outlines the hypothetical next steps that would be required to validate 
the production approach that is presented in Chapter 5.  Finally, Chapter 7 contains overall 
conclusions from this study and suggestions for future work. 
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2  Materials and methods 
2.1  General cell culture methods 
2.1.1  PS46.2 cell line 
A stable ProSavin
® producer cell line, PS46.2, that had previously been adapted to growth in 
suspension  was  utilised  for  the  majority  of  work  described  herein.    PS46.2  is  a  human 
embryonic kidney (HEK)293T cell line that has been stably transfected with the four plasmids 
required  to  create  a  ProSavin
®  producer  cell  line  (Stewart  et  al.,  2009;  2011).    PS46.2 
constitutively  expresses  the  vector  genome,  but  expression  of  both  packaging  components 
(vesicular stomatitis virus envelope  protein (VSV-G) and  EIAV Gag/Pol) is controlled  by the 
tetracycline  (tet)  repressor  (TetR)  regulatory  protein.    Expression  of  VSV-G  and  Gag/Pol  is 
initiated by addition of doxycycline (dox; Sigma-Aldrich, Poole, UK), an analogue of tet, to the 
culture  medium.    Adaption  of  PS46.2  to  suspension  growth  mode  was  carried  out  by  L. 
McCloskey  (Oxford  BioMedica,  Oxford,  UK)  using  a  method  of  gradual  serum  reduction  as 
described in Guy et al. (2013).  Suspension-adapted PS46.2 were kindly supplied by either L. 
McCloskey or S. Denby (Oxford BioMedica).  Cells provided by S. Denby were utilised for the 
initial shake flask and microwell studies described in Sections 3.2.1 and 3.2.2.  Cells obtained 
from L. McCloskey were used to generate working cell banks as described in Section 2.1.5; 
these stocks supplied all other suspension-based PS46.2 studies.  PS46.2 that had not been 
adapted to growth in suspension were required for the stability studies described in Chapter 6, 
these cells were kindly provided by H. Stewart (Oxford BioMedica). 
2.1.2  HEK293T cell line 
Adherent HEK293T (Stanford University, Stanford, CA, USA) were utilised for the production of 
lentiviral vectors by transient transfection (Section 2.10.3) and for titration of lentiviral vectors by 
either the rapid ProSavin
® titre assay (Section 2.11.2.1) or the DNA integration assay (Section 
2.11.2.3).    Early-passage  adherent  HEK293T  cells  were  obtained  from  the  Research/PAR 
Group  at  Oxford  BioMedica.    Suspension-adapted  HEK293T  (obtained  from  S.  Denby  and 
originally derived from the Stanford University adherent cell stock) were used for the shake flask 
versus microwell comparative study described in Section 3.2.3.   74 
 
 
2.1.3  D17 cell line 
For titration of lentiviral vectors expressing the LacZ marker gene (Section 2.11.2.2), adherent 
canine (D17) cells (ECACC, Salisbury, UK; Catalogue number: 89090403) were used.  Early-
passage D17 were obtained from the Research/PAR Group at Oxford BioMedica. 
2.1.4  Culture media 
Suspension-adapted  PS46.2  and  suspension-adapted  HEK293T  were  maintained  in 
Freestyle
TM 293 expression medium (Invitrogen, Paisley, UK) supplemented with 1 - 5 % (v/v) 
tet-free  foetal  calf  serum  (FCS;  PAA  Laboratories,  Yeovil,  UK).    Adherent  PS46.2  were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma-Aldrich) supplemented with 
2 mM L-glutamine (Sigma-Aldrich), 1 % (v/v) nonessential amino acids (Sigma-Aldrich) and 10 
%  (v/v)  tet-free  FCS.    Adherent  HEK293T  and  D17  cells  were  maintained  in  DMEM 
supplemented with 2 mM L-glutamine, 1 % (v/v) nonessential amino acids and 10 % (v/v) FCS 
(not tet-free; Lonza, Basal, Switzerland).   
Prior to use in cell culture, all FCS was heat-inactivated to reduce any complement factors and 
adventitious agents that may be present.  This was an extra precaution as FCS is  gamma-
irradiated and tested by the supplier for various adventitious agents prior to its release for cell 
culture purposes.  FCS  was heat-inactivated  in a  water bath set to  56  °C for 30 min, then 
aliquoted and stored at -20 °C until required.   
It is important to highlight that selection antibiotics were not added to the culture medium for any 
of the work described herein.  PS46.2 cells provided by L. McCloskey and H. Stewart had been 
previously cultured in the presence of the four antibiotics used for selection of PS46.2 (Stewart 
et al., 2009) to prevent loss of vector components.  However, stability of the vector components 
in the absence of selection antibiotics was demonstrated over multiple passages (up to 111 
days) for adherent PS46.2 by Stewart et al. (2011).  In addition, L. McCloskey tested functional 
vector production from suspension-adapted PS46.2 periodically over a 56 day period, and found 
titres to remain consistent over this timeframe also in the absence of antibiotic selection (Guy et 
al.,  2013).    Thus  for  the  work  described  herein,  selection  antibiotics  were  omitted  from  the 
culture medium in order to reduce process complexity.  As a precaution, PS46.2 cells were not 75 
 
 
passaged for periods longer than 56 days (inclusive of the time taken to generate cell banks as 
described in Section 2.1.5).  
2.1.5  Creation of PS46.2 cell banks  
Suspension-adapted PS46.2 that had been previously cryopreserved by L. McCloskey in culture 
medium  containing  1  or  5  %  (v/v)  tet-free  FCS  were  revived  and  expanded  using  methods 
outlined in Section 2.1.6.  After 10 days, cell banks of both the 1 % and 5 % (v/v) tet-free FCS-
containing cultures were generated.  Additionally at this stage, cells that had been expanded in 
medium supplemented with 1 % (v/v) tet-free FCS were transferred into medium containing 3 % 
(v/v) tet-free FCS and cultured for a further 10 days before also being banked.  To create cell 
banks,  cultures  with  >  90  %  cell  viability  were  transferred  into  50  mL  centrifuge  tubes  (BD 
Falcon
TM conical tubes; BD Biosciences, San José, CA, USA) and centrifuged for 5 min at 150 x 
g.  Culture supernatant was removed and cells were re-suspended at a density of 1 x 10
7 viable 
cells mL
-1 in growth medium supplemented with 10 % (v/v) dimethyl sulphoxide (DMSO; Sigma-
Aldrich).  1 mL aliquots of cell suspension were transferred into sterile Nunc
® cryovials (Fisher 
Scientific, Loughborough, UK) and stored at -85 °C in a Nalgene
® Mr Frosty
® freezing container 
(Fisher Scientific) for 5 days, after which cell stocks were transferred to -150 °C for long term 
storage.  When stocks of the 5 % (v/v) tet-free FCS-containing cell bank were low, cells from 
one  of the remaining  vials were revived and expanded for 10  days  before being banked in 
accordance with the procedures outlined above.  This cell bank demonstrated comparable cell 
growth and vector production capabilities to the preceding cell bank, when evaluated in parallel.  
All cell banks passed in-house sterility and mycoplasma testing, which was carried out by the 
laboratory management team at Oxford BioMedica. 
2.1.6  Revival of PS46.2 cell stocks and routine subculture 
For  revival  of  suspension-adapted  PS46.2,  one  cryovial  (containing  ~  1  x  10
7  cells)  was 
retrieved from -150 °C storage and quickly thawed in a 37 °C water bath; following which one of 
two protocols was used.  When reviving cells for the purpose of creating working cell banks and 
for studies described in Chapters 3, 4 and 6, the cell suspension was aseptically transferred to a 
125 mL shake flask (polycarbonate Erlenmeyer flask with vent cap; Sigma-Aldrich) and 20 mL 
pre-warmed media directly added drop-wise.  For work described in Chapter 5, cells were first 76 
 
 
aseptically transferred to a sterile 50 mL centrifuge tube, where 20 mL pre-warmed media was 
added drop-wise.  The tube was centrifuged for 5 min at 150 x g, after which the supernatant 
was  removed.    The  cell  pellet  was  resuspended  in  20  mL  pre-warmed  media  and  finally 
transferred to a 125 mL shake flask.  In the case of both revival methods, the shake flask was 
then placed inside a 36.5 °C humidified 5 % CO2 incubator on a shaking platform with 10 mm 
orbital diameter (IKA KS 260; Sigma-Aldrich) rotating at 150 rpm.  The centrifugation step was 
introduced  as  a  precautionary  measure  to  minimise  residual  DMSO  in  the  culture  medium, 
however  when  the  different  revival  methods  were  evaluated  in  parallel,  comparable  cell 
recoveries were observed.  For the maintenance of suspension-adapted PS46.2, shake flask 
cultures (250 mL polycarbonate Erlenmeyer flasks with vent caps, Sigma-Aldrich) at working 
volumes of 50 mL were routinely sub-cultured by dilution at 3 - 4 day intervals using a seeding 
density of 4 x 10
5 viable cells mL
-1.  Cultures were kept on a shaking platform with 10 mm orbital 
diameter, rotating at a rate of 150 rpm, and were incubated at 36.5 °C in a 5 % CO2 humidified 
incubator. 
For revival of adherent PS46.2, two cryovials (each containing ~ 5 x 10
6 cells) were retrieved 
from  -150  °C  storage  and  quickly  thawed  in  a  37  °C  water  bath.    Cells  were  aseptically 
transferred to a single 50 mL centrifuge tube and 25 mL pre-warmed media was added drop-
wise.  The tube was centrifuged for 5 min at 150 x g and supernatant was removed.  The cell 
pellet was resuspended in 25 mL pre-warmed media and transferred to a 75 cm
2 tissue culture 
flask (BD Falcon
TM vented flask; BD Biosciences), and incubated at 36.5 °C in a humidified 5 % 
CO2 incubator.  Adherent PS46.2 were maintained in 150 cm
2 tissue culture flasks (BD Falcon
TM 
vented flasks) containing 30 mL media, and were routinely sub-cultured at 3 - 4 day intervals 
using a seeding density of between 1.7 x 10
5 and 4.0 x 10
5 viable cells mL
-1.  To passage cells, 
the culture medium was removed and cells were washed with 10 mL phosphate buffered saline 
(PBS; Sigma-Aldrich).  4 mL TrypLE
TM Express dissociation agent (Invitrogen) was added to 
cells and the flask was incubated for 5 min at 36.5 °C to detach cells from the culture vessel.  
The dissociation agent was neutralised by addition of 6 mL media.  Cells were then diluted to 
the correct seeding density using fresh media and transferred to a new tissue culture flask.  
Cultures were kept in a 5 % CO2 humidified incubator at 36.5 °C. 77 
 
 
2.2  Evaluation of a shaken microwell system for suspension culture of 
lentiviral vector producer cells  
2.2.1  Growth kinetics and associated culture parameters for PS46.2 cultured in shake 
flasks and microwells 
The  growth  kinetics  and  culture  parameters  of  suspension-adapted  PS46.2  grown  in  shake 
flasks  versus  microwells  were  compared  (Section  3.2.1).    Triplicate  shake  flasks  (250  mL 
Erlenmeyer flasks with 50 mL working volume) and 18 wells of a microwell plate (standard 24 
round well ultra-low attachment microwell plate; Corning Inc., Oneonta, NY, USA) were seeded 
in parallel using a density of 4 x 10
5 viable cells mL
-1 in medium containing 5 % (v/v) tet-free 
FCS.  Microwells were operated with an 800 µL working volume (total well capacity is 3400 µL) 
as, based on the earlier work by Barrett et al. (2010), this was predicted to deliver an adequate 
supply of oxygen for the growth of mammalian cells.  Additionally, successful culture of both 
VPM 8 murine hybridoma (Micheletti et al., 2006; Barrett et al., 2010) and glutamine synthetase 
(GS)-CHO cell lines (Silk et al., 2010) had previously been demonstrated when using an 800 µL 
fill volume in conjunction with this particular plate design.  Microwell plates were sealed using a 
Duetz  sandwich  lid  in  conjunction  with  a  metal  clamp  (EnzyScreen  BV,  Leiden,  The 
Netherlands)  as  previously  described  (Duetz  et  al.,  2000;  Silk  et  al.,  2010).    The microwell 
system  described  here  was  subsequently  utilised  for  all  microscale  studies  included  in  this 
thesis.  Sandwich lids were sterilised by autoclaving at 121 °C for 20 min and were dried in a 
drying cabinet (this was kindly performed by a member of the laboratory management team at 
Oxford BioMedica).  Shake flasks and microwell plates were kept on an orbital shaking platform 
of  10  mm  diameter  (IKA  KS  260;  Sigma-Aldrich)  rotating  at  a  speed  of  150  or  180  rpm, 
respectively.  Cultures were maintained at 36.5 °C in a 5 % CO2 humidified incubator.  Sampling 
was conducted between 0 and 189 hr and various cell culture parameters (as listed in Sections 
2.11.1.1 to 2.11.1.4) were monitored.  To perform sampling at each time point, 1 mL culture was 
removed from each shake flask and triplicate wells of the microwell plate were sacrificed. 
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2.2.2  ProSavin
® induction and harvest in shake flasks and microwells 
ProSavin
® titres from shake flask and microwell cultures of suspension-adapted PS46.2 were 
compared (Section 3.2.2).  Shake flasks and microwell plates were initially set up as described 
in Section 2.2.1.  These cells were induced 24 hr later by addition of 1.0 µg mL
-1 dox and 10 mM 
sodium butyrate (NaBu; Sigma-Aldrich).  Vector harvests were performed 24 hr post-induction.  
To harvest vector from shake flasks, supernatants were sterile filtered using syringe filters of 
0.45 µm pore size (surfactant-free cellulose acetate membrane; Sartorius, Epsom, UK) and the 
resultant filtrate was stored in freezing vials (Sigma-Aldrich) at -80 °C.  To harvest vector from 
microwell plates, supernatants were loaded on to a Multiscreen
® HTS 96-well filter plate with 
0.45 µm pore size (surfactant-free mixed cellulose ester membrane; Millipore; Fisher Scientific) 
and centrifuged for 5 min at 2050 x g.  A 96-well U-bottom collection plate (BD Falcon
TM; BD 
Biosciences) was positioned underneath the filter plate during centrifugation.   The collection 
plate was covered with sterile SealPlate film (Anachem Ltd, Luton, UK) and stored at -80 °C.  
Titres were quantified using the rapid ProSavin
® titre assay (Section 2.11.2.1).  
2.2.3  Growth kinetics and associated culture parameters for HEK293T cells cultured in 
shake flasks and microwells 
The growth kinetics and culture parameters of suspension-adapted HEK293T cells grown in 
shake flasks versus microwells were compared (Section 3.2.3).  The set-up for this experiment 
was identical to that described for the earlier evaluative study based on the PS46.2 cell line 
(Section 2.2.1).  The only difference (other than the choice of cell line) was that the culture 
medium used in this study contained 1 %, rather than 5 %, (v/v) tet-free FCS.  
2.3  Characterisation of shake flask and microwell liquid phase mixing 
times  
The sodium thiosulphate method (Nienow et al., 1996) was used to characterise mixing times in 
a variety of vessel sizes and geometries (Section 3.2.4).  Mixing times were quantified in a 
microwell, Erlenmeyer shake flasks (125 mL, 250 mL and 500 mL sizes; Sigma-Aldrich) and an 
upright 2 L roller bottle (Corning
®; Sigma-Aldrich) whilst maintaining their characteristic working 79 
 
 
volume (0.8 mL for microwell plates; 20 % of total vessel volume for the shake flasks and roller 
bottle).   
Briefly, the vessel was filled to 99 % of the working volume with a 5 mM iodine solution (Sigma-
Aldrich), and securely mounted on an orbital shaking platform of 10 mm diameter.  A metal 
clamp stand was also mounted on the shaking platform, and positioned such that a pipette 
could be held directly over the culture vessel.  A pipette was then loaded with a volume of 1.8 M 
sodium thiosulphate (Sigma-Aldrich) that  equated to 1 % (v/v) of the  working volume.  The 
platform was then switched on, and once the desired speed was reached (140, 180, 220 or 260 
rpm for microwells; 150 rpm for the shake flasks and roller bottle), the sodium thiosulphate 
solution was dispensed into the vessel, and the time taken for complete decolourisation of the 
iodine solution recorded.  Each mixing time experiment was performed in triplicate. 
To visualise the mixing of small liquid additions made to bulk fluid within a shaken microwell 
(and reveal what would occur during cell culture e.g., during the addition of inducer compounds) 
the mixing time experiments described above were repeated using an inert food dye (Super 
Cook; Dr Oetker, Leeds, UK) in place of the sodium thiosulphate solution, and water in place of 
the iodine solution.  Images were captured at a rate of 125 frames per second using a high 
speed Photron DVR video system (Photron Ltd, Tokyo, Japan; kindly loaned by the Engineering 
and Physical Sciences Research Council [EPSRC] Engineering Instrument Pool) mounted on 
the shaking platform.  Images were obtained for shaking speeds of 140, 180 and 220 rpm, and 
a single flow visualisation experiment was performed for each condition. 
2.4  Design of Experiments (DoE) methodology applied to the ProSavin
® 
process  
2.4.1  Factorial design screening experiment 
2.4.1.1  Experimental design  
The  influence  of  various  operating  parameters  on  ProSavin
®  production  was  investigated  in 
microwell plates using a Design of Experiments (DoE) approach.  Initially, the relative impact of 
nine  factors  (Table  3.2)  on  ProSavin
®  titres  was  assessed  (Section  3.2.5).    DoE  software 80 
 
 
(Design Expert version 8; Stat-Ease, Minneapolis, MN, USA) was used to create a resolution IV 
fractional factorial design, where each factor was varied over two levels (high and low) designed 
to perturb the experimental system.  A full-factorial approach (covering all factor combinations) 
was not feasible, as this would equate to 512 experimental runs.  By employing a resolution IV 
fractional  factorial  design,  this  was  greatly  reduced  to  32  runs.    Table  3.3  shows  the 
experimental  plan  in  which  nine  factors  were  screened  in  32  experimental  runs,  plus  four 
replicated centre point experiments were conducted for estimation of pure error (see Section 
3.2.5.1).      Experimental  runs  were  carried  out  in  triplicate  using  the  microwell  platform  as 
described in Section 2.4.1.2, and titres were quantified using the rapid ProSavin
® titre assay 
(Section 2.11.2.1).   
It is important to note that, due to the requirement for different platform shaking speeds and 
diameters,  the  screening  experiment  was  completed  in  several  batches.    Batch-to-batch 
variability  is  usually  accounted  for  in  DoE  software  by  blocking  the  data  (centre  points  are 
carried out alongside each batch so software can adjust the generated model according to the 
variability  of  repeated  centre  points).    In  this  instance,  however,  centre  points  could  not  be 
carried out with every batch due to the use of a shaking platform with adjustable orbital diameter 
(i.e. centre points required a 20 mm diameter, while some runs required a 30 mm diameter; 
shaking platform was an SK-300 manufactured by Jeiotech, Seoul, Korea).  To minimise the 
likelihood  of  uncontrolled  batch-to-batch  variability  interfering  with  data  analysis  and 
interpretation, titres were normalised to (i.e. expressed as a percentage of) the titre of reference 
shake  flask  cultures  run  and  assayed  in  parallel  to  each  set  of  experiments.  Shake  flask 
procedures are described in Section 2.4.1.3.  
For statistical calculations the levels of each variable were coded as described previously (Islam 
et al., 2007), whereby the high level was coded as 1 and the low level was coded as -1.   Using 
Design Expert software, a regression model was fitted to normalised titre data.  A constant of 
0.16  was  added  to  titre  values  and  the  data  was  log  transformed  in  order  to  render  the 
distribution approximately normal.  Only main terms that were significant at the level p < 0.1 
were included in the model.   
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2.4.1.2  Microwell culture methods 
Experimental runs were carried out using microwell cultures as described in Section 2.2.2, apart 
from the following modifications: (i) to seed microwells, suspension cultures of PS46.2 were first 
centrifuged for 5 min at 150 x g, after which the supernatant was removed, enabling the cells to 
be resuspended in completely fresh medium at the required density, (ii) to harvest ProSavin
®, 
an additional centrifugation step (prior to filtration) was introduced to minimise filter clogging and 
maximise the volume of harvested vector - specifically, cultures were aliquoted into a 96-well U-
bottom plate and centrifuged for 5 min at 2050 x g, after which supernatants were loaded in to a 
96-well filter plate with 0.45 µm pore size and centrifuged for a further 5 min at 2050 x g, and (iii) 
freezing vials were used to store the collected filtrate at -80 °C.  Specific operating conditions 
were as detailed in Table 3.3 (Section 3.2.5.1). 
2.4.1.3  Reference shake flask culture methods 
Parallel to microwell experiments, ProSavin
® was produced using triplicate standard shake flask 
cultures  of  PS46.2.  Again,  this  protocol  is  a  revised  version  of  that  utilised  earlier  (Section 
2.2.2).    Here,  an  additional  centrifugation  step  was  introduced  prior  to  seeding,  which  was 
carried out as described in Section 2.4.1.2.  In addition, an extra centrifugation step (prior to 
filtration)  was  included  to  reduce  filter  clogging  during  ProSavin
®  harvests:  cultures  were 
transferred  into  50  mL  centrifuge  tubes  and  centrifuged  for  5  min  at  2050  x  g,  after  which 
supernatants  were  sterile  filtered  using  syringe  filters  of  0.45  µm  (the  resultant  filtrate  was 
transferred into freezing vials and stored at -80 °C). 
2.4.1.4  Photographs of cell aggregates 
During  the  screening  experiment  it  was  noted  that  the  cells  aggregated,  forming  distinct 
arrangements  that  seemed  dependent  on  the  cell  seeding  density,  serum  content  of  the 
medium and mixing conditions of the microwells.  To qualitatively capture this data, photographs 
were  taken  46  hr  subsequent  to  seeding  using  a  FinePix  F10  digital  camera  (Fujifilm, 
Düsseldorf, Germany) - see Section 3.2.5.2 and Figure 3.11 for details. 
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2.4.2  Three factor optimisation experiment with central composite face-centred (CCF) 
design 
A  central  composite  face-centred  (CCF)  experiment  was  conducted  to  identify  approximate 
operating ranges for post-induction period, liquid fill volume and concentration of dox (Section 
4.2.1.2).  These factors were varied over the ranges 22 - 70 hr, 600 - 1000 µL, and 1.0 - 2.6 µg 
mL
-1, respectively, while all other factors were given a fixed value (Table 4.1).  Table 4.2 shows 
the experimental plan for this experiment, in which the three factors were investigated in 20 
runs,  with  six  replicated  centre  point  experiments  included  for  estimation  of  pure  error  (see 
Section 4.2.1.2).   
Experimental runs were carried out in triplicate using the microwell platform as described in 
Section  2.4.1.2,  except  that  the  values  for  post-induction  period,  liquid  fill  volume  and 
concentration of dox were as detailed in Table 4.2, and all other operating conditions were fixed 
as detailed in Table 4.1.  Cell growth, ProSavin
® titre, and RNA copy number were quantified 
(methods described in Sections 2.11.1.1, 2.11.2.1, and 2.11.3.1), and the particle:infectivity (P:I) 
ratio was also calculated for each run, using the mean values for RNA copy number and titre 
(P:I ratio = RNA copy number / titre).  ProSavin
® titre and P:I ratio data was entered into Design 
Expert software and the behaviour of the system was modelled using a quadratic or two-factor 
interaction fit equation, respectively.  An inverse transformation was applied to titre values, and 
a log transformation was applied to P:I ratio values, in order to render the distribution of each 
data set approximately normal.  Model terms that were not significant at the level p < 0.1 were 
removed via backward elimination, starting with the least significant model terms, in order to 
maximise the resulting regression function of the model. 
ProSavin
®  was  produced  using  reference  shake  flask  cultures,  according  to  the  protocol 
outlined in Section 2.4.1.3, parallel to this experiment, for the purpose of monitoring natural 
process variation only.  It was not necessary to normalise microwell data to parallel shake flask 
data prior to analysis as was reported for the screening experiment (Section 2.4.1.1), as all 
experimental runs were carried out simultaneously as a single batch. 
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2.4.3  Further CCF experiment for two factor optimisation 
To further refine the operating ranges for post-induction period and dox concentration, a second 
CCF experiment was conducted (Section 4.2.1.3).  Post-induction period and concentration of 
dox were varied over the ranges 18 - 26 hr, and 1.0 - 5.0 µg mL
-1, respectively, while liquid fill 
volume  was  fixed  at  1000  µL  (Table  4.3).    Table  4.4  shows  the  experimental  plan  for  this 
experiment, in which the two factors were investigated in 14 runs, with six replicated centre 
point experiments included for estimation of pure error (see Section 4.2.1.3).   
Experimental runs were carried out in triplicate (simultaneously as a single batch) using the 
microwell  platform as described in Section 2.4.1.2,  except that the  values for post-induction 
period and concentration of dox were as detailed in Table 4.4, and all other operating conditions 
were fixed as detailed in Table 4.3.  The same responses were measured as during the first 
CCF experiment (Section 2.4.2).  ProSavin
® titre data was entered into Design Expert software 
and the behaviour of the system was modelled using a quadratic fit equation.  Model terms that 
were not significant at the level p < 0.1 were removed via backward elimination, starting with the 
least significant model terms.  For the purpose of monitoring natural process variability only, 
ProSavin
® was produced using reference shake flask cultures (as outlined in Section 2.4.1.3) 
parallel to this experiment.   
2.4.4  Central  composite  circumscribed  (CCC)  experiment  to  identify  the  optimal 
settings for post-induction period and liquid fill volume 
A central composite circumscribed (CCC) experiment was conducted to predict optimum factor 
settings  (Section  4.2.1.4).    Post-induction  period  and  liquid  fill  volume  were  varied  over  the 
ranges 22 - 46 hr, and 700 - 1300 µL, respectively, while dox concentration was fixed at 3.0 µg 
mL
-1 (Table 4.5).  Table 4.6 shows the experimental plan for the CCC experiment, where two 
factors were investigated in 14 runs, and six replicated centre point experiments were included 
for estimation of pure error (see Section 4.2.1.4).   
Experimental runs were carried out in triplicate  (simultaneously as a single batch)  using the 
microwell  platform as described in Section 2.4.1.2,  except that the  values for post-induction 
period and liquid fill volume were as detailed in Table 4.6, and all other operating conditions 84 
 
 
were  fixed  as  detailed  in  Table  4.5.    The  same  responses  were  measured  as  during  the 
previous  CCF  experiments  (Sections  2.4.2  and  2.4.3),  plus  culture  pH  and  metabolite 
concentrations (glucose, lactate, glutamine and ammonium) were also quantified (methodology 
as described in Sections 2.11.1.3 and 2.11.1.4).  ProSavin
® titre and P:I ratio data was entered 
into  Design  Expert  software  and  the  behaviour  of  each  was  modelled  using  a  quadratic  fit 
equation.    An  inverse  transformation  was  applied  to  titre  values,  in  order  to  render  the 
distribution approximately normal; P:I ratio data was not transformed.  No terms were excluded 
from the model for titre, as it was judged that this yielded a model which better fitted the actual 
data points when viewed as a response surface plot.  For the model generated using P:I ratio 
data, terms that were not significant at the level p < 0.1 were removed via backward elimination, 
starting with the least significant model terms.  ProSavin
® was produced using reference shake 
flask cultures (as outlined in Section 2.4.1.3) parallel to this experiment.  
2.4.5  Verification of the predicted optimal settings for post-induction period and liquid 
fill volume based on the model fitted to the CCC experiment data 
Using Design Expert software, a regression model generated from the CCC experiment data 
was utilised to predict optimal factor settings for maximising ProSavin
® titre (Section 4.2.1.5).  
These were a post-induction period of ≈ 39.7 hr and a liquid fill volume of ≈ 854 µL, where the 
dox concentration was fixed at 3.0 µg mL
-1.  A verification experiment was thus performed at 
these settings (n = 9).  Harvests were also performed either side of the supposed optimum 
harvest time, at 15, 20, 45 and 62 hr post-induction (n = 3) to further delineate the critical impact 
harvest  timing  has  on  ProSavin
®  production.    The  experiment  was  carried  out  using  the 
microwell  platform as described in Section 2.4.1.2,  except that the  values for post-induction 
period and liquid fill volume were as described above, and all other operating conditions were 
fixed  as  for  the  CCC  experiment  (Section  2.4.4).    The  same  responses  were  measured  as 
during the CCF experiments (Sections 2.4.2 and 2.4.3), and end-of-culture photographs were 
also  taken  to  illustrate  the  degree  of  cell  aggregation  using  a  FinePix  F10  digital  camera.  
Culture  pH  (Section  2.11.1.3)  and  osmolality  (Section  2.11.1.2)  were  also  monitored.    To 
quantify  the  rate  of  fluid  loss  from  microwells  as  a  consequence  of  evaporation,  additional 
microwell  plates (n  = 3)  were seeded and  induced  in parallel for gravimetric analysis.  The 
plates  were  weighed  before  seeding  (to  establish  the  weight  of  the  vessel)  and  at  0  hr 85 
 
 
(immediately post-seeding). The plates were subsequently re-weighed after 23 hr (before the 
addition of inducer compounds), after 25 hr (after the addition of inducer compounds), and after 
38, 44, 63, 68, 85 and 92 hr.  The weight of the vessel was subtracted from each measurement, 
which  was  then  expressed  as  a  percentage  of  the  starting  culture  weight  (the  0  hr 
measurement).    Individual  data  points  were  plotted  and  the  average  rate  of  fluid  loss  was 
calculated from linear regression analysis of the 25 - 92 hr data.  
2.5  Calculation of dimensionless numbers to describe the liquid phase 
hydrodynamics in microwells  
Dimensionless numbers were used to make predictions about the fluid hydrodynamics in the 
shaken microwell system, based on the typical operating conditions for PS46.2 cell culture that 
had  been  established  during  the  screening  and  optimisation  experiments  (Section  4.2.2).  
Reynolds  number  (Re),  Froude  number  (Fr)  and  Phase  number  (Ph) were  calculated  using 
equations (1), (2) and (3), respectively, as described previously (Büchs et al., 2000b; Büchs et 
al.,  2001b).  All  calculations  assumed  a  microwell  diameter  of  15.6  mm,  a  platform  orbital 
shaking diameter of 20 mm, a platform shaking speed of 160 rpm, and the fluid properties of 
water at 37 °C (ρ = liquid density, kg m
-3; N = shaking frequency, s
-1; df = vessel diameter, m; μ 
= viscosity of fluid, Pa s; ds = shaking diameter, m; g = gravitational acceleration, m s
-2; VL = 
liquid fill volume, m
3).   
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2.6  Evaluation of the effect of daily dox additions on ProSavin
® titre 
An  additional  microwell  experiment  was  conducted  to  further  clarify  the  effect  of  dox 
concentration on PS46.2 productivity during extended cultures (Section 4.2.3).  The addition of 
dox  at  a  concentration  of  1.0  µg  mL
-1  or  3.0  µg  mL
-1  (added  once)  was  compared  to  a 
concentration of 1.0 µg mL
-1 added every 24 hr, the purpose being to determine whether dox 
could  have  been  being  lost  from  the  system  (e.g.  via  degradation)  over  time,  and  thus  full 
induction of cells was not being maintained over extended culture periods.  As only one factor 
was  under  investigation,  DoE  techniques  were  not  employed  for  the  design  of  this  study.  
ProSavin
®  production  was  carried  out  using  the  microwell  platform  as  described  in  Section 
2.4.1.2, except that dox concentrations were as described above, harvests were performed at 
22, 40, 46 and 70 hr post-(first)induction, and all other operating conditions were fixed as for the 
model verification experiment (Section 2.4.5).  Cell growth was monitored (Section 2.11.1.1) 
and ProSavin
® titre was quantified according to Section 2.11.2.1 (n = 4). 
2.7  Production  of  ProSavin
®  using  a  2  L  disposable  wave-mixed 
bioreactor system 
2.7.1  Description of the WAVE bioreactor system  
A WAVE bioreactor 20/50 (GE Healthcare, Buckinghamshire, UK) was used for scale-up studies 
(Chapter 5). Cells were cultured within a disposable bag chamber (Cellbag; GE Healthcare), 
while oxygen transfer and fluid mixing were facilitated by the mechanically driven rocking motion 
of  the  bioreactor  culture  platform.    The  bioreactor  base  unit  was  used  to  regulate  the 
temperature,  rocking  rate  and  rocking  angle,  while  a  separate  control  unit  (WAVEPOD;  GE 
Healthcare) was used to pump air mixed with CO2 into the Cellbag.  For all experiments a 2 L 
Cellbag  with  an  Oxywell  port  was  used;  a  probe  can  be  inserted  into  the  Oxywell  for 
measurement of dissolved oxygen (see Section 2.11.1.5).  The Cellbag has a fill port for large 
additions  of  inoculum  or  media,  which  is  comprised  of  a  39”  length  of  C-Flex
®  tubing  that 
terminates in a female luer connector.  A self-sealing sampling port facilitates the addition and 
removal of small volumes of liquid without the requirement for a tissue culture hood.  Air is 
passed into and out of the Cellbag through 0.2 µm filters; a heater prevents the exhaust filter 87 
 
 
from becoming blocked with condensation and a pressure release valve ensures the Cellbag 
remains inflated.    
2.7.2  Base protocol for ProSavin
® production using the WAVE bioreactor system 
Here, the initial protocol used for operation of the WAVE bioreactor (Section 5.2.1.1) is detailed.  
Subsequent modifications to the protocol (relating to the studies described in Sections 5.2.1.2 
and 5.2.2) are described in Section 2.7.3. 
2.7.2.1  Inoculum preparation 
Suspension-adapted PS46.2 were first expanded in shake flasks (Section 2.1.6).  Cultures were 
pooled, then aliquoted into 50 mL centrifuge tubes and centrifuged for 5 min at 150 x g. Spent 
media was removed and cells were resuspended at a density of 1.2 x 10
6 viable cells mL
-1 in 
fresh medium (containing 5 % tet-free FCS) ready to seed the Cellbag. 
2.7.2.2  WAVE bioreactor operation 
A liquid fill volume of 50 % (1 L) was chosen as this enabled the full capacity of the system to be 
exploited as stated by the manufacturer.  1 L of inoculum was syringed into a Cellbag via the fill 
port.  The Cellbag had been pre-inflated with air comprising 5 % CO2 and was clamped to the 
rocking platform; the end of the tubing used for addition of the inoculum had been retained 
inside a tissue culture hood to preserve sterility until addition of inoculum had been completed.  
The bioreactor base unit was used to set a temperature of 36.5 °C, rocking rate of 10 rocks min
-
1 and rocking angle of 6°, while the WAVEPOD pumped air mixed with CO2 into the Cellbag at a 
rate of 0.1 L min
-1.  The  CO2 concentration  was set to 5 % for the  duration  of the culture.  
Induction  was  performed  after  24  hr  by  addition  of  3.0  µg  mL
-1  dox  and  2  mM  NaBu,  and 
harvests were performed at five time points between 17 and 66 hr post-induction.  Samples for 
measurement  of  cell  culture  parameters  (cell  growth  [Section  2.11.1.1]  and  pH  [Section 
2.11.1.3]) were taken throughout the culture.  To enable representative sampling the platform 
rocking rate was increased to 40 rocks min
-1 for roughly 1 min and approximately 1.5 mL culture 
was removed.  For vector harvests, approximately 8 mL of culture was transferred into a 15 mL 
centrifuge tube (BD Falcon
TM conical tube; BD Biosciences) and centrifuged for 5 min at 2050 x 
g, after which the supernatant was sterile filtered using a syringe filter with 0.45 µm pore size, 88 
 
 
and  the  resultant  filtrate  was  stored  in  freezing  vials  at  -80  °C.  For  comparison,  triplicate 
microwell  cultures  were  seeded,  induced  and  harvested  in  parallel,  using  the  operating 
conditions described in Section 2.4.5.  ProSavin
® titre was quantified according to the methods 
outlined in Section 2.11.2.1. 
2.7.3  Variations in the base protocol for ProSavin
® production using the WAVE 
bioreactor system 
2.7.3.1  General modifications 
For the studies described in Sections 5.2.1.2 and 5.2.2, some modifications were made to the 
base protocol for operation of the WAVE bioreactor.  Firstly, the working volume of the Cellbag 
was reduced to 0.5 L, which is 25 % of the total volume.  Secondly, the CO2 concentration was 
reduced from 5 % to 1 % after 24 hr culture (at the time of induction), in an attempt to retain the 
culture pH at approximately pH 7.  Thirdly, all media and inoculum additions (with the exception 
of when pre-coating the Cellbag – see Section 2.7.3.2) were made to the Cellbag using a sterile 
tubing  welder.    Specifically,  a  BIOEAZE
®  lid  (Sigma-Aldrich)  was  transferred  to  a  Nalgene
® 
media bottle (Thermo Fisher Scientific, Wilmington, DE, USA) containing the media/inoculum 
inside a tissue culture hood.  The C-Flex
® tubing of the BIOEAZE
® lid was aseptically welded to 
the  C-Flex
®  tubing  of  the  Cellbag  fill  port  using  a  SCD
®  IIB  sterile  tubing  welder  (Terumo, 
Lakewood, CO, USA). 
2.7.3.2  Study to determine the impact of pre-coating the Cellbag on ProSavin
® titre 
For the study described in Section 5.2.1.2, the impact of pre-coating the Cellbag was explored.  
The  manufacturer  recommends  pre-coating  the  Cellbag  when  chemically-defined  lipid 
supplements are used, as these can be stripped from the culture medium via an interaction with 
the internal surface of the culture chamber (General Electric Company, 2008b). To pre-coat, the 
Cellbag was first inflated with air mixed with 5 % CO2 and clamped to the rocking platform.  0.5 
L of culture medium containing 5 % (v/v) tet-free FCS was added to the Cellbag (using a syringe 
as described in Section 2.7.2.2) then air inlet and outlet vents were closed.  The Cellbag was 
heated to 36.5 °C and highly agitated, using a rate of 40 rocks min
-1 (angle 6°), so that the entire 
surface area of the chamber likely to be immersed during cell culture was coated.  After 3 days 89 
 
 
the medium was removed.  To remove medium, a sterile tubing welder was used, as described 
in Section 2.7.3.1.  The Cellbag was then seeded in parallel with a Cellbag that had not been 
pre-coated.    Inoculum for each  Cellbag  was  broadly  prepared  as  described  earlier  (Section 
2.7.2.1), except that cells were resuspended at a density of 1.5 x 10
6 viable cells mL
-1 in 400 mL 
medium.  After the cell suspension had been added to each Cellbag, a further 100 mL medium 
was added to rinse through any cells remaining in the tubing.  For each Cellbag, this yielded a 
final cell concentration of 1.2 x 10
6 viable cells mL
-1 and a final working volume of 0.5 L.  Both 
Cellbags were then operated in parallel according to the procedures described in Section 2.7.2, 
excepting  the  modifications  noted  in  Section  2.7.3.1.    To  supplement  ProSavin
®  titre 
measurements, RNA copy numbers (Section 2.11.3.1) were also quantified using supernatants 
from the Cellbag that was not pre-coated.  
2.7.3.3  Investigation into the effect of rocking rate on the production of ProSavin
® 
For the work described in Section 5.2.2, eight separate bioreactor runs were performed, using 
rocking  rates  of  6,  12,  18  and  24  rocks min
-1  (n  =  2).    Inoculum  was  broadly  prepared  as 
described earlier (Section 2.7.2.1), with the exception that cells were resuspended at a density 
of 3.0 x 10
6 viable cells mL
-1 in 200 mL medium.  Inoculum was added to a Cellbag already 
containing 200 mL medium (used for calibration of the oxygen probe; see Section 2.11.1.5).  A 
further  100  mL medium  was  then  added  to  rinse  any  cells  remaining  in  the  tubing  into  the 
Cellbag.  This yielded a final cell concentration of 1.2 x 10
6 viable cells mL
-1 and a final working 
volume of 0.5 L.  Cellbags were then operated according to the procedures described in Section 
2.7.2.2,  excepting  the  modifications  noted  in  Section  2.7.3.1.    In  addition  to  ProSavin
®  titre 
measurements (Section 2.11.2.1), RNA copy number (Section 2.11.3.1) and product enhanced 
reverse transcriptase (PERT; Section 2.11.3.2) data was collected.  To monitor natural process 
variability,  ProSavin
®  was  produced  using  reference  shake  flask  cultures  according  to  the 
protocol outlined in Section 2.4.1.3, parallel to all WAVE runs (parallel microwell cultures were 
not performed).   
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2.8   Stability of ProSavin
® at 36.5 °C 
2.8.1  Half-life of ProSavin
® in crude supernatants at 36.5 °C 
The decline of ProSavin
® over time was characterised in cell culture supernatants incubated at 
a temperature of 36.5 °C (Section 6.2.1.1).  To generate material for these studies, ProSavin
® 
was  produced  using  PS46.2  shake  flask  cultures  as  described  in  Section  2.4.1.3,  and  the 
resultant  filtrate  was  stored  in  50  mL  centrifuge  tubes  at  -80  °C  until  required.    For 
commencement of the stability experiments, aliquots of crude supernatant were thawed and 
pooled.   
In the first (of two) experiments, 854 µL volumes of crude supernatant were aliquoted into either 
a freezing vial, a static microwell plate, or a shaken microwell plate (orbital diameter 20 mm; 
shaking speed 160 rpm).  Triplicate vials representing time 0 were placed immediately at -80 
°C, while the remaining samples were incubated at 36.5 °C in a 5 % CO2 humidified incubator.  
Subsequently at 24, 48, 72, 96 and 168 hr, triplicate samples for each condition were retrieved 
and transferred to -80 °C storage (supernatants from microwells were transferred to freezing 
vials  prior  to  -80  °C  storage).  ProSavin
®  titre  analysis  was  later  performed  as  described  in 
Section 2.11.2.1, and the half-life of functional ProSavin
® was calculated from linear regression 
analysis of natural log transformed data.  In addition, the samples that had been incubated in 
vials were analysed using the PERT assay (Section 2.11.3.2), and the half-life of viral RT was 
calculated  from  linear  regression  analysis  of  natural  log  transformed  data  (note  that  these 
samples had previously undergone two freeze-thaw cycles). 
In the second experiment, 850 µL aliquots of supernatant were prepared, allowing 4 vials for 
titre measurements and 4 vials for RNA copy number measurements per time point.  Samples 
representing  time  0  were  placed  immediately  at  -80  °C,  while  the  remaining  vials  were 
incubated at 36.5 °C in a 5 % CO2 humidified incubator.  Subsequently, at 3, 6, 9, 12, 24, 30, 36 
and 48 hr vials were retrieved and stored at -80 °C.  The rapid ProSavin
® titre assay (Section 
2.11.2.1) and RNA copy number assay (Section 2.11.3.1) were later performed, and the half-life 
of functional ProSavin
® and viral RNA was calculated from linear regression analysis of natural 
log transformed data.  In addition, the stability of viral RT was assessed using the PERT assay 91 
 
 
(Section 2.11.3.2) (n = 4).  The vials used for PERT analysis had undergone one freeze-thaw 
cycle, as they had formerly been defrosted for RNA copy number analysis. 
2.8.2  Studies to determine if lentiviral vector losses differ in the presence or absence 
of producer cells 
To study whether lentiviral vector losses differed in the presence or absence of producer cells 
(Section 6.2.1.2), an EIAV lentiviral vector that expressed the LacZ marker gene, and thus could 
be  quantified  in  isolation  from  produced  ProSavin
®  particles,  was  used.    An  EIAV  lentiviral 
vector expressing LacZ that was pseudotyped with VSV-G and was, except for the difference in 
transgene,  analogous  to  ProSavin
®  was  kindly  provided  by  the  Research  Group  at  Oxford 
BioMedica.  This vector had been generated by transient transfection of adherent HEK293T 
cells, and was provided frozen (-80 °C) in crude supernatant at a reported concentration of 
around 3 x 10
6 TU mL
-1.    
Two experiments were conducted.  In the first experiment, the impact of cells and induction 
compounds on the proportion of LacZ vector remaining after 48 hr incubation was evaluated in 
four conditions (+/- cells; +/- induction reagents), as outlined in Table 2.1.  Microwells were 
employed for this study and were kept on a shaking platform (orbital diameter 20 mm; shaking 
speed 160 rpm) in a 5 % CO2 humidified incubator at 36.5 °C.  Microwells were seeded using 
850 µL cell suspension or fresh medium without cells, according to Table 2.1.  To generate 
seeding  material  (conditions  3  and  4  only;  Table  2.1),  suspension  cultures  of  PS46.2  were 
centrifuged for 5 min at 150 x g, after which the supernatant was removed and the cells were 
resuspended in fresh medium at a density of 1.2 x 10
6 viable cells mL
-1.  After 24 hr, induction 
reagents (3.0 µg mL
-1 dox and 2 mM NaBu) were added to microwells (conditions 2 and 4 only; 
Table 2.1).  At this stage LacZ vector was also added.  To achieve a final concentration of 
around  6  x  10
4  TU  mL
-1,  which  is  representative  of  typical  concentrations  of  functional 
ProSavin
® during a standard production run, 17 µL of the solution containing LacZ vector was 
added per well.  Supernatant was harvested immediately from triplicate wells per condition, and 
after 48 hr the remaining wells were harvested (n = 3).  Vector harvests were performed as 
described  earlier  (Section  2.4.1.2).    The  number  of  functional  LacZ  particles  in  collected 
supernatants was quantified using the procedure outlined in Section 2.11.2.2.  92 
 
 
Table 2.1  Summary of the four conditions (+/- cells; +/- inducer compounds) for which the 
reduction in functional LacZ vector particles over time was evaluated.  The culture medium in all 
instances was Freestyle
TM 293 expression medium supplemented with 5 % (v/v) tet-free FCS.  
Six microwells were seeded for each condition.  LacZ vector was added to all conditions at the 
time of induction (24 hr post-seeding); the proportion remaining after 48 hr culture was then 
assessed.  
Condition #  Seeding material  Induction reagents added? 
1  Medium only  No 
2  Medium only  Yes 
3  Cell suspension  No 
4  Cell suspension  Yes 
In the second experiment, the proportion of LacZ vector remaining after 24 hr incubation when 
diluted in two different media, that either had or had not been pre-conditioned, was compared 
(Table 2.2).  Prior to use, the four media were transferred into 50 mL centrifuge tubes and were 
centrifuged for 5 min at 2050 x g, after which supernatants were sterile filtered using syringe 
filters of 0.45 µm pore size.  The osmolality (Section 2.11.1.2) and pH (Section 2.11.1.3) of the 
four media was measured.  833 µL media and 17 µL LacZ vector was added to freezing vials 
(six vials per condition).  Triplicate vials per condition were placed immediately at -80 °C, while 
the remaining vials were incubated at 36.5 °C for 24 hr, after which they too were removed to -
80 °C.  The number of functional LacZ vector particles was later quantified using the methods 
outlined in Section 2.11.2.2.  
Table 2.2   Summary of the four conditions (two different media; +/- pre-conditioning) for 
which the reduction in functional LacZ vector particles over time was evaluated.  Suspension 
medium was Freestyle
TM 293 expression medium supplemented with 5 % (v/v) tet-free FCS, 
while adherent medium was that typically used for HEK293T and D17 cell culture (see Section 
2.1.4).    Conditioned  suspension  medium  had  been  previously  used  for  the  culture  of  non-
induced suspension-adapted PS46.2 for 3 days; conditioned adherent medium had previously 
been used for the culture of HEK293T for 3 days.   
Condition #  Medium  Pre-conditioned? 
1  Suspension medium  No 
2  Suspension medium  Yes 
3  Adherent medium  No 
4  Adherent medium  Yes 93 
 
 
2.9  Evaluation  of  different  strategies  for  the  mitigation  of  ProSavin
® 
inactivation during upstream processing 
2.9.1  Storage of generated material at 4 °C 
Two studies were conducted to evaluate whether storage of ProSavin
® at 4 °C could mitigate 
the rapid inactivation observed at 36.5 °C (Section 6.2.2.1).   To generate material for these 
studies, ProSavin
® was produced using PS46.2 shake flask cultures as described in Section 
2.4.1.3, and the resultant filtrate was stored in 50 mL centrifuge tubes at -80 °C until required.  
For commencement of the stability experiments, aliquots of crude supernatant were thawed and 
pooled.  
In the first experiment, 854µL crude supernatant was aliquoted into freezing vials.  Triplicate 
vials representing time 0 were placed immediately at -80 °C, while the remaining samples were 
placed in a fridge with a temperature of 4.1 ± 0.5 °C (mean ± SD; temperature was monitored 
for the duration of the experiment using a TempTale
®4 temperature monitor [Sensitech
®, Nieuw-
Vennep, The Netherlands]).  24, 48, 72, 96 and 168 hr later triplicate samples were retrieved 
and stored at -80 °C.  ProSavin
® titre analysis was later performed as described in Section 
2.11.2.1.  This study was carried out in parallel with the first 36.5 °C stability study described in 
Section 2.8.1. 
In the second experiment, ProSavin
® inactivation at  4 °C  was evaluated over a longer time 
course.  850 µL crude supernatant was aliquoted into freezing vials.  Four vials representing 
time 0 were placed immediately at -80 °C and the remaining samples were placed in a fridge 
with temperature 4.2 ± 0.5 °C (mean ± SD; again, temperature was monitored for the duration of 
the experiment using a TempTale
®4 monitor).  Subsequently, at 24, 48, 72, 96, 120, 144, 192, 
240, 312 and 384 hr time points, quadruplet samples for each assay were retrieved and stored 
at -80 °C. ProSavin
® titre analysis was later performed as described in Section 2.11.2.1, and 
RNA copy number measurements were also carried out (Section 2.11.3.1).  This study was set-
up in parallel with the second 36.5 °C stability study described in Section 2.8.1.   
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2.9.2  Reduction of production temperature to 31.5 °C 
A study was conducted to evaluate whether lowering the temperature by 5 °C (to 31.5 °C) from 
typical production temperatures could improve titres for our system (Section 6.2.2.2).  ProSavin
® 
was produced using PS46.2 shake flask cultures broadly according to the procedure outlined in 
Section 2.4.1.3, except that flasks were incubated either at 31.5 or 36.5 °C (n = 4).  In addition, 
to ensure that cells were of a similar density at the time of induction, flasks were seeded at a 
higher than normal density (1.6 x 10
6 viable cells mL
-1) and were induced much earlier (2 hr 
post-seeding).    Vector  harvests  were  performed  24,  44  and  67  hr  post-induction,  for  which 
approximately 4 mL culture was removed (cell counts [Section 2.11.1.1] were also performed 
using a small proportion of this material).  ProSavin
® titre analysis was carried out using the 
methods described in Section 2.11.2.1.  
2.9.3  Adjustment  of  cell  culture  osmolality  by  supplementation  of  glucose,  fructose 
and/or sorbitol 
The effect of increased osmolality (attained by supplementation of the medium with glucose, 
fructose and/or sorbitol) on ProSavin
® titre was evaluated using microwell suspension cultures 
of PS46.2 (Section 6.2.2.3).  A full factorial design was created using Design Expert software, 
whereby the concentration of each sugar type was varied over two levels (high and low).  Table 
6.4 shows the experimental plan in which three factors were evaluated in 12 experimental runs, 
with four replicated centre point experiments included for estimation of pure error.    
Cell culture media supplemented with glucose, fructose or sorbitol (singularly or in combination 
according to Table 6.4; all from Sigma-Aldrich) were prepared as described here.  Fructose and 
sorbitol were provided as dry powders and thus required dissolving in tissue culture grade water 
(Sigma-Aldrich) prior to use, while glucose was supplied as a ready-to-use 45 % (w/v) sterile 
solution.  For each experimental condition, a concentrated solution of glucose, fructose, and/or 
sorbitol was prepared and sterile filtered through a 0.2 µm filter (Sartorius).  The concentrated 
solution was then added to cell culture medium, such that the solution comprised 9.3 % (v/v) of 
the final volume, and the resulting concentration of glucose, fructose, and/or sorbitol was as 
stated in Table 6.4.  For one experimental condition, neither glucose, fructose nor sorbitol were 
required; in this instance cell culture medium containing 9.3 % (v/v) tissue culture grade water 95 
 
 
was  used.    The  osmolality  of  the  different  media  was  measured  (as  was  the  osmolality  of 
standard culture medium without supplementation or partial dilution with water).   
Suspension-adapted PS46.2 were initially transferred into shake flasks containing fresh media 
supplemented with glucose, fructose and/or sorbitol at the concentrations stated in Table 6.4, 
and cultured for 3 days using standard conditions as described in Section 2.1.6.  To initiate the 
microwell experiment, cultures were then centrifuged for 5 min at 150 x g, supernatant was 
removed and cells were resuspended at a density of 2 x 10
6 viable cells mL
-1 in fresh medium 
(supplemented  according  to  Table  6.4).    Experimental  runs  (Table  6.4;  including,  for 
comparison,  cells  in  standard  non-modified  medium)  were  seeded  in  triplicate  using  the 
microwell  platform, with 850 µL culture per  well.   Microwells  were kept on shaking platform 
(orbital diameter 20 mm; shaking speed 160 rpm) in a 5 % CO2 humidified incubator at 36.5 °C.  
To ensure that cells were of a similar density at the time of induction, induction reagents (3.0 µg 
mL
-1 dox and 2 mM NaBu) were added to microwells 2 hr post-seeding (note that the seeding 
density was higher than that typically used, to compensate for this short post-induction period).  
Cell density measurements (Section 2.11.1.1) and vector harvests were carried out 23, 44 and 
65 hr post-induction (n = 1 at each time point).  Vector harvests were carried out as described 
earlier (Section 2.4.1.2).  Titres were quantified using the rapid ProSavin
® titre assay (Section 
2.11.2.1).   
Parallel to this experiment, ProSavin
® was produced in shake flasks according to the protocol 
outlined  in  Section  2.4.1.3.    The  generated  material  was  utilised  to  assess  whether  the 
presence of different sugar types in the culture medium impacted on the transduction stage of 
the titre assay and thus indirectly influenced final titre measurements.  Immediately prior to cell 
transductions,  supernatants  harvested  from  shake flask  cultures  were  thus  split  into  several 
aliquots, which were supplemented such that the resulting concentrations of the different sugar 
types  were  as  stated  in  Table  6.4.    Titres  were  otherwise  determined  as  normal  (Section 
2.11.2.1).   
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2.10  Comparison of the stability of different lentiviral vector preparations 
incubated at 36.5 °C 
2.10.1  Description of experiments  
Experiments were conducted to examine whether the choice of production system (transient 
transfection versus stable producer cell lines) and vector genome (ProSavin
®, Vector 13.1 or 
enhanced  green  fluorescent  protein  [eGFP])  influenced  the  stability  of  generated  lentiviral 
particles  (Section  6.2.3).  ProSavin
®  was  generated  using  adherent  PS46.2  cultures  as 
described in Section 2.10.2, while ProSavin
®, Vector 13.1 (a lentiviral vector that expresses a 
candidate  therapeutic  transgene)  and  eGFP  lentiviral  vectors  were  produced  via  transient 
transfection as outlined in Section 2.10.3.  Aliquots of crude supernatant were thawed and small 
volumes of 70, 320 and 1300 µL (for later analysis using the PERT, RNA copy number and titre 
assays, respectively) were dispensed into freezing vials.  Triplicate vials of each volume were 
prepared for each time point to be assessed (7 time points in total).  The time points were 
chosen based on preliminary studies (data not shown), such that the depletion of functional 
particles to low levels (but still within the quantifiable range of titre assays) could be observed.  
Vials representing time 0 were placed immediately at -80 °C, while the remaining samples were 
incubated at 36.5 °C in a 5 % CO2 humidified incubator.  Vials of ProSavin
® that had been 
generated using adherent PS46.2 cultures were subsequently moved to -80 °C storage after 8, 
24, 32, 48, 72 and 96 hr incubation.  Vials containing supernatant that had been produced by 
transient transfection of adherent HEK293T were moved to -80 °C storage after incubation for 2, 
4, 6, 8, 12 and 24 hr (ProSavin
®), 8, 24, 32, 48, 72 and 96 hr (Vector 13.1), and 8, 24, 48, 72, 
144 and 240 hr (eGFP vector).  ProSavin
® titres were quantified using two methods (Sections 
2.11.2.1 and 2.11.2.3); however, one set of cell transductions was performed and the cells were 
split 3 days later so that each assay could be continued in isolation.  Vector 13.1 and eGFP 
vector titres were quantified using the DNA integration assay (Section 2.11.2.3) only.  RNA copy 
number  (Section  2.11.3.1)  and  PERT  (Section  2.11.3.2)  analysis  was  carried  out  for  all 
preparations.    The  half-life  of  functional  vector  and  viral  RNA  was  calculated  from  linear 
regression analyses of natural log transformed data.   97 
 
 
A second batch of ProSavin
® was produced by transient transfection of HEK293T, and also 
tested (n = 1).  Crude vector was aliquoted into freezing vials (650 µL per vial); vials  were 
moved to -80 °C storage after 0, 4, 8, 22 and 32 hr incubation.  Biological titre was quantified 
using the rapid ProSavin
® titre assay (Section 2.11.2.1).   
2.10.2  Production of ProSavin
® using adherent stable producer (PS46.2) cells  
ProSavin
®  for  use  in  stability  studies  was  produced  using  adherent  cultures  of  PS46.2.  
Adherent  PS46.2  were  seeded  in  10  cm  dishes  (BD  Falcon
TM  tissue  culture  treated;  BD 
Biosciences) at a density of 1 x 10
7 viable cells mL
-1 in 10 mL medium.  Cells were kept in a 5 % 
CO2 humidified incubator at 36.5 °C, and were induced after 20 - 22 hr by addition of 1.0 µg mL
-
1 dox and 10 mM NaBu.  Medium was replaced 6 - 8 hr post-induction with 6 mL medium 
containing  1.0  µg  mL
-1  dox  (without  NaBu).    20  -  23  hr  later  harvests  were  performed: 
supernatants were sterile filtered using syringe filters of 0.45 µm pore size and the resultant 
filtrate was stored in 15 mL centrifuge tubes at -80 °C. 
2.10.3  Production  of  lentiviral  vectors  by  transient  transfection  of  adherent  HEK293T 
cells 
Vectors for use in stability studies were also produced by three plasmid transient co-transfection 
of  adherent  HEK293T.    The  codon-optimised  EIAV  Gag/Pol  expression  plasmid  pESGPK 
(Stewart  et  al.,  2009)  and  VSV-G  envelope  expression  plasmid  pHGK  were  used  in  all 
instances (Figure 2.1).  pHGK is a derivative of phG[VSVG2] (Farley et al., 2007) in which the 
ampicillin  selectable  marker  has  been  replaced  with  a  kanamycin  resistance  gene.  For 
production  of  ProSavin
®,  the  genome  expression  plasmid  pONYK1  was  used.    The  vector 
construct  expressed  by  pONYK1  is  identical  to  that  previously  described  for  pONYK1-ORT 
(Farley et al., 2007; Jarraya et al., 2009; Stewart et al., 2009; Stewart et al., 2011); pONYK1 
differs from pONYK1-ORT only in that it contains a kanamycin selectable marker on the plasmid 
backbone,  i.e  outside  the  LTRs.  Vector  13.1  was  generated  using  the  genome  plasmid 
pONYK13.1 which encodes a candidate therapeutic gene, and eGFP vectors were produced 
using  the  genome  plasmid  PONYKG,  which  encodes  the  eGFP  reporter  gene.  All  vector 
constructs are displayed in Figure 2.1.  Plasmids were kindly provided by the Research Group 
at Oxford BioMedica. 98 
 
 
For transient transfections, 10 cm dishes were seeded with HEK293T cells at a density of 3.5 x 
10
5 viable cells mL
-1, using 10 mL medium per dish.   Dishes were incubated at 36.5 °C in a 5 % 
CO2 humidified incubator.  Three-plasmid transient transfections were performed 21 - 26 hr later 
using Lipofectamine
® 2000 CD transfection reagent (Invitrogen).  25 µL Lipofectamine
® 2000 
CD was added drop-wise to 315 µL OptiPRO
TM medium (Invitrogen) and incubated at room 
temperature for 5 min.  Meanwhile, the following were combined with 340 µL OptiPRO
TM: 2 µg 
EIAV  Gag/Pol  expression  plasmid,  0.08  µg  VSV-G  envelope  plasmid,  and  4  µg  genome 
plasmid.  The plasmid mix was then combined with the Lipofectamine
® 2000 CD mix, and the 
whole was incubated at room temperature for 15 - 45 min before being added to cells.  Cells 
were induced 14 - 19 hr post-transfection with 10 mM NaBu; medium was replaced 6.5 - 8 hr 
later with 6 mL fresh medium (not containing NaBu).  Vector harvests were performed 21 - 23 hr 
following medium exchange: supernatants were sterile filtered using syringe filters of 0.45 µm 
pore size, and the resultant filtrate was stored in 15 mL centrifuge tubes at -80 °C.  
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Figure 2.1  Diagram of lentiviral vector constructs.  Each construct is encoded by a different 
plasmid,  as  indicated.    Full-length  equine  infectious  anaemia  virus  (EIAV)  vector  genome 
transcripts are expressed from an immediate-early cytomegalovirus (CMV) / EIAV long terminal 
repeat (LTR) RU5 chimeric promoter.  All vectors contain a deletion in the U3 region (∆U3) of 
the  3’-LTR  causing  self-inactivation  (SIN)  of  the  vector  upon  transduction.    The  ProSavin
® 
transgenes (tyrosine hydroxylase [TH], aromatic L-amino acid decarboxylase [AADC] and GTP 
cyclohydrolase 1 [CH1]), Vector 13.1 transgene (Nucleotide of Interest (NOI)) and enhanced 
green fluorescent protein (eGFP) reporter gene are indicated where relevant.  Also indicated 
(where  present)  are:  Gag/Pol,  vesicular  stomatitis  virus  glycoprotein  (VSV-G),  intron  (INT), 
polyadenylation signal (pA), EIAV packaging signal (Ψ), neomycin (neo) open reading frame 
(ORF), internal ribosome entry site (IRES), and woodchuck hepatitis virus post transcriptional 
regulatory element (WPRE).  Plasmid size is given in base pairs (bp).  All plasmids contain a 
kanamycin Escherichia coli selectable marker.   
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2.11  Analytics 
2.11.1  Analytical techniques for the measurement of cell culture parameters  
2.11.1.1  Cell density and viability 
Cell number and viability were determined using a Cedex XS cell counter (Roche Diagnostics 
Ltd,  Burgess  Hill,  UK)  and  the  trypan  blue  exclusion  method  (as  described  by  the 
manufacturer).  The Cedex XS is a semi-automated cell counter that employs digital image 
recognition technology to enumerate live and dead cells.  Samples diluted in trypan blue (Roche 
Diagnostics  Ltd)  are  loaded  onto  a  Cedex  Smart  Slide  (Roche  Diagnostics  Ltd)  and  then 
analysed.    A  sample  size  of  approximately  10  µL  is  required,  and  eight  samples  can  be 
analysed using a single slide.   
2.11.1.2  Osmolality 
Cell  culture  samples  of  50  µL  volume  were  analysed  using  a  cryoscopic  OSMOMAT
®  030 
osmometer (Gonotec GmbH, Berlin, Germany), which uses the freezing point depression of a 
solution to calculate osmolality.  Prior to sample measurements, a two-point calibration  was 
performed using distilled water and a 300 mOsmol kg
-1 calibration solution (Gonotec).  This 
yields a measuring range of 0 - 700 mOsmol kg
-1 with ± 1 % linearity (gonotec, 2006). 
2.11.1.3  pH 
For studies described in Chapters 3 and 4, cell culture pH was measured immediately post-
sampling  using  a  blood  gas  analyser  (ABL800  BASIC;  Radiometer  Ltd,  West  Sussex,  UK), 
which  had  been  calibrated  according  to  the  manufacturer’s  instructions.  This  instrument 
requires a sample volume of 195 µL.  As the blood-gas analyser was unavailable for use during 
the later studies described in Chapter 5, pH indicator strips (pH-Fix 6.0 - 7.7; Fisher Scientific; 
catalogue number FB33013) were utilised instead.  The colour of the indicator strip, directly 
following immersion in the sample solution, was compared with a reference chart in order to 
determine pH.   
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2.11.1.4  Concentration of metabolites 
A YSI 7100 multiparameter bioanalytical system (YSI Inc, Yellow Springs, OH, USA), which had 
been  calibrated  according  to  the  manufacturer’s  instructions,  was  used  to  measure  the 
concentration  of  glucose  (D-glucose),  lactate  (L-lactate),  glutamine  (L-glutamine)  and 
ammonium (ammonium ions, NH4
+).  Culture samples (~ 1 mL) were transferred into 1.5 mL 
microcentrifuge tubes (Eppendorf UK LTD, Stevenage, UK) and stored at -20 °C until analysis, 
which was carried out within one month.  Note that a sample volume of 20 - 25 µL is required for 
analysis of each metabolite.  For the study described in Section 4.2.1.4, culture samples were 
first  centrifuged  (2300  x  g  for  1  min)  and  the  supernatant  was  transferred  into  a  fresh 
microcentrifuge  tube  prior  to  -20  °C  storage.    This  step  was  introduced  as  a  precaution  to 
prevent  the  instrument  becoming  clogged  with  cell  debris.    The  YSI  determines  the 
concentrations of glucose, lactate and glutamine (separately) using enzyme sensor technology, 
while  ammonium  concentration  is  determined  using  an  ion  selective  electrode  (see  YSI 
Incorporated (2003) for more details).  
2.11.1.5  Dissolved oxygen in WAVE bioreactor cultures 
For measurement of dissolved oxygen in WAVE bioreactor cultures, a dissolved oxygen optical 
probe  (DOOPT-PROBE;  GE  Healthcare)  was  attached  to  the WAVEPOD  control  unit.    The 
probe  contains  immobilised  dye  molecules  whose  luminescence  is  quenched  by  molecular 
oxygen  (General  Electric  Company,  2008c).    Outside  of  the  Cellbag,  the  probe  was  initially 
calibrated  to  0  %  and  100  %  air  saturation,  using  a  zero  oxygen  standard  solution  (GE 
Healthcare) and gaseous air, respectively.  The probe was then inserted into the Oxywell port of 
a Cellbag containing 200 mL culture medium.  The Cellbag was rocked at a rate of 18 rocks 
min
-1 using an angle of 2°, such that the probe was continually immersed in medium.  The 
Cellbag was incubated at 36.5 °C while air comprising 5 % CO2 was continually passed through 
the headspace at a rate of 0.1 L min
-1.  After approximately 20 min, when the oxygen reading 
had  plateaued,  the  100  %  calibration  was  re-performed  (to  adjust  for  the  effects  of  liquid 
immersion and the shift in temperature on oxygen levels since the initial calibration).  
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2.11.2  Analytical techniques for the quantification of lentiviral vector biological titre 
2.11.2.1  Rapid ProSavin
® titre assay (flow cytometry) 
The ProSavin
® titre assay using flow cytometry was the most common method employed to 
quantify  functional  lentivirus  vector  titres.    As  compared  to  the  DNA  integration  assay,  high 
numbers of samples can be processed in a relatively short time frame.  This assay uses the 
tyrosine  hydroxylase  (TH)  enzyme,  expressed  from  the  ProSavin
®  transgene  cassette,  as  a 
marker to identify cells that have been successfully transduced by ProSavin
®.  Target cells that 
had  been  exposed  to  ProSavin
®-containing  supernatants  underwent  immunostaining,  to 
fluorescently label TH-expressing cells, and were then analysed using flow cytometry. 
Target cells (adherent HEK293T) were seeded in 12-well tissue culture plates (BD Falcon
TM; BD 
Biosciences) at a density of 9 x 10
4 viable cells mL
-1 in 1 mL medium per well.  Cells were 
incubated at 36.5 °C in a 5 % CO2 humidified incubator.  16 - 28 hr later, cells in at least two 
representative wells were counted.  Provided that densities were between 1 x 10
5 and 3 x 10
5 
viable  cells  mL
-1,  transductions  were  subsequently  performed.    Dilutions  of  ProSavin
® 
containing supernatants were prepared using standard HEK293T culture medium supplemented 
with polybrene (final concentration 6 - 8 µg mL
-1; Sigma-Aldrich).  Polybrene is a polycation 
regularly  reported  to  enhance  retroviral  vector  transduction  efficiency  (Davis  et  al.,  2002).  
Similar  titres  were  attained  whether  6  or  8  µg  mL
-1  was  polybrene  used  (data  not  shown).  
Culture medium was removed from target cells and replaced with 0.5 mL diluted vector.  Wells 
were topped-up 3 - 6 hr later with 1 mL fresh medium.  3 days later cells were transferred to a 
96-well U-bottom plate to  enable  immunostaining. Cells  were fixed for 15 min using fixative 
solution (Fix & Perm Medium A; Invitrogen), then incubated for 1 hr in the presence of a rabbit 
anti-tyrosine  hydroxylase  antibody  (Millipore,  Hayward,  CA,  USA)  diluted  1:500  in 
permeabilisation solution (Fix & Perm Medium B; Invitrogen).  Cells were incubated for a further 
1 hr in the presence of an Alexa Fluor
® 488 goat anti-rabbit antibody (Invitrogen) diluted 1:500 
with  permeabilisation  solution.    Cells  were  washed  with  PBS  prior  to  each  step  of  the 
immunostaining procedure, and, following centrifugation at 2050 x g for 5 min, supernatant was 
discarded at each stage by rapid inversion of the plate.  Following immunostaining, cells were 103 
 
 
re-suspended  in  PBS  and  stored  at  4  °C  or  kept  on  ice  until  analysis  by  flow  cytometry.  
Negative and positive (reference) controls were included in each assay. 
Flow  cytometry  was  performed  using  either  a  BD  FACSCalibur™  or  BD  FACSVerse
TM  flow 
cytometer (both BD Biosciences).  Comparable titre results were attained when the same set of 
samples was analysed by both instruments (data not shown).  Size and fluorescence data was 
collected for 10,000 events per sample.  Data was transferred to WinList™ software (version 5.0 
or  7.0;  Verity  Software  House,  Topsham,  ME,  USA)  for  analysis.  WinList™  software  was 
utilised to obtain the percentage of HEK293T cells that exceeded a set fluorescence threshold 
based on background fluorescence of non-transduced cells (Figure 2.2).  Cells exceeded this 
threshold if they had been transduced by ProSavin
®, were producing tyrosine hydroxylase, and 
had been labelled by the immunostaining protocol.  To minimise the likelihood of analysing cells 
with  multiple  copies  of  vector,  results  were  only  considered  valid  if  less  than  20  %  of  cells 
exceeded the set fluorescence threshold (Sastry et al., 2002).  Thus, assuming one transducing 
unit per transduced cell, ProSavin
® titre (in terms of TU mL
-1) could be calculated using the 
following equation: titre = [(% transduced cells / 100) x number of cells per well at transduction x 
dilution factor)] / volume of vector in mL.   
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Figure 2.2  Example  illustration  of  the  method  utilised  to  determine  the  proportion  of 
positive tyrosine hydroxylase (TH)-expressing cells in a given sample following flow cytometry.  
Plots were generated using WinList
TM software.  Scatter plot (a) illustrates the forward scatter 
(FSC)  and  side  scatter  (SSC)  of  a  non-transduced  (negative)  fluorescent-stained  HEK293T 
population.  An elliptical gate (R1) has been drawn around the cell population to exclude debris 
from further analyses.  Only cells within the R1 region are subsequently analysed; once drawn, 
this  region  applies  for  all  samples  within  a  given  assay.    In  histogram  (b),  Alexa  488 
fluorescence of R1 cells (same population as displayed in (a)) is presented.   Here, the cell 
population has been utilised to set a threshold above which positive TH-expressing cells may be 
discriminated from background fluorescence (R2).  Once drawn, this region also applies for all 
samples within a given assay.  Once R1 and R2 have been specified, analysis of test samples 
can  proceed.    For  illustrative  purposes,  histogram  (c)  shows  the  fluorescence  of  a  non-
transduced  cell  population  that  has  not  been  stained  with  fluorescent  antibodies.    Mean 
fluorescence is greatly reduced compared to that observed in histogram (b), demonstrating the 
importance of using stained non-transduced cells for defining R2.  Histogram (d) shows the 
fluorescence of cells transduced with ProSavin
® that was generated from standard shake flask 
cultures (crude supernatants were diluted 1 in 2).  Cells within the R2 region are expressing TH; 
the percentage denoted is utilised to calculate titre.  A linear relationship exists between dilution 
factor and the observed percentage of positive (TH-expressing) cells (data not shown). 
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2.11.2.2  Rapid titre assay for lentiviral vectors expressing LacZ  
To quantify vectors containing the LacZ marker gene, transduced target cells were stained with 
X-Gal.  Cell colonies expressing β-galactosidase (the enzyme encoded by the LacZ gene) could 
then be visualised using an optical microscope and enumerated.  Target cells (adherent D17) 
were seeded in 12-well tissue culture plates at a density of 8 x 10
4 viable cells mL
-1 in 1 mL 
medium per well.  Cells were incubated at 36.5 °C in a 5 % CO2 humidified incubator.  16 - 28 hr 
later, duplicate dilution series were prepared for each vector sample using standard D17 culture 
medium supplemented with polybrene (final concentration 8 µg mL
-1).  Culture medium was 
removed  from  target  cells  and  replaced  with  0.5  mL  diluted  vector.    Positive  and  negative 
(untransduced) controls were also included in each assay.  3 - 6 hr later wells were topped up 
with 1 mL medium.  3 days later culture medium was removed and cells were fixed for 5 min 
using 0.5 mL formalin (VWR, Lutterworth, UK).  Cells were washed with PBS and 0.5 mL X-Gal 
stain was added.  X-Gal stain consisted of 0.4 mg mL
-1 X-Gal (Melford Laboratories, Ipswich, 
UK; from a 20 mg mL
-1 stock that had been prepared using N, N-dimethylformamide [Sigma-
Aldrich]), 2 mM MgCl2 (Sigma-Aldrich), 4 mM potassium ferrocyanide (Sigma-Aldrich), and 4 
mM potassium ferricyanide (Sigma-Aldrich), in PBS.  X-Gal, MgCl2, potassium ferrocyanide and 
potassium ferricyanide were kindly supplied by the Research Group at Oxford BioMedica.  Cells 
were  incubated  at  36.5  °C.    The  next  day,  blue  β-galactosidase-expressing  colonies  were 
visualised using an optical microscope and, for wells containing 20 - 200 colonies, the number 
of colonies per well was counted.  Titre (in terms of TU mL
-1) was then calculated using the 
following equation: titre = (number of colonies per well x dilution factor) / volume at transduction 
in mL. 
2.11.2.3  DNA integration assay 
The DNA integration assay has been previously described in detail (Martin-Rendon et al., 2002; 
Radcliffe et al., 2008; Stewart et al., 2009).  Briefly, this assay uses quantitative real-time PCR 
(q-PCR)  and  primers  specific  to  the  EIAV  packaging  signal  (Ψ)  to  quantify  the  amount  of 
proviral  DNA  in  transduced  target  cells.   Target  cell  seeding  and  vector  transductions  were 
carried out as described earlier (Section 2.11.2.1).  Transduced cells were passaged every 2 - 3 
days for 10 days to eliminate non-integrated vector DNA.  Cells were harvested by transferring 106 
 
 
approximately  1.5  x  10
6  viable  cells  mL
-1  into  a  1.5  mL  microcentrifuge  tube,  which  was 
centrifuged at 300 x g for 5 min.  Supernatant was removed and cell pellets were stored at -80 
°C.  DNA was extracted from cell pellets using a QIAamp DNA Blood Mini Kit (Qiagen, Crawley, 
UK) according to the manufacturer’s instructions.  DNA was resuspended in a final volume of 80 
µL and stored at -20 °C.  For DNA quantitation based on absorbance measurement at 260 nm, 
a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific) was utilised according to the 
manufacturer’s instructions.  DNA results generated using the NanoDrop 1000 matched those 
attained when the same samples were analysed using a Beckman Du
® 640 spectrophotometer 
(Beckman Coulter, High Wycombe, UK; data not shown).   
To  set  up  TaqMan
®  reactions  a  PCR  mix  was  prepared,  which  contained  15  µL  TaqMan
® 
Universal PCR Master Mix (Applied Biosystems
®; Invitrogen), 300 nM EIAV Ψ forward primer (5’ 
ATT GGG AGA CCC TTT GAC ATT G 3’), 300 nM Ψ reverse primer (5’ ACC AGT AGT TAA 
TTT CTG AGA CCC TTG TA 3’) and 200 nM EIAV Ψ probe (5’ [FAM] CAC CTT CTC TAA CTT 
CTT  GAG  CGC  CTT  GCT  [TAMRA]  3’),  made  up  to  a  total  volume  of  24  µL.    The 
concentrations of primers and probe are provided in terms of the final volume (30 µL), which is 
reached by the addition of 6 µL DNA.  Each test sample was analysed in duplicate using 50 - 
750 ng DNA per reaction.  A plasmid DNA standard containing EIAV Ψ of known copy number 
was used to generate a dilution series for a standard curve.  In addition, DNA derived from a 
transduced clonal cell  line containing one copy  of EIAV vector genome per cell  (the ‘single 
integrant’ or ‘SI’) was quantified in parallel to test samples. The primers, probe, DNA standard 
and SI were obtained from the PAR Group at Oxford BioMedica.   Appropriate negative and 
positive (reference) controls were also included in each assay.  Following the addition of DNA to 
the PCR mix, 25 µL was transferred to a 96-well optical plate (Applied Biosystems
®) and the 
number of copies of Ψ per reaction was quantified using an ABI Prism
® 7900HT Sequence 
Detection System (Applied Biosystems
®).  Cycling conditions were: 50 °C for 2 min; 95 °C for 10 
min; 95 °C for 15 sec; 60 °C for 1 min.  The last two steps were repeated for 40 cycles.   
Data  analysis  was  performed  using  the  supported  Sequence  Detection  System  software 
package according to the manufacturer’s recommendations.  The cycle threshold (Ct) value is 
the  cycle  at  which  the  fluorescent  signal  of  a  given  reaction  significantly  exceeds  the 
background  level;  this  parameter  thus  reflects  the  amount  of  DNA  template.    Data  was 107 
 
 
scrutinised  to  ensure  the  following  criteria  were  satisfied:  (i)  duplicate  reactions  returned  Ct 
values within one cycle of each other, (ii) at least three data points were used to construct the 
standard curve, (iii) the R
2 of the trendline fitted to standard data was ≥ 0.98, (iv) the reaction 
efficiency (calculated from the slope of the trendline) was between 83 and 115 %, (v) all sample 
data were within the quantifiable range of the assay and finally (vi) significant fluorescent signal 
was detected in the positive control (reference) reactions, and not detected in negative control 
reactions.    
To determine titres from Ψ data, values were first adjusted to account for the amount of input 
DNA.  The number of Ψ copies per cell was then determined by dividing the number of copies 
of Ψ in unknown (test) samples by the number of copies of Ψ in SI DNA.  Titre (in terms of TU 
mL
-1) could then be calculated using the following equation: titre = [(number of copies of Ψ per 
cell x number of cells per well at transduction x dilution factor)] / volume of vector in mL. 
2.11.3  Analytical  techniques  for  the  quantification  of  total  lentiviral  vector  particle 
numbers 
2.11.3.1  RNA copy number assay 
The  RNA  copy  number  assay  was  performed  similarly  to  as  previously  described  (Martin-
Rendon  et  al.,  2002;  Rohll  et  al.,  2002;  Stewart  et  al.,  2009).    In  brief,  this  assay  uses 
quantitative real-time RT PCR (qRT-PCR) and primers specific to the EIAV Ψ to quantify the 
number of genomic RNA molecules in a vector preparation.  RNA was isolated from 140 µL 
crude supernatant (or 25 µL crude supernatant diluted in 115 µL PBS) using a QIAamp Viral 
RNA Mini Kit (Qiagen) according to the manufacturer’s instructions.  RNA was resuspended in a 
final  volume  of  60  µL.    Removal  of  residual  DNA  was  performed  using  a  DNA-free
TM  Kit 
(Ambion
®; Invitrogen).  5 µL extracted RNA was combined with 3 µL DNaseI (2 U µL
-1), 5 µL 
incubation buffer and 37  µL  water and incubated at 37 ± 1  °C for 1 hr.  The reaction  was 
stopped  by  incubation  at  room  temperature  for  2 min  in  the  presence  of  10  µL  inactivation 
reagent.  The inactivation reagent was subsequently pelleted by centrifugation and the RNA-
containing supernatant transferred to a fresh tube. 108 
 
 
To set up TaqMan
® reactions a PCR mix was prepared, which contained 15 µL TaqMan
® One-
Step  RT-PCR  Master  Mix,  0.75  µL  MultiScribe
TM  RT  and  RNase  Inhibitor  Mix  (Applied 
Biosystems
®), 300 nM EIAV Ψ forward primer, 300 nM Ψ reverse primer and 100 nM EIAV Ψ 
probe,  made  up  to  a  total  volume  of  27  µL.    The  concentrations  of  primers  and  probe  are 
provided in terms of the final volume (30 µL), which is reached by the addition of 3 µL RNA 
template.  The nucleotide sequences of the primers and probe are as stated in Section 2.11.2.3.  
A second PCR mix was prepared in which the MultiScribe
TM RT and RNase Inhibitor Mix was 
omitted, in order to assess DNA contamination levels.  Each RNA template was analysed in 
duplicate  (+RT)  and  singularly  (-RT).    ‘Unknown’  samples  were  diluted  10
0  -  10
2.    A  cRNA 
standard containing EIAV Ψ of known copy number was used to generate a dilution series for a 
standard curve.  The primers, probe and cRNA standard were obtained from the PAR Group at 
Oxford BioMedica.  Appropriate negative and positive (reference) controls were also included in 
each assay.  Following addition of template RNA to PCR mix, 25 µL was transferred to a 96-well 
optical plate and RNA copies mL
-1 were quantified  using  an  ABI Prism
® 7900HT Sequence 
Detection System. Cycling conditions were: 48 °C for 30 min; 95 °C for 10 min; 95 °C for 15 sec; 
60 °C for 1 min. The last two steps were repeated for 40 cycles.  If RNA extractions, DNaseI 
treatment and set-up of the TaqMan plate could not be completed sequentially on the same 
day, extracted RNA was stored in the interim at either -20 °C (up to 5 days) or -80 °C (up to 6 
months). 
Data  analysis  was  performed  using  Sequence  Detection  System  software  according  to  the 
manufacturer’s recommendations, and data was scrutinised to ensure the assay acceptance 
criteria were met.  Criteria were as outlined in Section 2.11.2.3, plus the following condition was 
added: (vii) the DNA copy number returned in each –RT reaction should be at least 10-fold 
lower than the RNA copy number returned for parallel +RT reactions. 
2.11.3.2  Product enhanced reverse transcriptase (PERT) assay 
The PERT assay was performed using a method similar to that previously described (Martin-
Rendon et al., 2002; Rohll et al., 2002; Stewart et al., 2009).  This assay uses a mild detergent 
to release RT associated with lentiviral vector particles.  qRT-PCR is then performed, in which 
the RT liberated from vector particles is utilised to convert MS2 (bacteriophage) RNA into cDNA.  109 
 
 
The amount of cDNA synthesised is proportional to the amount of RT present in the reaction, 
and as the amount of RT present in the reaction directly relates to the number of lentiviral vector 
particles initially present within the sample, a prediction of biological titre (PERT predicted TU 
mL
-1) can accordingly be made.  
To disrupt vector particles, 25 µL sample (crude supernatant) was added to 25 µL disruption 
buffer (40 mM Tris-HCl [pH 7.5], 50 mM KCl, 20 mM DTT, 0.2 % [v/v] Igepal
® CA-630) (Martin-
Rendon et al., 2002; Rohll et al., 2002).  Serial dilutions of disrupted vector stocks were carried 
out using PBS (10
2 - 10
3).  In parallel to unknown (test) samples, an EIAV-based lentiviral vector 
preparation of known biological titre was disrupted and diluted to generate a standard curve.  
The  disruption  buffer  and  vector  for  creation  of  the  standard  curve  were  obtained  from  the 
Research/PAR Group at  Oxford BioMedica.   To set up TaqMan
® reactions a PCR mix was 
prepared  that  consisted  of  15  µL  TaqMan
®  Universal  PCR  Master  Mix  No  AmpErase  UNG 
(Applied Biosystems
®), 0.4 U µL
-1 RNase Inhibitor (Ambion
®), 300 nM PERT forward primer (5’ 
TTC TGC TCA ACT TCC TGT CGA 3’), 300 nM PERT reverse primer (5’ CAC AGG TCA AAC 
CTC CTA GGA ATG 3’) and 150 nM PERT probe (5’ [FAM] CGA GAC GCT ACC ATG GCT 
ATC GCT GTA G [TAMRA] 3’) made up to a total volume of 26.78 µL.  The concentrations of 
RNase Inhibitor, primers and probe are provided in terms of the final volume (30 µL), which is 
reached  by  the  addition  of  0.225  µL  MS2  RNA  (Roche  Diagnostics  Ltd)  and  3  µL  sample 
(source of RT). The primers and probe were obtained from the Research/PAR Group at Oxford 
BioMedica, and are specific for MS2 RNA.  Negative controls (-RNA template or -RT source) 
were also included in each assay.  Once the MS2 RNA and disrupted sample and had been 
added to the PCR mix, 25 µL was transferred to a 96-well optical plate and PERT predicted TU 
mL
-1  was  quantified  using  an  ABI  Prism
®  7900HT  Sequence  Detection  System  (cycling 
conditions as described in Section 2.11.3.1). 
Data  analysis  was  performed  using  Sequence  Detection  System  software  according  to  the 
manufacturer’s  recommendations.    Data  was  scrutinised  to  ensure  the  assay  acceptance 
criteria were met.  Criteria were as outlined in Section 2.11.2.3, except a broader range in terms 
of reaction efficiency (60 - 115 %) was accepted. 
   110 
 
 
2.11.4  Software 
Unless otherwise stated, Excel (Microsoft
®, Berkshire, UK) was used to solve all fluid mixing, 
lentiviral vector titre, and lentiviral vector particle number calculations.  Except where stated, 
Origin  Pro  9  software  (OriginLab  Corporation,  Northampton,  MA,  USA)  was  used  for  linear 
regression analyses and to create all graphs. 
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3  Development of a microwell platform for use in lentiviral 
vector bioprocess development 
3.1  Introduction and aims 
Lentiviral vectors have the capacity to stably integrate a therapeutic gene of interest into the 
genome of both dividing and non-dividing cells in vivo, conferring long-term gene expression 
(Naldini et al., 1996a; Naldini et al., 1996b).  Lentiviral vectors are thus efficient gene delivery 
tools,  and  several  promising  candidates  are  in  development  for  a  range  of  gene  therapy 
applications (see Section 1.3.2).  The first clinical trial to utilise a lentiviral vector was initiated in 
2003 (Manilla et al., 2005; Levine et al., 2006) and since then (up to January 2014) 71 lentiviral 
vector-based  clinical  trials  have  been  undertaken  (http://www.wiley.co.uk/genmed/clinical/ 
accessed 26.02.14).  While lentiviral vectors continue to make good progress in the clinic, of 
mounting  concern  is  whether  existing  manufacturing  processes  are  capable  of  generating 
adequate quantities of material to fulfil expected commercial demands (Ansorge et al., 2010; 
Schweizer and Merten, 2010; Segura et al., 2013).  Lentiviral vectors used in clinical trials are 
currently produced in multi-layered cell factories by transient transfection of adherent human 
embryonic kidney (HEK)293 cell lines (or their derivatives) using between two and five plasmids 
(Slepushkin et al., 2003; Negré et al., 2008; Schweizer and Merten, 2010; Merten et al., 2011; 
Stewart  et  al.,  2011;  Ausubel  et  al.,  2012).    This  approach  is  not,  however,  suited  to  the 
generation of a licensed product.  Transient transfection techniques are costly and technically 
challenging to scale-up and batch-to-batch variability is common, while the presence of large 
quantities  of  transfected  plasmid  DNA  may  exacerbate  the  risk  of  replication  competent 
lentivirus (RCL) formation (Cockrell and Kafri, 2007; Stewart et al., 2009; Ansorge et al., 2010; 
Schweizer  and  Merten,  2010;  Rodrigues  et  al.,  2011;  Segura  et  al.,  2013).    Adherent  cell 
expression systems are also not amenable to scale-up and the growth of HEK293-derived cells 
as monolayers means that production capacity can only be increased by “scaling-out”, through 
introducing  more  cell  factories  (Schweizer  and  Merten,  2010).    Consequently,  for  product 
commercialisation,  the  development  of  producer  cell  lines  that  have  all  genes  for  vector 
production stably integrated and are amenable to growth in suspension is highly desirable.  This 
would eliminate the requirement for a transient transfection step and mean that scale-up into 112 
 
 
multi-litre  bioreactors  would  also  become  feasible.    However,  the  successful  creation  of  a 
suspension-grown lentiviral vector producer cell line that generates commercially-relevant titres 
has  been  reported  just  once  (Broussau  et  al.  (2008);  see  Section  1.4.1).    This  is  clearly, 
therefore, an area warranting significant attention.  To date, progress has likely been hindered 
by  the  difficulties  encountered  when  developing  suspension-adapted  producer  cell  lines.    In 
particular,  the  tendency  of  HEK293-derived  cells  to  aggregate  when  cultured  in  suspension 
(Merten et al., 2001), changes in the morphology and membrane properties of cells following 
suspension adaption (Ansorge et al., 2010), and the use of non-optimised culture conditions 
(Segura et al., 2013) can all play a role in diminishing titres.  To aid the development of scalable 
manufacturing processes for lentiviral vectors, a deeper understanding of the factors impacting 
on titres from suspension cultures of stable producer cell lines is clearly required.  As a range of 
parameters  may  influence  titres,  numerous  experiments  are  needed  to  characterise  their 
various  effects.    Microscale  bioprocessing  combined  with  Design  of  Experiments  (DoE) 
techniques could simplify this process (see Sections 1.5.1 and 1.5.2, respectively).  Orbitally 
shaken  microwell  plates  are  low-cost  and  simple  to  use,  require  little  space  and  culture 
materials, and allow numerous parameters to be evaluated quickly and simultaneously (Kumar 
et al., 2004; Neubauer et al., 2013).  As compared to the traditional one-factor-at-a-time (OFAT) 
approach to process optimisation, DoE better characterises the effects of multiple parameters 
using a smaller set of experiments that are linked in a rational manner (Czitrom, 1999; Tye, 
2004; Anderson and Whitcomb, 2007; Eriksson et al., 2008).  The value of combining microwell 
experimentation  and  DoE  techniques  has  been  demonstrated  for  the  optimisation  of  protein 
expression from microbial expression systems (Islam et al., 2007; Holmes et al., 2009), however 
such an approach has not been applied to lentiviral vector process development.   Thus, the 
primary aim of this first results chapter is to develop a microwell experimental platform that can 
support  suspension  cultures  of  lentiviral  vector  producer  cells,  and  to  evaluate  its  utility  (in 
conjunction with DoE techniques) for the rapid screening of multiple operating parameters to 
identify  those  most  affecting  titres.    As  it  is  important  that  any  data  generated  using  the 
microwell platform should remain relevant upon scale-up to larger vessels, engineering scaling 
parameters were considered.  Mixing time (see Section 1.5.3) was chosen for evaluation as the 
utility of this criterion for scale-up of a mammalian cell culture process from a shaken microwell 
to  a  WAVE  bioreactor  (the  vessel  format  that  will  ultimately  be  trialled  for  lentiviral  vector 113 
 
 
production in this work- see Chapter 5) has previously been demonstrated (Gill et al., 2011).  
Throughout this chapter, the ProSavin
® production process (based on suspension cultures of 
PS46.2)  will  be  utilised  as  a  model  system  (see  Sections  1.3.3  and  1.4.5).    The  specific 
objectives of this chapter are: 
  To evaluate a shaken 24-well plate system for the suspension culture of HEK293T-
derived lentiviral vector producer cells (PS46.2), and to establish production methods 
compatible with this format.  
  To  assess  whether  mixing  time  could  form  an  appropriate  basis  for  scale-up  of  the 
lentiviral vector production process from a shaken microwell to a WAVE bioreactor.  
  To demonstrate the utility of the microwell platform when combined with a DoE-guided 
approach, for the rapid screening of multiple operating parameters to ascertain their 
relative impact on lentiviral vector (ProSavin
®) titre.  
Results included in Section 3.2.5 of this chapter were published in: Guy, H. M., McCloskey, L., 
Lye, G. J., Mitrophanous, K. A. and Mukhopadhyay, T. K.  (2013). Characterization of Lentiviral 
Vector Production Using Microwell Suspension Cultures of HEK293T-Derived Producer Cells. 
Human Gene Therapy Methods 24(2):125-139.  Permission to reproduce this content has been 
granted by Mary Ann Liebert, Inc. 
3.2  Results 
3.2.1  Evaluation  of  a  shaken  microwell  system  for  suspension  culture  of  ProSavin
® 
producer cells (PS46.2) 
The  first  objective  of  this  work  was  to  evaluate  whether  shaken  microwells  could  support 
suspension cultures of PS46.2.  The microwell format chosen for evaluation was a standard 24 
round  well  ultra-low  attachment  plate  (Corning  Inc.),  for  which  utility  (as  assessed  by  the 
successful culture of murine hybridoma and CHO cell lines) had been previously demonstrated 
(Micheletti  et  al.,  2006;  Barrett  et  al.,  2010;  Silk  et  al.,  2010).  Although  smaller  microwell  
culture formats exist, such as the 96-well shaken system (0.2 mL working volume) employed by 
Deshpande et al. (2004) for cultivation of CHO cells, here a working volume of ≥ 0.5 mL was 
required  for  analytical  purposes.    To  minimise  evaporation  the  plate  was  sealed  using  a 114 
 
 
sandwich lid (Duetz et al., 2000) in conjunction with a metal clamp as previously described (Silk 
et al., 2010).  Silk et al. (2010) reported that use of this cover limited the rate of fluid loss to 3 % 
day
-1,  making  it  the  preferred  choice  over  the  Diversified  Biotech  Breathe-Easy  membrane 
(Sigma-Aldrich) that was employed during the earlier microwell studies conducted by Micheletti 
et al. (2006) and Barrett et al. (2010).  The reported rate of fluid loss when using this cover was 
6.3 % day
-1 (Silk et al., 2010).   
Process development studies based on the PS46.2 cell line had, until this point, ordinarily been 
performed  in  shake  flasks.    It  was  desirable  for  future  process  development  studies  to  be 
performed  in  microwells,  rather  than  shake  flasks,  due  to  the  associated  cost  savings  and 
increased  opportunity  for  parallelisation  and  thus  experimental  throughput.    Standard  shake 
flask cultures of PS46.2 (50 mL working volume) were seeded in parallel to microwell cultures 
(0.8 mL working volume), to provide a set of reference data against which the microwell results 
could be compared.  Samples were removed from both vessels up to 189 hr post-seeding to 
enable  analysis  of  the  following  parameters:  viable  cell  concentration,  cell  viability,  pH, 
osmolality, and concentration of metabolites (glucose, lactate, glutamine and ammonium).  At 
each sampling point  a small  volume (~ 1 mL) of culture  was removed from triplicate shake 
flasks,  while  triplicate  microwell  cultures  were  sacrificed.    The  initial  choice  of  microwell 
operating  conditions  was  based  on  established  shake  flask  procedures  for  PS46.2  (Oxford 
BioMedica) and on previously published methods relating to the cultivation of mammalian cells 
using the elected microwell format (Micheletti et al., 2006; Barrett et al., 2010; Silk et al., 2010).  
For a detailed description of the methods used see Section 2.2.1. 
The  primary  objective  of  this  study  was  to  ascertain  whether  microwells  could  support 
comparable  viable  cell  concentrations  to  shake  flasks.    For  this  purpose,  comparability  was 
defined according to whether a similar viable cell concentration (i.e. within ± 1 SD) was reached 
at the same time point in both vessels.  All other parameters were monitored to gain greater 
insight into the growth dynamics of PS46.2 within each vessel, and were of secondary interest.  
For these parameters, comparability was determined according to whether the data for the two 
systems exhibited the same trend.  Data was not subjected to statistical testing (e.g. ANOVA) 
as this was deemed inappropriate due to the small number of replicates involved (n ≤ 3).  115 
 
 
3.2.1.1  Cell growth and viability 
As  illustrated  in  Figure  3.1,  the  growth  profiles  of  PS46.2  cultured  in  both  shake  flask  and 
microwell formats were comparable, as similar peak viable cell concentrations (within ± 1 SD) 
were reached at the same time point.  In both cases, the highest viable cell concentrations were 
observed on the third day of culture at 73 hr post-seeding, when densities reached 3.3 x 10
6 
cells mL
-1 in shake flasks and 4.0 x 10
6 cells mL
-1 in microwells.  There were differences in cell 
viabilities, however, which tended to be higher for shake flasks than microwells.  This was most 
obvious at 73 hr post-seeding when the viability of shake flask cultures was 93.3 %, while the 
viability  of  microwell  cultures  was  73.3  %.    As  indicated  by  the  fact  that  viable  cell 
concentrations were similar, the total (viable and dead) cell concentration was markedly lower in 
shake flasks than microwells at this time point (3.5 x 10
6 cells mL
-1 versus 5.4 x 10
6 cells mL
-1, 
respectively).    This  implies  that  microwell  cultures  of  PS46.2  had  a  faster  growth  rate,  and 
therefore it is possible that some factor became limiting to cell survival sooner for these cultures 
-  leading  to  the  observed  divergence  in  cell  viability  between  the  two  vessel  types.    Some 
dissimilarity between shake flasks and microwells in terms of cell growth was expected as the 
physical environment within each vessel is not identical (this will be discussed in Section 3.2.4).  
In addition, no attempt was made to improve comparability between the two systems as the 
initial cell growth data was deemed sufficiently similar as to satisfy the purpose of the study, i.e. 
it could be concluded that the microwell system was capable of supporting similar cell densities 
to shake flasks and further evaluation of the system, with a view to its application for early 
process development work, was therefore warranted.  
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Figure 3.1  Comparison of parallel shake flask and microwell PS46.2 cultures in terms of 
cell growth and viability (n = 3).  Shake flasks and microwells were seeded with PS46.2 at a 
density of 4 x 10
5 viable cells mL
-1 in medium containing 5 % foetal calf serum (FCS).  The 
orbital shaking diameter was 10 mm, while the shaking speed was maintained at 150 rpm for 
shake flasks and 180 rpm for microwells.  Mean data is plotted and error bars represent ± one 
standard deviation (SD). 
3.2.1.2  pH and osmolality 
In order to better understand the observed growth dynamics of PS46.2; pH, osmolality, and 
metabolite data (collected at the same time as growth data) were also analysed.  The normal 
pH of media designed to support mammalian cell cultures ranges from 6.8 - 7.5 (Brusick, 1986).  
During batch cultivations pH typically decreases over time as lactic acid is released as a by-
product of cell metabolism (Naciri et al., 2008).  In the present study, the starting pH of the 
culture medium was 7.5 for both shake flask and microwell cultures (Figure 3.2).  Consistent 
with an actively dividing and thus respiring cell population, the pH steadily decreased until 73 hr 
post-seeding,  when  values  of  6.9  (shake  flasks)  and  7.0  (microwells)  were  recorded, 
corresponding  with  peak  viable  cell  densities.    As  was  expected,  the  decrease  in  pH  was 
consistent with increasing lactate concentrations (Figure 3.3).  As the pH did not fall appreciably 117 
 
 
below 7.0 in either culture vessel, it is unlikely that culture acidification was responsible for the 
observed decline in viable cell numbers after 73 hr.  From 73 hr until the end of the culture 
period the pH again rose (in-line with diminishing lactate concentrations) and at 189 hr values of 
7.3 (shake flasks) and 7.5 (microwells) were recorded.  Overall, the pH profiles for shake flask 
and microwell cultures were similar (Figure 3.2).   
When handling low volumes, evaporation is a well-recognised concern (Berthier et al., 2008), 
particularly with regards to cell culture (Girard et al., 2001; Deshpande et al., 2004) where it can 
cause elevated osmolalities and as a consequence potentially compromise cell health (Silk et 
al., 2010).  In the current study, the osmolality of shake flask cultures was 0.290 osmol kg
-1 at 
the start of the cultivation period and declined marginally during the culture, measuring 0.267 
osmol kg
-1 after 189 hr (Figure 3.2).  The osmolality of microwell cultures once seeded (0 hr) 
was  similar  to  shake  flasks  (0.288  osmol  kg
-1),  but  this  value  rose  slightly  throughout  the 
cultivation period, reaching 0.316 osmol kg
-1 by 189 hr.  The higher osmolality in microwells as 
compared  to  shake  flasks  was  expected  based  on  the  findings  of  Silk  et  al.  (2010),  who 
reported that although more liquid was lost from shake flask cultures than microwell cultures 
(310 µL day
-1 versus 24 µL day
-1, respectively), this accounted for a much smaller proportion of 
the total starting volume (just 0.6 % versus 3 %, respectively).  Thus assuming evaporation 
occurred to a similar extent in the current study, which is reasonable given that the vessels and 
fill volumes used were identical and the operating conditions were also alike, a greater rise in 
culture osmolality as a result of evaporation  was to be anticipated for microwell cultures as 
compared to shake flask cultures.  The observed increase in microwell osmolality is unlikely to 
have  negatively  impacted  on  PS46.2  cell  growth.    Mammalian  cell  cultures  are  normally 
maintained at an osmolality of around 300 osmol kg
-1 (Hu and Aunins, 1997).  Shen and Kamen 
(2012) reported that for suspension cultures of HEK293, raising the media osmolality from its 
standard level of 0.290 osmol kg
-1 to 0.330 osmol kg
-1 (higher than in the present study) had no 
detrimental effect on cell growth, however, raising the osmolality further to 0.370 osmol kg
-1 
reduced growth rates to around 80 % of those observed for standard cultures.  Overall, the 
increase in microwell osmolality observed was small, and evaporation does not present a major 
concern  when  considering  further  development  work  when  using  this  microwell  platform  in 
conjunction with the PS46.2 cell line - a typical ProSavin
® production run lasts around 48 hr 118 
 
 
(Section 2.2.2), over which period microwell osmolalities are unlikely to be significantly raised as 
compared  to  starting  values  (here,  microwell  osmolality  was  0.298  osmol  kg
-1  after  45  hr 
cultivation).    If  the  microwell  platform  were  to  be  used  for  significantly  extended  cultivation 
periods, the addition of diluted bolus feeds could be considered as a means to offset fluid losses 
due to evaporation, as described by Silk et al. (2010).  
 
Figure 3.2  Comparison of parallel shake flask and microwell PS46.2 cultures in terms of 
pH and osmolality (n = 3).  Operating conditions were as stated for Figure 3.1.  Mean data is 
plotted and error bars represent ± 1 SD. 
3.2.1.3  Glucose and lactate 
The concentrations of glucose, lactate, glutamine, and ammonium in the culture medium were 
also monitored.  Batch-cultured mammalian cells exhibit an inefficient metabolic phenotype that 
is  characterised  by  the  incomplete  oxidation  of  glucose  via  the  glycolytic  pathway  (the  end 
product,  pyruvate,  is  reduced  to  lactate,  facilitating  the  oxidation  of  nicotinamide  adenine 
dinucleotide [NADH] to NAD+ for re-use in glycolysis) and the incomplete oxidation of glutamine 119 
 
 
via the glutaminolytic pathway (yielding ammonia and non-essential amino-acids) (Schneider et 
al.,  1996;  Elias  et  al.,  2003;  Quek  et  al.,  2010).    A  lack  of  glucose  or  glutamine,  or  an 
accumulation of ammonia or lactate, can contribute to cell death (Krampe and Al-Rubeai, 2010), 
thus  to  better  understand  the  observed  growth  profiles  for  PS46.2  (Section  3.2.1.1)  the 
concentrations of these key metabolites were monitored throughout the culture period.   
As expected, the concentration of glucose in the culture medium decreased over time for both 
shake flask and microwell cultures (Figure 3.3).  In shake flasks the glucose concentration was 
2.7 g L
-1 at the start of the culture (0 hr) but just 0.3 g L
-1 at the end (after 189 hr).  Values for 
microwell cultures were similar: the glucose concentration was 3.0 g L
-1 at the time of seeding (0 
hr) but after 189 hr only 0.2 g L
-1 remained.  The glucose supply was not exhausted in either 
vessel, however, and glucose is unlikely to have become a limiting nutrient at any point during 
the  culture.    Siegwart  et  al.  (1999)  previously  reported  no  difference  in  the  growth  rate  of 
bioreactor suspension cultures of HEK293 when a either a starting glucose concentration of 21 
mM (3.8 g L
-1) was used or the glucose concentration was controlled at just 1 mM (0.2 g L
-1), 
and also noted that no growth lag occurred when shifting the glucose concentration from 21 to 1 
mM for the initiation of the low-glucose controlled cultures.  In the current work, following a peak 
in  viable cell concentration 73  hr post-seeding,  by  93 hr cell  numbers had declined  in  both 
shake flasks and microwells (Figure 3.1), at which time a reasonable supply of glucose was still 
present in the culture medium (values of 0.7 g L
-1 and 1.0 g L
-1 were recorded for shake flask 
and microwell cultures, respectively).  Glucose limitation is therefore unlikely to have instigated 
the drop off in viable cell numbers recorded at 93 hr, and thus the impact of other metabolites 
on the observed growth kinetics must be considered. 
In both vessel types the observed reduction in available glucose over time was concurrent with 
an accumulation of lactate between 0 and 73 hr post-seeding (Figure 3.3).  Over this period the 
lactate concentration in shake flasks increased from 0.2 g L
-1 (0 hr) to 1.6 g L
-1 (73 hr), and in 
microwells rose from 0.3 g L
-1 (0 hr) to 2.2 g L
-1 (73 hr).  Lactate concentrations in excess of 
around 20 - 30 mM (1.8 - 2.7 g L
-1) have been reported to negatively impact on mammalian cell 
growth (Reuveny et al., 1986; Ozturk et al., 1992; Nadeau et al., 1996; Schneider et al., 1996; 
Cruz et al., 2000; Patel et al., 2000).  Here, the concentration of lactate reached potentially 
inhibitory levels in microwells, but not in shake flasks.  It has been well documented that for 120 
 
 
non-pH controlled systems the reduction in extracellular pH associated with raised lactate levels 
is often the predominant factor responsible for slowed cell growth rates or decreased viabilities 
(Omasa et al., 1992; Ozturk et al., 1992; Schneider et al., 1996; Patel et al., 2000).  In this 
study,  although  the  culture  pH  declined  in-line  with  the  increasing  lactate  levels,  significant 
culture acidification was not observed (Figure 3.2, Section 3.2.1.2).  Overall, it therefore seems 
unlikely that accumulation of lactate instigated the decline in viable cell numbers observed in 
both vessels post-73 hr. 
Finally, it is important to note that lactate concentrations declined after 73 hr, and by 189 hr 
values of 0.4 g L
-1 (shake flasks) and 0.6 g L
-1 (microwells) were recorded (Figure 3.3).  For both 
vessel types, the fall in lactate concentration was concurrent with an increase in pH (Figure 3.2).  
The capacity of mammalian cells to switch to lactate consumption during the later phases of cell 
culture has been documented (Siegwart et al., 1999; Altamirano et al., 2006; Ma et al., 2009; Li 
et  al.,  2012;  Mulukutla  et  al.,  2012).    Lactate  consumption  is  obviously  desirable  as  its 
accumulation is reversed and its cytotoxic impact thus moderated, and during the production of 
recombinant proteins at least, a switch to lactate consumption during the later stages of culture 
has been strongly linked to an increase in cell productivity (Mulukutla et al., 2012).  It is unclear 
what triggered the metabolic shift to lactate consumption – it was unlikely induced by a lack of 
glucose, as this substrate remained available in reasonable quantities throughout the culture 
period.   121 
 
 
 
Figure 3.3  Comparison of parallel shake flask and microwell PS46.2 cultures in terms of 
glucose and lactate concentrations (n = 3 for all points except the 73 hr microwell sample, for 
which n = 1).  Operating conditions were as stated for Figure 3.1.  Mean data is plotted and 
error bars represent ± 1 SD. 
3.2.1.4  Glutamine and ammonium 
As  well  as  containing  glucose,  the  FreeStyle
TM  293  expression  medium  used  in  this  work 
contained  GlutaMAX™  (Invitrogen)  as  a  glutamine  supplement.    Although  glutamine 
supplementation  is  essential  for  successful  mammalian  culture  (Quek  et  al.,  2010),  it 
spontaneously degrades to release ammonia which can build-up in the medium and have a 
cytotoxic  impact  (Hassell  et  al.,  1991).    GlutaMAX™  is  a  dipeptide  and  stable  precursor  to 
glutamine,  which  is  only  hydrolysed  to  glutamine  and  alanine  in  the  presence  of  peptidase 
(which  is  released  from  mammalian  cells  during  culture),  thus  when  using  GlutaMAX™  the 
amount of ammonia produced via the chemical degradation of glutamine is reduced (Quek et 
al., 2010).  In this study, the glutamine concentration peaked 22 hr post-seeding when values of 
0.27 g L
-1 (shake flasks) and 0.31 g L
-1 (microwells) were recorded, indicating that GlutaMAX™ 
was quickly hydrolysed once in contact with cells (Figure 3.4).  After 93 hr glutamine levels in 122 
 
 
shake flasks and microwells had declined to 0.10 g L
-1 and 0.14 g L
-1, respectively.  Siegwart et 
al. (1999) previously reported that when glutamine concentrations were below 1.6 mM (0.23 g L
-
1) the growth rate of suspension-grown HEK293 slowed by 3 - 4 fold, and at concentrations less 
than  1.0  mM  (0.15  g  L
-1)  the  cells  ceased  to  consume  glutamine  at  all,  although  viabilities 
remained  high  for  several  days,  and  the  authors  suggested  that  ammonia  may  have  been 
utilised as an alternative nitrogen source during this period.  Based on the findings of Siegwart 
et al. (1999) by 73 hr glutamine levels were probably limiting in the current study, and by 93 hr 
glutamine may no longer have been being metabolised.  Consistent with this hypothesis is the 
observation that viable cell numbers declined post-73 hr (Figure 3.1).  In addition, from 93 hr to 
189 hr glutamine levels again rose in shake flask and microwell cultures to 0.17 g L
-1 and 0.22 g 
L
-1, respectively, implying that although hydrolysis of GlutaMAX™ continued during this period, 
the glutamine released was no longer consumed to the same extent as earlier in the culture.   
Throughout the culture period, ammonium steadily accumulated in the medium of shake flasks 
and microwells (Figure 3.4).  Build-up of ammonia is undesirable during mammalian cell culture 
as  it  perturbs  electrochemical  gradients  and  causes  intracellular  acidification,  and  energy 
consumption  increases  as  the  cells  strive  to  maintain  pH  homeostasis;  it  can  also  induce 
apoptosis (Cruz et al., 2000).  Although the extent to which ammonia is tolerated depends on 
the specific cell line in question (Mirabet et al., 1997), concentrations as low as 2 mM (0.04 g L
-
1)  have  been  reported  to  significantly  impair  mammalian  cell  growth  (Reuveny  et  al.,  1986; 
Ozturk  et  al.,  1992;  Schneider  et  al.,  1996;  Cruz  et  al.,  2000;  Henry  and  Durocher,  2011; 
Rajendra et al., 2011).  The toxic effects of ammonia are thus apparent at approximately ten-
fold  lower  concentrations  than  those  of  lactate.    In  the  current  study,  an  ammonium 
concentration of 0.04 g L
-1 was reached after just 45 hr culture for both vessel types, and final 
concentrations recorded after 189 hr were two to three-fold higher at 0.09 g L
-1 (shake flasks) 
and 0.12 g L
-1 (microwells).  As ammonium concentrations did not fall at any point, it seems 
unlikely that ammonia was utilised as a nitrogen source when glutamine became scarce, as was 
noted previously during the batch culture of suspension-based HEK293 cells (Siegwart et al., 
1999).  Considering the relatively high ammonium concentrations observed in this study, it is 
reasonable to suppose that this compound had some cytotoxic impact on PS46.2, particularly 
during the latter stages of the culture period, and may have contributed to the observed decline 123 
 
 
in viable cell numbers post-73 hr.  Finally, it is worth highlighting here the work of Cruz et al. 
(2000),  who  found  that  stirred  cultures  of  BHK  cells  were  more  susceptible  than  stationary 
cultures to the effects of elevated ammonia levels: 3.5 mM (0.06 g L
-1) reduced growth rates by 
50 % in stationary cultures, however just 1.1 mM (0.02 g L
-1) effected the same inhibition in 
stirred cultures, while overall cell death was induced at concentrations above 7.6 mM (0.14 g L
-
1) and 2.6 mM (0.05 g L
-1), respectively.  The authors hypothesised that agitation may promote a 
higher  uptake  of  ammonia  by  the  cell  (Cruz  et  al.,  2000),  thus  worth  consideration  is  the 
potential sensitivity of suspension-adapted PS46.2 to elevated ammonia levels when cultured 
using shaken systems. 
 
 
Figure 3.4  Comparison of parallel shake flask and microwell PS46.2 cultures in terms of 
glutamine and ammonium concentrations (n = 3 for all points except the 73 hr microwell sample, 
for which n = 1, and the 189 hr microwell sample [glutamine only], for which n = 2).  Operating 
conditions were as stated for Figure 3.1.  Mean data is plotted and error bars represent ± 1 SD.   
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3.2.2  ProSavin
® production using the shaken microwell system  
As the growth and associated culture kinetics of suspension-adapted PS46.2 cultured in shake 
flasks  versus  microwells  were  found  to  be  comparable  (Section  3.2.1),  lentiviral  vector 
production  was  next  evaluated.    Shake  flasks  and  microwells  were  seeded  in  parallel  and 
induced  24  hr  later  by  the  addition  of  1.0  µg  mL
-1  dox  and  10  mM  NaBu.    Harvests  were 
performed  24  hr  post-induction  and  titres  determined  using  the  rapid  ProSavin
®  titre  assay 
(Section 2.11.2.1).  Note that the microwell and shake flask procedures were broadly similar, 
except that a 96-well filter plate was used to clarify microwell supernatants, as the syringe filter 
used for shake flask harvests was not appropriate for microlitre volumes (NB a separate study 
verified  that  the  two  filtration  methods  yielded  comparable  ProSavin
®  titre  and  RNA  copy 
number results when a single batch of material was processed in parallel [data not shown]).  
Full details of the methods used are provided in Section 2.2.2.  Shake flask titres were found to 
be 2.48 ± 0.73 x 10
4 TU mL
-1 (mean ± 1 SD; n = 3), while microwell titres were 1.80 ± 0.43 x 10
4 
TU mL
-1 (mean ± 1 SD;  n = 4).  Microwell titres were within two-fold (and within ± 1 SD) of 
those recorded for shake flasks, thus, even without prior optimisation of the microwell process, 
reasonable comparability between the two vessel types was achieved.  As cell growth kinetics 
and  associated  culture  parameters  were  also  found  to  be  similar  at  the  two  culture  scales 
(Section 3.2.1), taken together the data indicate that microwells could be used effectively in 
place of shakes flasks for early phase process development studies based on the PS46.2 cell 
line.   
3.2.3  Application  of  the  shaken  microwell  system  for  the  suspension  culture  of  a 
second (HEK293T) cell line 
To verify the broader applicability of the microwell platform, the culture kinetics of a second 
HEK293T cell line (not stably integrated with lentiviral vector DNA) grown in shake flasks versus 
microwells  were  also  examined.    Shake  flasks  and  microwells  were  seeded  in  parallel  and 
samples  were  removed  up  to  189  hr  post-seeding  to  enable  analysis  of  viable  cell 
concentration, cell viability, pH, osmolality, and concentration of metabolites (glucose, lactate, 
glutamine and ammonium).  At each sampling point approximately 1 mL of culture was removed 
from  triplicate  shake  flasks,  while  triplicate  microwell  cultures  were  sacrificed.    The 125 
 
 
methodology, which was analogous to that previously employed during the earlier evaluative 
study based on the PS46.2 cell line (for which the results were presented in Section 3.2.1), is 
described in full in Section 2.2.3.  The only notable difference between the two studies (other 
than the choice of cell line), was that the culture medium used in this study contained 1 % foetal 
calf serum (FCS), whereas in the earlier study (Section 3.2.1) the culture medium contained 5 % 
FCS.  The same criteria for comparability were used as described in Section 3.2.1. 
3.2.3.1  Cell growth and viability 
As illustrated in Figure 3.5, the growth profiles of HEK293T cultured in both shake flask and 
microwell formats were similar.  Comparable maximum viable cell concentrations were reached 
in both vessels (within ± 1 SD).  However, these were observed on the third day of culture (72 hr 
post-seeding) for shake flasks (2.6 x 10
6 cells mL
-1) and on the sixth day of culture (144 hr post-
seeding) for microwells (2.2 x 10
6 cells mL
-1).  An obvious peak in viable cell numbers was not 
observed in either vessel (Figure 3.5), however, and cell densities did not reach as high as 
those observed during the earlier culture of PS46.2 (Section 3.2.1.1, Figure 3.1).  It is therefore 
likely that this particular HEK293T cell line was slower growing than PS46.2, and that peak cell 
densities  were  achieved  on  either  the  fourth  or  fifth  day  of  culture  when  sampling  was  not 
conducted, thus this data was not captured in the current experiment.  The viability of HEK293T 
cells  in  shake  flasks  and  microwells  remained  comparable  throughout  the  cultivation  period 
(Figure 3.5).  126 
 
 
 
Figure 3.5  Comparison of shake flask and microwell HEK293T cultures in terms of cell 
growth and viability (n = 3).  Shake flasks and microwells were seeded with HEK293T cells at a 
density of 4 x 10
5 viable cells mL
-1 in medium containing 1 % FCS.  The orbital shaking diameter 
was 10 mm, while the shaking speed was maintained at 150 rpm for shake flasks and 180 rpm 
for microwells.  Mean data is plotted and error bars represent ± 1SD. 
3.2.3.2  pH and osmolality 
The starting pH of the culture medium was 7.6 for shake flask cultures and 7.5 for microwell 
cultures (Figure 3.6).  The pH steadily decreased throughout the culture and after 189 hr the pH 
in shake flasks was ≤ 6.3 (a value of 6.3 was recorded for one replicate – the pH of the other 
two replicates was below the quantifiable limit [6.3] of the instrument) and in microwells was 6.4. 
The pH profiles for shake flask and microwell cultures were comparable.  The decrease in pH 
was consistent with increasing lactate concentrations (Figure 3.7).  At the 72 hr time point, the 
pH was 6.7 in both vessels, thus it is possible that culture acidification contributed to cell death.  
Note that the pH profile observed here (Figure 3.6) differed markedly to that observed earlier for 
the PS46.2 cell line (Section 3.2.1.2, Figure 3.2). 127 
 
 
The osmolality of shake flasks varied little throughout the culture period, measuring 0.280 osmol 
kg
-1 at the start (0 hr) and 0.297 osmol kg
-1 at the end (189 hr post-seeding) (Figure 3.6).  As 
expected, because of evaporation (see Section 3.2.1.2), the osmolality of microwell cultures, 
however, increased over time.  Microwell osmolalities rose from 0.284 osmol kg
-1 (0 hr) to 0.344 
osmol  kg
-1  (189  hr).    The  189  hr  value  is  slightly  higher  than  that  previously  recorded  in 
microwells  following  189  hr  cultivation  of  PS46.2  (Figure  3.2),  however,  for  lentiviral  vector 
process  development  work,  where  it  is  anticipated  that  cultivations  will  be  terminated  much 
earlier than 189 hr, this does not present a concern (Section 3.2.1.2). 
 
 
Figure 3.6  Comparison of parallel shake flask and microwell HEK293T cultures in terms of 
pH and osmolality (n = 3 for all points except the 189 hr shake flask pH sample, for which n = 1 
as  the  pH  values  for  the  other  two  replicates  were  below  the  quantifiable  limit  [6.3]  of  the 
instrument).  Operating conditions were as stated for Figure 3.5.  Mean data is plotted and error 
bars represent ± 1 SD. 
3.2.3.3  Glucose and lactate 
The concentration of glucose in the culture medium declined over time for both shake flask and 
microwell cultures (Figure 3.7).  In shake flasks the glucose concentration was 4.2 g L
-1 at the 128 
 
 
start of the culture (0 hr) but just 0.2 g L
-1 at the end (after 189 hr).  Values for microwell cultures 
were similar: the glucose concentration was 4.2 g L
-1 at the time of seeding (0 hr) but after 189 
hr only 0.1 g L
-1 remained.  It seems unlikely that glucose became a limiting nutrient for shake 
flask cultures (see discussion in Section 3.2.1.3), however, the possibility cannot be ruled out 
for microwell cultures.   
In both vessel types the observed decline in glucose over time was concurrent with a build-up of 
lactate (Figure 3.7).  The highest lactate values were observed on the sixth day of culture (144 
hr post-seeding) for both shake flask (3.1 g L
-1) and microwell cultures (3.5 g L
-1).  At the end of 
the culture (189 hr), lactate concentrations were still high, measuring 2.6 g L
-1 in shake flasks 
and 3.2 g L
-1 in microwells.  It is likely that these elevated lactate levels produced the significant 
reduction in culture pH noted earlier (Figure 3.6), and thus were indirectly detrimental to cell 
health.    Consequently,  this  cell  line  responded  very  differently  to  lactate  accumulation  than 
PS46.2, which was able to switch to lactate consumption after 73 hr culture and prevent culture 
acidification (Section 3.2.1.3, Figures 3.2 and 3.3).  Parental and sub-clonal Chinese hamster 
ovary (CHO) cell lines have previously been demonstrated to display distinct lactate profiles, 
which the authors concluded was due to differences in their mitochondrial oxidative capacity 
(Zagari  et  al.,  2013).    Thus,  the  metabolic  response  of  any  one  cell  line  to  changing 
environmental conditions will likely be unique, and conclusions relating to one cell line should 
not be generalised, even to other closely related clones. 129 
 
 
 
Figure 3.7  Comparison of parallel shake flask and microwell HEK293T cultures in terms of 
glucose and lactate concentrations (n = 3).  Operating conditions were as stated for Figure 3.5.  
Mean data is plotted and error bars represent ± 1 SD. 
3.2.3.4  Glutamine and ammonium 
As noted earlier (Section 3.2.1.4), the FreeStyle
TM 293 expression medium used in this work 
contained  GlutaMAX™,  which  is  hydrolysed  to  glutamine  and  alanine  in  the  presence  of 
peptidase that is released during cell culture.  Here, as observed previously during the culture of 
PS46.2 cells (Figure 3.4), GlutaMAX™ was quickly hydrolysed once in contact with cells and 
glutamine concentrations peaked 22 hr post-seeding in both shake flasks and microwells, when 
values of 0.30 g L
-1 and 0.32 g L
-1 were recorded, respectively (Figure 3.8).  By 72 hr, glutamine 
levels had fallen to 0.16 g L
-1 (shake flasks) and 0.19 g L
-1 (microwells), and were likely limiting 
in both vessels (see earlier discussion in Section 3.2.1.4).  Unlike as was observed during the 
cultivation of PS46.2 (Figure 3.4), glutamine concentrations remained low until termination of 
the  culture  at  189  hr,  at  which  point  values  of  0.05  g  L
-1  (shake  flasks)  and  0.04  g  L
-1 
(microwells) were recorded (Figure 3.8), suggesting that the HEK293T cultures continued to 
metabolise glutamine throughout the culture period. 130 
 
 
Throughout  the  culture  period,  ammonium  gradually  accumulated  in  shake  flasks  and 
microwells (Figure 3.8).   Interestingly,  at the start of the culture (0 hr), the concentration  of 
ammonium was 0.05 g L
-1 in shake flasks and 0.06 g L
-1 in microwells, thus already at levels 
potentially inhibitory to cell growth (see discussion in Section 3.2.1.4).  It is unclear why this 
should be the case when spontaneous degradation of glutamine to ammonia should be reduced 
in FreeStyle
TM 293 expression medium due to the substitution of glutamine with GlutaMAX™ (a 
stable glutamine precursor).  One explanation for this finding could be that peptidases present 
within  the  FCS  used  to  supplement  the  culture  medium  hydrolysed  the  GlutaMAX™  and 
released  glutamine,  which  subsequently  degraded  to  ammonia,  during  storage  of  the 
supplemented  medium  (supplemented  medium  was  stored  at  4  °C  for  up  to  one  month  – 
however,  as  a  precaution,  for  subsequent  studies  this  was  reduced  to  three  weeks).  
Ammonium concentrations were two to three-fold higher by 189 hr, when concentrations of 0.11 
g L
-1 and 0.13 g L
-1 were recorded in shake flasks and microwells, respectively (Figure 3.8).  It is 
therefore probable that ammonia exerted a cytotoxic impact on HEK293T cells throughout the 
culture period.  The ammonium profile observed here was similar to that previously observed for 
the PS46.2 cell line (Figure 3.4).  Overall, the cell growth, pH, and metabolite profiles for shake 
flask and microwell HEK293T cultures were comparable, indicating that the cells responded to 
changing environmental conditions similarly in both vessels.  This demonstrates that the utility 
of the microwell platform is not restricted solely to the PS46.2 cell line, but that its application 
may be extended to other HEK293T cell derivatives.      131 
 
 
 
Figure 3.8  Comparison of parallel shake flask and microwell HEK293T cultures in terms of 
glutamine  and  ammonium  concentrations  (n  =  3).    Operating  conditions  were  as  stated  for 
Figure 3.5.  Mean data is plotted and error bars represent ± 1 SD.   
3.2.4  Assessment of mixing time as a scaling criterion 
The 24-well plate system trialled here successfully supported ProSavin
® production based on 
suspension cultures of PS46.2 (Sections 3.2.1 and 3.2.2), making it an attractive low-volume 
alternative  to  shake  flasks  for  early  phase  process  development  work.    However,  for  the 
microwell platform to be usefully employed, any data generated should be relevant to larger 
scales  (Micheletti  et  al.,  2006;  Marques  et  al.,  2010).    As  discussed  in  Section  1.5.3,  no 
universal strategy exists for bioprocess scale-up.  The low oxygen requirements of mammalian 
cells (Micheletti et al., 2006) mean that use of the oxygen mass transfer coefficient (kLa; refer to 
Section 1.5.3) as a scaling criterion is inappropriate while, on the other hand, the sensitivity of 
mammalian cells to shear forces (Kretzmer and Schügerl, 1991) mean that maintaining similar 
hydrodynamic conditions is likely crucial.  Power per unit volume (P/V; refer to Section 1.5.3) 
directly relates to shear rate, and matched average P/V values have been used as a basis for 
scaling antibody production processes from microwells to shake flasks (Micheletti et al., 2006; 132 
 
 
Barrett et al., 2010).  However, this approach is unlikely to be effective for the translation of cell 
culture processes from shaken vessels to WAVE bioreactors.  P/V within a microwell varies 
spatially (Barrett et al., 2010), while in a WAVE bioreactor P/V varies both spatially and over 
time (as a direct function of the rocking motion) (Eibl et al., 2009).  Even if the overall average 
P/V for each system could be matched, the actual level of hydrodynamic stress experienced by 
cells is likely to be very different, thus scaling on the basis of a matched average P/V value is 
likely to be inappropriate in this instance.  An alternative scaling criterion to P/V is mixing time.  
Mixing time has previously been used as a scaling criterion for the translation of an antibody 
production process from a shaken microwell with 850 µL working volume to a WAVE bioreactor 
with 1 L or 4 L working volume (Gill et al., 2011).  Encouraged by this report, the potential of 
mixing  time  as  a  scaling  criterion  for  translation  of  the  ProSavin
®  production  process  (as 
described  in  Section  3.2.2)  from  a  shaken  microwell  to  a  WAVE  bioreactor  was  assessed.  
Mixing time experiments were carried out for a shaken microwell and, for comparison, other 
small-scale culture vessels, using the iodine decolourisation method as  described in Section 
2.3.   
Listed in Table 3.1 are the mixing time values obtained for a shaken microwell and various other 
small scale culture vessels.  For a microwell operated under conditions initially found to yield 
acceptable cell growth kinetics and lentiviral vector titres (Sections 3.2.1 and 3.2.2; fill volume 
800 µL and shaking speed 180 rpm), the mixing time was extremely long (1037 s).  This is in 
agreement with the findings of Barrett et al. (2010), who reported that for a microwell with an 
800 µL fill volume and Re of around 1000 (here, Re was calculated to be 1049), the mixing time 
was approximately 1000 s.  As illustrated in Figure 3.9, there is little deformation of the fluid 
surface at this shaking speed and when a small volume of liquid is added (as during the mixing 
time  experiments)  this  descends  to  the  base  of  the  microwell,  where  it  spreads  out  and 
gradually rises and disperses within the bulk fluid (the time taken for complete homogeneity to 
be achieved is equivalent to the mixing time).  This visualisation also mimics what would most 
probably happen during the addition of inducer compounds (dox and NaBu) during cell culture.  
It  is  evident  that  heterogeneities  would  exist  temporarily,  which  may  be  of  concern  if  these 
compounds exert a toxic influence at high concentrations (Barrett et al., 2010).  This concern is 133 
 
 
exacerbated by the fact that microwells are typically stationary when such additions are made 
(microwells are transferred to a biological safety cabinet to preserve sterility).   
Table 3.1  Mixing time values for various small scale culture vessels.  The diameter of the 
shaking platform was 10 mm.  Mixing times were determined using the iodine decolourisation 
method as outlined Section 2.3.  Mean data is presented and error bars represent ± 1 SD (n = 
3).   
Vessel 
type 
Total capacity 
(mL) 
Working 
volume (mL) 
Shaking 
speed (rpm) 
Mixing time 
(s) 
Microwell   3.4  0.8  140  1374 ± 30 
Microwell   3.4  0.8  180  1037 ± 40 
Microwell   3.4  0.8  220  333 ± 20 
Microwell   3.4  0.8  260  15 ± 1 
Shake flask  125  25  150  29 ± 4 
Shake flask  250  50  150  24 ± 7 
Shake flask  500  100  150  29 ± 3 
Roller bottle  2000  4000  150  8 ± 1 
As expected, the mixing time was slower when the shaking speed was decreased to 140 rpm, 
and faster when the shaking speed was increased to 220 and 260 rpm (Table 3.1).  Eibl et al. 
(2010b) reported that mixing times for a WAVE bioreactor, when operated under various rocking 
conditions and with a standard 40 - 50 % fill volume, were in the range of 9 to 264 s for a 2 L 
system (the scale later evaluated in this work – see Chapter 5), and 65 to 874 s for a 200 L 
system (the scale hypothetically required for commercial production of ProSavin
®).  Thus, if the 
mixing time in microwells is to be reproduced in both a 2 L and 200 L WAVE bioreactor, a value 
of between 65 and 264 s is necessary, for which a platform shaking speed of between 220 and 
260 rpm would be required (see Table 3.1).  As preliminary experiments indicated that such 
conditions were unfavourable for PS46.2 cell growth (data not shown), the use of mixing time as 
a scaling criterion was deemed impracticable.  Furthermore, the observation that the mixing 
time was around 40-fold shorter for a 250 mL shake flask shaken at 150 rpm (24 ± 7 s) as 
compared to a microwell shaken at 180 rpm, yet cell growth kinetics and lentiviral vector titres 
obtained  using  the  two  vessels  under  these  operating  conditions  were  equivalent  (Sections 
3.2.1 and 3.2.2), suggests that mixing time is not a good indicator of culture performance and 
thus  its  use  as  a  scaling  parameter  is  not  appropriate  here.    Consequently,  a  DoE-guided 
approach  was  undertaken  to  identify  the  operating  parameters  which  do  impact  on  PS46.2 134 
 
 
culture performance (Section 3.2.5), and their optimal ranges (Chapter 4).  This information was 
used  in  conjunction  with  knowledge  of  the  hydrodynamic  environment  favoured  by  cells 
(obtained by the calculation of dimensionless numbers) to inform the design of a large scale 
culture process, which was subsequently trialled (Chapter 5).  Thus, rather than relying on a 
single parameter as the basis for scale-up studies, a more holistic approach was implemented. 
 
Figure 3.9  High speed video images of a small liquid addition (8 µL inert dye) made to a 
microwell containing 792 µL water.  The microwell was mounted on a shaking platform of 10 
mm diameter rotating at a speed of 180 rpm. 
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3.2.5  Microwell screening experiment to determine the relative impact of nine process 
parameters on ProSavin
® titre 
3.2.5.1  Results of the screening experiment 
Having  demonstrated  that  ProSavin
®  production  (based  on  suspension  cultures  of  PS46.2) 
could be successfully carried out using a 24-well plate system (Sections 3.2.1 and 3.2.2), a low-
cost,  high-throughput  approach  to  bioprocess  optimisation  could  now  be  implemented.  
However,  as  an  appropriate  criterion  for  scale-up  was  not  yet  identified  (Section  3.2.4),  the 
future  translation  of  any  improvements  obtained  at  the  microwell  scale  to  larger  vessels 
(preferably,  WAVE  bioreactors),  remained  a  concern.    Consequently,  a  microwell-based 
structured  approach  to  bioprocess  development  was  undertaken  that  had  two  aims:  (i)  to 
identify and optimise critical factors affecting ProSavin
® production from the PS46.2 suspension 
cell line (as previously noted, current titres fell short of those required for clinical application – 
Section 1.4.5), and (ii) to use the acquired knowledge to inform the design of a large scale 
process.  As a large number of parameters could potentially impact on ProSavin
® production, it 
was  logical  to  employ  DoE  methodology  to  explore  their  various  effects.    As  discussed  in 
Section 1.5.2, typically the first objective when implementing DoE is familiarisation, to determine 
what is experimentally possible (Eriksson et al., 2008).  This had been largely accomplished 
through the earlier work described in Sections 3.2.1 and 3.2.2 and through a handful of pilot 
studies (data not shown).  This information, in conjunction with that derived from both published 
(Stevenson et al., 2009; Stewart et al., 2009; Stewart et al., 2011) and unpublished (Oxford 
BioMedica) sources, was therefore used to aid the design of a screening experiment (the next 
step in the DoE process).  In this experiment, the relative impact of nine factors (Table 3.2) on 
ProSavin
® titres was assessed.  A fractional factorial design was generated, which reduced the 
number of experimental runs to one sixteenth of those otherwise required for a full factorial 
design.  Even with this reduction, 36 experimental runs still needed to be carried out and, as it 
was  desirable  for  these  to  be  performed  in  triplicate,  the  microwell  platform  proved 
indispensable.  For a detailed overview of the methods employed see Section 2.4.1.   
   136 
 
 
Table 3.2  Specification  of  the  factors  and  settings  investigated  during  the  screening 
experiment.  Dox is an abbreviation of doxycycline. 
Factor (units)  Abbreviation 
Settings 
-1  0  1 
Shaking speed (rpm)  x1  120  160  200 
Shaking diameter (mm)  x2  10  20  30 
Pre-induction period (hr)  x3  2   24  46 
Post-induction period (hr)  x4  6  26  46 
Liquid fill volume (µL)  x5  800   1400  2000 
Cell seeding density (viable cells mL
-1)  x6  4.0 x 10
5  1.2 x 10
6  2.0 x 10
6 
Concentration of serum (% [v/v])  x7  1  3  5 
Concentration of dox (µg mL
-1)  x8  0.2  1.0  1.8 
Concentration of NaBu (mM)  x9  2  10  18 
The design matrix for the screening experiment and results ( expressed as  normalised titre 
values) are presented in Table 3. 3.  A regression model was fitted to normalised titre data, 
which had undergone a natural log transformation, as described in Section 2.4.1.1.  Only main 
terms that were significant at the level  p < 0.1 were included in the model.  The model yielded 
an adjR
2 of 0.63 and predR
2 of 0.58, indicating that 63 % of response variation was accounted 
for by the model, and 58 % of variation in response data was predicted by the model.  As the 
difference between the adjR
2 and predR
2 was < 0.3 and the predR
2 value was ≥ 0.5 (but < 0.9), 
the  model  fit  was  deemed  sufficiently  accurate  for  the  purposes  of  identifying  main  factor 
effects.  Analysis of variance (ANOVA) statistics are presented in Table 3.4.  The results show 
that the model was significant (p < 0.0001), and that post-induction period (p < 0.0001), liquid fill 
volume (p = 0.0003), and concentration of dox (p = 0.0076) all had a significant influence on 
ProSavin
® titres.   Post-induction period  had the largest effect, accounting for 40.9 % of the 
observed response variation, followed by liquid fill volume (17.3 %) and concentration of dox 
(8.5 %).  As illustrated by the coefficient plot (Figure 3.10), higher vector titres were achieved at 
the high settings of post-induction period (46 hr) and concentration of dox (1.8 µg mL
-1), and at 
the low setting of liquid fill volume (800 µL).  Logically, this model is correct, as only runs with 
this  combination  of  high  and  low  settings  for  post-induction  period,  liquid  fill  volume  and 
concentration  of  dox  (runs  10,  11,  14  and  15)  produced  normalised  titre  values  of  ≥  20  % 
(yielding values of 20, 84, 156, and 73 %, respectively; Table 3.3).   The ANOVA results also 
revealed that the model ‘lack of fit’ was significant (p = 0.0452), and this is because around one 
third  (33.4  %)  of  the  observed  variation  in  ProSavin
®  titre  could  not  be  accounted  for  by 
differences in those terms included in the model (post-induction period, liquid fill volume and 137 
 
 
concentration of dox).  Further exploration of the data using DoE software revealed that this 
unexplained response variation was mostly caused by the terms that had been excluded from 
the model, i.e. by the collective impact of the other six factors, plus various interaction effects.  
Interaction terms were not included in the model as factorial designs do not support their valid 
interpretation  (interactions  terms  are  confounded  with  each  other  and/or  the  main  effects).  
When considered individually, the main and interaction terms that had been excluded from the 
model  each  made  a  minor  contribution  to  the  observed  response  variation  as  compared  to 
those terms that were included in the model.  Their combined influence, however, accounted for 
most  (29.1  %)  of  the  unexplained  response  variation,  while  curvature  in  the  model  (due  to 
centre point data falling above or below that predicted by the factorial design points) accounted 
for 3.9 %.  The remaining unexplained response variation (0.4 %) was caused by uncontrolled 
process  variability  (i.e.  pure  error).    Therefore,  lack of  model  fit  seems,  to  a certain  extent, 
inevitable when investigating a large number of factors using a reduced experimental design.  
Although clearly something to be aware of, a significant ‘lack of fit’ value should not, on its own, 
prevent use of the model, as the aim of screening is simply to identify the most critical factors 
influencing a system, and not to use the model in any sort of predictive capacity.  Here, as the 
effects  of  post-induction  period,  liquid  fill  volume,  and  concentration  of  dox  were  clearly 
distinguishable  over  and  above  those  of  the  other  factors,  the  screening  experiment 
successfully achieved its aim.    
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Table 3.3  Resolution  IV  fractional  factorial  design  matrix for  the  screening  experiment.  
Nine  factors  were  evaluated  over  two  levels  (high/low)  to  ascertain  their  relative  impact  on 
ProSavin
® titre, and four centre point experiments were included for estimation of pure error.  
Factors  and  their  ranges  were  coded  according  to  Table  3.2.    Each  run  was  performed  in 
triplicate and mean titres values (expressed as a percentage of control shake flask titres – see 
Section 2.4.1) are presented.  
Run  x1  x2  x3  x4  x5  x6  x7  x8  x9  Titre  (% of control)  
1  -1  -1  -1  -1  -1  1  1  1  1  3.77 
2  1  -1  -1  -1  -1  -1  -1  -1  -1  1.17 
3  -1  1  -1  -1  -1  -1  -1  -1  1  3.16 
4  1  1  -1  -1  -1  1  1  1  -1  0.44 
5  -1  -1  1  -1  -1  -1  -1  1  -1  0.33 
6  1  -1  1  -1  -1  1  1  -1  1  0.59 
7  -1  1  1  -1  -1  1  1  -1  -1  1.64 
8  1  1  1  -1  -1  -1  -1  1  1  5.34 
9  -1  -1  -1  1  -1  -1  1  -1  -1  14.62 
10  1  -1  -1  1  -1  1  -1  1  1  19.86 
11  -1  1  -1  1  -1  1  -1  1  -1  84.19 
12  1  1  -1  1  -1  -1  1  -1  1  7.42 
13  -1  -1  1  1  -1  1  -1  -1  1  2.63 
14  1  -1  1  1  -1  -1  1  1  -1  155.72 
15  -1  1  1  1  -1  -1  1  1  1  72.70 
16  1  1  1  1  -1  1  -1  -1  -1  6.96 
17  -1  -1  -1  -1  1  1  -1  -1  -1  0.00 
18  1  -1  -1  -1  1  -1  1  1  1  1.56 
19  -1  1  -1  -1  1  -1  1  1  -1  1.19 
20  1  1  -1  -1  1  1  -1  -1  1  0.55 
21  -1  -1  1  -1  1  -1  1  -1  1  0.33 
22  1  -1  1  -1  1  1  -1  1  -1  0.00 
23  -1  1  1  -1  1  1  -1  1  1  2.63 
24  1  1  1  -1  1  -1  1  -1  -1  0.00 
25  -1  -1  -1  1  1  -1  -1  1  1  8.30 
26  1  -1  -1  1  1  1  1  -1  -1  5.32 
27  -1  1  -1  1  1  1  1  -1  1  5.14 
28  1  1  -1  1  1  -1  -1  1  -1  4.69 
29  -1  -1  1  1  1  1  1  1  -1  0.99 
30  1  -1  1  1  1  -1  -1  -1  1  1.17 
31  -1  1  1  1  1  -1  -1  -1  -1  0.99 
32  1  1  1  1  1  1  1  1  1  8.50 
33  0  0  0  0  0  0  0  0  0  4.87 
34  0  0  0  0  0  0  0  0  0  7.06 
35  0  0  0  0  0  0  0  0  0  10.44 
36  0  0  0  0  0  0  0  0  0  9.84 
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Table 3.4  Analysis of variance (ANOVA) results of the regression model for normalised 
titre  (transformed  as  described  in  Section  2.4.1.1).    df  is  an  abbreviation  for  ‘degrees  of 
freedom’.    The  percentage  contribution  of  a  given  factor  to  the  observed  variation  in  the 
response was calculated as follows: [xi sum of squares / corrected total sum of squares] x 100. 
Source  Sum of squares  df  Mean square  F value  p value 
Model  64.05  3  21.35  21.28  < 0.0001 
     Post-induction period (x4)  39.27  1  39.27  39.14  < 0.0001 
     Liquid fill volume (x5)  16.64  1  16.64  16.58  0.0003 
     Concentration of dox (x8)  8.14  1  8.14  8.11  0.0076 
Residual  32.11  32  1.00     
     Lack of fit  31.75  29  1.09  9.27  0.0452 
     Pure error  0.35  3  0.12     
Corrected total  96.16  35       
 
Figure 3.10  Coefficient  plot  of  the  regression  model  for  normalised  titre  (transformed  as 
described in Section 2.4.1.1), with confidence intervals set at 95 %.  The size of each coefficient 
indicates the relative influence of that factor on titre.  A positive coefficient indicates that an 
increase in that factor (relative to its centre point value) would result in an increase in titre, while 
for negative coefficients the reverse is true.  
Here, a method combining DoE and microwell cultures was employed to rapidly identify the 
critical factors influencing the production of ProSavin
® (an EIAV-derived lentiviral vector) from a 
suspension-adapted producer cell line (PS46.2).  Out of nine factors, three were identified as 
having a significant influence on ProSavin
® titre (Table 3.4) and together accounted for 66.6 % 140 
 
 
of the observed response variation.  Of these factors, post-induction period had the greatest 
impact, with higher titres being attained at the high setting of 46 hr (Figure 3.10).  ProSavin
® 
production  is  tightly  regulated  by  the  tet-ON  system,  and  the  addition  of  dox  stimulates 
expression of both EIAV gag/pol and the cytotoxic VSV-G component (Stewart et al., 2009; 
Stewart et al., 2011).  In PS46.2, particle assembly and budding can only proceed once Gag/Pol 
and Env proteins have accumulated to sufficient levels within the cell cytoplasm.  As normalised 
titre values were extremely low for runs with a post-induction period of 6 hr (< 6 %; Table 3.3), 
supernatants were likely harvested before particle assembly was fully underway.  For PS46.2 
grown  adherently,  it  was  previously  reported  that  a  post-induction  period  of  22  hr  yielded 
optimum  titres  (Stewart  et  al.,  2011).    The  influence  of  post-induction  period  on  ProSavin
® 
production using suspension cultures of PS46.2 will be examined in greater depth in Chapter 4. 
Liquid fill volume had the second largest effect on titre, with higher titres being attained at the 
low setting of 800 µL (Figure 3.10).  For the same 24-well plate format as employed here, it has 
been previously reported that when a shaking speed of 120 rpm and shaking diameter of 20 
mm was used, a 2000 µL liquid fill volume led to poor oxygenation of mammalian cell cultures 
(kLa = 1.3 hr
-1; dissolved oxygen tension < 10 % between 60 and 96 hr culture) and lower cell 
densities, while an 800 µL fill volume did not (kLa = 3.2 hr
-1; dissolved oxygen tension > 60 % 
throughout the culture) (Barrett et al., 2010).  In the current study, runs conducted using a 2000 
µL  liquid  fill  volume  produced  normalised  titre  values  of  <  9  %,  over  a  range  of  shaking 
conditions (Table 3.3).  It was observed that cells tended to form aggregates that localised on 
the bottom of microwells (irrespective of the shaking conditions employed – see Figure 3.11, 
which is discussed in greater depth in Section 3.2.5.2) and, taken together with the findings of 
Barrett  et  al.  (2010),  it  may  be  conjectured  that  an  oxygen  deprived  microenvironment  was 
created at the base of microwells operating with a 2000 µL fill volume (note that oxygen transfer 
is achieved through surface aeration only), which was unfavourable for ProSavin
® production.  
Although cells also accumulated on the bottom of microwells operating with a 800 µL liquid fill 
volume  (Figure  3.11),  the  rate  of  oxygen  transfer  within  these  cultures  was  likely  superior 
(Barrett et al., 2010), meaning that oxygen limited conditions were less likely to develop as a 
result.  141 
 
 
Concentration of dox had the third largest effect on titre, with higher titres being attained at the 
high setting of 1.8 µg mL
-1 (Figure 3.10).  Normalised titre values were low (< 15 %) for all runs 
conducted at the low setting of 0.2 µg mL
-1 (Table 3.3).  For mammalian cells encoding a tet-ON 
regulatory  system,  dox  has  been  shown  to  induce  gene  expression  in  a  dose-dependent 
manner; the level at which maximum expression is attained varies according to the particular 
application, however values of 0.5 to 2.0 µg mL
-1 appear typical (Koponen et al., 2003; Tang et 
al.,  2009).    PS46.2  encodes  a  tet-ON  regulatory  system,  thus  it  is  probable  that  a  dox 
concentration of 0.2 µg mL
-1 was insufficient for the full induction of cells in the current study.  
Induction of adherent cultures of PS46.2 is typically achieved using a dox concentration of 1.0 
µg  mL
-1  (Stewart  et  al.,  2009;  Stewart  et  al.,  2011).  Obvious  differences  exist  in  the  fluid 
hydrodynamics between shaken and static cell cultures thus, although a dox concentration of 
1.0 µg mL
-1 was initially adopted for microwell feasibility studies (Section 3.2.2), it was unknown 
whether this value was optimal - hence the inclusion of dox concentration as parameter in the 
screening  experiment.    From  this  experiment  it  may  be  concluded  that  lowering  the  dox 
concentration to 0.2 µg mL
-1 is detrimental for ProSavin
® titres, however, to identify its optimal 
operating range, this parameter, along  with  post-induction period and  liquid fill  volume, was 
consequently taken forward for further investigations as described in Chapter 4. 
3.2.5.2  Impact of microwell operating conditions on cellular aggregation 
The propensity for HEK293-derived cell lines to aggregate when cultured in suspension has 
been well documented (Wurm and Bernard, 1999; Liu et al., 2006; Zhao et al., 2007).  During 
the screening experiment, it was observed that the size and arrangement of aggregates varied 
widely, depending on the specific combination of operating conditions employed.  Although not 
photographed at the time, in an attempt to qualitatively capture this data, triplicate wells were 
later seeded according to each possible high/low combination of the factors considered most 
relevant (shaking speed, shaking diameter, liquid fill volume, cell seeding density and serum 
concentration of medium) using the parameter settings provided in Table 3.2.  Cells were not 
induced, but were photographed 46 hr after seeding (as described in Section 2.4.1.4).  Figure 
3.11  shows  a  representative  photograph  from  each  set  of  conditions  which,  when  viewed 
collectively, illustrate the general trends as discussed below.   142 
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Firstly,  different  hydrodynamic  conditions  gave  rise  to  distinct  aggregate  formations.    A 
combination of high shaking speed (200 rpm) and high shaking diameter (30 mm) seemed to 
favour the formation of cell layer that extended across the base of microwell (Figure 3.11 [a] and 
[b], bottom row of photographs).  A high liquid fill volume (2000 µL) when combined with a high 
cell density (2 x 10
6 viable cells mL
-1)
 had a similar effect, although the layer of cells did not 
extend to the edge of the microwell in all instances (Figure 3.11 [a] and [b], right hand column of 
photographs).  For all other microwell combinations, the morphology of cell aggregates was 
much  more  diverse.    The  effect  of  fluid  hydrodynamics  on  the  formation  of  HEK293  cell 
aggregates in spinner flasks has been previously discussed.  Liu et al. (2006) found that both 
low (25 rpm) and high (100 rpm) impeller speeds favoured the formation of large aggregates 
that had an average diameter of 351 µm and 442 µm, respectively, following a 7 day culture 
period.  It is hypothesised that this may have been caused by the low fluid velocity at 25 rpm, 
and by the high incidence of aggregate-aggregate collisions at 100 rpm (Liu et al., 2006).  When 
a  mid-range  impeller  speed  of  50  or  75  rpm  was  used,  aggregates  were  smaller  (average 
diameter 210 µm or 175 µm, respectively, after 7 days culture), and the growth and viability of 
cultures was improved (Liu et al., 2006).  Zhao et al. (2007) also reported that the optimum 
impeller speed in spinner flasks for minimising HEK293 aggregation, while retaining cell growth 
and viability, was 50 rpm.  From the purely pictorial data available, it is difficult to draw firm 
conclusions about the relationship between fluid hydrodynamics and cellular aggregation in the 
current study, and such attempts are further complicated by the fact that several factors (not all 
of them relating to the fluid environment) are at play.  It is worth noting, however, that the runs 
found to yield the highest titres during the screening experiment (runs 10, 11, 14 and 15) all had 
a low fill volume and high-low or low-high combination of shaking speed and shaking diameter.  
The data presented in Figure 3.11 indicates that cells likely spread out as a layer on the base of 
the microwell (rather than combined as a single large mass) during these runs.  The low fill 
volume likely ensured sufficient oxygenation of the cultures (as discussed in Section 3.2.5.1) 
and, although far from conclusive, the observation that none these runs combined low-low or 
high-high settings of shaking speed and diameter supports the notion that a mid-range level of 
agitation favours higher cell productivity.     144 
 
 
Secondly, and somewhat predictably, a high cell seeding density (2 x 10
6 viable cells mL
-1) 
tended to increase the size and/or extent of cell aggregates, as compared to a low seeding 
density of 4 x 10
5 viable cells mL
-1 (compare adjacent columns in Figure 3.11 [a] and [b]).  For 
HEK293 cells cultured in spinner flasks, it has been previously reported that aggregate diameter 
increased over time as the cell population expanded (Liu et al., 2006; Liu et al., 2009).  This is 
probably because cell-cell collisions, from which aggregate formation may arise, become more 
likely as cell densities increase.  Liquid fill volume was also found to affect the arrangement of 
cellular aggregates, with differing results depending on the particular shaking conditions and 
serum concentration employed (compare alternate columns in Figure 3.11 [a] and [b]).  It should 
be acknowledged that for a given starting cell density (no. of viable cells mL
-1), the total number 
of cells per well was 2.5 times greater when a fill volume of 2000 µL, as compared to 800 µL, 
was used.  Fill volume therefore not only influenced the mixing characteristics of the culture, but 
also affected the total number of cells present, and both these factors may have played a role in 
determining the arrangement of cellular aggregates.    
Finally, a high concentration of FCS in the medium (5 %) led to the formation of aggregates that 
were more closely compacted, as compared to when a low concentration of FCS (1 %) was 
used (compare photographs in Figure 3.11 [a] with their counterpart in Figure 3.11 [b]).  It is 
probable that the calcium component of the FCS was responsible for this effect.  Peshwa et al. 
(1993) previously reported that suspension cultured HEK293 cells rapidly formed clumps upon 
transferral from a medium containing 0.1 mmol L
-1 calcium ions (Ca
2+)
 to one containing 0.5 
mmol L
-1 Ca
2+, while cell growth rates were unaffected.  Zhao et al. (2007) reported a positive 
linear relationship between Ca
2+ concentration (0.0 - 0.4 mmol L
-1) and the diameter of HEK293 
cell aggregates, which varied in size from approximately 25 to 65 µm (quantified 36 hr post-
seeding).  Throughout  the  feasibility  studies  described  in  Sections  3.2.1  and  3.2.3,  Ca
2+ 
concentration data was collected (Ca
2+ concentration and pH were measured simultaneously 
using the blood gas analyser).  This data revealed that the Ca
2+ concentration was lower for 
HEK293T cultures supplemented with 1 % FCS (0.27 ± 0.00 mmol L
-1 [mean ± SD]; n = 6) than 
for HEK293T-derived (PS46.2) cultures supplemented with 5 % FCS (0.40 ± < 0.01 mmol L
-1 
[mean  ±  SD];  n  =  6)  when  measured  immediately  post-seeding.    Thus,  higher  Ca
2+ 
concentrations  accompany  higher  FCS  concentrations,  and  the  supposition  that  increased 145 
 
 
levels of Ca
2+ are responsible for the denser aggregation observed in the current experiment is 
therefore plausible. 
In general, high levels of aggregation are undesired as cells in the centre of clumps can become 
non-viable due to diffusional limitations (Peshwa et al., 1993).  Also, with regard to lentiviral 
vector  production,  diffusional  limitations  may  impede  the  induction  of  cells  in  the  centre  of 
clumps  and  the  close  crowding  of  cells  may  obstruct  viral  budding,  which  together  would 
compromise  the  overall  productivity  of  the  culture.    The  extreme  aggregative  behaviour 
observed during the screening experiment may have negatively impacted on titres which were, 
on the whole, low (Table 3.3).  The data presented here should inform the design of microwell-
based bioprocess development studies  – operating  conditions producing  aberrant aggregate 
morphologies that are unlikely to either: (i) yield optimal titres or (ii) be replicable upon scale-up, 
should ideally be avoided.   
3.3  Chapter discussion 
3.3.1  Establishment  of  a  microwell  platform  for  use  in  lentiviral  vector  process 
development 
The first objective of this chapter was to establish whether a shaken 24-well plate system could 
support  suspension  cultures  of  lentiviral  vector  producer  cell  lines.    A  HEK293T-derived 
producer  cell  line  (PS46.2)  was  seeded  in  microwells  (0.8  mL  working  volume)  and  culture 
kinetics and lentiviral vector (ProSavin
®) production were assessed.  Data was compared to that 
obtained from parallel shake flask cultures (50 mL working volume), which represent the current 
standard  small-scale  culture  vessel,  and  for  which  operating  protocols  had  been  previously 
established.  Overall, the culture kinetics between the two vessel types (in terms of cell growth, 
pH, and metabolite consumption and production) were similar, and lentiviral vector (ProSavin
®) 
titres were also comparable (Sections 3.2.1 and 3.2.2).  Although some degree of evaporation 
was  expected  from  microwells,  the  effect  on  culture  osmolalities  was  slight  and  should  not 
inhibit use of this platform for batch cultivations.  Together, the data indicate that microwells 
could be used effectively in place of shakes flasks for early phase process development studies 
based on the PS46.2 cell line, greatly increasing the opportunity for parallelisation and thus 
experimental  throughput.    To  date,  microscale  methods  for  mammalian  cell  culture  have 146 
 
 
primarily been employed to aid the development of recombinant protein production processes 
(Girard et al., 2001; Davies et al., 2005; Micheletti et al., 2006; Barrett et al., 2010; Silk et al., 
2010),  and  this  is  the  first  study,  to  my  knowledge,  to  employ  microwells  with  a  view  to 
optimising the manufacturing process for a viral vector. 
The  microwell  operating  conditions  employed  in  this  study  were  also  found  to  support 
successful  culture  of  another  cell  line  (HEK293T  not  stably  transfected  with  lentiviral  vector 
DNA)  grown  in  medium  containing  1  %  FCS.    A  similar  degree  of  comparability  between 
microwell and shake flask cultures was demonstrated as in the PS46.2 study, with regards to 
cell growth, pH, osmolality and metabolite concentrations (Section 3.2.3).  This demonstrates 
that  the  applicability  of  the  microwell  platform  may  be  extended  to  other  HEK293T  cell 
derivatives.   
This work also facilitated insight into the metabolism of key nutrients by the PS46.2 cell line, the 
findings of which could later inform process design, particularly if extended cultivations were 
desired.  A lack of glutamine and an accumulation of toxic levels of ammonia during the latter 
stages of the culture were likely limiting factors, while glucose availability and lactate build-up 
(leading to a lowering of pH) were of lesser concern.  Of interest was the observation that the 
HEK293T cell line responded differently to lactate accumulation than PS46.2, indicating that 
conclusions specifically relating to one cell line should not be generalised, even to other similar 
cell types.  Results obtained at the microscale can therefore be used to characterise differences 
in cell lines and their metabolic profile. This can be an important step in cell line selection and in 
defining ultimate scale-up requirements.  
3.3.2  Rejection of mixing time as a potential scaling criterion 
As it was critical that data generated using the microwell platform remained relevant upon scale-
up, the second objective of this chapter was to identify an appropriate criterion on which to base 
scale  translation  studies.    As  scale-up  from  microwells  to  WAVE  bioreactors  had  been 
previously  achieved  on  the  basis  of  mixing  time  (Gill  et  al.,  2011),  the  relevance  of  this 
parameter  for  scale-up  of  the  lentiviral  vector  production  process  was  evaluated.    For  a 
microwell operated under conditions found to yield acceptable cell growth kinetics and lentiviral 
vector titres, the mixing time (measured using the iodine decolourisation method) was extremely 147 
 
 
long (1037 s), and could not be matched in a WAVE bioreactor (for example, mixing times for a 
2  L  system  were  reported  to  range  from  9  to  264  s  (Eibl  et  al.,  2010b))  (Section  3.2.4).  
Consequently,  the  use  of  mixing  time  as  a  scaling  criterion  was  deemed  impracticable  and 
alternative criteria were sought using a DoE methodology.   
3.3.3  Identification of three factors that significantly impact on ProSavin
® titres  
The third objective of this chapter was to demonstrate the utility of the microwell platform for the 
rapid,  early  generation  of  relevant  bioprocess  design  data.    A  microwell-based  DoE-guided 
approach to bioprocess development was initiated, the first stage of which was experimental 
screening.  The relative influence of nine factors on ProSavin
® titres was assessed.  Each factor 
was  investigated  over  two  levels  using  a  fractional  factorial  design.    Three  factors  (post-
induction period, liquid fill volume and concentration of dox) were found to have a significant 
impact on titre (Section 3.2.5.1).  By identifying those factors which most impacted on ProSavin
® 
titres, the screening experiment achieved its primary aim.  It is clear that the sensitivity of titres 
to changes in post-induction period, liquid fill volume, and concentration of dox should be given 
particular consideration when designing a manufacturing route for lentiviral vectors, and these 
factors were thus taken forward for further optimisation studies (as described in Chapter 4).  It 
should  also  be  noted,  however,  that  although  the  other  six  parameters  were  found  not  to 
significantly impact on ProSavin
® titres in the present work, these results should be viewed in 
light of the operational ranges over which each parameter was investigated (Table 3.2), i.e. if 
broader ranges had been chosen, a greater impact on titres may have been observed.  It was 
noted, however, that these factors played a role in determining the size and arrangement of 
PS46.2 aggregates.  Increasing the cell density or concentration of FCS tended to  increase 
aggregation, while the relationship between the fluid hydrodynamics (which was dependent on 
the shaking speed, shaking diameter, and liquid fill volume) and aggregation was more difficult 
to  define  (Section  3.2.5.2).    Cellular  aggregation  is  undesirable  as  it  may  reduce  titres  and 
compromise scale-up studies, thus it is valuable to develop an understanding of how various 
operating  parameters  can  contribute  to  this  phenomenon.    This  study  represents  the  first 
application  of  a  DoE  approach  to  lentiviral  vector  upstream  development.  As  the  use  of 
suspension-adapted  stable  producer  cell  lines  is  highly  desirable  for  future  large  scale 148 
 
 
productions of clinical grade lentiviral vectors, the insights gained here should aid researchers 
working in this field. 
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4  Characterisation of lentiviral vector production using the 
microwell platform 
4.1  Introduction and aims 
Existing manufacturing processes for lentiviral vectors, based on the transient transfection of 
adherent  monolayers  of  HEK293-derived  cells  (Slepushkin  et  al.,  2003;  Negré  et  al.,  2008; 
Schweizer and Merten, 2010; Merten et al., 2011; Stewart et al., 2011; Ausubel et al., 2012), 
are  not  scalable,  and  for  commercialisation  the  development  of  stable  producer  cell  lines 
capable of growth in suspension is desired (Ansorge et al., 2010; Schweizer and Merten, 2010; 
Segura  et  al.,  2013).  However,  the  propensity  of HEK293-derived  cells  to  aggregate  when 
cultured  in  suspension  (Merten  et  al.,  2001),  changes  in  the  morphology  and  membrane 
properties of producer cells following suspension adaption (Ansorge et al., 2010) and a limited 
understanding of the culture conditions required for optimal productivity (Segura et al., 2013) 
has  greatly  hindered  progress  in  this  area  and,  to  date,  just  one  report  documenting  the 
successful creation of suspension-grown lentiviral vector producer cell lines has been published 
(Broussau et al., 2008).  In order for scalable manufacturing processes for lentiviral vectors to 
become  a  reality,  a  deeper  understanding  of  the  factors  that  impact  on  the  productivity  of 
suspension-adapted stable producer cells is clearly required.   
To address this issue, the overarching aim of this thesis was to test an approach to lentiviral 
vector process development that was based on a combination of microscale bioprocessing and 
Design of Experiments (DoE) techniques, which would theoretically allow the effect of multiple 
operating  parameters  to  be  quickly  characterised  through  a  series  of  logically  linked 
experiments (see Sections 1.5.1 and 1.5.2).  To help develop and demonstrate the approach, 
the  suspension-adapted  tet-ON  inducible  stable  producer  cell  line,  PS46.2,  was  employed 
(Stevenson  et  al.,  2009;  Stewart  et  al.,  2009;  Stewart  et  al.,  2011).    Suspension-adapted 
PS46.2 currently generates lentivirus (ProSavin
®) titres that are 5 to 20-fold lower than those 
required  for  clinical  purposes  (see  Section  1.4.5).    As  lack  of  a  scalable  bioprocess  for 
ProSavin
® could impede its future commercialisation it is important this issue is addressed.   150 
 
 
In  Chapter  3,  a  microwell  experimental  platform  was  established  for  use  in  lentiviral  vector 
process  development  studies  based  on  suspension  cultures  of  HEK293T-derived  producer 
cells.  A DoE screening experiment was subsequently carried out using the microwell platform 
to  identify  which  operating  parameters  most  significantly  impacted  on  ProSavin
®  titres  from 
suspension  cultures  of  PS46.2.    Out  of  nine  parameters,  three  were  identified  as  having  a 
substantial influence on ProSavin
® titres, which were: post-induction period, liquid fill volume 
and concentration of dox (Section 3.2.5).  The aim of this second results chapter is to model the 
effects of these important factors on ProSavin
® production, with a view to optimising production 
conditions and informing future scale-up studies.  The specific objectives are: 
  To employ  the microwell  platform and  DoE methodology  to (i) narrow the operating 
ranges  for  post-induction  period,  liquid  fill  volume  and  concentration  of  dox  and  (ii) 
subsequently predict their optimum settings. 
  To conduct microwell experiments to verify the predictive capability of the final model. 
  To describe the fluid mixing within microwells (operating under optimised conditions) 
using dimensionless numbers, with a view to informing scale translation studies. 
  To evaluate whether daily additions of dox to microwell suspension cultures of PS46.2 
could boost titres during long (70 hr) induction periods (this objective stemmed from the 
results associated with first objective).   
Results  included in this chapter  were  published  in:  Guy, H. M., et  al. (2013). Human Gene 
Therapy Methods, 24(2): 125-139.  Permission to reproduce this content has been granted by 
Mary Ann Liebert, Inc. 
4.2  Results  
4.2.1  Optimisation of ProSavin
® titres using microwell cultures of PS46.2 and Design of 
Experiments (DoE) techniques  
4.2.1.1  Overview of the DoE approach employed for optimisation studies  
A  series  of  DoE-guided  microwell-based  experiments  were  carried  out  to  establish  optimal 
operating conditions for the production of ProSavin
® from suspension cultures of PS46.2.  This 151 
 
 
section  provides  an  overview  of  the  approach  employed,  including  a  description  of  central 
composite designs.   
Of  the  nine  factors  initially  investigated  (Section  3.2.5),  three  were  found  to  have  a  critical 
influence on ProSavin
® titre: post-induction period, liquid fill volume and concentration of dox.  
These  factors  were  thus  taken  forward  for  further  characterisation  and  optimisation  studies, 
while all other factors were given a fixed value.  Following a broad screening experiment, the 
impact  of  a  small  number  of  critical  factors  can  be  investigated  in  greater  detail  using 
experiments of central composite design.  Central composite designs consist of (i) a basic two-
level  factorial  design  (i.e.  a  high  and  low  value  for  each  factor),  (ii)  repeated  centre  point 
experiments for estimation of pure error, and (iii) additional symmetrically arrayed axial points 
(Anderson and Whitcomb, 2007; Eriksson et al., 2008).  The inclusion of axial points means that 
a quadratic equation can  be fitted to response  data, enabling curvature  in the experimental 
system  to  be  modelled  and  subsequently  visualised  using  response  surface  methodology 
(Anderson and Whitcomb, 2007; Eriksson et al., 2008).  The primary benefit of this approach is 
that  it  can  direct  researchers  quickly  towards  the  optimal  operating  conditions  for  a  given 
system.   In central composite face-centred (CCF) designs, the axial points are at the centre of 
each face of the factorial design space.  In central composite circumscribed (CCC) designs, the 
axial points are outside of the factorial design space and, in order to retain the symmetry of the 
design region, are typically situated on the circumference of a circle with radius 1.4 (Eriksson et 
al., 2008).  Consequently, CCF designs require each factor to be varied over three levels (low, 
medium and high), while CCC designs require each factor to be varied over five levels (low
a, 
low, medium, high, high
a), where ‘a’ denotes that the design point is both axial and outside of 
the factorial design space.   
While CCF designs can be a more practical choice when it comes to data collection (e.g. vector 
harvests at three different time points is less laborious than vector harvests at five separate time 
points), a CCC design is better able to capture strong curvature within an experimental system 
(Eriksson et al., 2008).  Here, since the first two experiments described below (Sections 4.2.1.2 
and 4.2.1.3) were primarily conducted to identify appropriate ranges for each of the factors a 
CCF  design  was  deemed  sufficient.    As  the  final  DoE  experiment  (Section  4.2.1.4)  was 
conducted to ascertain whether a unique optimum set of conditions existed where maximum 152 
 
 
titres  could  be  achieved,  a  CCC  design  was  considered  most  appropriate.    For  statistical 
calculations the levels of each variable were coded as described previously (see Section 2.4.1.1 
and Islam et al. (2007)), while axial points included in the CCC design were coded as +/- 1.4.  
4.2.1.2  A  central  composite  face-centred  (CCF)  experiment  to  locate  the  optimal  operating 
ranges for post-induction period, liquid fill volume and concentration of dox 
Following on from the screening experiment described in Section 3.2.5 the next stage was to 
narrow the operating ranges for those factors found to significantly impact on ProSavin
® titres.  
As each factor had been previously investigated over just two levels, it was unknown whether 
the  optimal  settings  for  these  factors  had  been  included  within  the  experimental  region 
investigated during screening.  Thus this follow-on study was conducted with the experimental 
objective  to  locate  the  optimal  region  (see  Section  1.5.2).    Post-induction  period,  liquid  fill 
volume and dox concentration were varied over the ranges 22 - 70 hr, 600 - 1000 µL and 1.0 - 
2.6 µg mL
-1, respectively, using a CCF design, which enabled the impact of each factor to be 
examined over three levels (Section 4.2.1.1).  The high and low settings for each factor were 
chosen in accordance with the results obtained from the screening experiment, such that each 
factor range was varied symmetrically around the previous optimum identified.  The remaining 
six factors, that had not by themselves exerted a significant influence on ProSavin
® titres during 
experimental screening, were given a fixed value.  As it was conceivable that the following pairs 
of factors: (i) shaking speed and shaking diameter, and (ii) pre-induction period and cell seeding 
density, may have acted synergistically on ProSavin
® titres during the screening experiment it 
was deemed prudent to fix these factors at midpoint values for optimisation studies, avoiding 
extreme  combinations  (e.g.  high  shaking  speed  plus  high  shaking  diameter).  The  serum 
concentration of the media, and the concentration of NaBu (added at induction) were fixed at 
their high and low values (Table 3.2), respectively, as these were the values used during the 
experimental  run  that  yielded  the  highest  titre  during  screening  (run  14,  Table  3.3).    The 
materials and methods employed in this study are detailed in Section 2.4.2, and the settings for 
all factors are summarised in Table 4.1.  To increase our understanding of the impact of the 
chosen variable factors, the number of responses measured was also increased.  ProSavin
® 
titre  (functional  vector)  measurements  were  supplemented  with  RNA  copy  number 
measurements to give an indication of total viral particle numbers.  Viable cell concentration and 153 
 
 
cell viability at the time of harvest was also quantified.  The design matrix and results for this 
experiment are presented in Table 4.2.  ProSavin
® titre and particle:infectivity (P:I) ratio (RNA 
copy number / titre) values were entered into DoE software so that the behaviour of the system 
could be modelled.  
Table 4.1  Specification  of  the  factors  and  settings  investigated  during  the  first  central 
composite  face-centred  (CCF)  experiment.  Post-induction  period,  liquid  fill  volume  and 
concentration of dox (doxycycline) were investigated over the ranges specified, while the other 
six factors were given a fixed value. 
Factor (units)  Abbreviation  Fixed value 
Settings 
-1  0  1 
Shaking speed (rpm)  x1  160  -  -  - 
Shaking diameter (mm)  x2  20  -  -  - 
Pre-induction period (hr)  x3  24  -  -  - 
Post-induction period (hr)  x4  -  22  46  70 
Liquid fill volume (µL)  x5  -  600  800  1000 
Cell seeding density (viable cells mL
-1)  x6  1.2 x 10
6  -  -  - 
Concentration of serum (% [v/v])  x7  5  -  -  - 
Concentration of dox (µg mL
-1)  x8  -  1.0  1.8  2.6 
Concentration of NaBu (mM)  x9  2  -  -  - 154 
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A quadratic model was fitted to titre data, which had undergone an inverse transformation. The 
resulting model yielded an adjR
2 value of 0.98 and predR
2 value of 0.98 following refinement 
(which was carried out described in Section 2.4.2).  As the difference between the adjR
2 and 
predR
2  was  <  0.2  and  the  predR
2  value  was  ≥  0.9,  the  model  fit  was  deemed  excellent.  
Analysis of variance (ANOVA) statistics revealed that the model was significant (p < 0.0001) 
and that there was no significant ‘lack of fit’ (p = 0.1806).  Model coefficients for ProSavin
® titre 
responses are presented in Figure 4.1.  From the model coefficients, it is evident that post-
induction period exerted the largest effect on titre (p < 0.0001).  The direction of this effect was 
negative, indicating that higher titres were achieved when harvests were performed earlier, at 
22 hr, as opposed to 70 hr, post-induction.  The model term (post-induction period)
2 was also 
significant (p < 0.0001).  As squared terms represent curvature in the model, this indicates that 
the relationship between post-induction period and titre was non-linear.  Further analysis of the 
data  using  DoE  software  revealed  that  maximum  titres  were  most  likely  to  be  obtained 
sometime between 22 hr and 46 hr post-induction.  Dox concentration exerted a smaller effect 
on titre than post-induction period, and the direction of this effect was positive, indicating that 
the  higher  value  (2.6  µg  mL
-1)  yielded  higher  titres  (p  <  0.0001).    However,  there  was  an 
interaction  between  these  two  factors  (p  =  0.0015),  and  exploration  of  the  data  using  DoE 
software revealed that higher titres were only achieved at the high dox concentration when the 
post-induction period was prolonged (70 hr).  Liquid fill volume did not exert a significant effect 
on titre over the range studied in this experiment (p = 0.0654).  The maximum titre achieved in 
this first experiment was 4.0 x 10
4 TU mL
-1, where the post-induction period was 22 hr, liquid fill 
volume was 1000 µL and dox concentration was 2.6 µg mL
-1 (Run 7, Table 4.2).   156 
 
 
 
Figure 4.1  Coefficient  plot  of  the  refined  quadratic  model  for  titre  (inverse  transformed) 
with  confidence  intervals  set  at  95  %.    The  size  of  each  coefficient  illustrates  the  relative 
influence of that factor on titre.  A positive coefficient indicates that an increase in that factor 
(relative to its centre point value) would result in an increase in titre, while the reverse is true for 
negative  coefficients.    Due  to  the  inverse  transformation  of  titre  data,  it  was  necessary  to 
multiply coefficients by -1 to enable appropriate interpretation (in terms of the direction of the 
effect).   Post-induction period, liquid fill volume and concentration of dox were investigated over 
the  ranges  22  -  70  hr,  600  -  1000  µL  and  1.0  -  2.6  µg  mL
-1,  respectively,  using  a  central 
composite face-centred (CCF) design (Table 4.1).  Coefficients with confidence intervals that do 
not span zero are considered significant at the level p < 0.5.   
Titre data can be utilised in conjunction with RNA copy number data to calculate the proportion 
of particles in a given suspension that are functional (the P:I ratio).  For the conditions examined 
in the present experiment, the P:I ratio ranged from 1.6 x 10
5 to 1.5 x 10
6 (Table 4.2).  A two-
factor interaction model was fitted to P:I ratio values, which had undergone a log transformation. 157 
 
 
The  resulting  model  yielded  an  adjR
2  value  of  0.99  and  predR
2  value  of  0.98  following 
refinement  (which  was  carried  out  as  described  in  Section  2.4.2),  again  indicating  excellent 
model fit.  ANOVA statistics revealed that the model was significant (p < 0.0001), and that there 
was  no  significant  ‘lack  of  fit’  (p  =  0.2058).    Model  coefficients  for  P:I  ratio  responses  are 
presented in Figure 4.2.  A high P:I ratio is undesirable as this would indicate that the majority of 
particles within the harvested supernatant are non-functional.  Here, post-induction period had 
the greatest effect (p < 0.0001), and early harvests (22 hr) yielded a desirably lower P:I ratio.  
Using the data in Table 4.2, it may be observed that late harvests (70 hr) were associated with 
lower cell viabilities, lower titres and higher RNA copy numbers.  This may suggest that the 
increased worsening P:I ratio associated with longer harvest periods was caused by a release 
of lentiviral vector RNA into the supernatant as a result of cell death.  Liquid fill volume (p < 
0.0001) and concentration of dox (p < 0.0001) had a relatively lesser effect on the P:I ratio, but 
nonetheless  it  was  indicated  that  at  higher  settings  of  these  (1000  µL  and  2.6  µg  mL
-1, 
respectively)  a  greater  proportion  of  lentiviral  vector  particles  were  functional.    However, 
interaction effects existed between post-induction period and concentration of dox (p = 0.0413), 
and between liquid fill volume and concentration of dox (p = 0.0118).  Further exploration of the 
data using DoE software revealed that, in fact, neither liquid fill volume or concentration of dox 
alone affected the P:I ratio, and that the associated interaction effects were complex: a lower P:I 
ratio was only achieved at (i) the high liquid fill volume (1000 µL) if the concentration of dox was 
low (1.0 µg mL
-1), and (ii) at the high dox concentration (2.6 µg mL
-1) if the liquid fill volume was 
low (600 µL) or, if the fill volume was high (1000 µL), the post-induction period was prolonged 
(70 hr).  Overall, the influence of these factors was small as compared to the impact of post-
induction period (Figure 4.2), and it is possible that these minor effects were an artefact of the 
experimental procedure.  For this reason, and because P:I ratio data was of secondary interest 
after titre data, the minor contributions liquid fill volume and concentration of dox made to the 
model were not explored further.  
 158 
 
 
 
Figure 4.2  Coefficient plot of the refined two-factor interaction model for particle:infectivity 
(P:I) ratio (log transformed) with confidence intervals set at 95 %.  Factors and their ranges, and 
the experimental design were as noted for Figure 4.1.  
To briefly summarise, post-induction period was the factor that most influenced ProSavin
® titres 
and the P:I ratio in this experiment.  During experimental screening it was demonstrated that 
after 6 hr, titres were negligible (Section 3.2.5.1).  In this study, moderate titres were obtained 
between 22 and 70 hr post-induction, and earlier (22 hr) harvests were preferable in terms of 
maximising titres and minimising the P:I ratio (Table 4.2).  When the post-induction period was 
extended  to  70  hr,  titres  dropped  and  the  P:I  ratio  worsened  (see  Figures  4.1  and  4.2), 
indicating that functional ProSavin
® is inactivated in culture supernatants over time, and by 70 hr 
post-induction the rate of decay exceeds the rate of production.  Late harvests (70 hr post-
induction) were associated with reduced cell viabilities (< 75 %; Table 4.2), suggesting that cell 159 
 
 
death  may  have  contributed  to  the  decline  in  ProSavin
®  production.    Cell  death  may  have 
resulted from nutrient limitations, such as a lack of glutamine or an accumulation of ammonia 
(Section  3.2.1.4),  or  from  a  build-up  of  the  lentiviral  vector  envelope  protein,  VSV-G  -  the 
cytotoxic properties of which have been well documented (Burns et al., 1993; Yee et al., 1994; 
Yang et al., 1995; Ory et al., 1996).  HIV-based lentiviral vectors have been reported to decay 
rapidly at 37 °C, with a half-life of between 0.8 and 10.4 hr (Higashikawa and Chang, 2001; 
Carmo et al., 2009a; Carmo et al., 2009b).  In order to observe if the responses are a function of 
the vector half-life itself, the stability of ProSavin
®, and other EIAV-derived lentiviral vectors, will 
be investigated later in Chapter 6.  From the regression models generated here, the optimum 
harvest time (in terms of maximising ProSavin
® titres and minimising the P:I ratio) was predicted 
to fall between 22 and 46 hr post-induction.  The liquid fill volume, which was varied between 
600 and 1000 µL, did not affect ProSavin
® titres.  A high dox concentration (2.6 as opposed to 
1.0 µg mL
-1) yielded slightly higher titres, but only following extended cultivations (70 hr post-
induction).    Therefore  this  improvement  could  not  be  considered  to  be  of  real  benefit,  as 
harvests performed at 70 hr post-induction still yielded poorer titres than the earlier harvests 
performed at 22 hr post-induction.  A secondary experiment was conducted to confirm that the 
amount of residual dox left over from cell inductions did not affect the transduction stage of the 
ProSavin
®  titre  assay.    ProSavin
®-containing  supernatants  that  had  been  harvested  from 
standard shake flask cultures (methods as described in Section 2.4.1.3) were spiked with 0.0, 
1.3 or 2.6 µg mL
-1 dox (supplementary to the 1.0 µg mL
-1 which had been added during normal 
inductions) prior to storage at -80°C.  ProSavin
® titres were then quantified using the rapid flow 
cytometry method described in Section 2.11.2.1.  As illustrated in Figure 4.3, the addition of 
extra dox to supernatants prior to performing cell transductions had no effect on ProSavin
® titre, 
thus the presence of varying amounts of residual dox in harvested supernatants should not 
influence the efficiency of cell transductions performed during the titre assay.  160 
 
 
 
Figure 4.3  The influence of dox on cell transductions. ProSavin
®-containing supernatants 
that had been harvested from standard shake flask cultures (Section 2.4.1.3) were spiked with 
varying concentrations of dox prior to storage at -80°C, following which titres were quantified 
according to standard protocol (Section 2.11.2.1).  Mean values are presented, and error bars 
represent ± 1 SD (n = 3).   
4.2.1.3  A CCF experiment to further refine the operating ranges for post-induction period and 
concentration of dox 
Prior to conducting the final optimisation experiment (from which optimal factor settings might be 
predicted), it was necessary to further refine the experimental ranges for post-induction period 
and  concentration  of  dox.    In  terms  of  post-induction  period,  it  was  desirable  to  establish 
whether optimal titres were likely to be achieved between 6 and 22 hr post-induction, or whether 
this period could be excluded from the final experiment  – enabling a narrower experimental 
region to be investigated in greater detail.  With regards to dox concentration, it seemed prudent 
to evaluate whether increasing the dox concentration beyond 2.6 µg mL
-1 could
 further increase 
ProSavin
® titres during early harvests.  Post-induction period and concentration of dox were 
therefore varied over the ranges 18 - 26 hr and 1.0 - 5.0 µg mL
-1, respectively, using a CCF 
design, while all other factors were given a fixed value (Table 4.3).  Liquid fill volume was fixed 
at 1000 µL, as during the previous CCF experiment (Section 4.2.1.2), runs conducted using a 
1000 µL liquid fill volume yielded slightly higher titres than those conducted using a 600 µL fill 161 
 
 
volume (although this effect was not statistically significant:  p = 0.0654).  The materials and 
methods  employed  in  this  study  are  detailed  in  Section  2.4.3.    The  same  responses  were 
measured as for the previous CCF experiment, and the design matrix and results are presented 
in Table 4.4.   
Table 4.3  Specification of the factors and settings investigated during the second CCF 
experiment.  Post-induction period and concentration of dox were investigated over the ranges 
specified, while the other seven factors were given a fixed value. 
Factor (units)  Abbreviation  Fixed value 
Settings 
-1  0  1 
Shaking speed (rpm)  x1  160  -  -  - 
Shaking diameter (mm)  x2  20  -  -  - 
Pre-induction period (hr)  x3  24  -  -  - 
Post-induction period (hr)  x4  -  18  22  26 
Liquid fill volume (µL)  x5  1000  -  -  - 
Cell seeding density (viable cells mL
-1)  x6  1.2 x 10
6  -  -  - 
Concentration of serum (% [v/v])  x7  5  -  -  - 
Concentration of dox (µg mL
-1)  x8  -  1.0  3.0  5.0 
Concentration of NaBu (mM)  x9  2  -  -  - 
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Table 4.4  CCF design matrix for investigation into the effect of post-induction period (x4) 
and concentration of dox (x8) on cell growth and lentiviral vector production.  Each factor was 
varied over three levels and six centre point experiments were included for estimation of pure 
error.  Factors and their ranges were coded according to Table 4.3.  Each run was performed in 
triplicate  and,  where  relevant,  mean  values  ±  1  SD  are  presented.    Cell  concentration  and 
viability  measurements  were  performed  immediately  prior  to  lentiviral  vector  harvests.   
Predicted  values  were calculated  from the regression model fitted to  titre data (see Section 
2.4.3),  and  were  computed  using  the  “point  prediction”  tool  within  DoE  software  (similar 
predicted and measured values are indicative of a well-fitting model).    
Run  x4  x8 
Viable 
cells mL
-1 
(x 10
6) 
Cell 
viability 
(%) 
RNA copies 
mL
-1 (x 10
9) 
Titre (x 10
4 TU mL
-1)  P:I ratio 
(x 10
5) 
Measured  Predicted 
1  -1  -1  4.2 ± 0.7  96.7 ± 0.5  3.5 ± 0.6  3.5 ± 0.1  3.6  1.0 
2  1  -1  4.1 ± 0.3  97.3 ± 0.3  4.7 ± 1.4  6.2 ± 1.1  5.9  0.8 
3  -1  1  4.0 ± 0.2  93.9 ± 1.8  3.2 ± 0.7  3.4 ± 0.5  3.6  0.9 
4  1  1  3.7 ± 0.4  96.8 ± 0.6  6.1 ± 0.8  5.9 ± 0.3  5.9  1.0 
5  -1  0  3.0 ± 0.3  93.5 ± 0.6  3.0 ± 0.9  3.9 ± 0.1  3.6  0.8 
6  1  0  3.3 ± 0.4  96.0 ± 1.2  5.4 ± 1.0  5.5 ± 0.4  5.9  1.0 
7  0  -1  3.7 ± 0.7  96.8 ± 0.1  3.6 ± 0.5  3.5 ± 0.8  3.3  1.0 
8  0  1  3.0 ± 0.2  96.6 ± 0.3  3.8 ± 0.7  3.2 ± 0.4  3.3  1.2 
9  0  0  2.6 ± 0.2  95.8 ± 0.2  3.7 ± 0.5  3.4 ± 0.9  3.3  1.1 
10  0  0  2.7 ± 0.1  96.5 ± 0.2  4.2 ± 0.5  3.8 ± 0.2  3.3  1.1 
11  0  0  2.4 ± 0.1  94.7 ± 0.3  4.1 ± 0.8  4.1 ± 1.5  3.3  1.0 
12  0  0  2.8 ± 0.4  96.0 ± 0.6  3.3 ± 0.8  3.0 ± 0.2  3.3  1.1 
13  0  0  3.1 ± 0.8  97.3 ± 0.8  3.0 ± 0.8  2.7 ± 0.7  3.3  1.1 
14  0  0  2.6 ± 0.2  95.8 ± 1.4  2.9 ± 1.2  3.0 ± 0.2  3.3  1.0 
A quadratic model was fitted to titre data, and the resulting model yielded an adjR
2 value of 0.86 
and predR
2 value of 0.82 following refinement (which was carried out as described in Section 
2.4.3).  The model fit could therefore be considered good.  ANOVA statistics revealed that the 
model was significant (p < 0.0001), and that there was no significant ‘lack of fit’ (p = 0.9524).  
Only post-induction period and (post-induction period)
2 were included as significant model terms 
(p < 0.0001).  Figure 4.4 has been included to illustrate the impact of post-induction period and 
dox concentration on titre and RNA copy number data.  ‘Late’ harvests (26 hr post-induction) 
yielded the highest titres and, interestingly, from 22 to 26 hr a 67 to 84 % increase in mean titre 
was observed (Table 4.4; Figure 4.4), suggesting that even a few hours difference in harvest 
timing can be critical.  From this data it may be concluded that 22 hr would be an appropriate 
lower threshold for post-induction period in the final optimisation experiment.  Varying the dox 163 
 
 
concentration did not affect ProSavin
® titres in this experiment, indicating that 1.0 µg mL
-1 was 
sufficient for full cell induction over this timeframe.  The maximum titre achieved in this second 
CCF experiment was 6.2 x 10
4 TU mL
-1, where the post-induction period was 26 hr and the dox 
concentration was 1.0 µg mL
-1 (Run 2, Table 4.4).  It may be observed that RNA copy number 
values  rose  in  line  with  increasing  titres  (Figure  4.4),  thus  the  P:I  ratio  remained  relatively 
consistent over time (ranging from 0.8 to 1.2 x 10
5; Table 4.4).  Exploration of the P:I ratio data 
using DoE software revealed that neither factor significantly impacted on this response.  Cell 
viabilities were high (> 93 %) for all runs, while cell concentrations ranged between 2.4 and 4.2 
x 10
6 viable cells mL
-1 (Table 4.4).  
 
Figure 4.4  Effect of post-induction period and concentration of dox on titre (bars) and RNA 
copy number (lines).  Mean values are presented, and error bars represent ﾱ 1 SD (n ≥ 3).  All 
other operating parameters were fixed as outlined in Table 4.3.     
   164 
 
 
4.2.1.4  A central composite circumscribed (CCC) experiment to predict the optimum values for 
post-induction period and liquid fill volume 
A final DoE experiment was conducted to predict the optimum values for post-induction period 
and  liquid  fill  volume.    Experimental  screening  had  identified  these  factors,  along  with  dox 
concentration,  as  significantly  impacting  on  ProSavin
®  titres  (Section  3.2.5).    Subsequent 
experiments to narrow the operating ranges for these factors had demonstrated that: (i) the 
optimal setting for post-induction period was likely to fall between 22 and 46 hr, (ii) 1.0 µg mL
-1 
dox appeared sufficient for cell induction when harvests were performed after approximately 22 
hr, however for later harvests (70 hr) a higher dox concentration (2.6 µg mL
-1) conferred a slight 
benefit,  and  (iii)  titre  was  not  affected  by  liquid  fill  volume  over  the  range  600  to  1000  µL 
(Sections 4.2.1.2 and 4.2.1.3).  In this experiment, post-induction period was investigated over 
the range 22 - 46 hr, as this was expected to include the optimum setting.  Liquid fill volume was 
examined over the range 700 - 1300 µL.  This range was chosen as, although a 2000 µL fill 
volume was previously found to negatively impact on titres (Section 3.2.5), the region between 
1000 and 2000 µL had not been previously explored.  Although in the first CCF experiment 
liquid fill volume did not have a significant impact on titre over the range 600 - 1000 µL (p = 
0.0654),  the  p  value  for  this  factor  was  relatively  close  to  the  0.05  significance  limit.  The 
coefficient  for  this  factor  was  positive  (Figure  4.1),  indicating  that  slightly  higher  titres  were 
attained at the high setting (1000 µL), thus it was considered worthwhile to investigate whether 
increasing  the  fill  volume  above  1000  µL  could  produce  a  real  (i.e.  statistically  significant) 
improvement in titre.  Dox concentration was found to have no impact on titre over the range 1.0 
-  5.0  µg  mL
-1  in  the  second  CCF  experiment  (Section  4.2.1.3),  thus  a  fixed  mid-point 
concentration of 3.0 µg mL
-1 was used for this experiment.  Additionally, a value of 3.0 µg mL
-1 
was chosen rather than 1.0 µg mL
-1 as some harvests would extend to 46 hr which is beyond 
the post-induction period examined in the second CCF study.  Here then, the influence of post-
induction period and liquid fill volume was investigated using a central composite circumscribed 
(CCC) design, which enabled the impact of each factor to be examined over five levels (Section 
4.2.1.1).  All other factors were given a fixed value (Table 4.5).  The materials and methods 
employed  in  this  study  are  detailed  in  Section  2.4.4.    The  same  responses  as  had  been 
examined in the previous CCF experiments, plus metabolite concentrations (glucose, lactate, 165 
 
 
glutamine and ammonium) and culture pH, were monitored in this study.  The design matrix and 
results are presented in Table 4.6.   
Table 4.5  Specification  of  the  factors  and  settings  investigated  during  the  central 
composite circumscribed (CCC) experiment.  Post-induction period and liquid fill volume were 
investigated over the ranges specified, while the other seven factors were given a fixed value.  
Ab is an abbreviation for abbreviation. 
Factor (units)  Ab  Fixed 
value 
Settings 
-1.4  -1  0  1  1.4 
Shaking speed (rpm)  x1  160  -  -  -  -  - 
Shaking diameter (mm)  x2  20  -  -  -  -  - 
Pre-induction period (hr)  x3  24  -  -  -  -  - 
Post-induction period (hr)  x4  -  22  25.5  34  42.5  46 
Liquid fill volume (µL)  x5  -  700  788  1000  1212  1300 
Cell seeding density (viable cells mL
-1)  x6  1.2 x 10
6  -  -  -  -  - 
Concentration of serum (% [v/v])  x7  5  -  -  -  -  - 
Concentration of dox (µg mL
-1)  x8  3.0  -  -  -  -  - 
Concentration of NaBu (mM)  x9  2  -  -  -  -  - 
            166 
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A quadratic model was fitted to titre data, which had undergone an inverse transformation, and 
the resulting model yielded an adjR
2 value of 0.99 and predR
2 value of 0.96.  The model fit 
could thus be considered excellent.  ANOVA statistics revealed that the model was significant (p 
< 0.0001), and that there was no significant ‘lack of fit’ (p = 0.2385).  Post-induction period (p = 
0.0113), liquid fill volume (p < 0.0001) and (liquid fill volume)
2 (p < 0.0001) were significant 
model  terms.    Note  that  the  terms  ([post-induction  period]  x  [liquid  fill  volume])  and  (post-
induction period)
2 were also included in the model, although their influence was not significant 
(p = 0.1291 and p = 0.1672, respectively).  The response surface plot for titre is shown in Figure 
4.5.  At high liquid fill volumes varying the post-induction period appeared to have no effect on 
ProSavin
® titre, which remained low.  It would seem that there is a critical liquid fill volume of 
approximately 1000 µL, below which higher titres are achieved and post-induction period begins 
to have an effect on titre.  The maximum titre achieved in this experiment was 6.3 x 10
4 TU mL
-1 
where the post-induction period was 42.5 hr and liquid fill volume was 788 µL (Run 2, Table 
4.6).  The model was subsequently used to predict optimal values for post-induction period and 
liquid fill volume, and this work is discussed later (Section 4.2.1.5).    
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Figure 4.5  Response surface plot displaying the effect of post-induction period and liquid 
fill volume on titre.  This figure was generated using the quadratic model obtained by regression 
analysis of titre data presented in Table 4.6 (see Equation 4.1).  All other operating parameters 
were fixed as outlined in Table 4.5.  This figure was generated using Design Expert software.  
The relatively low mean titres attained for experimental runs 3, 4 and 8 (1.0 - 1.4 x 10
4 TU mL
-1; 
Table 4.6) were attributed to poor mixing of the cell culture, due to the high fill volumes utilised 
(≥ 1212 µL).  At these fill volumes, slightly higher lactate concentrations (≥ 2.9 g L
-1 at the time 
of harvest) were observed, as compared to experimental runs where the fill volume was ≤ 1000 
µL (Figure 4.6 [c]).  As expected, the higher lactate concentrations observed for runs 3, 4 and 8 
also corresponded to a lower cell culture pH (≤ 6.7 at the time of harvest) as compared to the 
other experimental runs (Figure 4.6 [a]).  Consistent with these findings, it has been previously 
reported that 2000 µL microwell cultures of Chinese  hamster ovary (CHO) cells (generating 
antibodies) produced more lactate and had a lower pH than 800 µL cultures, when a shaking 
speed of 120 rpm and shaking diameter of 20 mm was used and the microwell format matched 
that used in the current work (Barrett et al., 2010).  The authors suggested that inadequate 
oxygen transfer likely triggered this response, as dissolved oxygen levels were reduced to less 
than 10 % in these cultures (Barrett et al., 2010).  It is therefore probable that reduced oxygen 169 
 
 
availability, caused by inadequate mixing, instigated the increase in lactate production observed 
at high fill volumes in the current work.  Glucose, lactate and ammonium concentrations were 
also measured; however no obvious trends were observed in this data (Figure 4.6 [b], [d] and 
[e]).      
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Figure 4.6  The  pH  (a),  glucose  concentration  (b),  lactate  concentration  (c),  glutamine 
concentration (d), and ammonium concentration (e) of microwell cultures at the time of vector 
harvests.  Details of the operating conditions employed, and the corresponding cell growth, titre 
and  RNA  copy  number  data  for  each  run,  is  provided  in  Table  4.6.    Although  a  single 
measurement was performed to determine pH and metabolite concentrations for each run, a 
reasonable indication of the natural variability between repeat experiments may be gained from 
comparing runs 9 to 14 (inclusive), as these were repeated centre point experiments.  
A quadratic model was fitted to P:I ratio data, which yielded an adjR
2 value of 0.75 and predR
2 
value of 0.62 following model refinement (which was carried out as described in Section 2.4.4).  
The model fit could therefore be considered good.  ANOVA statistics revealed that the model 
 
 
(a) 
(c)  (b) 
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was significant (p = 0.0007), and that there was no significant ‘lack of fit’ (p = 0.8519).  Liquid fill 
volume (p < 0.0006) and (liquid fill volume)
2 (p < 0.0046), but not post-induction period (p = 
0.0728), were significant model terms.  The P:I ratio response surface plot is shown in Figure 
4.7.  From this plot it is clear that high fill volumes not only affect titre, but also have a negative 
effect on the proportion of functional particles in culture supernatants.  Post-induction period, on 
the other hand, did not have a significant impact on the P:I ratio between 26 and 42 hr. 
 
Figure 4.7  Response surface plot displaying the effect of post-induction period and liquid 
fill volume on the P:I ratio.  This figure was generated using a refined quadratic model obtained 
by regression analysis of the P:I data presented in Table 4.6.  All other operating parameters 
were fixed as outlined in Table 4.5.  This figure was generated using Design Expert software.    
4.2.1.5  Verification  of  the  predicted  optimal  values  for  post-induction  period  and  liquid  fill 
volume 
The  regression  model  (vector  titre  in  terms  of  actual  factors)  generated  from  the  CCC 
experimental data (Section 4.2.1.4) took the form: 172 
 
 
         
(4.1) 
 
Where: Y = vector titre, x4 = post-induction period, and x5 = liquid fill volume.  This equation 
(4.1) was used to predict the optimal factor settings.  These were a post-induction period of ≈ 
39.7 hr and a liquid fill volume of ≈ 854 µL, for which a titre of 9.3 x 10
4 TU mL
-1 was predicted.  
Minimising the P:I ratio was not included as a goal for predicting the optimal factor settings, as 
the P:I ratio was not affected by post-induction period in the final CCC experiment.  In addition, 
the predicted optimal setting for liquid fill volume based on maximising titre was consistent with 
previous data and fell within the more favourable lower portion of the response surface plot for 
P:I ratio (Figure 4.7).  A verification experiment was thus performed at these settings (n = 9).  All 
other factors were fixed as for  the final CCC experiment (Table 4.5), and the materials and 
methods for this study are detailed in Section 2.4.5.   
The measured P:I ratio was 0.6 x 10
5, lower than had been previously attained up until this point 
during the DoE experiments (Sections 4.2.1.2 to 4.2.1.4), and the ProSavin
® titre was 6.1 ± 0.2 
x 10
4 TU mL
-1, which was 65 % of the predicted optimum (9.3 x 10
4 TU mL
-1).  This implied 
some lack of fit of the model (Figure 4.5).  However, in agreement with data obtained during the 
earlier DoE experiments, harvests performed either side of the supposed optimum harvest time 
indicated that there is more likely a plateau in titre at around 6 x 10
4 TU mL
-1, as opposed to a 
unique harvest time where a ‘peak’ in titre can be achieved (Figure 4.8).  This ‘harvest window’ 
falls approximately between 26 and 46 hr, in agreement with Figure 4.5, as harvests carried out 
earlier than 26 hr post-induction typically yielded lower titres (Table 4.6 run 5; Figure 4.4; Figure 
4.8), as did harvests carried out later than 46 hr post-induction (Table 4.2 runs 2, 4, 6, 8, 10; 
Figure 4.8).  However, this window is unlikely to be fixed, as for example during the first CCF 
study (Table 4.2), lower titres were observed at 46 hr post-induction than were observed in the 
final CCC study (Table 4.6), indicating that the precise cut-off for the harvest window may vary 
slightly between batches.  Overall, it may be concluded that the model has accurately predicted 
the optimum harvest window, but has slightly overestimated the attainable titre.     
2
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Figure 4.8  ProSavin
®  titre  and  RNA  copy  number  in  an  experiment  to  evaluate  the 
accuracy of the final central composite circumscribed (CCC) model.  Values displayed directly 
below each pair of data indicate the P:I ratio (x 10
5) for that time point.  The liquid fill volume 
was 854 µL and all other operating parameters were fixed as for the final CCC experiment 
(Table 4.5).  The optimal harvest time (in terms of maximising titre) predicted by the final CCC 
model  (≈  39.7  hr  post-induction)  is  indicated.    Mean  values  are  presented  and  error  bars 
represent ﾱ 1 SD (n ≥ 3). 
Cell growth was also monitored during the verification experiment (Figure 4.9).  A drop in viable 
cell concentration and viability was observed 15 hr post-induction.  It is feasible that dox and/or 
NaBu exerted a cytotoxic impact immediately after their addition, as it was earlier demonstrated 
that  heterogeneities  exist  temporarily  in  microwells  following  small  liquid  additions  (Section 
3.2.4),  meaning  that  abnormally  high  concentrations  of  these  compounds  may  have  briefly 
come  into  contact  with  cells,  before  being  fully  dispersed  within  the  bulk  fluid.    The  cells 
subsequently recovered and a peak in density of 3.6 x 10
6 viable cells mL
-1 was observed 45 hr 
post-induction (cell viability remained > 80 % throughout the duration of the study).   174 
 
 
 
Figure 4.9  The concentration and viability of PS46.2 cells over time, observed during an 
experiment to evaluate the accuracy of the final CCC model.   Operating conditions were as 
noted for Figure 4.8.  The point of cell induction (24 hr) and optimal harvest time (in terms of 
maximising  titre)  predicted  by  the  final  CCC  model  (≈  39.7  hr  post-induction)  are  indicated.  
Mean values are presented and error bars represent ﾱ 1 SD (n ≥ 3).  Insert is a representative 
photograph of aggregated PS46.2 in a microwell, taken at the end of the culture (90 hr). 
Culture pH and osmolality were also monitored throughout the culture period (Figure 4.10).  The 
pH declined from 7.4 at the start of the culture (0 hr) to 6.9 by the supposed optimal harvest 
time (39.7 hr post-induction / 63.7 hr post-seeding), and remained at 6.9 until the end of the 
culture (62 hr post-induction / 86 hr post-seeding).  This slight acidification of the culture may 
have negatively impacted on ProSavin
® titres, which plateaued and declined after 39.7 hr post-
induction  (Figure  4.8),  as  the  half-life  of  lentiviral  vectors  has  been  previously  reported  to 
decrease rapidly either side of pH 7 (Higashikawa and Chang, 2001).    Culture acidification 
may also have contributed to the reduction in cell concentration and viability observed during 
the latter stages of the culture (Figure 4.9).   175 
 
 
 
Figure 4.10  The  pH  and  osmolality  of  PS46.2  cultures  over  time,  observed  during  an 
experiment to evaluate the accuracy of the final CCC model.   Operating conditions were as 
noted for Figure 4.8.  The point of cell induction (24 hr) and optimal harvest time (in terms of 
maximising  titre)  predicted  by  the  final  CCC  model  (≈  39.7  hr  post-induction)  are  indicated.  
Mean values are presented and error bars represent ± 1 SD (n = 3).   
The  osmolality  was  0.271  osmol  kg
-1  at  the  time  of  seeding  (0  hr)  and  increased  slightly 
throughout the culture, reaching 0.298 osmol kg
-1 by the end (86 hr post-seeding).  This minor 
increase in osmolality should not have affected PS46.2 cell growth (see earlier discussion in 
Section 3.2.1.2).  To supplement osmolality data, the rate of fluid evaporation from microwells 
was also determined by gravimetric analysis.  Linear regression analysis of this data (R
2 > 0.99) 
revealed that the average rate of fluid loss from microwells was -2.2 % day
-1, thus for a starting 
volume of 854 µL this translates to a loss of -18.8 µL day
-1.  Based on this data, by the time the 
culture was terminated (86 hr), the recorded values for cell concentration, titre and RNA copy 
number  were  theoretically  8.6  %  higher  than  they  would  have  been,  had  no  evaporation 
occurred (earlier measurements would have been affected to a lesser degree).  Overall, the 176 
 
 
extent of evaporation and associated increase in osmolality observed in this study was small, 
and the impact of these parameters on microwell response data was predicted to be negligible.   
4.2.2  Description  of  liquid  phase  hydrodynamics  in  microwells  using  dimensionless 
numbers 
Momentum, gravitation and surface forces can have a substantial impact on the mixing of fluid 
in a microwell, which in turn can affect the productivity of lentiviral vector producer cells.  The 
fluid mixing in a microwell can be described using dimensionless numbers (see Section 1.5.3), 
and  by  characterising  microwells  operating  under  those  conditions  known  to  favour  high 
productivity,  this  information  may  help  to  inform  subsequent  scale-up  studies.    Using  the 
previously  optimised  operating  conditions  for  PS46.2  cell  culture  (i.e.  factor  settings  as 
described for the verification experiment, Section 4.2.1.5), the Reynolds number (Re), Froude 
number (Fr) and Phase number (Ph) were calculated as detailed in Section 2.5.  The Re was 
calculated  to  be  932.    Microwell  Re  has  been  previously  linked  to  flow  regimes  in  shaken 
systems (Barrett et al., 2010), and the relatively low Re recorded here indicates that flow was 
probably laminar.  These conditions likely favoured cellular aggregation, such as that observed 
during the verification experiment (see insert, Figure 4.9).  For shaken bioreactors, the Ph and 
Fr indicate whether the fluid is following the movement of the shaking platform (“in-phase”) or 
not (“out-of-phase”), and only for conditions where the Ph > 1.26 and the Fr > 0.4 is “in-phase” 
operation  predicted  (Büchs  et  al.,  2000b;  Barrett  et  al.,  2010).    “In  phase”  conditions  are 
associated with better mixing and gas transfer.  Here, the Ph was calculated to be 9.12 and the 
Fr was calculated to be 0.29.  Although the Ph value was greater than 1.26, the Fr value was 
below the 0.4 value required for efficient mixing.  This indicates that the influence of gravity on 
fluid  hydrodynamics  cannot  be  neglected  (Lotter  and  Büchs,  2004).    Synonymous  with  the 
gravity effects predicted by a low Fr was the observation that PS46.2 tended to form aggregates 
in the central bottom region of the microwells (see insert, Figure 4.9).  Overall the data suggests 
that gentle agitation conditions promote optimal PS46.2 cell growth and ProSavin
® production.  
However, as microwell cultures rely solely on surface aeration for oxygen delivery, these mild 
mixing conditions may have led to the creation of an oxygen-deprived microenvironment at the 
base  of  the  microwell  when  fill  volumes  greater  than  approximately  1000  µL  were  used.  
Evidence  for  this  may  be  observed  in  Table  4.6  and  Figure  4.6,  where  higher  lactate 177 
 
 
concentrations  and  a  lower  pH  were  associated  with  high  (≥  1212  µL)  fill  volume  cultures, 
presumably as a consequence of oxygen limitations (see discussion in Section 4.2.1.4), and this 
had a detrimental impact on ProSavin
® titres and the P:I ratio. 
4.2.3  Evaluation of the effect of daily dox additions on ProSavin
® titres using microwell 
cultures of PS46.2 
It was demonstrated during the earlier CCF experiments that for harvests performed ≤ 26 hr 
post-induction, a dox concentration of 1.0 µg mL
-1 was sufficient for full cell induction, as higher 
dox concentrations (2.6 - 5.0 µg mL
-1) did not yield higher titres (Sections 4.2.1.2 and 4.2.1.3).  
However, for later harvests (70 hr post-induction), a higher dox concentration (2.6 µg mL
-1) did 
confer a small benefit (Section 4.2.1.2).  It was hypothesised that dox may have been lost from 
the system (e.g. via degradation) over time, meaning that the full induction of cells was not 
being maintained over extended culture periods when a starting concentration of 1.0 µg mL
-1 
was used.  To test this hypothesis, a further microwell experiment was carried out in which the 
addition  of  dox  at  a  concentration  of  1.0  or  3.0  µg  mL
-1  (added  once)  was  compared  to  a 
concentration of 1.0 µg mL
-1 added every 24 hr.    Harvests were performed at 22, 40, 46 and 
70  hr  post-(first)induction  and  ProSavin
®  titres  subsequently  quantified.    The  materials  and 
methods for this study are detailed in Section 2.6.  
No benefit was observed from supplementing extra dox either as a higher starting concentration 
of 3.0 µg mL
-1 or by adding a further 1.0 µg mL
-1 daily (Figure 4.11).  This suggests that the 
small benefit conferred by a higher dox concentration (2.6 µg mL
-1 as compared to 1.0 µg mL
-1) 
observed  in  the  first  CCF  experiment  at  70  hr  post-induction  was  likely  an  artefact  of  the 
experimental  procedure,  caused  by  the  minimal  number  of  repeated  experiments  employed 
during the DoE study, and 1.0 µg mL
-1 is likely sufficient for full cell induction even during this 
extended timeframe.   
It should be noted that, overall, titres were lower in this experiment than were to be expected 
based on the earlier optimisation experiments (Sections 4.2.1.2 to 4.2.1.5).  This was not a 
result of poorer cell growth as cell densities reached between 3.8 and 4.3 x 10
6 viable cells mL
-
1, and cell viabilities also remained high (> 82 %) throughout the study (Figure 4.12).  For the 
purpose  of  monitoring  natural  process  variability,  ProSavin
®  was  produced  using  reference 178 
 
 
shake  flask  cultures,  according  to  the  protocol  outlined  in  Section  2.4.1.3,  in  parallel  to  all 
microwell experiments described in this chapter.  This data is presented in Table 4.7.  For this 
experiment, reference shake flask titres were two- to three-fold lower than those attained during 
the earlier optimisation experiments (Table 4.7), indicating that the relatively low microwell titres 
observed here were likely caused by inherent differences in the cell stock or particular batch of 
media used.  The data collected from reference shake flask cultures demonstrates the typical 
uncontrolled  batch-batch  variability  associated  with  the  production  of  ProSavin
®  using 
suspension cultures of PS46.2.   
 
Figure 4.11  The effect of dox supplementation on ProSavin
® titres over time.  The addition 
of dox to microwell cultures of PS46.2 at a concentration of 1.0 or 3.0 µg mL
-1 (added once) was 
compared to a concentration of 1.0 µg mL
-1 added every 24 hr.  Harvests were performed at 22, 
40, 46 and 70 hr post-(first)induction.  The liquid fill volume was fixed at 854 µL (as for the 
verification  experiment,  Section  4.2.1.5),  while  the  shaking  speed,  shaking  diameter,  pre-
induction period, cell seeding density, concentration of serum and concentration of NaBu were 
fixed as for the final CCC experiment (Table 4.5).  Mean values are presented and error bars 
represent ± 1 SD (n = 4).   179 
 
 
 
Figure 4.12  The effect of dox supplementation on the concentration and viability of PS46.2 
cells over time.  The addition of dox to microwell cultures of PS46.2 at a concentration of 1.0 or 
3.0 µg mL
-1 (added once) was compared to a concentration of 1.0 µg mL
-1 added every 24 hr.  
Cell concentration and  viability  were determined immediately  prior to  vector harvests (which 
were performed at 22, 40, 46 and 70 hr post-[first]induction).  All operating conditions were as 
stated for Figure 4.11.  Mean values are presented and error bars represent ± 1 SD (n = 3).   
Table 4.7  Comparison  of  the  maximum  microwell  titres  achieved  (for  a  single  set  of 
operating conditions during a single experiment), with titres achieved from reference shake flask 
cultures run and assayed in parallel.  Shake flask culture methods are described in Section 
2.4.1.3. 
Microwell experiment 
(section number) 
Maximum microwell 
titre (x 10
4 TU mL
-1) 
(A) 
Reference shake flask 
titre (x 10
4 TU mL
-1) 
(B) 
(A) expressed 
as a % of (B) 
4.2.1.2  4.0 ± 0.4 (n = 3)  2.0 ± 0.3 (n = 3)  200 
4.2.1.3  6.2 ± 1.1 (n = 3)  3.1 ± 0.6 (n = 3)  200 
4.2.1.4  6.3 ± 0.6 (n = 3)  2.3 ± 0.4 (n = 3)  273 
4.2.1.5  6.2 ± 0.7 (n = 3)  3.2 ± 0.4 (n = 3)  194 
4.2.3  2.4 ± 0.2 (n = 4)  1.0 ± 0.1 (n = 3)  240 
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4.3  Chapter discussion 
Using microwell cultures and DoE techniques, an earlier screening experiment (Section 3.2.5) 
had  identified  post-induction  period,  liquid  fill  volume  and  concentration  of  dox  as  important 
factors influencing the production of ProSavin
® from suspension cultures of PS46.2.  Following 
on from this work, the overall aim of this chapter was to further characterise the influence of 
these critical factors on ProSavin
® production, with a view to optimising production conditions 
and informing the design of a large scale bioprocess.  The first objective was to narrow the 
operating ranges for post-induction period, liquid fill volume and concentration of dox, and to 
subsequently predict their optimum settings.  This work was described in Sections 4.2.1.1 to 
4.2.1.4.  The second objective was to verify the predictive capability of the final model.  The 
results of this study were presented in Section 4.2.1.5.  The third objective was to describe the 
fluid  mixing  within  microwells  (operating  under  optimised  conditions)  using  dimensionless 
numbers.  The outcomes of these calculations were described in Section 4.2.2.  Finally, the 
fourth objective was to evaluate whether daily additions of dox to microwell suspension cultures 
of  PS46.2  could  improve  titres  during  extended  (70  hr)  induction  periods.    This  objective 
stemmed from the earlier results described in Section 4.2.1, and the findings of this study were 
presented in Section 4.2.3.  As the outcome of each individual experiment has already been 
briefly discussed in the sections mentioned, the purpose here was to bring these discussions 
together  and  consider  the  overall  conclusions  that  may  be  drawn  regarding  the  impact  of 
harvest timing (Section 4.3.1), microwell mixing (Section 4.3.2), and dox concentration (Section 
4.3.3), on the production of ProSavin
® from suspension cultures of PS46.2.  
4.3.1  The timing of ProSavin
® harvests is critical  
It was demonstrated that an optimal time frame existed between approximately 26 and 46 hr 
post-induction,  during  which  maximal  titres  of  around  6  x  10
4  TU  mL
-1  could  be  attained, 
representing an approximately two-fold improvement in titre as compared to reference shake 
flask cultures (Section 4.2.1 and Table 4.7).  It is unsurprising that post-induction period was a 
critical parameter affecting the production of ProSavin
® during the batch culture of PS46.2 cells, 
as  vector  production  is  tightly  regulated  by  the  tetracycline  (tet)  repressor  (TetR)  regulatory 
protein,  which  controls  expression  of  both  EIAV  gag/pol  and  the  cytotoxic  VSV-G  vector 181 
 
 
component (Stewart et al., 2009; Stewart et al., 2011).  ProSavin
® production is thus initiated by 
the addition of dox, and likely terminated when cell death occurs – potentially as a result of 
nutrient  limitations,  such  as  a  lack  of  glutamine  or  an  accumulation  of  ammonia  (Section 
3.2.1.2).  It  is  also  possible  that  cell  death  may  result  from  VSV-G  accumulation.    This 
membrane protein is expressed on the surface of ProSavin
® and has been previously reported 
to have cytotoxic properties (Burns et al., 1993; Yee et al., 1994; Yang et al., 1995; Ory et al., 
1996).  Titres declined after approximately 46 hr post-induction, when the rate of ProSavin
® 
inactivation exceeded the rate of production.  Although a half-life of between 0.8 and 10.4 hr 
has been reported for HIV-based lentiviral vectors when at 37 °C (Higashikawa and Chang, 
2001; Carmo et al., 2009a; Carmo et al., 2009b), the half-life of EIAV-derived lentiviral vectors 
has not been previously reported, therefore this will be investigated in Chapter 6.   
Although a broad region of operability in terms of harvest time was identified (approximately 
located between 26 and 46 hr), a small amount of variation between experiments was also 
observed, indicating that the precise cut-off points for this harvest window are likely to be batch 
specific.  Therefore, for the development of a robust manufacturing process, it may be prudent 
to  establish  a  harvest  window  which  incorporates  a  margin  of  safety.    Alternatively,  further 
understanding of the relationship between certain process variables and  ProSavin
® titre may 
facilitate harvest time to be defined on a batch-by-batch basis.  For example, the potential of in 
situ permittivity measurements for real-time detection of lentiviral vector release has recently 
been demonstrated (Ansorge et al., 2011).  The future incorporation of such tools into large 
scale  lentiviral  vector  manufacturing  processes  may  enable  operators  to  identify  a  harvest 
window  that  is  specific  for  each  batch  of  vector  produced,  ensuring  that  yields  of  lentiviral 
vectors are of a consistently high titre. 
4.3.2  Gentle  fluid  mixing  and  low  fill  volumes  promote  PS46.2  cell  growth  and 
ProSavin
® production  
The hydrodynamic environment experienced by cells can vary dramatically depending on the 
type  of  production  vessel  and  mode  of  mixing,  therefore  to  inform  future  scale-up  studies, 
dimensionless  numbers  were  used  to  describe  fluid  mixing  within  microwells.    This  data 
revealed that, for microwells operated under optimised conditions, fluid flow was likely laminar 182 
 
 
and dominated by gravitational forces, leading to gentle mixing of the culture (Section 4.2.2).  
Previous data demonstrated that the hydrodynamic forces within microwells can affect the size 
and arrangement of PS46.2 aggregates (Section 3.2.5.2), and synonymous with the prediction 
of mild mixing conditions strongly influenced by gravitational forces, was the observation that 
PS46.2 formed aggregates that collected on the central bottom region of microwells (Figure 4.9 
insert).  It is unclear whether cellular aggregation limited the productivity of suspension-adapted 
PS46.2 in this work, as the best titres achieved were approximately seven-fold lower than those 
reportedly attained when using adherent cultures of PS46.2 (Stewart et al., 2009).  
When  fill  volumes  exceeded  around  1000  µL,  lower  pH  and  higher  lactate  values  were 
observed, in conjunction with lower ProSavin
® titres and a higher P:I ratio (Section 4.2.1.4).  As 
microwell cultures rely solely on surface aeration for oxygen transfer, it is probable that when fill 
volumes  were  increased,  an  oxygen  poor  microenvironment  developed  at  the  base  of 
microwells,  and  this  triggered  PS46.2  to  increase  lactate  production.    The  consequent 
accumulation of lactate caused acidification of the culture, which in turn likely compromised the 
productivity of PS46.2 cells, as well as increased the rate of ProSavin
® inactivation, as the half-
life of lentiviral vectors has previously been reported to decrease rapidly either side of pH 7 
(Higashikawa and Chang, 2001).  Thus, gentle fluid mixing combined with low (≤ 1000 µL) fill 
volumes appear to promote ProSavin
® production when using microwell suspension cultures of 
PS46.2. 
4.3.3  1 µg mL
-1 dox is sufficient for the full induction of PS46.2 suspension cells 
No  data  pertaining  to  the  optimal  dox  concentration  required  for  complete  induction  of  the 
suspension PS46.2 system was available.  PS46.2 incorporates the  tet-ON system and, for 
adherent cultures, 1.0 µg mL
-1 dox was reported to be sufficient for cell induction (Stewart et al., 
2011).  As there are obvious differences in the fluid hydrodynamics between shaken  versus 
static  cell  cultures,  we  investigated  whether  a  higher  dox  concentration  conferred  any 
improvement in ProSavin
® titre when using suspension cultures of PS46.2.  In-line with reported 
findings for adherent PS46.2, however, we concluded that a concentration of 1.0 µg mL
-1 dox 
was  sufficient  for  full  induction  of  suspension-adapted  PS46.2  cells  when  harvests  were 
performed up to 70 hr post-induction. 183 
 
 
4.3.4  Concluding remarks 
The use of suspension-adapted stable producer cell lines is highly desired for future large scale 
productions  of clinical grade  lentiviral  vectors (Ansorge et al.,  2010;  Schweizer and Merten, 
2010; Segura et al., 2013).  Here, an approach combining microscale bioprocessing and DoE 
techniques  was  used  to  rapidly  characterise  the  impact  of  three  important  factors  on  the 
production of ProSavin
® (an EIAV-derived lentiviral vector) from suspension cultures of PS46.2 
(a stable producer cell line).  This approach enhanced our knowledge of the design space, and 
the  data  was  subsequently  used  to  establish  operating  conditions  for  the  production  of 
ProSavin
® in a WAVE bioreactor as described in Chapter 5.  The approach demonstrated here, 
and the insights gained from its application to ProSavin
® bioprocess development, should prove 
useful to researchers looking to develop a suspension-based process for the manufacture of 
lentiviral vectors.   
 
 
 
   184 
 
 
5  Scale-up of lentiviral vector production to 2 L WAVE 
bioreactor scale 
5.1  Introduction and aims 
To validate the microwell platform (Chapters 3 and 4) for use in future lentiviral vector process 
development  studies,  it  was  necessary  to  demonstrate  that  any  data  generated  using  the 
platform was readily scalable.  As discussed in Section 1.5.3, no universal strategy exists for 
scale-up  and,  for  each  new  system,  key  process  parameters  likely  to  affect  product  quality 
require  prompt  identification  and  characterisation  (Betts  and  Baganz,  2006;  Marques  et  al., 
2010).    Scale-up  of  the  ProSavin
®  process  to  a  wave-mixed  bioreactor  based  on  a  single 
criterion, mixing time, was earlier rejected as inappropriate, as values obtained in microwells 
could  not  be  replicated  at  large  scale  (Section  3.2.4)  and  therefore  alternative  criteria  were 
sought  using  a  DoE  approach.    An  initial  screening  experiment  in  microwells  found  that 
ProSavin
®  titres  were  significantly  affected  by  post-induction  period,  liquid  fill  volume  and 
concentration  of  dox  (Section  3.2.5),  and  subsequent  optimisation  studies  established 
approximate operating ranges for these parameters of 26 - 46 hr, 600 - 1000 μL and 1.0 - 5.0 μg 
mL
-1, respectively (Sections 4.2.1 and 4.2.3).  Post-induction period was an important parameter 
as ProSavin
® titres are ultimately a function of particle production rates, which vary over time, as 
well as particle inactivation rates, which curb the accumulation of functional vector in culture 
supernatants.    Liquid  fill  volume  was  a  critical  parameter  as  it  affects microwell  mixing  and 
oxygen  transfer  rates.    High  fill  volumes  (≥  1212  μL)  were  associated  with  high  lactate 
concentrations, low pH values and reduced ProSavin
® titres (Section 4.2.1.4).  Calculation of 
the  dimensionless  numbers,  Re,  Fr,  and  Ph,  revealed  that  fluid  flow  in  microwells  is  likely 
laminar and dominated by gravitational forces, and these mild mixing conditions encouraged the 
settling  of  cellular  aggregates  (Section  4.2.2).    As  oxygen  transfer  is  achieved  via  surface 
aeration,  it  is  likely  that  when  culture  volumes  exceeded  around  1000  µL,  an  oxygen  poor 
microenvironment developed at the base of microwells, which triggered an increase in cellular 
lactate  production  that  in  turn  led  to  acidification  of  the  culture  and  compromised  titres.  
Ensuring adequate aeration, while maintaining gentle agitation conditions, was thus crucial for 
maximising ProSavin
® titres when using microwells (note that in a wave-mixed bioreactor, the fill 185 
 
 
volume,  rocking  rate  and  rocking  angle  determine  the  fluid  mixing  and  oxygen  transfer 
characteristics of the culture).  Lastly, microwell experiments revealed that a dox concentration 
of 1.0 μg mL
-1 was sufficient for full cell induction over typical production timescales (Sections 
4.2.1  and  4.2.3),  and  increasing  the  concentration  to  5.0  μg  mL
-1  had  no  effect  on  titres, 
indicating that this parameter may be given a fixed value within this range.  The overall aim of 
this chapter was to discover if the insights obtained at the microwell scale were relevant upon 
scale-up  of  the  process  to  a  wave-mixed  bioreactor,  in  order  to  verify  whether  (or  not)  the 
microwell  platform  could  be  usefully  employed  in  the  future  to  support  the  development  of 
lentiviral vector processes. 
As discussed earlier (Section 1.4.2), the development of scalable lentiviral vector manufacturing 
processes is an area urgently requiring attention (Ansorge et al., 2010; Schweizer and Merten, 
2010; Segura et al., 2013).  To date, just four production strategies based on suspension cell 
culture have been developed and trialled using laboratory scale (2.3 - 3.0 L working volume) 
stirred tank (Segura et al., 2007; Broussau et al., 2008; Ansorge et al., 2009) or disposable 
wave-mixed (Witting et al., 2012) bioreactors.  Although one of these approaches used a tet-ON 
inducible  packaging cell line  (Broussau  et al., 2008), the remaining three approaches relied 
solely on the use of transient transfection techniques (Segura et al., 2007; Ansorge et al., 2009; 
Witting et al., 2012) making them ill-suited to the generation of licensed product (see summary 
Table 1.9 and Sections 1.4.1 and 1.4.2 for more information).  In this chapter, a fifth process, 
based on the suspension culture of tet-ON stable producer cells using a laboratory scale WAVE 
bioreactor (GE Healthcare) was developed.  A WAVE bioreactor, rather than a conventional 
stirred tank bioreactor, was chosen for evaluation, as this system provides culture conditions 
that are most representative of those found to be optimal within microwells (see Section 4.2.2), 
that is, a low shear environment characterised by bubble-free aeration and laminar flow (Oncül 
et al., 2010; Eibl et al., 2010b).  The specific objectives of this chapter are: 
  To use the insights gained at the microwell scale (Chapters 3 and 4) to establish a basic 
operating protocol for ProSavin
® production in a 2 L WAVE bioreactor.   
  To evaluate the impact of rocking rate and post-induction period on culture performance 
in order to verify whether the key conclusions generated using the microwell system 
(i.e.  oxygenation  plus  gentle  agitation  are  critical;  optimal  time  to  harvest  is 186 
 
 
approximately  26  -  46  hr  post-induction)  hold  relevance  following  scale-up  of  the 
process to a WAVE bioreactor. 
Results included in Section 5.2.1 of this chapter were published in: Guy, H. M., et al. (2013). 
Human  Gene  Therapy  Methods,  24(2):  125-139.  Permission  to  reproduce  this  content  has 
been granted by Mary Ann Liebert, Inc. 
5.2  Results 
5.2.1  Evaluation of a 2 L WAVE bioreactor system for ProSavin
® production  
5.2.1.1  Initial feasibility study using standard operating conditions 
The first objective of this work was to establish a working protocol for ProSavin
® production in a 
20/50 WAVE bioreactor (GE Healthcare), fitted with a 2 L disposable Cellbag (GE Healthcare).  
A full description of the system employed is provided in Section 2.7.1.  An initial pilot run was 
performed  using  the  system  in  which  the  choice  of  key  operating  parameters:  cell  seeding 
density, time to induction and concentration of inducer compounds, was based on optimised 
microwell conditions, while harvest timings reflected those evaluated during the final microwell 
verification experiment (Section 4.2.1.5).  The initial liquid fill volume chosen was the maximum 
1 L working volume (50 %) recommended by the manufacturer, as this enabled the full capacity 
of the system to be exploited.  Further decisions regarding bioreactor-specific variables such as 
rocking rate, rocking angle, air flow rate and starting CO2 concentration were made using the 
manufacturer’s  recommendations  in  conjunction  with  available  literature  pertaining  to 
HEK293(T) cell growth and/or virus production in wave-mixed bioreactors (Singh, 1999; Genzel 
et al., 2006; Wernli et al., 2008; Throm et al., 2009; Greene et al., 2012; Witting et al., 2012).  
Based on earlier observations of gentle fluid mixing in the microwell system (Section 4.2.2), a 
relatively slow rocking rate of 10 rocks min
-1 was chosen corresponding to the lowest rocking 
rate reported for the cultivation of suspension cells in reviewed literature.  Suspension-adapted 
PS46.2 cells were used to seed the WAVE bioreactor and, for comparison, parallel microwell 
plates (which were operated under optimised conditions).  Cells were induced after 24 hr, and 
ProSavin
®  harvests  were  performed  at  17,  23,  40,  47  and  65  hr  post-induction  (±  1  hr).  187 
 
 
Samples were collected throughout the culture period for analysis of cell growth, culture pH and 
ProSavin
® titre.  A full description of the protocol employed is provided in Section 2.7.2.   
Cell growth and viability data is presented in Figure 5.1.  Although both the WAVE bioreactor 
and microwell cultures were seeded using the same cell stock (prepared at a density of 1.2 x 
10
6 viable cells mL
-1), immediately post-seeding the viable cell concentration within the WAVE 
bioreactor was 75 % (9.4 x 10
5 viable cells mL
-1) of that recorded for parallel microwell cultures 
(1.3 x 10
6 viable cells mL
-1).  Likely as a direct consequence of this lower starting cell density, 
the viable cell concentration within the WAVE bioreactor subsequently remained consistently 
between 61 and 76 % of that recorded for parallel microwell cultures (Figure 5.1).  Cell viability 
data  obtained from the WAVE bioreactor and  parallel microwells  was similar,  with  viabilities 
remaining above 80 % throughout the culture (Figure 5.1).  Cellular aggregation was observed 
in the WAVE bioreactor, however, the size and extent of aggregates was generally similar to 
that observed in parallel microwells (Figure 4.9 insert). 
The slightly lower cell recoveries observed for the WAVE bioreactor culture immediately post-
seeding were probably caused by the method of inoculation used.  The cells were syringed into 
the Cellbag through a length of C-Flex tubing
® that extended into a tissue culture hood, as at 
this point no sterile tubing welder was available for use.  While it is unlikely that cell losses 
arose as a consequence of shear damage inflicted by this approach (cell viabilities were > 90 % 
and comparable to those observed in microwells at 0 hr), it is possible that some cells were left 
in the tubing.  A different approach for seeding the Cellbag was adopted for the later studies 
described in Sections 5.2.1.2 and 5.2.2, which involved flushing the inoculum addition line with 
media after the addition of cells (details of the method are provided in Sections 2.7.3.2 and 
2.7.3.3).  This appeared to resolve the issue for subsequent WAVE runs (Figures 5.3 and 5.6), 
as starting cell concentrations were 1.0 - 1.2 x 10
6 viable cells mL
-1 (86 - 100 % of the target 
density) in all instances except where the Cellbag had been pre-coated with media (starting cell 
concentration was 6.9 x 10
5 viable cells mL
-1; 58 % of the target density), which could have 
been due to rapid adherence of cells to the vessel interior in this experiment (Section 5.2.1.2).   188 
 
 
 
Figure 5.1  Growth  and  viability  of  PS46.2  cells  cultured  in  a WAVE  bioreactor  using  a 
Cellbag with 50 % (1 L) fill volume (n = 1).  Data from parallel reference microwell cultures of 
PS46.2 is also shown (n = 3).  Production of ProSavin
® was induced after 24 hr, as indicated on 
the graph.  The materials and methods for this study are described in Section 2.7.2.  Mean data 
is plotted and error bars represent ± 1 SD (sample material obtained from the WAVE culture 
was subjected to three repeat measurements, from which the mean and SD were calculated, 
while microwell data represents three measurements taken from three separate wells).  
Despite the reasonable growth and high viability of PS46.2 when cultured within the WAVE 
bioreactor (Figure 5.1), ProSavin
® titres were relatively low (Figure 5.2).  The best titre achieved 
in the WAVE bioreactor was just 8.9 x 10
3 TU mL
-1 (40 hr post-induction), which was 12 % of 
the best titre achieved in parallel microwells (7.2 x 10
4 TU mL
-1; 23 hr post-induction).  It was 
noted during the earlier microwell experiments that when fill volumes of greater than 1000 µL 
were used, cellular lactate production was elevated (presumably due to oxygen limitations as 
oxygen  transfer  is  facilitated  by  surface  aeration  only  within  microwells),  which  led  to 
acidification  of  the  medium  and  a  reduction  in  ProSavin
®  titres  (see  Section  4.2.1.4).    Like 
microwell cultures, WAVE bioreactor cultures rely on surface aeration for oxygen transfer, and 
thus may also be subjected to oxygen restrictions under certain operating conditions.  In this 
study, the pH within the WAVE bioreactor dropped from 7.0 to 6.7 after 41 hr, and remained at 189 
 
 
6.7 until termination of the culture, while the pH within microwells stabilised at 7.0 (Table 5.1).  
Earlier microwell studies had demonstrated that relatively small decreases in the culture pH can 
be symptomatic of large reductions in ProSavin
® titres: cultures with a fill volume above 1 mL 
yielded pH values of 6.7 and titres four- to six-fold lower than equivalent cultures with a fill 
volume less than or equal to 1 mL and pH of between 6.8 and 7.2 (Section 4.2.1.4).  The low pH 
within the WAVE bioreactor was indicative of oxygen limited conditions caused by inadequate 
mixing of the culture.  The combined use of a low rocking rate (10 rocks min
-1) and high fill 
volume (1 L) was likely responsible for this effect.  
Finally,  culture  osmolality  (Section  2.11.1.2)  was  measured  at  one  time  point  (40  hr  post-
induction) to verify that evaporation was not an issue when using the WAVE bioreactor.  The 
recorded value was 0.277 osmol kg
-1 (n = 1), while for parallel microwells the osmolality was 
0.278 osmol kg
-1 (n = 1; combined material from triplicate wells).  Both of these values are well 
within the normal range expected during suspension culture of PS46.2 (see Section 3.2.1.2), 
and consequently this parameter was not investigated further.   
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Figure 5.2  ProSavin
®  titres  (measured  using  the  rapid  ProSavin
®  titre  assay;  Section 
2.11.2.1) obtained from PS46.2 cells cultured in a WAVE bioreactor using a Cellbag with 50 % 
(1 L) fill volume (n = 1).  Data from parallel reference microwell cultures of PS46.2 is also shown 
(n = 3).  The materials and methods for this study are described in Section 2.7.2.  Mean data is 
plotted and error bars represent ± 1 SD (sample material obtained from the WAVE culture was 
subjected to three repeat measurements, from which the mean and SD were calculated, while 
microwell data represents three measurements taken from three separate wells).  
Table 5.1  pH  measured  at  various  time  points  during  the  culture  of  PS46.2  cells  in  a 
WAVE  bioreactor  using  a  Cellbag  with  50  %  (1  L)  fill  volume  (n  =  1).    Data  from  parallel 
reference microwell cultures of PS46.2 is also shown (n = 1).  Production of ProSavin
® was 
induced after 24 hr.  The materials and methods for this study are described in Section 2.7.2.  
pH measurements were performed at the time points noted ± 1 hr.  
Culture duration (hr)  Post-induction period (hr) 
pH 
WAVE bioreactor  Microwell 
0  -  7.7  7.7 
22  -  7.3  7.3 
41  17  6.7  7.0 
47  23  6.7  7.0 
64  40  6.7  7.0 
71  47  6.7  7.0 
89  65  6.7  7.0 
 191 
 
 
5.2.1.2  Refinement of the operating procedure based on results obtained at the microwell scale  
The first experiment using the WAVE bioreactor yielded a relatively low maximum titre (Section 
5.2.1.1), thus some modifications to the procedure were made and subsequently trialled in a 
second evaluative study.  Based on the discovery during microwell experiments that maintaining 
a relatively low liquid fill volume was critical for maximising ProSavin
® yields (Section 4.2.1.4), 
the working volume of the Cellbag was reduced to 0.5 L, which is 25 % of the total volume 
(equivalent  to  850  µL  in  the  microwell  system).    A  further  modification  was  that  the  CO2 
concentration was reduced to 1 % (from 5 %) after 24 hr culture (at the time of induction), to 
help retain the culture pH at approximately pH 7.  Finally, the impact of pre-coating the Cellbag 
was  explored.    The  manufacturer  recommends  pre-coating  the  Cellbag  when  chemically-
defined  lipid  supplements  are  used,  as  the  internal  surface  of  the  culture  chamber  can 
sequester  these  compounds  from  the  culture  medium  (General  Electric  Company,  2008b).  
Although such supplements are not used during suspension culture of PS46.2, it was unknown 
whether any of the components of FreeStyle
TM 293 Expression Medium or tet-free FCS were 
susceptible to depletion in this manner.  It was thus deemed prudent to investigate whether pre-
coating the bag proffered any benefit for cell growth or vector production.   
In this experiment, two Cellbags were therefore operated in parallel where one Cellbag was pre-
coated  and  the  other  was  not.    Suspension-adapted  PS46.2  cells  were  used  to  seed  both 
Cellbags and, for comparison, parallel microwell plates, which were operated under optimised 
conditions.  Cells were induced after 24 hr, and ProSavin
® harvests were performed at 18, 22, 
41, 47 and 66 hr post-induction (± 1 hr).  Samples were collected throughout the culture period 
for  analysis  of  cell  growth,  culture  pH  and  ProSavin
®  titre.    Oxygen  saturation  was  also 
monitored in the Cellbag that had been pre-coated, and RNA copy number measurements were 
performed using supernatants from the Cellbag that had not been pre-coated.  A full description 
of the protocol employed is provided in Section 2.7.3.2.   
Cell  growth  and  viability  data  is  presented  in  Figure  5.3.    Pre-coating  the  Cellbag  had  a 
detrimental effect on both cell growth and viability.  In the pre-coated Cellbag, the maximum cell 
concentration recorded was 2.6 x 10
6 viable cells mL
-1, which was reached after 90 hr.  By this 
point the cell viability had dropped to just 60.6 %.  In the Cellbag that had not been pre-coated, 192 
 
 
the cell concentration peaked earlier (after 71 hr culture) and was 48 % higher (3.9 x 10
6 viable 
cells mL
-1).  The cell viability was also consistently higher throughout the culture (Figure 5.3), 
and after 90 hr was 69.6 %.  It was surprising that pre-coating the Cellbag had such a marked 
negative impact on PS46.2 cell growth and viability.  During the study, obvious differences in 
the aggregative behaviour of PS46.2 were noted between the two Cellbags.  In the Cellbag that 
had  not  been  pre-coated,  cellular  aggregation  was  similar  to  that  observed  in  the  first 
experiment (Section 5.2.1.1).  In the pre-coated Cellbag, however, the extent of aggregation 
was severe, and large masses of cells adhered to the base of the Cellbag at the periphery of 
the rocked liquid flow, where the cells were routinely exposed to the air-liquid interface.  It may 
be  reasonably  conjectured  that  this  phenomena  was  responsible  for  the  relatively  low  cell 
numbers and reduced viability of this culture.  It is possible that, in pre-coating the Cellbag, 
some  components  from  the  tet-free  FCS  or  media  allowed  the  cells  to  form  a  biofilm  and 
aggregate.  The cell concentration and viability of parallel microwell cultures were higher than in 
either  of  the WAVE  bioreactor  cultures  (Figure  5.3).    It  should  be  noted,  however,  that  the 
maximum cell concentration recorded here (6.3 x 10
6 viable cells mL
-1 at 65 hr) was exceptional, 
and that in previous microwell experiments (Chapter 4) the cell concentrations recorded were 
typically closer to those recorded in the Cellbag that was not pre-coated (e.g. compare Figure 
4.9 and Figure 5.3).   193 
 
 
 
Figure 5.3  Growth and viability of PS46.2 cells cultured in a WAVE bioreactor using two 
Cellbags, each with a 25 % (0.5 L) fill volume.  For comparison, one Cellbag was pre-coated (p-
c) with media (n = 1), while the other was not (n = 1).  Data from parallel reference microwell 
cultures of PS46.2 is also shown (n = 3).  Production of ProSavin
® was induced after 24 hr, as 
indicated on the graph.  The materials and methods  for this study are described in Section 
2.7.3.2.  Mean data is plotted and error bars represent ± 1 SD (sample material obtained from 
each WAVE culture was subjected to three repeat measurements, from which the mean and SD 
were  calculated,  while  microwell  data  represents  three  measurements  taken  from  three 
separate wells).  
ProSavin
® titre data displayed a similar trend to cell data.  WAVE bioreactor titres attained from 
the Cellbag that was not pre-coated consistently exceeded those achieved from the Cellbag that 
was pre-coated (Figure 5.4).  The relatively low titres recorded for the pre-coated Cellbag were 
likely  a direct result  of the poorer cell  growth  and viability  within this culture  due to cellular 
aggregation effects.  Encouragingly, however, the maximum titres achieved from both WAVE 
bioreactor cultures were higher than those observed during the previous study (Section 5.2.1.1).  
The maximum titre achieved from the Cellbag that was not pre-coated was 2.5 x 10
4 TU mL
-1 
(41 hr post-induction), which was 47 % of the maximum titre achieved in parallel microwells (5.2 
x  10
4  TU  mL
-1;  22  hr  post-induction).    RNA  copy  numbers  were  also  quantified  using 194 
 
 
supernatants from this Cellbag, and this data was used in conjunction with titre data to calculate 
particle:infectivity (P:I) ratio values for each time point (P:I ratio = RNA copy number / titre).  
This  data  is  also  included  in  Figure  5.4.    As  was  observed  during  the  earlier  microwell 
optimisation studies (Section 4.2.1), culture supernatants harvested from the WAVE bioreactor 
contained an increasing proportion of defective particles over time and by 41 hr post-induction, 
when  the maximum titre was recorded, the P:I ratio  was 1.1 x 10
5 (Figure  5.4).  This is  in 
reasonable agreement with the P:I ratio of 0.9 x 10
5 recorded in the earlier microwell verification 
experiment at 45 hr post-induction (when the maximum titre was recorded; Figure 4.8).   
 
Figure 5.4  ProSavin
®  titres  obtained  from  PS46.2  cells  cultured  in  a  WAVE  bioreactor 
using two Cellbags, each with a 25 % (0.5 L) fill volume.  For comparison, one Cellbag was pre-
coated (p-c) with media (n = 1), while the other was not (n = 1).  Data from parallel reference 
microwell  cultures  of  PS46.2  is  also  shown  (n  =  3).    RNA  copy  number  values  are  also 
presented for one WAVE culture (Cellbag not pre-coated), and the particle:infectivity (P:I) ratio 
(x 10
5) is also displayed directly above each RNA data point.  The materials and methods for 
this study are described in Section 2.7.3.2.  Mean data is plotted and error bars represent ± 1 
SD  (sample  material  obtained  from  each  WAVE  culture  was  subjected  to  three  repeat 
measurements, from which the mean and SD were calculated, while microwell data represents 
three measurements taken from three separate wells).  195 
 
 
In this study, two key modifications to the initial WAVE bioreactor operating protocol (Section 
5.2.1.1)  were  made:  (i)  the  working  volume  of  the  Cellbag  was  reduced,  and  (ii)  the 
concentration of CO2 pumped through the headspace was lowered during the latter stages of 
the culture.  It is clear that using a 25 % Cellbag fill volume is more conducive to ProSavin
® 
production than using a 50 % fill volume via comparison of Figures 5.4 and 5.2.  Here, the pH in 
both Cellbags, as well as in microwells, stabilised at 7.0 (Table 5.2).  This suggests that the 
cultures were adequately mixed and did not experience oxygen limited conditions, such as likely 
occurred  when  a  50  %  fill  volume  was  used.    Consistent  with  this  hypothesis  was  the 
observation that in situ oxygen saturation levels in the pre-coated Cellbag remained reasonably 
high (> 57 %) throughout the culture period (Table 5.3).  However, it should be noted that, as 
well as the reduction in fill volume, the concentration of CO2 mixed with air and pumped through 
the headspace was also reduced (from 5 to 1 % after 24 hr) in this experiment, and it is possible 
this modification to the procedure could also have contributed to stabilise the pH and improve 
titres as CO2 blending can have a acidifying effect on cell culture media.  Overall, it seems 
unlikely that the 5 % CO2 concentration employed for the duration of the 50 % fill volume WAVE 
bioreactor study (Section 5.2.1.1) caused the observed acidification of the culture after 41 hr.  In 
this earlier study (Section 5.2.1.1), parallel microwell cultures were also exposed to a 5 % CO2 
atmosphere, yet a similar drop in culture pH was not observed.  In addition, the Freestyle
TM 293 
expression medium used for this work is buffered for use in an 8 % CO2 atmosphere.  This 
suggests  that  lactate  build-up  (caused  by  a  limited  availability  of  oxygen)  instigated  the 
reduction in pH observed in the earlier experiment (Section 5.2.1.1) and lowering the fill volume 
counteracted this effect in the current study.  Overall, a working strategy has been developed 
for ProSavin
® production using a WAVE bioreactor, which yields titres within two to three-fold 
and a P:I ratio comparable to those commonly achieved in microwells.  
   196 
 
 
Table 5.2  pH  measured  at  various  time  points  during  the  culture  of  PS46.2  cells  in  a 
WAVE bioreactor using two Cellbags, each with a 25 % (0.5 L) fill volume.  For comparison, one 
Cellbag was pre-coated (p-c) with media (n = 1), while the other was not (n = 1).  Data from 
parallel reference microwell cultures of PS46.2 is also shown (n = 1).  Production of ProSavin
® 
was induced after 24 hr.  The materials and methods for this study are described in Section 
2.7.3.2.  pH measurements were performed at the time points noted ± 1 hr.  
Culture 
duration (hr) 
Post-induction 
period (hr) 
pH 
WAVE bioreactor (p-c)  WAVE bioreactor  Microwell 
0  -  7.7  7.7  7.7 
23  -  7.3  7.0  7.3 
42  18  7.0  7.0  7.0 
46  22  7.0  7.0  7.0 
65  41  7.0  7.0  7.0 
71  47  7.0  7.0  7.0 
90  66  7.0  7.0  7.0 
 
Table 5.3  Oxygen saturation recorded at various time points during the culture of PS46.2 
cells in a WAVE bioreactor using a Cellbag with 25 % (0.5 L) fill volume.  The Cellbag had been 
pre-coated  with  media  (note:  before  being  replaced  with  inoculum,  this  media  served  to 
calibrate the oxygen probe).  Production of ProSavin
® was induced after 24 hr.  The materials 
and methods for this study are described in Section 2.7.3.2.  Oxygen saturation values were 
recorded at the time points noted ± 1 hr.  
Culture duration (hr)  Post-induction period (hr)  Oxygen saturation (%) 
0  -  94.8 
16  -  77.7 
23  -  74.9 
42  18  57.7 
46  22  58.8 
65  41  63.9 
71  47  70.2 
90  66  79.8 
5.2.2  Investigation into the effect of WAVE bioreactor rocking rate and post-induction 
period  on  ProSavin
®  production  to  establish  the  accuracy  of  microwell 
predictions 
Following proof-of-principle studies (Section 5.2.1), a reasonable operating procedure had been 
established for ProSavin
® production using the WAVE bioreactor, although titres remained lower 
than  those  achieved  using  the  microwell  system.    Earlier  microwell  experiments  had 
demonstrated  that  manipulation  of  the  culture  mixing  conditions  was  crucial  for  maximising 
ProSavin
® yields; high fill volumes had led to reduced titres (see Sections 3.2.5.1 and 4.2.1.4).  197 
 
 
Thus, this study examined whether altering the culture mixing conditions could also improve 
titres generated using the WAVE system.  Rocking rate, rather than fill volume, was varied in 
order to produce different mixing conditions within the WAVE bioreactor, as it was undesirable 
to  further  reduce  the  (already  low)  working  volume.    Eight  separate  bioreactor  runs  were 
performed,  using  rocking  rates  of  6,  12,  18  and  24  rocks  min
-1  (n  =  2).    According  to  the 
manufacturer a rocking rate of 6 rocks min
-1 is generally the minimum required for bulk mixing 
and particle suspension in a WAVE bioreactor (General Electric Company, 2008a).  Rocking 
rates  of  between  6  and  15  rocks  min
-1  have  been
  employed  for  the  culture  of  anchorage-
dependent HEK293-derived cell lines (General Electric Company, 2008a; Throm et al., 2009; 
Greene et al., 2012), while rocking rates of 10 to 22 rocks min
-1 have been used for the culture 
of suspension-adapted HEK293-derivatives (Singh, 1999; Wernli et al., 2008).  To maximise the 
likelihood of detecting conditions optimal for PS46.2 growth and ProSavin
® production, a broad 
range  of  rocking  rates  were  consequently  evaluated  in  the  current  study  that  encompassed 
those  previously  employed  for  the  successful  maintenance  of  HEK293-based  cells  (Singh, 
1999; Wernli et al., 2008; General Electric Company, 2008a; Throm et al., 2009; Greene et al., 
2012).  Earlier microwell experiments had also demonstrated the critical impact of harvest timing 
on ProSavin
® titres, therefore multiple harvests were performed during each run.   
In brief, the WAVE bioreactor was seeded with suspension-adapted PS46.2 cells, which were 
induced after 24 hr, and ProSavin
® harvests were performed at 17, 23, 41, 47 and 65 hr post-
induction.  Samples  were  collected throughout the culture  period for the analysis of various 
parameters (see Sections 5.2.2.1 to 5.2.2.5 below).  To monitor process variability, ProSavin
® 
was produced using reference shake flask cultures parallel to all WAVE runs, and this data is 
presented in Section 5.2.2.6.  A full description of the protocol employed is provided in Section 
2.7.3.3.   
5.2.2.1  Cell growth kinetics 
Viable cell concentration data is displayed in Figures 5.5 and 5.6.  Figure 5.5 illustrates the 
extent of variability between duplicate WAVE bioreactor runs.  Overall, cell growth was similar 
between duplicate runs, although the data collected during the first run performed at 12 rocks 
min
-1 (Figure 5.5 [b], [1]) and the second run performed at 18 rocks min
-1 (Figure 5.5 [c], [2]) 198 
 
 
appears somewhat erratic.  This was attributed to cellular aggregation, which, except for when a 
rocking rate of 6 rocks min
-1 was used, was reasonably extensive during all runs.  Typically, 
some  cells  adhered  to  the  Cellbag,  while  those  in  solution  formed  a  combination  of  large, 
loosely aggregated (i.e ‘stringy’) clumps, and smaller spherical clumps.  The rocking rate was 
increased  immediately  prior  to  sample  removal  during  all  WAVE  runs  to  aid  representative 
sampling  (see  Section  2.7.2.2).    While  this  did  help  to  create  a  more  homogenous  cell 
population, large clumps of cells often remained intact and, their inclusion (or not) in cell count 
samples may have skewed measurement data.  When a rocking rate of 6 rocks min
-1 was used, 
cellular  aggregates  were  much  finer,  giving  the  appearance  of  suspended  silt,  and  no  cells 
adhered to the Cellbag, thus a representative sample for cell counts was more easily obtained.  
It is unclear why cellular aggregation was more extensive when higher rocking rates (12 - 24 
rocks min
-1) were used, although it was established during the earlier microwell studies (Section 
3.2.5.2)  that  the  hydrodynamic  environment  can  impact  on  PS46.2  aggregate  formation.    A 
modified Reynolds number (Remod) has been previously developed and used to describe fluid 
flow in a 2 L WAVE bioreactor (Eibl and Eibl, 2006; Eibl et al., 2010b).  However, insufficient 
information was reported to enable calculation of this parameter for our system as, for example, 
the equation incorporated a correction factor (C) for which values were not provided (Eibl and 
Eibl, 2006).  Despite this, a reasonable indication of the fluid conditions likely prevailing during 
the culture of PS46.2 cells could be obtained from scrutinising the Remod data presented by Eibl 
and Eibl (2006).  For a 2 L Cellbag operating with a 10 - 50 % liquid fill volume, it was reported 
that turbulent flow predominated when the Remod exceeded around 600 (Eibl and Eibl, 2006; 
Eibl et al., 2010b).  When the liquid fill volume and rocking angle were fixed at 50 % and 6°, 
respectively, the Remod was close to 600 when a rocking rate of 6 rocks min
-1 was used, but was 
significantly higher (> 1000) when a rocking rate of 12, 18 or 24 rocks min
-1 was employed (Eibl 
and Eibl, 2006).  It is likely that the Remod values for our system differed slightly to these due to 
the use of a lower 25 % fill volume.  Despite this, the data indicate that runs conducted using a 
rocking rate of 12, 18 or 24 rocks min
-1 were most likely characterised by turbulent conditions, 
while cultures undertaken using a rocking rate of 6 rocks min
-1 may have experienced laminar 
flow.  It is possible that cell-to-cell and cell-to-Cellbag collisions occurred at a relatively higher 
frequency  and  velocity  when  the  rocking  rate  equalled  or  exceeded  12  rocks  min
-1,  thus 
opportunities for aggregate formation were increased.  To assess the impact of rocking rate on 199 
 
 
cell  growth,  viable  cell  concentration  data  from  duplicate  runs  was  combined  (Figure  5.6).  
Rocking  rate  had  no  obvious  impact  on  cell  growth,  with  cells  reaching  a  similar maximum 
density (3.0 - 5.2 x 10
6 viable cells mL
-1) at a similar stage of the culture (65  - 89 hr post-
seeding) in all runs (n = 8). 
 
Figure 5.5  Growth of PS46.2 cells in a WAVE bioreactor rocked at a rate of (a) 6 rpm, (b) 
12 rpm, (c) 18 rpm, or (d) 24 rpm, where ‘rpm’ is an abbreviation for rocks min
-1.  Cells were 
cultured using a Cellbag with 25 % (0.5 L) fill volume, and production of ProSavin
® was induced 
after 24 hr, as indicated by the dotted vertical line.  Materials and methods for this study are 
described in full in Section 2.7.3.3.  Eight separate bioreactor runs were performed (two at each 
rocking  condition),  and  data  from  individual  runs  is  presented  (at  each  time  point,  sample 
material was subjected to three repeat measurements, and the mean ± 1 SD is displayed). 
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Figure 5.6  Summary graph illustrating the growth of PS46.2 cells in a WAVE bioreactor 
rocked  at  a  rate  of  6,  12,  18,  or  24  rpm  (where  ‘rpm’  is  an  abbreviation  for  rocks  min
-1).  
Production  of  ProSavin
®  was  induced  after  24  hr,  as  indicated  by  the  dotted  vertical  line.  
Operating  conditions  were  as  noted  for  Figure  5.5.    Eight  separate  bioreactor  runs  were 
performed (two at each rocking condition), and mean data from duplicate runs is presented 
(error bars represent the range). 
Cell viability data is presented in Figures 5.7 and 5.8.  Data from duplicate runs was comparable 
(Figure 5.7), indicating that there is little variability between repeated WAVE bioreactor runs with 
regards to cell survival.  Note that, as viability measurements are expressed as a proportion 
(%), they are not liable to be skewed by the over- or under-representation of cellular aggregates 
within a sample.  Cell survival was affected by rocking rate (Figure 5.8).  When a rocking rate of 
6 rocks min
-1 was used, cell viabilities remained high, measuring between 86.1 and 86.3 % at 
the termination of the culture (89 hr post-seeding).  When a rocking rate of 12, 18 or 24 rocks 
min
-1  was  used,  however,  viabilities  were  relatively  lower  by  the  end  of  the  culture  period, 
measuring between 58.8 and 73.8 %.  It has previously been reported that power input typically 
increases  with  rocking  rate  over  the  range  6  to  24  rocks  min
-1  (Eibl  et  al.,  2010b).  
Consequently, cells cultured using a rocking rate of 6 rock min
-1 were likely subjected to the 201 
 
 
lowest level of hydrodynamic stress in the current study, and this may account for their relatively 
higher rate of survival.  
 
 
Figure 5.7  Viability of PS46.2 cells in a WAVE bioreactor rocked at a rate of (a) 6 rpm, (b) 
12 rpm, (c) 18 rpm, or (d) 24 rpm, where ‘rpm’ is an abbreviation for rocks min
-1.  Production of 
ProSavin
® was induced after 24 hr, as indicated by the dotted vertical line.  Operating conditions 
were as noted for Figure  5.5.  Eight separate bioreactor runs were performed (two at each 
rocking  condition),  and  data  from  individual  runs  is  presented  (at  each  time  point,  sample 
material was subjected to three repeat measurements, and the mean ± 1 SD is displayed). 
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Figure 5.8  Summary graph illustrating the viability of PS46.2 cells in a WAVE bioreactor 
rocked  at  a  rate  of  6,  12,  18,  or  24  rpm  (where  ‘rpm’  is  an  abbreviation  for  rocks  min
-1).  
Production  of  ProSavin
®  was  induced  after  24  hr,  as  indicated  by  the  dotted  vertical  line.  
Operating  conditions  were  as  noted  for  Figure  5.5.    Eight  separate  bioreactor  runs  were 
performed (two at each rocking condition), and mean data from duplicate runs is presented 
(error bars represent the range). 
5.2.2.2  Dissolved oxygen and pH data 
In  situ  dissolved  oxygen  was monitored  during  the  bioreactor  runs,  as  described  in  Section 
2.11.1.5.    Data  collected  during  duplicate  runs  was  comparable  (Figure  5.9),  indicating  that 
there is little variability between WAVE bioreactor runs performed at the same rocking rate in 
terms  of  cellular  oxygen  demands.    Oxygen  saturation  levels  remained  highest  (≥  81.1  %) 
during the runs performed at 24 rocks min
-1, and declined in line with decreasing rocking rates 
(Figure 5.10), with levels falling as low as 36.8 and 27.7 % during the runs performed at 6 rocks 
min
-1.  As viable cell concentrations, and therefore likely cellular oxygen  requirements, were 
similar during all runs regardless of rocking rate (Figure 5.6), this indicates that the oxygen 
transfer rate (kLa) increased in line with rocking rate.  This is consistent with previous reports 
that kLa is a function of rocking rate (Singh, 1999; General Electric Company, 2008a).  Finally, it 203 
 
 
has  previously  been  reported  that,  during  the  continuous  culture  of  hybridoma  cells,  cell 
viabilities  increased  as  dissolved  oxygen  levels  decreased,  presumably  because  oxidative 
damage  to  cellular  components  was  reduced  (Miller  et  al.,  1987).    It  is  worth  considering, 
therefore, whether the low oxygen levels observed during the WAVE runs performed at 6 rocks 
min
-1 (Figure 5.10) could also have contributed to the higher cell viabilities of these cultures as 
compared to the other runs (Figure 5.8).   
 
Figure 5.9  Oxygen saturation of PS46.2 cultures in a WAVE bioreactor rocked at a rate of 
(a) 6 rpm, (b) 12 rpm, (c) 18 rpm, or (d) 24 rpm, where ‘rpm’ is an abbreviation for rocks min
-1.  
Production  of  ProSavin
®  was  induced  after  24  hr,  as  indicated  by  the  dotted  vertical  line.  
Operating  conditions  were  as  noted  for  Figure  5.5.    Eight  separate  bioreactor  runs  were 
performed (two at each rocking condition), and data from individual runs is presented (n = 1). 
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Figure 5.10  Summary graph illustrating the oxygen saturation of PS46.2 cells in a WAVE 
bioreactor rocked at a rate of 6, 12, 18, or 24 rpm (where ‘rpm’ is an abbreviation for rocks min
-
1).  Production of ProSavin
® was induced after 24 hr, as indicated by the dotted vertical line.  
Operating  conditions  were  as  noted  for  Figure  5.5.    Eight  separate  bioreactor  runs  were 
performed (two at each rocking condition), and data from duplicate runs is presented (error bars 
represent the range). 
Culture  pH  was  monitored  during  all  WAVE  bioreactor  runs  using  pH  indicator  strips  as 
described  in  Section  2.11.1.3.    This  data  is  presented  in  Table  5.4.    Data  from  the  runs 
conducted using rocking rates of 12, 18 or 24 rocks min
-1 were similar, with the pH typically 
stabilising at 7.0.  Only pH data collected during the runs performed at 6 rocks min
-1 was notably 
different.  Consistent with the earlier microwell (Section 4.2.1.4) and WAVE bioreactor (Section 
5.2.1.1) findings that poor mixing leads to acidification of the culture, the pH fell as low as 6.4 
(47 hr post-seeding) during the runs performed at 6 rocks min
-1.  This effect was likely produced 
by  increased  lactic  acid  production  as  a  result  of  limited  oxygen  availability  (see  earlier 
discussions  in  Sections  4.2.1.4  and  5.2.1.1),  and  consistent  with  this  supposition  was  the 
observation that dissolved oxygen levels were also lowest for these cultures (Figure 5.10).  As 
the optimum dissolved oxygen level for mammalian cell growth has been reported to be around 
50  %  of  saturation  with  air  (Miller  et  al.,  1987),  it  is  reasonable  to  suppose  that  the  runs 205 
 
 
performed using a rocking rate of 6 rocks min
-1 were oxygen limited (Figure 5.10).  Although the 
observed reduction in dissolved oxygen did not negatively impact on the growth or viability of 
PS46.2 cultures (Section 5.2.2.1), the associated fall in culture pH (Table 5.4) indicates that the 
cells responded to these lower oxygen levels by increasing lactic acid production.  The culture 
pH subsequently recovered slightly and stabilised at 6.7 (Table 5.4), indicating that the cells 
may  have  switched  to  lactate  consumption  during  the  latter  stages  of  the  culture,  as  was 
previously observed (see Sections 3.2.1.2 and 3.2.1.3). 
Table 5.4  pH  measured  at  various  time  points  during  the  culture  of  PS46.2  cells  in  a 
WAVE bioreactor rocked at a rate of 6, 12, 18, or 24 rpm (where ‘rpm’ is an abbreviation for 
rocks min
-1).  Production of ProSavin
® was induced after 24 hr.  Operating conditions were as 
noted  for  Figure  5.5.    Eight  separate  bioreactor  runs  were  performed  (two  at  each  rocking 
condition), and data from individual runs is presented (n = 1).  
Culture 
duration 
(hr) 
Post-
induction 
period (hr) 
pH 
6 rpm  12 rpm  18 rpm  24 rpm 
(1)  (2)  (1)  (2)  (1)  (2)  (1)  (2) 
0  -  7.7  7.7  7.7  7.7  7.7  7.7  7.7  7.7 
24  0  7.0  6.7  7.3  7.3  7.3  7.3  7.3  7.0 
41  17  6.7  6.7  7.0  7.0  7.0  7.0  7.0  7.0 
47  23  6.4  6.4  7.0  7.0  7.0  7.0  7.0  7.0 
65  41  6.4  6.7  7.0  7.0  7.0  7.0  7.0  6.7 
71  47  6.7  6.7  7.0  7.0  7.0  7.0  7.0  7.0 
89  65  6.7  6.7  6.7  7.0  7.0  7.0  6.7  6.7 
5.2.2.3  ProSavin titre
® data 
Titre data is presented in Figures 5.11 and 5.12.  To note, duplicate bioreactor runs performed 
at the same rocking rate did not yield comparable titres (Figure 5.11).  Although titre profiles 
were similar, as peak titres were observed at approximately the same harvest point (± 6 hr, 
Figure 5.11), maximum titres values obtained during duplicate runs differed by 1.4 fold (24 rocks 
min
-1), 1.7 fold (18 rocks min
-1), 2.2 fold (12 rocks min
-1) and 4.6 fold (6 rocks min
-1).  The fold-
differences between duplicate runs performed at 24, 18 and 12 rocks min
-1 equalled or slightly 
exceeded those observed for parallel shake flasks (Section 5.2.2.6), perhaps indicating  that 
WAVE cultures are marginally more susceptible to  batch-to-batch  variation than small scale 
cultures.    The  fold-difference  between  duplicate  runs  performed  at  6  rocks  min
-1  greatly 
exceeded  that  observed  for  parallel  shake  flasks,  suggesting  that  the  sub-optimal  culture 206 
 
 
conditions  prevailing  throughout  these  runs  may  have  exerted  an  additional  pressure  that 
resulted in variable culture performance. 
From the mean data, it may be observed that runs performed using a mid-range rocking rate of 
12 or 18 rocks min
-1 typically yielded the highest ProSavin
® titres (Figure 5.12).  The lower titres 
observed for runs performed using a rocking of 6 or 24 rock min
-1 may be attributed to cellular 
oxygen  limitations  (leading  to  increased  lactate  production  and  culture  acidification)  in  the 
former, and exposure of the vector to relatively high levels of turbulence in the latter (this is 
discussed further in Section 5.3.2).  Overall, these results therefore correspond with the earlier 
microwell observations that adequate aeration combined with gentle fluid mixing is critical for 
maximising ProSavin
® titres (Section 4.3.2).   
 
Figure 5.11  ProSavin
®  titres  obtained  from  PS46.2  cells  cultured  in  a  WAVE  bioreactor 
rocked  at  a  rate  of  (a)  6  rpm,  (b)  12  rpm,  (c)  18  rpm,  or  (d)  24  rpm,  where  ‘rpm’  is  an 
abbreviation for rocks min
-1.  Operating conditions were as noted for Figure 5.5.  Eight separate 
bioreactor runs were performed (two at each rocking condition), and data from individual runs is 
presented (at each time point, sample material was subjected to three repeat measurements, 
and the mean ± 1 SD is displayed). 
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Figure 5.12  Summary graph illustrating ProSavin
® titres obtained from PS46.2 cells cultured 
in a WAVE bioreactor rocked at a rate of 6, 12, 18, or 24 rpm (where ‘rpm’ is an abbreviation for 
rocks min
-1).  Operating conditions were as noted for Figure 5.5.  Eight separate bioreactor runs 
were  performed  (two  at  each  rocking  condition),  and  mean  data  from  duplicate  runs  is 
presented (error bars represent the range). 
During the earlier microwell investigations, it was discovered that the optimum time to harvest 
was  within  a  period  spanning  approximately  20  hr,  which  fell  between  26  and  46  hr  post-
induction, although it was noted that this window was likely to vary slightly between batches 
(Section  4.2.1.5).    For  the  runs  performed  using  agitation  conditions  most  conducive  to 
ProSavin
® production (i.e.  those performed at 12 or  18 rocks min
-1), the highest titres  were 
attained at 23 hr post-induction (Figure 5.12).  By 41 hr post-induction, titres had reduced to 75 - 
87 % of those observed at 23 hr post-induction.  Thus the optimum harvest window occurred 
slightly  earlier  during  the  WAVE  bioreactor  experiments  than  was  predicted  based  on  the 
previous  (Section  4.2.1.5)  microwell  data.    However,  the  microwell  cultures  carried  out  in 
parallel to the first two pilot WAVE runs also yielded maximum titres at 22 - 23 hr post-induction, 
with values declining to 68 - 78 % of the maximum by 40 - 41 hr post-induction (Figures 5.2 and 
5.4).  This implies that batch-batch variability in the seeding material was most likely responsible 208 
 
 
for the shift in the optimum harvest window (the experiments described in this chapter were 
conducted during a separate time period to the experiments described in Chapters 3 and 4, thus 
the batch of medium used differed, for example) and as the optimum harvest time was also 
close  to  (within  3  hr  of)  the  optimum  harvest  window  predicted  during  the  earlier  (Section 
4.2.1.5) microwell experiments, it may be concluded that the microwell data provided a good 
indication of the best time to harvest when using the WAVE system.  The maximum titre values 
obtained were 2.4 - 4.1 x 10
4 TU mL
-1 during the runs performed at 18 rocks min
-1, and 1.8 - 3.7 
x 10
4 TU mL
-1 during the runs performed at 12 rocks min
-1.  Maximum values obtained during 
the runs performed at 18 rocks min
-1 were within two to three-fold of the best titres attained 
using microwells operating under optimised conditions to date (7.2 x 10
4 TU mL
-1; Figure 5.2). 
5.2.2.4  Product enhanced reverse transcriptase (PERT) data 
To supplement titre data, harvested supernatants were also analysed using the PERT assay, as 
described in Section 2.11.3.2.  This method generates a prediction of biological titre (PERT 
predicted TU mL
-1) based on the amount of reverse transcriptase (RT) enzyme present within a 
given sample.  An assumption is made to correlate the total RT present in a sample to the 
number of virus particles, however it is not able to predict functionality of the particles.  This 
data is presented in Figures 5.13 and 5.14.  Overall there was little variability between duplicate 
runs.  Consistent with biological titre data (Figure 5.11 [a]), the greatest difference between 
duplicate runs occurred when a rocking rate of 6 rocks min
-1 was used (Figure 5.13 [a]), with the 
second run outperforming the first (maximum PERT values differed by 2.2-fold). 
PERT predicted titres were affected by rocking rate (Figure 5.14).  The results were broadly 
consistent with biological titre data (Figure 5.12), in that the runs performed at 18 rocks min
-1 
yielded the highest values overall, followed by in descending order, runs performed at 12, 24 
and  6  rocks  min
-1.    However,  in  comparing  Figure  5.12  with  5.14  we  see  that  there  is  a 
disagreement in the trends presented.  Figure 5.12 shows titres reaching a maximum at 17 - 23 
hr  post  induction,  with  the  exception  of  6  rocks  min
-1,  and  then  a  general  decline  in  titre.  
However, Figure 5.14 shows PERT predicted titres increasing  over time.  The PERT assay 
overestimated  functional  titre  values  by  9-  to  192-fold,  with  the  fold-difference  generally 
increasing over time (Table 5.5).  This reflects the fact that viral RT associated with ProSavin
® 209 
 
 
particles is relatively stable and unlikely to be degraded over these production timescales, while 
functional ProSavin
® particles were likely subjected to continuous inactivation (see Chapter 6).  
The inherent robustness of the RT enzyme makes the PERT assay useful for gaining insight 
into cellular productivity over time (as the RT is not liable to rapid decay, it presumably builds up 
in the supernatant at a rate relative to that at which lentiviral vector particles are produced).  
Here, for those runs performed using a rocking rate of 6 rocks min
-1, PERT values started low 
(relative to all other runs), but increased steadily throughout the duration of the culture (Figure 
5.13 [a]).  For all other runs, PERT values increased until around 47 hr post-induction, after 
which they levelled off or increased only marginally (Figure 5.13 [b-d]).  Note that maximum 
biological  titre  values  were  also  observed  later  (41  -  47  hr  post-induction)  during  the  runs 
performed at 6 rocks min
-1 (Figure 5.11 [a]), as compared to all other runs (17 - 23 hr post-
induction; Figure 5.11 [b-d]).  Overall, the data suggest that lentiviral vector production  was 
inhibited  during  the  early  stages  of  the  culture  when  a  rocking  rate  of  6  rocks  min
-1  was 
employed, and this led to functional titres peaking later as compared to all other runs.  This was 
likely a consequence of the sub-optimal (i.e. acidic and oxygen poor) conditions experienced by 
these cultures (Section 5.2.2.2). 
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Figure 5.13  Product  enhanced  reverse  transcriptase  (PERT)  predicted  titres  obtained 
during the culture of PS46.2 cells in a WAVE bioreactor rocked at a rate of (a) 6 rpm, (b) 12 
rpm,  (c)  18  rpm,  or  (d)  24  rpm,  where  ‘rpm’  is  an  abbreviation  for  rocks  min
-1.    Operating 
conditions were as noted for Figure 5.5.  Eight separate bioreactor runs were performed (two at 
each rocking condition), and data from individual runs is presented (at each time point, sample 
material was subjected to three repeat measurements, and the mean ± 1 SD is displayed). 
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Figure 5.14  Summary graph illustrating PERT predicted titres obtained during the culture of 
PS46.2 cells in a WAVE bioreactor rocked at a rate of 6, 12, 18, or 24 rpm (where ‘rpm’ is an 
abbreviation for rocks min
-1).  Operating conditions were as noted for Figure 5.5.  Eight separate 
bioreactor runs were performed (two at each rocking condition), and mean data from duplicate 
runs is presented (error bars represent the range). 
Table 5.5  Fold  difference  between  PERT  predicted  titres  and  actual  biological  titres  at 
various time points during the culture of PS46.2 cells in a WAVE bioreactor rocked at a rate of 
6,  12,  18,  or  24  rpm  (where  ‘rpm’  is  an  abbreviation  for  rocks  min
-1).    Fold-difference  was 
calculated using mean data values from Figures 5.11 and 5.13 (i.e. fold difference = PERT 
predicted  titre  /  titre).    Operating  conditions  were  as  noted  for  Figure  5.5.    Eight  separate 
bioreactor runs were performed (two at each rocking condition), and data from individual runs is 
presented (n = 1).  
Post-induction period (hr) 
PERT predicted titre / titre 
6 rpm  12 rpm  18 rpm  24 rpm 
(1)  (2)  (1)  (2)  (1)  (2)  (1)  (2) 
17  49  34  13  9  15  9  19  12 
23  49  33  17  11  22  13  33  18 
41  41  27  42  21  38  26  62  42 
47  64  29  44  37  56  35  101  59 
65  113  72  103  65  140  69  192  114 
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5.2.2.5  RNA copy number data 
To supplement ProSavin
® titre (Section 5.2.2.3) and PERT predicted titre (Section 5.2.2.4) data, 
total  lentivirus  particles  were  also  quantified  using  the  RNA  copy  number  assay.    Duplicate 
WAVE bioreactor runs generated similar RNA copy number profiles (Figure 5.15).  Both RNA 
copy number (Figure 5.15) and PERT (Figure 5.13) data thus appear less susceptible to batch-
to-batch  variability  as  compared  to  functional  titre  values  (Figure  5.11).    This  is  probably 
because a strand of RNA or a molecule of RT is significantly less complex than a functioning 
lentiviral  vector,  thus  fewer factors  likely  play  a  role  in  determining  their  final  concentration.  
Runs  performed  using  a  rocking  rate  of  12,  18  or  24  rock  min
-1  yielded  similar  RNA  copy 
number profiles, with values typically peaking at 41 - 47 hr post-induction (measuring 2.5 - 4.0 x 
10
9  RNA  copies  mL
-1),  after  which  values  levelled  off  or  declined  marginally  (Figure  5.16).  
Similar to PERT data, those runs performed using a rocking rate of 6 rocks min
-1 displayed a 
different profile: RNA copy number values started low (relative to all other runs), but increased 
steadily for the duration of the culture, reaching 2.1 - 2.5 x 10
9 RNA copies mL
-1 by 65 hr post-
induction  (Figure 5.16).  The RNA copy number data support the notion that lentiviral vector 
production was impeded during the early stages of the culture when a rocking rate of 6 rocks 
min
-1 was employed. 
RNA copy number data was used in conjunction with ProSavin
® titre data to calculate P:I ratio 
values for each time point (P:I ratio = RNA copy number / titre).  This data is presented in Table 
5.6.    As  was  observed  during  the  earlier  microwell  optimisation  studies  (Section  4.2.1)  and 
during  the  second  pilot  WAVE  study  (Section  5.2.1.2),  culture  supernatants  contained  an 
increasing proportion of defective particles over time, and the highest (worst) P:I ratios were 
observed at the termination of the culture (65 hr post-induction; Table 5.6).  The lowest (best) 
P:I ratio values were attained during the runs performed at 18 rocks min
-1 and during the second 
run performed at 12 rocks min
-1, where values of 0.4 - 0.5 x 10
5 were recorded at 17 and 23 hr 
post-induction (Table 5.6), corresponding with the times at which the highest functional titres 
values were also recorded (Figure 5.11 [b-c]).   213 
 
 
 
Figure 5.15  RNA copy number data obtained during the culture of PS46.2 cells in a WAVE 
bioreactor rocked at a rate of (a) 6 rpm, (b) 12 rpm, (c) 18 rpm, or (d) 24 rpm, where ‘rpm’ is an 
abbreviation for rocks min
-1.  Operating conditions were as noted for Figure 5.5. Eight separate 
bioreactor runs were performed (two at each rocking condition), and data from individual runs is 
presented (at each time point, sample material was subjected to three repeat measurements, 
and the mean ± 1 SD is displayed).   
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Figure 5.16  Summary graph illustrating RNA copy number data obtained during the culture 
of PS46.2 cells in a WAVE bioreactor rocked at a rate of 6, 12, 18, or 24 rpm (where ‘rpm’ is an 
abbreviation for rocks min
-1).  Operating conditions were as noted for Figure 5.5.  Eight separate 
bioreactor runs were performed (two at each rocking condition), and mean data from duplicate 
runs is presented (error bars represent the range). 
Table 5.6  Particle:infectivity (P:I) ratios (RNA copy number / titre) at various time points 
during the culture of PS46.2 cells in a WAVE bioreactor rocked at a rate of 6, 12, 18, or 24 rpm 
(where ‘rpm’ is an abbreviation for rocks min
-1).  Operating conditions were as noted for Figure 
5.5.  Eight separate bioreactor runs were performed (two at each rocking condition), and data 
from individual runs is presented (n = 1: values were calculated using mean data from Figures 
5.11 and 5.15).  
Post-induction period (hr) 
P:I ratio (x 10
5) 
6 rpm  12 rpm  18 rpm  24 rpm 
(1)  (2)  (1)  (2)  (1)  (2)  (1)  (2) 
17  1.7  0.9  0.6  0.4  0.5  0.4  1.2  0.8 
23  2.1  0.9  1.0  0.4  0.5  0.5  1.6  1.2 
41  2.5  1.1  2.1  0.9  1.0  0.9  3.3  3.7 
47  3.5  1.1  1.9  1.3  1.5  1.4  4.7  3.8 
65  6.4  2.2  3.8  2.1  3.0  2.6  8.8  5.6 
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5.2.2.6 Capturing experimental variance - Parallel shake flask reference data 
Due to equipment limitations, it was not feasible to conduct more than one WAVE bioreactor run 
at a time.  The eight bioreactor runs were therefore conducted on different days.  In order to 
distinguish differences between runs that were caused by the controlled variable from those 
likely arising due to experimental variance in the process, the following precautions were taken: 
(i) two independent bioreactor runs were conducted for each rocking condition, (ii) cell growth 
parameters and lentiviral vector characteristics were quantified three times at each sampling 
point,  (iii)  cells  used  to  seed  the  Cellbag  were  derived  from  the  same  cell  bank,  and  were 
always used at the same passage number (ten days post-revival), (iv) excepting the difference 
in rocking rate, exactly the same procedure was followed during each run, and (v) data from 
reference shake flask cultures was collected in parallel to each run. 
Reference  shake  flask  data  is  presented  in  Figure  5.17.    Triplicate  flasks  were  seeded  in 
parallel to each WAVE bioreactor run and ProSavin
® was generated using standard methods 
(Section  2.4.1.3).    Harvested  supernatants  were  then  analysed  alongside  samples  from  the 
corresponding WAVE bioreactor run.  The main purpose of collecting data from reference shake 
flask  cultures  was  to  monitor  process  variability,  and  to  help  identify  the  source  of  any 
inconsistencies, had they arisen, in the WAVE bioreactor data and thus to ascertain whether a 
particular cell stock or batch of media used during a particular run could have been responsible 
for any anomalous results.  The data collected from the eight sets of reference shake flasks was 
relatively consistent, indicating that batch-to-batch differences in the inoculum material used to 
seed the WAVE bioreactor were small (Figure  5.17).  The  viable cell concentration of flask 
cultures (recorded at the time of vector harvest) ranged from 3.2 to 4.5 x 10
6 cells mL
-1, while 
viabilities  were  between  92  and  95  %  (Figure  5.17  [a-b]).    Recorded  ProSavin
®  titres  were 
between 3.3 and 5.5 x 10
4 TU mL
-1, PERT predicted titres between 0.6 and 1.1 x 10
6 TU mL
-1, 
and  RNA  copy  numbers  between  2.0  and  3.8  x  10
9  RNA  copies  mL
-1  (Figure  5.17  [c-e]).  
Although batch-to-batch variances therefore existed, the difference between the highest and 
lowest recorded values for all measured parameters was less than 2-fold.  Also, importantly, the 
variation between control flasks was random, indicating that the trends observed in the WAVE 
bioreactor dataset were real and had not been artificially introduced as a consequence of seed 
stock differences.  For example, WAVE runs performed using a rocking rate of 18 rocks min
-1 216 
 
 
produced consistently higher titres than those conducted using a rocking rate of 24 rocks min
-1 
(Figure 5.11), however this trend was not replicated in control flask titres.  Overall, it may be 
concluded that the use of different cell stocks and media during each WAVE run should not 
have impacted on the overall findings arising from this dataset (Sections 5.2.2.1 to 5.2.2.5).     217 
 
 
 
Figure 5.17  Reference shake flask data collected in parallel to WAVE bioreactor runs.  (a) 
Viable cell concentration, (b) cell viability, (c) titre, (d) PERT predicted titre, and (e) RNA copy 
number data.  The corresponding WAVE bioreactor run to which shake flask data relates is 
indicated by the rocking rate (rpm, an abbreviation for ‘rocks min
-1’) and whether it was the first 
(1) or second (2) of duplicate runs carried out using those conditions.  Triplicate shake flasks 
were seeded using the same cell stock as was used to seed the WAVE bioreactor.  Shake flask 
operating conditions were as outlined in Section 2.4.1.3.  One vector harvest was performed (24 
hr post-induction), and cell data (a-b) was collected immediately prior to vector harvests.  Mean 
values are presented and error bars represent ± 1 SD (n = 3).   218 
 
 
5.3  Chapter discussion 
The development of scalable cell culture processes for the manufacture of lentiviral vectors is 
an area requiring urgent attention (Ansorge et al., 2010; Schweizer and Merten, 2010; Segura 
et al., 2013).  Here, the insights gained during the earlier microwell investigations (Chapters 3 - 
4) were used to rapidly establish operating conditions for ProSavin
® production in a 2 L WAVE 
bioreactor.   Although WAVE  bioreactors have been previously  employed for lentiviral  vector 
production  (Throm  et  al.,  2009;  Greene  et  al.,  2012;  Witting  et  al.,  2012),  the  protocols 
described employed either anchorage-dependent tet-OFF producer cells (Throm et al., 2009; 
Greene et al., 2012) or suspension-adapted cells that required 4 plasmid transient transfection 
(Witting et al., 2012).  Consequently, this chapter comprises the first description of lentiviral 
vector production in a WAVE bioreactor using a suspension-adapted stable producer (tet-ON) 
cell line. 
5.3.1  Insights  obtained  at  the  microwell  scale  enabled  rapid  establishment  of  a 
protocol for ProSavin
® production in a WAVE bioreactor  
The  first  objective  of  this  work  was  to  establish  a  basic  operating  procedure  for  ProSavin
® 
production  using  a  WAVE  bioreactor  fitted  with  a  2  L  Cellbag.    An  initial  evaluative  study, 
conducted  using  a  1  L  fill  volume,  yielded  an  acidic  culture  environment  and  low  titres 
(maximum: 8.9 x 10
3 TU mL
-1; Section 5.2.1.1).  Earlier microwell data had shown that culture 
acidification  occurs  when  high  fill  volumes  are  used,  presumably  because  this  restricts  the 
supply of oxygen to cells, which respond by increasing lactate production. This subsequently 
accumulates and forces a reduction in culture pH (Sections 3.2.1.2, 3.2.1.3 and 4.2.1.4).  A 
second evaluative study was therefore conducted using a reduced Cellbag fill volume of 0.5 L.  
The maximum titre value obtained during this run was appreciably higher (2.5 x 10
4 TU mL
-1) 
and  no  culture  acidification  was  observed  (Section  5.2.1.2).    Thus,  insights  obtained  at  the 
microwell  scale  into  the  relationship  between  pH,  titre  and  fill  volume  enabled  rapid 
establishment of an operating procedure in a WAVE bioreactor that yielded titres within two to 
three-fold of the maximum titres we have obtained in microwells to date.  Note that, although the 
potential benefit of pre-coating the Cellbag with culture medium was also trialled, this was found 
to exacerbate cellular aggregation and negatively impact on ProSavin
® titres. 219 
 
 
5.3.2  The importance of gentle mixing, oxygenation and harvest timing were verified 
using the WAVE bioreactor 
Earlier  microwell  studies  had  revealed  that  liquid  fill  volume  and  post-induction  period  were 
critical factors influencing ProSavin
® production from suspension cultures of PS46.2 (Sections 
3.2.5 and 4.2.1).  Liquid fill volume affects microwell mixing, and it was demonstrated that low fill 
volumes  (≤  30  %  of  total  well  volume)  combined  with  gentle  agitation  conditions  promoted 
PS46.2 cell growth and ProSavin
® production (Sections 3.2.5, 4.2.1 and 4.2.2).  The optimum 
time to harvest was found to be restricted to within a window spanning a period of around 20 hr 
(between 26 and 46 hr post-induction, although it was noted this was likely to be batch-specific; 
Sections 4.2.1.5 and 4.3.1).  As further optimisation of these factors in the WAVE bioreactor 
could  lead  to  improvements  in  titres,  a  further  set  of  eight  bioreactor  runs  were  performed 
(Section 5.2.2).  As the earlier WAVE bioreactor runs (Section 5.2.1) had demonstrated that a 
0.5  L  (25  %)  fill  volume  was  able  to  deliver  sufficient  aeration  (oxygen  saturation  levels 
remained > 50 % and no culture acidification occurred), this factor remained fixed, while the 
rocking rate was varied (6, 12, 18 and 24 rock min
-1; n = 2) to generate different mixing regimes, 
and  multiple  harvests  were  performed.    By  monitoring  various  cell  culture  parameters  (cell 
growth, dissolved oxygen and pH) and lentiviral vector characteristics (ProSavin
® [functional] 
titres, PERT predicted titres and RNA copy numbers), it was possible to gain insight into how 
these responses both interacted and reacted to changes in rocking rate.  
Overall,  the  runs  performed  using  rocking  rate  of  18  rocks  min
-1,  closely  followed  by  those 
performed using a rocking rate of 12 rocks min
-1, yielded the highest titres and best P:I ratios 
(Sections 5.2.2.3 and 5.2.2.5).  The relatively low titres (≤ 1.9 x 10
4 TU mL
-1) observed during 
the runs conducted at 6 rocks min
-1 were attributed to the sub-optimal conditions experienced 
by these cultures as a result of  inadequate mixing.  During these runs, oxygen levels were 
consistently lower than the 50 % saturation value thought optimal for maintaining mammalian 
cell growth (Miller et al., 1987), and significant acidification of the culture (to pH 6.4) occurred 
(Section  5.2.2.2).  The  culture  acidification  that  occurred  during  the  6  rocks min
-1  run  likely 
reduced the productivity of PS46.2 cells, as well as increased the rate of ProSavin
® inactivation, 
as lentiviral vectors have been reported to decay at a faster rate when subjected to acidic (as 
compared to pH neutral) conditions (Higashikawa and Chang, 2001).  During all other runs, 220 
 
 
dissolved oxygen levels remained above 50 %, and the culture pH stabilised at around pH 7.  
Interestingly, cell growth did not appear inhibited during the runs performed at 6 rocks min
-1 as 
cell  viabilities  were  consistently  high,  above  85  %;  for  all  other  rocking  rates,  cell  viabilities 
dropped to below 75 % (Section 5.2.2.1).  The cell viability was perhaps preserved during the 
runs conducted at 6 rock min
-1 because exposure to hydrodynamic stress
 (Eibl et al., 2010b) 
and oxidative damage (Miller et al., 1987) was reduced.  Although a rocking rate of 6 rocks min
-1 
was not damaging to cell growth or survival, it was detrimental for lentiviral vector production.  
PERT predicted titres and RNA copy numbers were initially (i.e. when measured at 17 hr post-
induction)  lowest  during  the  runs  conducted  at  6  rock  min
-1  as  compared  to  all  other  runs, 
however,  their  levels  steadily  increased  throughout  the  culture  (during  all  other  runs  levels 
stabilised after 47 hr post-induction; Sections 5.2.2.4 and 5.2.2.5).  Functional titres also peaked 
later (41 - 47 hr post-induction) during the runs performed at 6 rocks min
-1 (in all other runs 
maximum titres were obtained 17 - 23 hr post-induction; Section 5.2.2.3).  Taken together, the 
data  indicates  that  lentiviral  vector  production  was  inhibited  during  the  early  stages  of  the 
culture when a rocking rate of 6 rocks min
-1 was used.  It seems that, although the cells are able 
to  survive  on  relatively  little  oxygen  (Figure  5.10:  6  rocks  min
-1  produced  the  least  oxygen 
blending), the production of lentiviruses requires an increased supply of oxygen that a rocking 
rate of 6 rocks min
-1 could not deliver.  Titres were also relatively low (≤ 1.6 x 10
4 TU mL
-1) when 
the rocking rate was increased to 24 rocks min
-1.  These cultures experienced consistently high 
dissolved oxygen levels (> 80 %; Section 5.2.2.2), but otherwise performed similarly to the 12 
and 18 rocks min
-1 cultures.  Of the rocking rates examined, a rocking rate of 24 rocks min
-1 
likely produced the most turbulent conditions (Eibl and Eibl, 2006; Eibl et al., 2010b), and it is 
possible that this environment accelerated the rate of vector inactivation: the low titres obtained 
during these runs were not accompanied by reduced PERT and RNA copy  number values, 
which suggests that the stability, rather than the production, of vector particles may have been 
compromised.  Overall, it may be concluded that a mid-range rocking rate (12 - 18 rocks min
-1) 
is optimal for ProSavin
® production.  A rocking rate of 18 rocks min
-1 produced consistently high 
titres (maximum: 2.4 - 4.1 x 10
4 TU mL
-1), while a rocking rate of 12 rocks min
-1 produced more 
varied results (maximum titres: 1.8 - 3.7 x 10
4 TU mL
-1).  The P:I ratio at the time at which 
maximum titres were obtained was 5 x 10
4 during the runs performed at 18 rocks min
-1, which is 
around half of that previously observed in microwells (e.g. Section 4.2.1.5).  This is most likely a 221 
 
 
direct consequence of titres peaking earlier in the WAVE cultures as defective particles would 
have had less time to accumulate.  Although no real improvement in titre was accomplished as 
a result of these investigations since maximum titre values were similar to those attained during 
the earlier pilot run (Section 5.2.1.2), a greater understanding of the operational design space 
has been achieved.    
The objective of these studies was ultimately to verify whether the conclusions generated using 
the microwell system held true following scale-up of the process.  The observation that titres 
were compromised when cultures experienced either vigorous agitation (i.e. when a rocking rate 
of 24 rocks min
-1 was used) or limited oxygen availability (i.e. when a rocking rate of 6 rocks 
min
-1  was  used),  supports  the  notion  that  a  combination  of  gentle  agitation  and  adequate 
oxygenation is important for maximising titres.  Evidence that the microwell system correctly 
predicted the optimum time at which to perform harvests was given by the  observation that 
maximum titres were achieved at 23 hr post induction (during the 12 or 18 rocks min
-1 runs), 
which  was  within  3  hr  of  the  optimum  harvest  window  predicted  during  the  earlier  (Section 
4.2.1.5) microwell experiments, but precisely matched the microwell data collected in parallel to 
the  first  two  pilot  WAVE  runs  (Figures  5.2  and  5.4).    Overall,  the  microwell  investigations 
correctly  predicted  the  important  parameters  affecting  ProSavin
®  titres  in  WAVE  bioreactor 
cultures,  and  consequently  the  microwell  platform  may  be  usefully  applied  to  the  future 
development of lentiviral vector processes. 
5.3.3  Concluding remarks 
In summary, the potential of wave-mixed bioreactor technology for future applications to large-
scale  lentiviral  vector  production  based  on  suspension-adapted  producer  cells  has  been 
demonstrated.    The  bioprocess  design  data  generated  using  the  microscale  experimental 
platform  was  fundamental  in  aiding  the  rapid  establishment  of  operating  conditions  for 
ProSavin
® production in the WAVE bioreactor.  In particular, post-induction period and liquid fill 
volume were key factors affecting ProSavin
® titres at the microwell scale, and optimisation of 
these factors proved crucial in the development of the larger scale process.  The microwell 
system can therefore be considered a valuable bioprocess development tool.   222 
 
 
The  WAVE  bioreactor  was  simple  to  set-up,  and  the  procedure  for  ProSavin
®  production 
straight-forward.  As maximum titres were observed at 23 hr post-induction when a rocking rate 
of 12 or 18 rocks min
-1 was used, the entire process, from cell inoculation to lentiviral vector 
harvest, could theoretically be accomplished in three days.  As the culture vessel is disposable, 
no down-time between runs is required.  In addition, scale-up to larger vessels should be readily 
achievable (Eibl et al., 2010b).  
Finally, it is evident that titres do not accumulate over time (Section 5.2.2.3) and that functional 
ProSavin
® may have a short half-life at the temperature at which cell culture is performed.  It is 
conceivable that higher titres may be achieved if a perfusion system were developed, as this 
would allow vector particles to be continually separated from cells via filtration and stored at 4 
°C, potentially preventing the rapid loss of functionality seen at these higher temperatures.  In 
addition, the dilution of cytotoxic vector proteins (VSV-G) and metabolic by-products, such as 
lactate; and the addition of fresh nutrients, could extend cellular productivity.  With a view to 
informing the design of enhanced large-scale processes for lentiviral vectors, the next chapter 
examines  the  rate  at  which  ProSavin
®  and  other  lentiviral  vectors  are  inactivated  and  tests 
approaches to slow the rate of decay. 
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6  Evaluation of lentiviral vector stability during upstream 
processing 
6.1  Introduction and aims 
Throughout  the  earlier  microwell  (Chapters  3  and  4)  and  WAVE  bioreactor  (Chapter  5) 
investigations, post-induction period (i.e. harvest timing) was consistently found to be a critical 
factor  impacting  on  ProSavin
®  titres.    Titres  increased  following  the  induction  of  ProSavin
® 
producer cells (PS46.2), then plateaued and declined, and in three days the optimum harvest 
window  had  passed  (Figure  4.8,  Figure  5.12).    The  early  data  suggested  that  functional 
ProSavin
®  is  inactivated  in  culture  supernatants,  and  during  the  latter  stages  of  batch 
cultivations the rate of decay either surpasses the rate of production or the rate of production 
declines.  HIV-1 based lentiviral vectors have been reported to exhibit a half-life of between 0.8 
and 10.4 hr at 37 °C (Higashikawa and Chang, 2001; Zhang et al., 2004; Carmo et al., 2009a; 
Carmo  et  al.,  2009b),  however  the  half-life  of  EIAV-based  lentiviral  vectors  at  production 
temperature was not known.  This information could aid the design of improved manufacturing 
processes  for  EIAV-based  lentiviral  vectors.    Thus,  the  overall  aim  of  this  chapter  was  to 
investigate the rate at which ProSavin
® and other EIAV-based lentiviral vectors are inactivated, 
plus test approaches to moderate the rate of decay.  The specific objectives of this chapter are:   
  To  characterise  the  stability  of  functional  ProSavin
®,  vector  RNA  and  reverse 
transcriptase (RT) under typical production conditions (36.5 °C) 
  To  propose  (based  on  a  review  of  relevant  literature)  and  test  approaches  for 
mitigating ProSavin
® inactivation during upstream processing  
  To investigate whether the stability of EIAV-based lentiviral vectors is a function of 
the particular production method or transgene employed 
Results included in Section 6.2.1.1 of this chapter were published in: Guy, H. M., et al. (2013). 
Human  Gene  Therapy  Methods,  24(2):  125-139.  Permission  to  reproduce  this  content  has 
been granted by Mary Ann Liebert, Inc. 
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6.2  Results 
6.2.1  Characterisation of ProSavin
® stability under typical production conditions  
6.2.1.1  Stability of ProSavin
® in crude supernatants at 36.5 °C 
The stability of functional ProSavin
®, vector RNA and RT in cell culture supernatants incubated 
at 36.5 °C was characterised.  In the first experiment, supernatants harvested from standard 
shake flask cultures of PS46.2 were aliquoted into shaken microwells, static microwells or static 
vials and incubated for various time periods of up to 168 hr (Section 2.8.1).  ProSavin
® titres 
were subsequently quantified and this data is presented in Figure 6.1.  Similar decay kinetics 
were observed for all vessels.  As the data obtained from the static vials was representative of 
that  obtained  when  using  the  microscale  culture  system,  future  stability  studies  were 
consequently conducted using this format.  
 
Figure 6.1  Functional  ProSavin
®  stability  profiles  during  the  incubation  of  crude 
supernatants at 36.5 °C in shaken microwells, static microwells and static vials.  Titres were 
quantified using the rapid ProSavin
® titre assay (Section 2.11.2.1).  The experimental procedure 
was as described in Section 2.8.1.  Mean data is presented and error bars represent ± 1 SD (n 
= 3).  Exponential trend lines were fitted according to the results of linear regression analysis 
(presented in Table 6.2): to construct trend lines, the slope value [b] and the exponent of the 
intercept value [a] were entered into the equation y = ae
bx.   225 
 
 
To calculate the half-life (t½) of functional ProSavin
®, titre data was transformed by taking the 
natural logarithm and analysed using linear regression.  The slope value (b) was then entered 
into the following equation (Bryan et al., 1990):  
𝑡1
2
 = 
−ln  (2)
𝑏              (6.1) 
Half-life confidence intervals were calculated using the ‘Slopest’ method as described by Bryan 
et al. (1990), where b (in Equation 6.1) was replaced with the upper and lower limits of the 
confidence interval for the slope.  All titre data collected between 0 - 168 hr was initially included 
in linear regression analyses.  However, for all datasets (shaken microwell, static microwell, and 
static vial) this resulted in poor model fit.  As a representative example, results from the analysis 
of shaken microwell data are presented in Figure 6.2.  The coefficient of determination (R
2) 
value was 0.713, and the linear fit and residual plots indicated that a linear model inadequately 
described the change in (log transformed) titre values over time.   
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Figure 6.2  Results  of  linear  regression  analysis  of  the  shaken microwell  dataset.    Titre 
data (quantified according to Section 2.11.2.1) was transformed prior to analysis by taking the 
natural logarithm.  Plots illustrate the line of linear fit (a) and the standardized residuals (b).  A 
random scattering of data points about the horizontal (zero) axis of the standardized residual 
plot (not as observed here) is indicative of a well-fitting linear model.  The statistical output of 
the linear regression is also provided (c).  Slope and intercept values include a 95 % confidence 
interval.  A p value < 0.05 indicates that the slope is significantly different from zero.  The half-
life of functional ProSavin
® (with upper and lower 95 % confidence limits) was calculated using 
Equation 6.1 as described earlier.   
As  the  majority  (93  -  94  %)  of  functional  ProSavin
®  was  inactivated  by  48  hr,  titres  values 
obtained after this point, at 72, 96 and 168 hr, were exceptionally low (≤ 8.4 x 10
2 TU mL
-1; 
Table 6.1), and approached the limit of detection of the assay.  It was therefore considered 
whether  titre  values  obtained  during  the  latter  stages  of  the  incubation  period  should  be 
excluded from linear regression analyses.  It was evident that by 72 hr titres approached levels 
at which the precision of the ProSavin
® assay (which is based on flow cytometry; see Section 
2.11.2.1)  was  compromised,  as  coefficient  of  variation  (CV)  values  associated  with  these 
samples equalled or significantly exceeded 20 % (Table 6.1).  To determine a threshold above 
which titre values may be considered accurate and consequently suitable for inclusion in linear 
regression analyses, a dilution series of lentiviral vector samples was prepared and quantified to 
enable the establishment of a lower limit of quantification (LOQ) for the ProSavin
® assay.  This 
work is described in Appendix B.  It was demonstrated that when a standard population size of 
10,000 cells is analysed using flow cytometry, accurate quantitation may be expected when the 
      
(c) 
  Intercept (a)  Slope (b)  R
2  p value  t½ (hr) 
9.24 ± 0.89  -0.0305 ± 0.0103  0.713  < 0.0001  22.7 (17.0, 34.3) 227 
 
 
proportion of transduced cells is equal to or greater than around 0.2 %, and consequently this 
value was employed as the LOQ for all stability studies described in this chapter.   
Table 6.1  ProSavin
® titres (quantified according to Section 2.11.2.1) during the incubation 
of crude supernatants at 36.5 °C in shaken microwells, static microwells and static vials.  The 
experimental procedure was as described in Section 2.8.1.  Coefficient of variation (CV) values 
represent the ratio of the standard deviation (SD) to the mean (CV = [SD / mean] * 100).   
Time 
(hr) 
Shaken microwell  Static microwell  Static vial 
Mean 
titre (TU 
mL
-1) 
1 SD  CV 
(%) 
Mean 
titre (TU 
mL
-1) 
1 SD  CV 
(%) 
Mean 
titre (TU 
mL
-1) 
1 SD  CV 
(%) 
0  2.9x10
4  4.2x10
3  14  2.9x10
4  4.2x10
3  14  2.9x10
4  4.2x10
3  14 
24  6.4x10
3  1.1x10
3  17  7.2x10
3  1.5x10
3  21  6.5x10
3  1.2x10
3  18 
48  2.0x10
3  3.6x10
2  18  1.8x10
3  1.3x10
2  7  1.9x10
3  1.5x10
2  8 
72  5.4x10
2  3.3x10
2  61  8.4x10
2  1.6x10
2  20  6.4x10
2  4.8x10
2  75 
96  1.9x10
2  1.5x10
2  81  4.3x10
2  2.2x10
2  50  1.5x10
2  1.1x10
2  76 
168  2.5x10
2  2.0x10
2  82  1.0x10
2  1.8x10
2  173  7.2x10
1  9.0x10
1  125 
With regard to the ProSavin
® titre data obtained during the stability experiment (Figure 6.1), 
from 72 hr onwards at least one replicate per time point per condition fell below the LOQ of the 
assay.  Taken together  with the observation of high CV values at these time points, it  was 
concluded that these samples had not been accurately quantified, and thus linear regression 
analyses were re-performed with these points excluded.  For all datasets (shaken microwell, 
static microwell, static vial), this markedly improved the fit of the linear model.  As an example, 
linear fit and residual plots generated following the analysis of shaken microwell data are shown 
in Figure 6.3.  Statistical outputs from all datasets are included in Table 6.2.  In all cases the R
2 
value exceeded 0.97.  The average half-life of functional ProSavin
® in crude supernatants at 
36.5 °C was calculated to be 12.2 ± 0.2 hr, regardless of vessel.  As so many data points had 
been excluded from these analyses, however, it was desirable to gather more information at 
earlier time points to  verify  these results.   In  particular,  it  was noted that  the distribution of 
standardized  residuals  appeared  to  curve  slightly  as  a  function  of  time  (Figure  6.3  [b]), 
suggesting that the linear model may yet be inappropriate. 228 
 
 
      
Figure 6.3   Scatter plots illustrating the line of linear fit (a) and the standardized residuals 
(b) obtained following linear regression analysis of the shaken microwell dataset.  Only values 
obtained during the first 48 hr of incubation were included in analyses.  Titre data (quantified 
according to Section 2.11.2.1) was transformed prior to analysis by taking the natural logarithm.   
Table 6.2  Results of linear regression analysis of the shaken microwell, static microwell 
and static vial datasets.  Only values obtained during the first 48 hr of incubation were included 
in  analyses.  Titre  data  (quantified  according  to  Section  2.11.2.1)  was  transformed  prior  to 
analysis by taking the natural logarithm.  Slope and intercept values include a 95 % confidence 
interval.  The half-lives (t½) of functional ProSavin
® (with upper and lower 95 % confidence 
limits) were calculated using Equation 6.1 as described earlier.   
To better understand the inactivation profile of ProSavin
® at 36.5°C, a second experiment was 
conducted  in  which  a  greater  number  of  time  points  were  examined  over  a  shorter  period.  
Supernatants harvested from standard shake flask cultures of PS46.2 were aliquoted into vials 
and incubated for various time periods of up to 48 hr (Section 2.8.1).  ProSavin
® titres were 
subsequently quantified, and this data is presented in Figure 6.4.  Linear regression analysis of 
natural log transformed data returned an average half-life value of 12.0 hr (Figure 6.5 [c]), in 
agreement with the earlier data (Table 6.2).  Despite a reasonable R
2 value (0.957), however, 
the distribution of standardized residuals appeared to curve as a function of time (Figure 6.5 
[b]), similar to as noted previously (Figure 6.3 [b]).  Further exploration of the data revealed that 
Condition  Intercept (a)  Slope (b)  R
2  p value  t½ (hr) 
Shaken microwell  10.21 ± 0.23  -0.0560 ± 0.0073  0.979  < 0.0001  12.4 (11.0, 14.2) 
Static microwell  10.26 ± 0.19  -0.0577 ± 0.0060  0.987  < 0.0001  12.0 (10.9, 13.4) 
Static vial  10.22 ± 0.18  -0.0566 ± 0.0059  0.987  < 0.0001  12.4 (11.1, 13.7) 229 
 
 
removal of the data obtained at the last two time points (36 and 48 hr) improved the linear fit: 
the curvature was eradicated from residual data, and the R
2 improved slightly to 0.973 (Figure 
6.5 [e] and [f]).  Following refinement of the linear model, the average half-life of ProSavin
® was 
calculated to be 10.1 hr during a 0 - 30 hr incubation period (Figure 6.5 [f]).  As the 36 and 48 hr 
data points were within the quantifiable range of the ProSavin
® assay, the data indicate that the 
ProSavin
® inactivation profile may be biphasic, and that the average rate of decay is slower 
after 36 hr.   
 
Figure 6.4  Functional ProSavin
® stability profile during the incubation of crude supernatant 
at 36.5 °C.  Titres were quantified using the rapid ProSavin
® titre assay (Section 2.11.2.1).  The 
experimental procedure was as described in Section 2.8.1.  Mean data is presented and error 
bars represent ± 1 SD (n = 4).  The exponential trend line was fitted according to the results of 
linear regression analysis presented in Figure 6.5 (f).  Trend line construction was completed as 
detailed for Figure 6.1.   230 
 
 
 
Figure 6.5  Linear regression analysis of ProSavin
® titres (quantified according to Section 
2.11.2.1) obtained during the incubation of crude supernatant at 36.5 °C (see Figure 6.4).  Titre 
values  were  transformed  by  taking  the  natural  logarithm  prior  to  analysis.      Plots  obtained 
following  analysis  of  all  data  points  (0  -  48  hr)  illustrate  the  line  of  linear  fit  (a)  and  the 
standardized residuals (b), while the statistical output of the linear regression is also provided 
(c).  (d), (e) and (f) are the corresponding results obtained following model refinement (where 
the  36  and  48  hr  data  points  were  excluded).    Slope  and  intercept  values  include  a  95  % 
confidence interval.  The half-life of functional ProSavin
® (with upper and lower 95 % confidence 
limits) was calculated using Equation 6.1 as described earlier.   
 
      
    (c) 
 
 
         
                 (f) 
 
Intercept (a)  Slope (b)  R
2  p value  t½ (hr) 
10.08 ± 0.10  -0.0579 ± 0.0043  0.957  < 0.0001  12.0 (11.1, 12.9) 
Intercept (a)  Slope (b)  R
2  p value  t½ (hr) 
10.18 ± 0.07  -0.0687 ± 0.0047  0.973  < 0.0001  10.1 (9.4, 10.8) 231 
 
 
To gain greater insight into the mechanism underlying ProSavin
® inactivation at 36.5 °C, vector 
RNA and reverse transcriptase (RT) activity were also quantified.  RNA copy number data is 
presented in Figure 6.6.  The average half-life of vector RNA was calculated to be 23.3 hr over 
the incubation period 3 - 48 hr.  As functional ProSavin
® displayed a half-life that was much 
shorter than this (10.1 hr; Figure 6.5 [f]), it is therefore unlikely that vector RNA degradation is 
the primary mechanism for ProSavin
® inactivation.  The PERT assay measures the amount of 
RT enzyme present within a given sample and uses this information to generate a prediction of 
biological titre (Section 2.11.3.2).  PERT data is presented in Figure 6.7.  Over the time period 
examined in this study (0 - 48 hr) PERT predicted titres did not decline (Figure 6.7 [a]).  For 
interest,  samples  obtained  during  the  earlier  0  -  168  hr  ProSavin
®  stability  study  (for  which 
biological titre data is displayed in Figure 6.1) were also analysed using the PERT assay (Figure 
6.7 [b]).  In agreement with Figure 6.7 [a], PERT predicted titres remained stable during the first 
48 hr of incubation (Figure 6.7 [b]), however did subsequently decline.  An approximate linear 
model was fitted to natural log transformed data obtained between 48 and 168 hr incubation, 
and the average half-life of vector RT was calculated to be 80.6 hr over this period (Figure 6.7 
[c]).  Overall, it may be concluded that degradation of the RT enzyme is unlikely to contribute to 
ProSavin
® inactivation (the majority [> 90 %] of functional particles were inactivated within 48 hr 
incubation [Figure 6.1; Figure 6.4] over which period the amount of vector RT associated with 
ProSavin
® particles did not decline [Figure 6.7]).   232 
 
 
 
Figure 6.6  (a) Vector RNA stability profile during the incubation of crude supernatant at 
36.5 °C, and (b) results of the corresponding linear regression.  The experimental procedure 
was as described in Section 2.8.1.  Mean data is presented in plot (a) and error bars represent ± 
1 SD (n = 4).  Exponential trend line construction was completed using the method detailed in 
Figure  6.1,  using  the  results  presented  in  table  (b).    Note  that  the  0  hr  data  points  were 
excluded from linear regression analysis to obtain the best model fit.  Values were transformed 
by taking the natural logarithm prior to linear regression analysis.  Slope and intercept values 
include a 95 % confidence interval.  The half-life of vector RNA (with upper and lower 95 % 
confidence limits) was calculated using Equation 6.1 as described earlier.   
 
 
 
    (b) 
  Intercept (a)  Slope (b)  R
2  p value  t½ (hr) 
21.97 ± 0.08  -0.0298 ± 0.0032  0.921  < 0.0001  23.3 (21.0, 26.1) 233 
 
 
 
Figure 6.7  Vector  reverse  transcriptase  (RT)  stability  profiles  during  the  incubation  of 
crude supernatant at 36.5 °C.  (a) Results following 0 - 48 hr incubation (second experiment) 
and  (b)  results  following  0  -  168  hr  incubation  (first  experiment;  static  vial  dataset).    The 
statistical output of the linear regression fitted to 48 - 168 hr data (obtained during the first 
experiment) is also provided (c).  Experimental procedures were as described in Section 2.8.1.  
In plots (a) and (b) mean data is presented and error bars represent ± 1 SD (n = 4 [a] or n = 3 
[b]).  Construction of the exponential trend line (represented by a dashed line in plot [b]) was 
completed using the method detailed in Figure 6.1, using the results presented in table (c).  
PERT predicted titre values were transformed by taking the natural logarithm prior to analysis by 
linear regression.  Slope and intercept values include a 95 % confidence interval.  The half-life 
of vector RT (with upper and lower 95 % confidence limits) was calculated using Equation 6.1 
as described earlier.   
 
 
    (c) 
  Intercept (a)  Slope (b)  R
2  p value  t½ (hr) 
 13.61 ± 0.15  -0.0086 ± 0.0014   0.947  < 0.0001  80.6 (69.3, 96.3) 234 
 
 
6.2.1.2  Investigation into whether autotransduction of producer cells may exacerbate lentiviral 
vector losses during upstream processing 
By incubating crude supernatant at 36.5 °C, the studies described in Section 6.2.1.1 established 
a rate of ProSavin
® inactivation that is likely representative of that which occurs during standard 
upstream processing.  However, as it is known that PS46.2 cells are autotransduced following 
induction of vector production (Stewart et al., 2011), it was considered that these studies may 
underestimate  the  true  extent  of  vector  loss  during  upstream  processing  as,  due  to  the 
preclusion of cells from supernatants during these studies, autotransduction did not occur.  A 
study was thus devised to determine whether cell autotransduction is likely to lead to significant 
vector loss during upstream processing.  In order to mimic the environment experienced by 
lentiviral vector particles during upstream processing as accurately as possible, it was desirable 
for vector losses to be measured over time in the presence of induced producer cells.  In order 
to  achieve  this,  it  was  necessary  to  use  an  EIAV  lentiviral  vector  that  expressed  the  LacZ 
marker gene, as this vector could be quantified in isolation from produced ProSavin
® particles.   
An experiment was devised where the proportion of LacZ vector remaining after 48 hr when 
incubated  in  the  presence  of  cells  that  were  or  were  not  induced,  was  compared  to  the 
proportion  remaining  when  incubated  in  fresh  culture  medium  without  cells  (+/-  induction 
reagents).  The materials and methods for this study are described in full in Section 2.8.2, while 
the results (LacZ titre data) are presented in Figure 6.8.  Surprisingly, in the presence of cells, 
around twice the amount of functional LacZ vector particles remained after 48 hr incubation, 
than when LacZ vector had been incubated in fresh medium alone (Figure 6.8).  Subjecting this 
dataset to rigorous statistical testing would be inappropriate due to the inclusion of only a limited 
number  of  replicates  (three  per  condition).    However,  it  may  be  observed  that  the  95  % 
confidence  intervals  associated  with  LacZ  titres,  following  48  hr  incubation,  overlap  in  all 
instances  except  when  comparing  the  ‘medium  +  induction  reagents’  and  ‘cells  +  induction 
reagents’  conditions  (Figure  6.8).    This  indicates  that  the  difference  between  these  two 
conditions was likely statistically significant at the level p < 0.05, while no conclusion can be 
drawn regarding all other pairs of conditions.  It was hypothesised that the presence of cells 
may have ‘conditioned’ the medium, altering its properties in a way that helped mitigate vector 
inactivation; therefore this was investigated in a second study (described below).  Overall, this 235 
 
 
first study suggests that vector losses due to the autotransduction of producer cells are likely to 
be negligible during upstream processing.  However, firm conclusions are not possible due to 
the  unexpected  benefit  conferred  by  the  presence  of  cells  in  terms  of  vector  stability  (i.e. 
autotransduction may have led to vector losses, but any losses were outweighed by the stability 
benefits conferred by the presence of the cells). 
 
Figure 6.8  Reduction in LacZ biological titres over time when incubated in four different 
conditions (+/- cells; +/- induction reagents [IR]).  The materials and methods for this study were 
described in Section 2.8.2.  The culture medium in all instances was Freestyle
TM 293 expression 
medium supplemented with 5 % (v/v) tet-free FCS.   LacZ vector was added to all conditions 24 
hr post-seeding (at the same time as induction reagents, where applicable).  LacZ titres were 
quantified at this time (0 hr) and after a further 48 hr.  Mean data is presented and error bars 
represent  the  95  %  confidence  interval  (n  =  3).    The  percentage  remaining  after  48  hr  is 
indicated for each condition.   
In a second experiment, the proportion of LacZ vector remaining after 24 hr incubation when 
diluted  1  in  50  in  standard  media,  which  either  had  been  pre-conditioned  (i.e.  spent  media 
previously used for the culture of cells) or had not been pre-conditioned (i.e. fresh media) was 
compared.  The materials and methods for this study are described in Section 2.8.2, while the 
results  (LacZ  titre  data)  are  presented  in  Figure  6.9.    It  appeared  that  pre-conditioning  the 236 
 
 
culture medium conferred some small benefit in terms of lentiviral vector stability, as an average 
of 52.85 % LacZ vector remained after 24 hr incubation in pre-conditioned media, as compared 
to an average of 42.75 % in fresh media (combined averages of both suspension and adherent 
culture  medium  data).    However,  the  95  %  confidence  intervals  associated  with  LacZ  titres 
following  24  hr  incubation  overlapped  in  all  instances  (Figure  6.9),  thus  it  was  unlikely  the 
observed differences between conditions were statistically significant.  In the first experiment, 
the  proportion  of  LacZ  remaining  was  lower  (6.2  -  16.0  %;  Figure  6.8)  than  in  the  current 
experiment, and this was because a longer incubation period of 48 hr was used.  It is therefore 
possible that clearer differences between the conditions examined in the current study (Figure 
6.9)  may  have  evolved  had  a  48  hr  incubation  period  (such  as  that  employed  in  the  first 
experiment) been used.  The osmolality, pH and electrolyte concentrations of cell culture media 
were measured, and this data revealed that both pre-conditioned media had a pH closer to 
neutral  than  the  fresh  media  (Table  6.3).    As  it  has  been  previously  reported  that  lentiviral 
vectors decay at a faster rate when subjected to slightly alkaline conditions (Higashikawa and 
Chang, 2001), this offers a possible explanation for why the inclusion of cells in culture medium 
may moderate lentiviral vector inactivation.  Lentiviral vector stability did not appear affected by 
the  particular  media  type  (i.e.  suspension  versus  adherent)  used  (Figure  6.9),  despite  the 
differing properties of the two media formulations (Table 6.3).  The insights obtained from this 
work  have  potential  application  with  regard  to  the  development  of  fed-batch  or  perfusion 
strategies for lentiviral vector production (the ratio of fresh:spent media should be considered) 
and when developing formulations for lentiviral vector storage.  237 
 
 
 
Figure 6.9  Reduction in LacZ biological titres over time when incubated in four different 
conditions (two different media; +/- pre-conditioning [PC]).  The materials and methods for this 
study  were  described  in  Section  2.8.2.    The  suspension  medium  was  Freestyle
TM  293 
expression medium supplemented with 5 % (v/v) tet-free FCS, while adherent medium was that 
typically  used  for  HEK293T  and  D17  cell  culture  (see  Section  2.1.4).  ‘Pre-conditioned’ 
suspension  medium  had  been  previously  used  for  the  culture  of  non-induced  suspension-
adapted PS46.2; ‘pre-conditioned’ adherent medium had previously been used for the culture of 
HEK293T.  LacZ vector was added to all conditions and LacZ titres were quantified at the start 
of the experiment (0 hr) and after 24 hr.  Mean data is presented and error bars represent the 
95 % confidence interval (n = 3).  The percentage remaining after 24 hr is indicated for each 
condition.   
Table 6.3   Osmolality,  pH  and  electrolyte  concentrations  (Na
+  and  Ca
2+)  of  cell  culture 
media that had or had not previously been used for the cultivation of cells (i.e. pre-conditioned, 
PC).  Media were as described in Figure 6.9.   Note that samples were equilibrated in a 5 % 
CO2 (36.5 °C) incubator before analysis, to obtain pH values most likely representative of those 
prevailing during the incubation of diluted lentiviral vector samples. 
Medium type  Osmolality (osmol kg
-1)  pH 
Electrolyte concentrations (mmol L
-1) 
Na
+  Ca
2+ 
Suspension  0.275  7.4  106  0.29 
Suspension +PC  0.263  7.2  111  0.29 
Adherent  0.329  7.6  145  1.39 
Adherent +PC  0.321  7.1  148  1.26 238 
 
 
6.2.2  Evaluation of strategies to moderate or offset losses in functional ProSavin
® 
particles due to their inactivation during upstream processing  
Having characterised  the  stability of functional ProSavin
®,  vector RNA  and  vector RT under 
typical production conditions (Section 6.2.1.1), the next objective was to trial approaches for 
mitigating ProSavin
® inactivation that could be applied during upstream processing.  A review of 
related  literature  revealed  three  strategies  of  potential  relevance  for  the  ProSavin
®  process.  
These  were  based  on  (i)  the  storage  of  generated  vector  at  4  °C  (of  relevance  for  the 
development  of  perfusion-based  processes),  (ii)  a  reduction  in  the  temperature  at  which 
ProSavin
® is produced (to 31.5 °C), and (iii) adjustment of the osmotic properties of the culture 
medium using glucose, fructose and/or sorbitol.  The background to each approach, and the 
results of its application to the ProSavin
® process, are outlined below. 
6.2.2.1  Storage at 4 °C 
Although  HIV-1  derived  lentiviral  vectors  pseudotyped  with  VSV-G  have  been  reported  to 
display a longer half-life when stored at 4 °C as compared to 37 °C (Higashikawa and Chang, 
2001), the stability of EIAV-derived lentiviral vectors at lowered temperatures was not known.  
Consequently,  to  inform  the  development  of  enhanced  manufacturing  procedures  for  EIAV-
derived lentiviral vectors, two studies were conducted to assess whether storage of ProSavin
® 
at  4  °C  could  moderate  the  rapid  inactivation  observed  at  36.5  °C.    Initially,  supernatants 
harvested  from  standard  shake  flask  cultures  of  PS46.2  were  aliquoted  into  vials  and 
refrigerated  for  various  time  periods  of  up  to  168  hr  (Section  2.9.1).  Temperatures  were 
monitored  throughout  the  study  using  a  TempTale
®4  (Sensitech
®)  temperature  monitor 
(readings  were  taken  at  intervals  of  30  min),  and  the  average  temperature  (±  1  SD)  was 
observed to be 4.1 ± 0.5 °C, with a range of 3.3 to 5.3 °C.  ProSavin
® titres were subsequently 
quantified and this data is presented in Figure 6.10 (a).  Titres remained high throughout the 
study, with 58 % remaining after 168 hr (7 days).  Linear regression analysis of natural log 
transformed  titre  data  revealed  that  functional  ProSavin
®  decayed  with  a  half-life  of  around 
144.4 hr during the first 96 hr (Figure 6.10 [b]).  Note that, in order to achieve the best model fit, 
the  168  hr  data  points  were  excluded  from  the  linear  regression  analysis.    The  difference 
between the 96 hr and 168 hr data points was negligible (1.76 x 10
4 versus 1.66 x 10
4 TU mL
-1, 239 
 
 
respectively), suggesting that the decay rate considerably slowed or halted during this period.  
To  verify  this  observation,  a  second  experiment  was  conducted  in  which  supernatants 
harvested  from  standard  shake  flask  cultures  of  PS46.2  were  aliquoted  into  vials  and 
refrigerated  for  various  time  periods  of  up  to  384  hr  (16  days;  Section  2.9.1).  Again, 
temperatures were monitored every 30 min for the duration of the study using a TempTale
®4 
temperature monitor, and the average temperature (± 1 SD) was found to be 4.2 ± 0.5 °C, with a 
range of 2.9 to 5.7 °C.  ProSavin
® titre data is presented in Figure 6.10 (c).  The results support 
the earlier findings that, although titres declined steadily during the initial ~ 96 hr of cold storage, 
the decay profile subsequently levelled out, and after 384 hr (16 days) 52 % of the initial titre 
remained.  Variability in the data points made it difficult to pinpoint exactly when this shift in 
decay  rate  occurred  (Figure  6.10  [c]),  thus  linear  regression  analysis  was  performed  using 
natural log transformed titres obtained between 0 and 96 hr, in agreement with the earlier study 
(Figure 6.10 [a] and [b]).  From this analysis, the half-life of ProSavin
® was calculated to be 
150.7 hr over this time period (Figure 6.10 [d]), which is reasonable agreement with the half-life 
calculated during the first study (144.4 hr, Figure 6.10 [b]).  The stability of vector RNA at 4 °C 
over a period of 384 hr was also examined (Figure 6.11).  No discernable reduction in RNA 
copy number was observed, which supports the earlier conclusion based on the 36.5 °C stability 
data that RNA degradation is unlikely to be the primary mechanism for ProSavin
® inactivation.  
The data indicate that refrigeration of harvested ProSavin
®-containing supernatants can prevent 
vector RNA degradation for at least up to 16 days. 240 
 
 
 
Figure 6.10  Functional ProSavin
® stability profiles during the storage of crude supernatant 
at 4 °C.  Titres were quantified using the rapid ProSavin
® titre assay (Section 2.11.2.1).  Results 
from two separate studies are shown, in which ProSavin
® was stored at 4 °C for a period of 0 - 
168 hr (titre data [a] and linear regression results [b]) or 0 - 384 hr (titre data [c] and linear 
regression results [d]).  Experimental procedures were as described in Section 2.9.1.  In plots 
(a) and (c) mean data is presented and error bars represent ± 1 SD (n = 3 [a] or n = 4 [c]).  
Exponential trend lines were constructed according to the method described in Figure 6.1, using 
results obtained from linear regression analysis of natural log transformed data (linear fitting 
was conducted using data obtained between 0 and 96 hr only).  Slope and intercept values 
include a 95 % confidence interval.  The half-life of functional ProSavin
® (with upper and lower 
95 % confidence limits) was calculated using Equation 6.1 as described in Section 6.2.1.1.   
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Intercept (a)  Slope (b)  R
2  p value  t½ (hr) 
10.26  ± 0.09  -0.0048 ± 0.0016   0.762  < 0.0001  144.4 (108.3, 216.6) 
Intercept (a)  Slope (b)  R
2  p value  t½ (hr) 
10.24  ± 0.10  -0.0046 ± 0.0016   0.644  < 0.0001  150.7 (111.8, 231.0) 241 
 
 
 
Figure 6.11  Vector RNA stability profile during the storage of crude supernatant at 4 °C.  
ProSavin
®  was stored at 4 °C for a period of 0 - 384 hr; experimental procedures were as 
described in Section 2.9.1.  Mean data is presented and error bars represent ± 1 SD (n = 4).   
6.2.2.2  Production at 31.5 °C 
Various studies using gamma-retroviral vector production systems have reported improved titres 
following a reduction in culture temperature from 37 °C to 32 °C due, at least in part, to the 
increased stability of gamma-retroviral vectors at the lower temperature (Kotani et al., 1994; Lee 
et al., 1996; Kaptein et al., 1997; McTaggart and Al-Rubeai, 2000).  However, this strategy has 
not  been  applied  to  lentiviral  vector  production.    Consequently,  a  study  was  conducted  to 
evaluate  whether  lowering  the  temperature  by  5  °C  (to  31.5  °C)  from  typical  production 
temperatures (36.5 °C) could improve ProSavin
® titres.  ProSavin
® was generated using shake 
flask cultures of PS46.2 incubated either at 31.5 or 36.5 °C.  Standard operating procedures 
were broadly followed, except that flasks were seeded using a slightly higher than normal cell 
density (1.6 x 10
6 viable cells mL
-1) and were induced after 2 hr to ensure similar numbers of 
cells  were  induced  in  both  conditions.  If  inductions  were  performed  after  24  hr,  potential 
differences in cell growth rate at the two temperatures could lead to different numbers of cells 242 
 
 
being induced, which would distort the data.  Harvests were performed at 24, 44 and 67 hr post-
induction.  The experimental procedure for this study is outlined in full in Section 2.9.2. 
Cell growth was monitored throughout the culture period and this data is presented in Figure 
6.12.  Little cell growth was observed in shake flasks incubated at either temperature, and peak 
viable cell concentrations observed 26 hr post-seeding were 2.0 x 10
6 and 1.8 x 10
6 viable cells 
mL
-1 for cultures incubated at 31.5 and 36.5 °C, respectively.  Viable cell concentrations, as well 
as cell viabilities, remained highest in the cultures incubated at 31.5 °C (Figure 6.12).  At the 
end  of  the  culture  period  (69  hr  post-seeding),  1.3  x  10
6  viable  cells  mL
-1  remained  in  the 
cultures incubated at 31.5 °C, as compared to 4.3 x 10
5 viable cells mL
-1 in those incubated at 
36.5 °C, while viabilities were 75 % versus 34 %, respectively.  Although reduction of the culture 
temperature to 31.5 °C enabled greater cell survival, titres were compromised (Figure 6.13).  At 
both temperatures, the highest titres were obtained at 24 hr post-induction.  However, maximum 
titre values attained from the 31.5 °C cultures were just 5.6 x 10
3 TU mL
-1, around five-fold lower 
than those attained from the 36.5 °C cultures (2.7 x 10
4 TU mL
-1).  Thus, even if ProSavin
® 
generated using a production temperature of 31.5 °C did decay at a relatively slower rate than 
ProSavin
® produced at 36.5 °C (which was not tested), any potential benefit was far outweighed 
by the reduced productivity of these cultures, indicating that lowered temperature cultivation of 
PS46.2 is unlikely to prove an effective strategy for enhancing titres upstream. 
   243 
 
 
 
Figure 6.12  Viable cell concentration and viability of PS46.2 cells over time when cultured 
using either standard (36.5 °C) or reduced (31.5 °C) temperatures.  Shake flask cultures were 
seeded at a density of 1.6 x 10
4 viable cells mL
-1, and were induced 2 hr later as indicated by 
the dotted line.  The materials and methods for this study are described in full in Section 2.9.2.  
Mean data is presented and error bars represent ± 1 SD (n = 4). 
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Figure 6.13  ProSavin
®  titres  (quantified  according  to  Section  2.11.2.1)  generated  using 
PS46.2  cells  cultured  using  either  standard  (36.5  °C)  or  reduced  (31.5  °C)  temperatures.  
Experimental procedures were as noted for Figure 6.12.  Mean data is presented and error bars 
represent ± 1 SD (n = 4).   
6.2.2.3  Adjustment of medium osmolality 
Recent studies have demonstrated that supplementation of the culture medium with different 
sugar types alters its osmotic properties and can improve retroviral vector yields (Coroadinha et 
al.,  2006a;  2006b;  2006c),  although  this  approach  has  not  been  applied  to  lentiviral  vector 
production.  The purpose of this study was to trial whether adjustment of the sugar content and 
thus osmolality of the culture medium could confer any benefit for the ProSavin
® process.  In 
order to establish the background and rationale for this study, a brief overview of the relevant 
literature (Coroadinha et al., 2006a; 2006b; 2006c) is first provided.   
All  studies  described  by  Coroadinha  et  al.  (2006a),  (2006b)  and  (2006c)  were  based  on 
adherent culture of a human HT1080-derived retroviral (Moloney murine leukaemia virus) vector 
producer cell line, and employed a standard medium comprised of DMEM supplemented with 
10 % (v/v) FCS, 6 mM glutamine and 25 mM glucose, which had an osmolality of around 0.325 245 
 
 
- 0.335 osmol kg
-1.  Coroadinha et al. (2006a) reported that supplementation of this standard 
medium  with  140  mM  fructose  enhanced  titres  four-fold,  while  Coroadinha  et  al.  (2006b) 
demonstrated a similar improvement when using 140 mM glucose or 140 mM fructose in place 
of the 25 mM glucose included in standard medium, and also noted that the medium osmolality 
was increased to 0.464 osmol kg
-1 as a result of these modifications.  Coroadinha et al. (2006c) 
reported that raising the osmolality of the standard medium to between 0.410 and 0.450 osmol 
kg
-1  by  the  addition  of  sorbitol  (the  concentration  of  which  was  not  reported)  yielded  an 
improvement in titres of up to two-fold.  The titre improvements described in these papers were 
attributed to the combined effect of increased cellular productivity and improved vector stability 
(Coroadinha et al., 2006a; 2006b; 2006c).  A decrease in the cholesterol to phospholipid ratio of 
vector membranes was found to be responsible for the enhanced vector stability observed at 
increased osmolalities (Coroadinha et al., 2006c).   
In  the  current  work,  the  effect  of  increased  osmolality  attained  by  supplementation  of  the 
medium with glucose, fructose and/or sorbitol on ProSavin
® titres was evaluated using microwell 
suspension cultures of PS46.2.  In order to evaluate a broad range of conditions, and thus 
maximise  the  likelihood  of  capturing  any  that  could  confer  benefit,  a  full  factorial  screening 
experiment was designed, where the concentration of each sugar type  was assessed, either 
singularly or in combination, over the range 0 - 100 mM as indicated in Table 6.4.  A number of 
factors defined the concentration range evaluated in this work.  Firstly, the standard culture 
medium used in this work (FreeStyle 293
TM expression medium supplemented with 5 % [v/v] tet-
free  FCS)  already  contained  glucose  at  an  estimated  concentration  of  around  23  -  25  mM 
(based on previous analysis of two different medium batches using the YSI instrument [methods 
Section 2.11.1.4]).  Note that the glucose content of FreeStyle 293
TM expression medium is not 
specified  by  the  manufacturer,  presumably  as  this  information  is  proprietary.    Further 
supplementation using 100 mM glucose, fructose or sorbitol (as in runs 2, 3 and 5; Table 6.4) 
therefore took the final concentration of sugars in the culture medium to around 123 - 125 mM, 
which was within the range reported by Coroadinha et al. (2006b) to be beneficial for retroviral 
vector production.  For all other runs supplemented with a combination of sugars (runs 4 and 7 - 
12; Table 6.4), the final concentration of sugars was higher than that previously investigated by 
Coroadinha et al. (2006a) or (2006b).  However, as Coroadinha et al. (2006c) reported that a 246 
 
 
medium  osmolality  of  0.410  and  0.450  osmol  kg
-1  adjusted  by  the  addition  of  an  unknown 
quantity of sorbitol was optimal for retroviral vector production, these conditions were included 
to allow a greater osmotic range to be evaluated (runs 8-12 yielded osmotic conditions close to 
or within this range; Table 6.4).  The low concentration setting evaluated in this work (0 mM; i.e. 
no supplementation) provided a baseline against which the effect of sugar additions could be 
assessed (run 1). 
Cells  were  cultivated  in  the  various  media  (Table  6.4)  according  to  standard  shake  flask 
procedures  for  an  acclimatisation  period  of  three  days.    The  concentration  and  viability  of 
PS46.2 cells following this period is detailed in Appendix C.  To control for variability in the 
growth  rate  of  PS46.2  when  cultured  in  the  different  media  conditions,  all  microwells  were 
seeded using the same density of viable cells (2 x 10
6 viable cells mL
-1) and were induced after 
2 hr for evaluation of ProSavin
® production.  ProSavin
® harvests were performed at 23, 44 and 
65  hr  post-induction.    The materials  and  methods  used  for  this  study  are  outlined  in  full  in 
Section 2.9.3.   
Table 6.4  Experimental design matrix for investigation into the effect of medium osmolality 
(adjusted by the addition of fructose, glucose and/or sorbitol) on cell growth and lentiviral vector 
production.  The concentration of each sugar type was varied over two levels as indicated, and 
the resulting osmolality of each medium is given (n = 1).  Four centre point experiments were 
also included for estimation of pure error.  Each medium was prepared as outlined in Section 
2.9.3.  REF denotes the standard medium without supplementation, or partial dilution with water 
(REF is therefore distinct from run 1, which contained an equivalent proportion of tissue culture 
grade water [9.3 % (v/v)] to that included in runs 2 - 12; see Section 2.9.3 for more details).  
Run 
Concentration of osmotic agent (mM)  Medium osmolality 
(osmol kg
-1)  Fructose  Glucose  Sorbitol 
1  -  -  -  0.255 
2  100  -  -  0.354 
3  -  100  -  0.361 
4  100  100  -  0.473 
5  -  -  100  0.346 
6  100  -  100  0.471 
7  -  100  100  0.470 
8  100  100  100  0.456 
9 - 12  50  50  50  0.412 
REF  -  -  -  0.275 247 
 
 
Cell growth data, collected at the time of vector harvests (23, 44 and 65 hr post-induction), is 
presented in Figure 6.14.  Cell numbers initially increased in the cultures that were either not 
supplemented (run 1 and REF) or had been supplemented with just one sugar (runs 2, 3 and 5), 
reaching a concentration of 3.1 - 4.4 x 10
6 viable cells mL
-1 by 23 hr post-induction.  In all other 
cultures, by 23 hr post-induction cell numbers had declined from their starting concentration of 
2.0 x 10
6 viable cells mL
-1 to 1.1 - 1.7 x 10
6 viable cells mL
-1 and continued to decline thereafter, 
with the exception of run 8, where cell numbers subsequently increased, reaching 2.4 x 10
6 
viable cells mL
-1 by 65 hr post-induction.  These findings are broadly consistent with those of 
Coroadinha  et  al.  (2006a),  (2006b)  and  (2006c),  who  reported  reduced  growth  of  HT1080-
derived retroviral vector producer cells when the standard medium (containing 25 mM glucose) 
was further supplemented with 140 mM fructose, 115 mM glucose, or sorbitol to an osmolality of 
0.410 - 0.500 osmol kg
-1.  
Cell viabilities followed a similar trend (Figure 6.14 [b]).  Viabilities were 91.2 - 95.0 % at 23 hr 
post-induction in cultures supplemented with 0 mM (run 1 and REF) or 100 mM (runs 2, 3 and 
5) sugar, and 31.4 - 78.0 % in all other runs.  Viabilities declined with subsequent harvests 
except in the case of run 8, where they increased (from 31.4 to 43.0 %).  Overall, the data 
suggest that PS46.2 were able to cope well with the addition of one sugar type to the culture 
medium (100 mM concentration; osmolality 0.346 - 0.361 osmol kg
-1), however were severely 
compromised when more than one sugar type was added to a final concentration of 150 - 200 
mM (osmolality 0.412 - 0.473 osmol kg
-1).  Interestingly, PS46.2 appears to have been able to 
adapt to the most extreme media condition evaluated - combined sugar supplementation to a 
final concentration of 300 mM (osmolality 0.456 osmol kg
-1).  
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Figure 6.14  Viable cell concentration (a) and cell viability (b) of induced microwell cultures 
of PS46.2 cultivated in medium supplemented with different sugar types.  Measurements were 
performed at 23, 44 and 65 hr post-induction.  Cells were seeded at a density of 2 x 10
6 viable 
cells  mL
-1,  as  indicated  by  the  dashed  line  (a),  and  were  induced  2  hr  later.    Experimental 
conditions  are  indicated  by  the  run  number  (see  Table  6.4).    Note  that  the  cells  had  been 
cultivated in shake flasks in the various media (Table 6.4) for an acclimatisation period of three 
days prior to initiation of this experiment.  The full materials and methods for this study are 
described in full in Section 2.9.3.  Data from individual microwells is presented. 
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ProSavin
® titres at 23, 44 and 65 hr post-induction are presented in Figure 6.15.  The highest 
titres, 5.4 x 10
4 TU mL
-1 and 4.4 x 10
4 TU mL
-1, were observed at 44 hr post-induction in the 
cultures that had not been supplemented with sugars (REF and run 1, respectively).  Moderate 
titres  (maximum:  2.1  -  2.9  x  10
4  TU  mL
-1)  were  attained  from  the  cultures  that  had  been 
supplemented  with  100  mM  fructose,  glucose  or  sorbitol  (runs  2,  3  and  5),  while  low  titres 
(maximum: 3.2 - 5.2 x 10
3 TU mL
-1) were obtained from cultures where all three sugar types had 
been added to a final concentration of 150 mM (runs 9 - 12).  Cultures supplemented with two 
or three sugar types to a final concentration of 200 - 300 mM (runs 4, 6, 7 and 8) generated little 
or no functional ProSavin
®.  The proportion of cells transduced by these samples was 0.00 - 
0.04 %, the same proportion as was transduced in the negative control populations (n = 6), 
indicating  that  any  positive  values  may  be  attributed  to  assay  noise  due  to  background 
fluorescence.  Titre data has also been plotted as a function of culture osmolality (Figure 6.16).  
Overall, it is clear that increasing culture osmolalities, whether engineered by the addition of 
fructose, glucose and/or sorbitol, are progressively detrimental for ProSavin
® titres. 
 
Figure 6.15  ProSavin
® titres (quantified according to Section 2.11.2.1) at 23, 44 and 65 hr 
post-induction  in  microwell  cultures  of  PS46.2  supplemented  with  different  sugar  types.  
Experimental conditions are indicated by the run number (see Table 6.4).  Procedures were as 
noted for Figure 6.14.  Data from individual microwells is presented. 250 
 
 
 
Figure 6.16  Scatter  plot  illustrating  ProSavin
®  titres  (quantified  according  to  Section 
2.11.2.1) in relation to medium osmolality.  Titre data is the same as that presented in Figure 
6.15,  and  was  obtained  following  the  culture  of  PS46.2  in  microwells  supplemented  with 
different  sugar  types.    Materials  and  methods  were  as  noted  for  Figure  6.14.    Data  from 
individual microwells is presented. 
Lastly, to verify that altering the sugar content of the culture medium had not impacted on the 
transduction  stage  of  the  ProSavin
®  titre  assay,  ProSavin
®-containing  supernatants  that  had 
been harvested from standard shake flask cultures (operated in parallel to microwells)  were 
adjusted to contain sugars at the concentrations specified in Table 6.4.  ProSavin
® titres were 
then quantified as normal using the flow cytometry method described in Section 2.11.2.1.  As 
illustrated  in  Figure  6.17,  adjustment  of  the  sugar  content  of  the  supernatants  prior  to 
performing  cell  transductions  had  no  effect  on  ProSavin
®  titres  (the  variability  between 
conditions was within the typical range observed for identical replicates, e.g. see Appendix B, 
Figure B.1). 251 
 
 
 
Figure 6.17  The  influence  of  sugar  supplementation  on  cell  transductions.  ProSavin
®-
containing supernatants that had been harvested from standard shake flask cultures (Section 
2.4.1.3) were supplemented to achieve resulting concentrations of fructose, glucose and sorbitol 
as stated in Table 6.4, following which titres were quantified according to standard protocol as 
described in Section 2.11.2.1 (n = 1).  The methods for this study are described in Section 2.9.3.  
6.2.3  Broader evaluation of EIAV lentiviral vector stability at 36.5 °C 
6.2.3.1  ProSavin
® generated using adherent PS46.2 or transient transfection techniques  
Earlier, the half-life of functional ProSavin
®, vector RNA and reverse transcriptase (RT) in crude 
supernatants  incubated at 36.5 °C  was established  (Section 6.2.1.1).  Functional  ProSavin
® 
predominantly  decayed  with  a  half-life  of  10.1  hr  (Figure  6.5),  while  vector  RNA  was  more 
robust  and  exhibited  a  half-life  of  23.3  hr  (Figure  6.6).    PERT  predicted  titres  (based  on  a 
measurement of vector RT activity) did not reduce during the first 48 hr incubation, after which 
they declined slowly, with a half-life of around 80.6 hr (Figure 6.7).  The ProSavin
® utilised in 
these  experiments  had  been  generated  using  suspension  cultures  of  PS46.2.    To  discover 
whether the stability characteristics of ProSavin
® depended on the particular production method 
employed, the decay kinetics of ProSavin
® that had been generated using adherent cultures of 252 
 
 
PS46.2 (Section 2.10.2) or by transient transfection of adherent HEK293T (Section 2.10.3) were 
here also examined.  Crude supernatants harvested from PS46.2 or HEK293T cultures were 
incubated at 36.5 °C for varying lengths of time up to 48 or 24 hr, respectively.  The time points 
were  chosen  such  that  the  depletion  of  functional  vector  to  low  levels,  but  still  within  the 
quantifiable range of the assays, might be observed (see Section 2.10.1 for a full description of 
the  methods  employed).  Functional  titres  were  quantified  using  the  ProSavin
®  titre  assay 
(Section  2.11.2.1)  and,  to  facilitate  later  comparison  with  the  results  presented  in  Section 
6.2.3.2, the DNA integration assay (Section 2.11.2.3).  PERT predicted titres and RNA copy 
numbers were also quantified.   
The half-life of functional ProSavin
® derived from adherent cultures of PS46.2 was calculated to 
be 16.1 hr based on results obtained using the ProSavin
® titre assay and 21.2 hr based on 
results obtained using the DNA integration assay (Figure 6.18).  Some discrepancy between the 
two methods was expected as, following the transduction of target cells, each assay measures 
a  different  parameter  -  the  DNA  integration  assay  measures  integrated  proviral  DNA  using 
qPCR, while the ProSavin
® titre assay measures transgene expression using flow cytometry.  
Starting DNA integration titres were 7.3 x 10
4 TU mL
-1, 55 % higher than starting ProSavin
® 
titres (4.7 x 10
4 TU mL
-1).  The difference in half-life subsequently observed could indicate that 
ProSavin
® particles lose their capacity to transfer working copies of the transgene, specifically 
the TH enzyme component, earlier than they become unable to transfer complete copies of the 
EIAV  Ψ  which  represents  the  region  amplified  and  quantified  using  qPCR.    Vector  RNA 
decayed at a slower rate than functional particles (half-life 82.3 hr; Figure 6.18), which supports 
the  notion  that  RNA  degradation  is  unlikely  to  be  the  primary  mechanism  for  ProSavin
® 
inactivation (Section 6.2.1.1).  The stability of functional ProSavin
® and vector RNA derived from 
adherent cultures of PS46.2 was superior to that derived from suspension cultures of PS46.2 
(Figures 6.5 and 6.6).  PERT predicted titres did not decline over the time period examined here 
(48 hr), which was consistent with earlier data (Figure 6.7), and suggests that the RT enzyme 
associated with ProSavin
® particles is relatively robust.   253 
 
 
 
Figure 6.18  Stability of functional ProSavin
®, vector RT and RNA during the incubation of 
crude  supernatant  (generated  from  adherent  cultures  of  PS46.2)  at  36.5  °C.    Functional 
(biological) titres were quantified using two methods: the ProSavin
® titre assay (based on flow 
cytometry; Section 2.11.2.1) and the DNA  integration assay (Section 2.11.2.3).  In addition, 
titres  were  predicted  based  on  a  measurement  of  vector  RT  activity  (PERT  predicted  titre; 
Section 2.11.3.2) and vector RNA copy numbers were also quantified (Section 2.11.3.1).  The 
experimental procedure was as described in Section 2.10.  Mean data is presented in plot (a) 
and error bars represent ± 1 SD (n = 3).  Exponential trend line construction was completed 
using  the  method  detailed  in  Figure  6.1,  using  the  results  of  linear  regression  analysis 
presented in table (b).  Note that PERT predicted titres were not analysed by linear regression, 
thus a trend line has not been fitted to this data.  Values were transformed by taking the natural 
logarithm  prior  to  linear  regression  analysis.    Slope  and  intercept  values  include  a  95  % 
confidence interval.  The half-life of functional ProSavin
® and vector RNA (with upper and lower 
95 % confidence limits) was calculated using Equation 6.1 as described in Section 6.2.1.1.   
   
          (a) 
 
(b) 
 
Measured response  Intercept (a)  Slope (b)  R
2  p value  t½ (hr) 
ProSavin
® titre  10.78 ± 0.09  -0.0431 ± 0.0037  0.969  < 0.0001  16.1 (14.9, 17.6) 
DNA integration titre  11.23 ± 0.11  -0.0326 ± 0.0046  0.920  < 0.0001  21.2 (18.6, 24.8) 
RNA copy number  21.38 ± 0.07  -0.0084 ± 0.0023  0.647  < 0.0001  82.3 (60.7, 127.7) 254 
 
 
Functional ProSavin
® derived from adherent cultures of HEK293T, which had been transiently 
transfected using three plasmids, displayed a unique stability profile that was characterised by 
two relatively discrete inactivation phases (Figure 6.19).  ProSavin
® titres declined with a half-
life of 18.0 hr during the initial 8 hr incubation, after which titres plummeted, displaying a half-life 
of 2.4 hr until the end of the incubation period (24 hr).  DNA integration titres exhibited a similar 
pattern: initially (between 0 and 8 hr) titres declined with a half-life of 21.5 hr, after which they 
fell rapidly, with a half-life of 3.2 hr.  The sudden rapid decline in functional ProSavin
® observed 
after 8 hr incubation was surprising, and to verify this result a second batch of material was 
produced and tested (n = 1).  A similar biphasic stability profile was observed (Figure 6.19), 
indicating that these results are likely representative of the decay kinetics of ProSavin
® derived 
from transiently transfected HEK293T cultures.  Interestingly, titres generated using this system 
were high as starting titre values were approximately ten-fold greater than those obtained from 
adherent cultures of PS46.2.  This suggests that during a standard production run either vector 
production  rates  are  high  enough  to  compensate  for  vector  losses  due  to  inactivation,  or 
harvests are completed before the second (accelerated) inactivation phase is fully underway 
(harvests are typically performed 21 - 23 hr post-medium exchange; see Stewart et al. (2009), 
(2011), and Section 2.10.3).  Vector RNA exhibited a similar stability profile, decaying at a rate 
only  marginally  slower  than  functional  particles  (Figure  6.19).    RNA  copy  numbers  declined 
slowly, with a half-life of 29.6 hr during the initial 12 hr incubation, after which they declined at 
an accelerated rate of approximately 4.6 hr.  The shift to a more rapid decay rate occurred 4 hr 
later than was observed for functional ProSavin
®, lending weight to the conclusion that RNA 
degradation is unlikely to be a primary cause of ProSavin
® inactivation. PERT predicted titres 
remained constant throughout the incubation period (24 hr), consistent with earlier observations 
(Figures 6.7 and 6.18).   255 
 
 
 
Figure 6.19  Stability of functional ProSavin
®, vector RT and RNA during the incubation of 
crude supernatant (generated by transient transfection using adherent cultures of HEK293T) at 
36.5 °C.  Biological (ProSavin
® and DNA integration) titres, PERT predicted titres and RNA copy 
numbers  were  quantified  as  noted  for  Figure  6.18  (full  experimental  procedures  were  as 
outlined in Section 2.10).  Mean data is presented in plot (a) and error bars represent ± 1 SD (n 
= 3), except in the case of the ProSavin
® titre (2
nd batch) data, where n = 1.  Exponential trend 
line construction was completed (except in the case of the ProSavin
® titre [2
nd batch] and PERT 
data)  according  to  the  method  detailed  in  Figure  6.1,  using  the  results  of  linear  regression 
analysis presented in table (b).  Values were transformed by taking the natural logarithm prior to 
linear regression analysis.  Slope and intercept values include a 95 % confidence interval.  The 
half-life of functional ProSavin
® and vector RNA (with upper and lower 95 % confidence limits) 
was calculated using Equation 6.1 as described in Section 6.2.1.1.     
 
   
        (a)  
 
(b) 
 
 
Measured response  Intercept (a)  Slope (b)  R
2  p value  t½ (hr) 
ProSavin
® titre           
1
st phase (0-8 hr)  12.99 ± 0.05  -0.0385 ± 0.0098  0.847  < 0.0001  18.0 (14.4, 24.2) 
2
nd phase (8-24 hr)  15.11 ± 0.34  -0.2864 ± 0.0209  0.993  < 0.0001  2.4 (2.3, 2.6) 
DNA integration titre           
1
st phase (0-8 hr)  13.52 ± 0.06  -0.0323 ± 0.0130  0.688  0.0001  21.5 (15.3, 36.0) 
2
nd phase (8-24 hr)  15.06 ± 0.24  -0.2163 ± 0.0150  0.994  0.0006  3.2 (3.0, 3.4) 
RNA copy number           
1
st phase (0-12 hr)  23.79 ± 0.08  -0.0234 ± 0.0116  0.532  < 0.0001  29.6 (19.8, 58.9) 
2
nd phase (12-24 hr)  25.34 ± 0.26  -0.1491 ± 0.0136  0.996  < 0.0001  4.6 (4.3, 5.1) 256 
 
 
6.2.3.2  Lentiviral vectors encoding eGFP or a candidate therapeutic transgene  
Lentiviral vectors expressing fluorescent marker genes, such as GFP, are commonly used for 
process development studies, as titres can be rapidly quantified using either microscopy or flow 
cytometry  techniques.    Use  of  a  marker  gene  in  place  of  a  therapeutic  transgene  is  only 
worthwhile, however, if the lentiviral vector production and decay kinetics are not altered by this 
substitution.  It is known that certain therapeutic transgenes, such as factor VIII for the treatment 
of haemophilia A, can inhibit functional vector production unless their expression is diminished 
by use of a tissue-specific promoter (Radcliffe et al., 2008).  The ProSavin
® transgenes (TH, 
AADC and CH1) are under the control of an internal cytomegalovirus (CMV) promoter (see 
Section  1.3.3,  Figure  1.3  and  Section  2.10.3,  Figure  2.1),  thus  are  likely  expressed  at 
reasonably high  levels  in  producer cells.  As it  was unknown  whether the stability of EIAV-
derived lentiviral vector particles was affected by the particular transgene(s) expressed from the 
genome construct, the effect of switching the ProSavin
® genome construct for one encoding 
either the marker gene enhanced GFP (eGFP), or an alternative candidate therapeutic gene 
was  investigated.    The  eGFP  vector  and  Vector  13.1  were  generated  via  the  transient 
transfection of adherent HEK293T cells using the same methodology, Gag/Pol and envelope 
plasmids  as  were  earlier  employed  in  the  production  of  ProSavin
®  (Section  2.10.3).    Crude 
supernatants containing the eGFP vector or Vector 13.1 were incubated at 36.5 °C for up to 240 
or  96  hr,  respectively.    Again,  the  length  of  the  incubation  period  was  chosen  such  that  a 
reduction in functional vector (here quantified using the DNA integration assay) to low, but not 
unquantifiable, levels could be observed (a full description of the methods employed is given in 
Section  2.10.1).  To  supplement  functional  titre  data,  PERT  predicted  titres  and  RNA  copy 
numbers were also assessed.   
The  eGFP  vector  was  found  to  be  remarkably  stable  at  36.5  °C  (Figure  6.20).    Functional 
particles exhibited a half-life of 44.1 hr, while vector RNA displayed a half-life of 181.5 hr, and 
PERT  predicted  titres  varied  little  throughout  the  incubation  period  of  240  hr.    The  decay 
kinetics were surprising, and completely unlike those observed for ProSavin
® generated using 
the  same  means  (Figure  6.19).    Vector  13.1  was  also  found  to  be  relatively  robust  in 
comparison to ProSavin
®: functional particles degraded with a half-life of 33.7 hr, while vector 
RNA  declined  at  a  rate  of  150.4  hr  (Figure  6.21).    PERT  predicted  titres,  again,  remained 257 
 
 
consistent throughout the incubation period (96 hr).  The differing half-lives were not correlated 
with size of the genome construct: although the eGFP expression plasmid (pONYKG) was the 
smallest (7,440 bp) of those evaluated, the Vector 13.1 expression plasmid (pONYK13.1) was 
the largest, and the ProSavin
® expression plasmid (pONYK1) was of intermediate size (11,296 
bp).    To  aid  comparison  of  the  various  stability  data  obtained  for  the  different  EIAV  vector 
preparations examined in this chapter, a summary table (Table 6.5) is included at the end of this 
section.  
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Figure 6.20  Stability of functional eGFP vector, vector RT and RNA during the incubation of 
crude supernatant (generated by transient transfection using adherent cultures of HEK293T) at 
36.5 °C.  Biological (DNA integration) titres, PERT predicted titres and RNA copy numbers were 
quantified as noted for Figure 6.18 (full experimental procedures were as outlined in Section 
2.10).  Mean data is presented in plot (a) and error bars represent ± 1 SD (n = 3).  Exponential 
trend line construction was completed according to the method detailed in Figure 6.1, using the 
results of linear regression analysis presented in table (b).  Values were transformed by taking 
the natural logarithm prior to linear regression analysis.  Slope and intercept values include a 95 
% confidence interval.  The half-life of functional eGFP vector and vector RNA (with upper and 
lower  95  %  confidence  limits)  was  calculated  using  Equation  6.1  as  described  in  Section 
6.2.1.1.     
 
       (a) 
 
(b) 
 
Measured response  Intercept (a)  Slope (b)  R
2  p value  t½ (hr) 
DNA integration titre  13.90 ± 0.12  -0.0157 ± 0.0011  0.979  < 0.0001  44.1 (41.2, 47.4) 
RNA copy number  22.78 ± 0.07  -0.0038 ± 0.0007  0.889  < 0.0001  181.5 (155.5, 218.7) 259 
 
 
 
Figure 6.21  Stability of functional Vector 13.1, vector RT and RNA during the incubation of 
crude supernatant (generated by transient transfection using adherent cultures of HEK293T) at 
36.5 °C.  Biological (DNA integration) titres, PERT predicted titres and RNA copy numbers were 
quantified as noted for Figure 6.18 (full experimental procedures were as outlined in Section 
2.10).  Mean data is presented in plot (a) and error bars represent ± 1 SD (n = 3).  Exponential 
trend line construction was completed according to the method detailed in Figure 6.1, using the 
results of linear regression analysis presented in table (b).  Values were transformed by taking 
the natural logarithm prior to linear regression analysis.  Slope and intercept values include a 95 
% confidence interval.  The half-life of functional Vector 13.1 and vector RNA (with upper and 
lower  95  %  confidence  limits)  was  calculated  using  Equation  6.1  as  described  in  Section 
6.2.1.1. 
        (a) 
 
(b) 
 
Measured response  Intercept (a)  Slope (b)  R
2  p value  t½ (hr) 
DNA integration titre  10.38 ± 0.08  -0.0206 ± 0.0015  0.976  < 0.0001  33.7 (31.3, 36.4) 
RNA copy number  22.44 ± 0.14  -0.0046 ± 0.0027  0.409  0.0018  150.4 (95.3, 355.5) 260 
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6.3  Chapter discussion 
Throughout the earlier microwell and WAVE bioreactor process development studies, described 
in Chapters 3 - 5, post-induction period was consistently observed to be a critical parameter 
impacting  on  ProSavin
®  titres.    Titres  declined  during  the  latter  stages  of  batch  cultures, 
indicating  that  functional  particles  were  inactivated  in  culture  supernatants  over  time.  The 
overall aim of this chapter was to characterise the stability of ProSavin
® and other EIAV-derived 
lentiviral vectors, under typical production conditions, as well as to investigate various strategies 
to  moderate  or  offset  losses  in  functional  particles,  with  a  view  to  informing  the  design  of 
improved upstream processes for EIAV-based lentiviral vectors.   
6.3.1  The half-life of functional ProSavin
® at 36.5 °C is short relative to the production 
timescale   
Firstly,  the  decay  kinetics  of  ProSavin
®  contained  within  crude  supernatants  derived  from 
suspension cultures of PS46.2 incubated at 36.5 °C were examined.  The majority (87 %) of 
functional  ProSavin
®  was  inactivated  during  the  first  30  hr  incubation  (Section  6.2.1.1).  
Functional ProSavin
® exhibited a half-life of 10.1 hr over this period (after 30 hr the rate of 
decay appeared to moderate slightly - observe that the 36 and 48 hr data points fall above the 
exponential trendline fitted to 0 - 30 hr data in Figure 6.4).  This half-life value is within the range 
(1.3 - 10.4 hr) previously reported for functional HIV-1 derived lentiviral vectors pseudotyped 
with VSV-G incubated in crude supernatants at 37 °C (Higashikawa and Chang, 2001; Zhang et 
al., 2004).  The half-life of functional ProSavin
®, though reasonably long in comparison to HIV-
derived lentiviral vectors, is short relative to the overall duration of PS46.2 batch cultivations, 
and provides insight into why harvest timing is such a critical factor affecting titres.  To gain 
insight into the mechanism of ProSavin
® inactivation, the stability profiles of vector RNA and RT 
were also examined.  During a 48 hr incubation period, vector RNA decayed with a half-life of 
23.3 hr, while PERT predicted titres (based on a measurement of vector RT) did not decline.  
Later studies, conducted at 4 °C or using different EIAV vector preparations (Sections 6.2.2.1 
and 6.2.3), also demonstrated that RNA copy numbers declined at a slower rate than functional 
titres,  while  PERT  predicted  titres  did  not  reduce  over  the  incubation  periods  investigated.  
Together, the data indicate that ProSavin
® inactivation is unlikely to be caused by RNA or RT 262 
 
 
degradation.    It  has  recently  been  hypothesised  that  loss  of  the  ability  to  perform  reverse 
transcription  is  the  main  mechanism  responsible  for  the  inactivation  of  retroviral  and  HIV-1 
derived  vectors  incubated  at  37  °C  (Carmo  et  al.,  2008;  2009b).    Carmo  et  al.  (2008)  and 
(2009b) reported that two early stages of the reverse transcription process (initiation of DNA 
synthesis and first strand transfer) were particularly thermolabile however degradation of vector 
RNA  or  RT  was  not  implicated  as,  consistent  with  our  findings,  these  components  were 
relatively stable at 37 °C.  The thermosensitivity of these two stages, and overall inactivation 
rate of HIV-1 derived vectors, was affected by the choice of envelope protein (amphotropic or 
RDpro)  (Carmo  et  al.,  2009b).    It  is  worth  bearing  in  mind,  therefore,  that  the  half-life  of 
ProSavin
® recorded here is likely also a function of the particular envelope protein (VSV-G) 
employed.  
6.3.2  Autotransduction has a negligible impact on vector titres; cellular conditioning of 
the medium may be important for vector stability  
Secondly,  it  was  considered  whether  vector  losses  during  upstream  processing  may  be 
exacerbated  due  to  the  autotransduction  of  PS46.2  producer  cells.    Stewart  et  al.  (2011) 
previously  reported  that,  following  four  days  (adherent)  cultivation  of  induced  PS46.2,  the 
number of vector genome copies per cell increased from approximately one to seven, indicating 
that  this  cell  line  is  susceptible  to  autotransduction  over  time  (Stewart  et  al.,  2011).    As 
theoretically this could represent a significant depletion in the number of functional particles 
available for harvesting, we investigated this phenomenon further.  An EIAV-derived lentiviral 
vector, which expressed LacZ and could thus be quantified independently to ProSavin
®, was 
incubated in the presence of microwell cultures of PS46.2 and, for comparison, in fresh medium 
not  containing  cells.    It  was  discovered  that,  contrary  to  expectations,  LacZ  titres  were 
diminished to a greater extent following 48 hr incubation in fresh medium, as compared to in the 
presence  of  PS46.2  (Section  6.2.1.2).    It  was  hypothesised  that  the  cells  ‘conditioned’  the 
medium in a way that helped to preserve functional LacZ vector.  This was explored further by 
incubating  LacZ  vector  in  medium  that  either  had  or  had  not  been  pre-conditioned  (i.e. 
previously  used  for  cell  cultivation).    The  change  in  titre  was  assessed  following  a  shorter 
incubation period (24 hr) and, although titres were slightly higher following incubation in the pre-
conditioned medium, the results were not conclusive.  As the benefit of medium conditioning 263 
 
 
was  slight  in  this  second  study,  it  is  unlikely  that  this  effect  masked  extensive  losses  of 
functional vector due to autotransduction in the first study, and overall it may be concluded that 
autotransduction is unlikely to significantly reduce ProSavin
® titres during upstream processing 
– at least not directly.  It is possible that autotransduction may reduce titres indirectly during 
extended cultivations by interfering with the genetic composition of producer cells, which could 
compromise  cellular  productivity  over  time,  however  this  has  not  been  investigated.    The 
unexpected discovery that conditioned media can better preserve functional lentiviral vectors 
has implications for the future design of e.g., fed-batch or perfusion based production strategies, 
where the ratio of fresh to conditioned medium requires consideration.   
6.3.3  Development of a perfusion strategy for ProSavin
® manufacture could improve 
upstream yields  
Three  strategies  to  reduce  ProSavin
®  inactivation  during  upstream  process  were  tested: 
refrigeration of crude supernatants at 4 °C, reduction in the temperature at which ProSavin
® is 
produced  (to  31.5  °C),  and  elevation  of  the  medium  osmolality  by  the  addition  of  fructose, 
glucose  and/or  sorbitol.    These  approaches  were  chosen  following  a  review  of  published 
literature: storage of crude supernatants at 4 °C has been shown to significantly extend the half-
life  of  HIV-1  derived  vectors  (Higashikawa  and  Chang,  2001),  while  a  5  °C  reduction  in 
production temperature (Kotani et al., 1994; Lee et al., 1996; Kaptein et al., 1997; McTaggart 
and  Al-Rubeai,  2000)  or  adjustment  of  the  medium  osmolality  by  sugar  supplementation 
(Coroadinha et al., 2006a; 2006b; 2006c) has been demonstrated to enhance retroviral vector 
titres, in part by increasing vector stability. 
The half-life of functional ProSavin
® at 4 °C was found to be approximately six days (Section 
6.2.2.1).  However, this rate only applied during the initial four days or so of storage at this 
temperature – after this point no further decay was observed when a time period of up to 16 
days was examined, thus more than 50 % of functional vector was preserved over this period.  
This  data  is  consistent  with  that  obtained  for  murine  leukaemia  virus  (retroviral)  and  HIV-1 
derived lentiviral vectors pseudotyped with VSV-G, which have also been reported to exhibit two 
distinct  phases  of  inactivation  at  both  37  and  4  °C  (Higashikawa  and  Chang,  2001).  
Higashikawa and Chang (2001) suggested that these biphasic decay kinetics may indicate the 264 
 
 
presence of two distinct vector populations within crude supernatants (one more fragile than the 
other), and this theory may be extended to EIAV-derived ProSavin
®.  Also synonymous with our 
data, HIV-1 derived vectors were reported to exhibit a substantially longer half-life at 4 °C as 
compared to during incubation at 37 °C: half-lives calculated for the second decay phase were 
around 200 versus 10.4 hr, respectively (Higashikawa and Chang, 2001).  Overall, as short-
term refrigeration of crude supernatants largely preserved ProSavin
® functionality, this suggests 
a perfusion strategy where supernatants are continually removed to low temperature storage 
could improve overall yields obtained during upstream processing.  A perfusion strategy has 
been previously applied successfully for the production of HIV-1 derived vectors in a stirred tank 
bioreactor (Ansorge et al., 2009).  However, this process was based on transient transfection of 
HEK293 cells using PEI  (Ansorge et al., 2009), and it remains for perfusion methods to be 
applied to the production of lentiviral vectors based on stable packaging or producer cells lines.   
6.3.4  Reducing the culture temperature, or increasing the medium osmolality, did not 
confer any benefit for ProSavin
® production    
Further  attempts  to  reduce  ProSavin
®  inactivation  and  thus  enhance  titres  during  upstream 
processing  were  unsuccessful.    Despite  numerous  reports  that  lowering  the  production 
temperature by  5 °C improved retroviral  vector  yields (Kotani et al., 1994; Lee et al., 1996; 
Kaptein et al., 1997; McTaggart and Al-Rubeai, 2000), when applied to the ProSavin
® process 
this approach severely compromised titres (maximum titres were around five-fold lower than 
those obtained from parallel cultures incubated at 36.5 °C; Section 6.2.2.2).  The failure of this 
strategy to yield any positive benefit when applied to the production of ProSavin
® likely arose 
from  inherent  differences  between  the  vector  systems  employed  (all  published  literature 
pertained to gamma-retroviral, rather than lentiviral, vectors). 
As it had also been reported that retroviral vector titres could be enhanced by elevating the 
medium osmolality through the addition of fructose, glucose and/or sorbitol (Coroadinha et al., 
2006a; 2006b; 2006c), a study was also undertaken to test whether this strategy could confer 
any benefit for the ProSavin
® process.  However, of the nine different conditions evaluated, all 
produced  a  reduction  in  titres  (Section  6.2.2.3).    Again,  the  use  of  a  different  vector  type 
(lentiviral  as  compared  to  gamma-retroviral)  and  a  different  production  approach,  likely 265 
 
 
accounted for this result.  As altering the osmotic properties of the medium through the addition 
of various sugar types affected ProSavin
® titres so greatly (zero values were obtained for the 
most  heavily  supplemented  conditions),  this  suggests  that  medium  osmolality  and/or  sugar 
content are important process factors that possess an optimal range.  The mildest conditions 
evaluated  were  those  where  the  culture  medium  was  supplemented  with  100  mM  fructose, 
glucose or sorbitol (note that the culture medium already contained glucose at a concentration 
of around 23 - 25 mM, see Section 6.2.2.3) and this raised the medium osmolality from 0.275 
osmol kg
-1 to 0.346 - 0.361 osmol kg
-1.  This increase was perhaps too extreme, and it may be 
worthwhile  for  future  studies  to  examine  the  effect  of  smaller  adjustments.    As  the  studies 
described by Coroadinha et al. (2006a), (2006b) and (2006c) employed an adherent cell line, 
they used a DMEM-based culture medium with a starting osmolality around 0.325 - 0.335 osmol 
kg
-1.  It is therefore possible that the reported titre benefits were not replicated here due to the 
use of a different medium, and this is something else that could be investigated in the future.  
Finally, it may be that an acclimation period of three days was insufficient for the cells to adjust 
to the altered conditions, therefore the effect of culturing the cells for a longer period in the 
different media before evaluating titres could also be examined.  
6.3.5  Different production methods and transgenes give rise to lentiviral vectors with 
distinct stability properties 
The  decay  kinetics  of  ProSavin
®  when  incubated
  at  36.5  °C  were  found  to  depend  on  the 
particular production system employed (Section 6.2.3.1).  Functional ProSavin
® derived from 
adherent cultures of PS46.2 exhibited a longer half-life (16.1 - 21.2 hr) than ProSavin
® derived 
from  suspension  cultures  of  PS46.2  (Section  6.2.1.1).    Functional  ProSavin
®  derived  from 
transiently transfected HEK293T cell cultures exhibited a decay profile characterised by  two 
relatively discrete phases.  Initially (between 0 and 8 hr), titres declined with a half-life of 18.0 - 
21.5 hr, however subsequently (between 8 and 24 hr incubation) titres exhibited a half-life of 2.4 
- 3.2 hr, and  were consequently rapidly diminished.    It is unclear why  ProSavin
® generated 
using the transient transfection process displays this unique biphasic stability profile, or what 
may be responsible for the rapid inactivation of functional vector post-8 hr incubation.  Vector 
particles would have had a distinct composition to those generated using the stable producer 
cell line (PS46.2).  Transfection reagents and plasmid DNA may have been co-packaged inside 266 
 
 
vector particles along with, presumably, differing quantities of the vector transgene products, 
which may have made particles more susceptible to inactivation.   
Switching the ProSavin
® genome construct for one encoding either the marker gene eGFP or a 
candidate therapeutic gene (Vector 13.1) also greatly influenced the decay kinetics of vectors 
generated by transient transfection (Section 6.2.3.2).  The eGFP vector was extremely stable 
(functional particles exhibited a half-life of 44.1 hr), and Vector 13.1 was also reasonably robust 
(functional  particles  displayed  a  half-life  of  33.7  hr)  when  compared  to  ProSavin
®  (Section 
6.2.3.1).  All transgenes are encoded downstream of an internal CMV promoter (Section 2.10.3, 
Figure 2.1) and it is hypothesised that transgene proteins expressed in producer cells impacted 
on the stability properties of lentiviral vectors to a relatively greater or lesser degree.  The half-
lives  of  the  eGFP  vector  and  Vector  13.1  significantly  exceed  previously  published  half-life 
estimates for HIV-1 derived vectors incubated in crude supernatants at 37 °C  (Higashikawa 
and Chang, 2001; Zhang et al., 2004; Carmo et al., 2009b).  This could reflect differences in the 
cell lines and protocols employed for vector production.  For example, the cholesterol content of 
producer  cell  membranes  (which  is  affected  by  factors  such  as  medium  composition, 
temperature and, presumably, cell type) has been cited as an important factor determining the 
stability of budding retroviral vectors (Beer et al., 2003; Carmo et al., 2006; Coroadinha et al., 
2006c).  It is also possible that lentiviral vectors derived from EIAV may be inherently more 
stable than those derived from HIV-1.  The differing life cycles of the wild-type virus provide a 
potential insight into why this may be the case: EIAV is transmitted between hosts via an insect 
vector  (thus  has  evolved  to  remain  viable  for  certain  periods  external  to  the  host),  while 
transmission of HIV-1 between individuals relies solely on the direct exchange of bodily fluid 
(Narayan  and  Clements,  1989).    In  addition,  wild-type  EIAV  is  naturally  exposed  to  higher 
temperatures  than  HIV,  as  the  average  core  body  temperature  of  a  horse  is  around  38  °C 
(Green  et  al.,  2005),  which  is  one  degree  higher  than  that  of  a  human.    Overall,  the  data 
indicate that the use of different production methods and vector genome constructs can have a 
considerable impact on resulting lentiviral vector decay kinetics, therefore optimisation of certain 
processing  factors,  particularly  harvest  timing,  should  be  completed  using  individual  vector 
systems.   
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7  Conclusions and future work 
7.1  Conclusions 
Lentiviral  vectors  used  in  clinical  trials  are  currently  produced  by  transient  transfection  of 
adherent HEK293(T) cells in multi-layered cell factories (Slepushkin et al., 2003; Negré et al., 
2008; Schweizer and Merten, 2010; Merten et al., 2011; Stewart et al., 2011; Ausubel et al., 
2012).  This approach cannot be scaled up, though scale-out is possible at considerable cost 
and logistical expense.  For commercialisation the development of alternative strategies based 
on  suspension-adapted  stable  producer  cell  lines  is  more  desirable  (Ansorge  et  al.,  2010; 
Schweizer  and  Merten,  2010;  Segura  et  al.,  2013).    To  assist  the  development  of  such 
strategies, this thesis established a microscale cell culture platform that enables key bioprocess 
design data to be acquired rapidly and cost-effectively.  The platform was used to define a 
scalable  upstream  process  for  ProSavin
®,  an  EIAV-derived  lentiviral  vector  developed  for 
treatment  of  Parkinson’s  disease  that  has  recently  completed  a  Phase  I/II  clinical  trial 
(Mitrophanous  et  al.,  1999;  Azzouz  et  al.,  2002;  Jarraya  et  al.,  2009;  Stewart  et  al.,  2009; 
Stewart et al., 2011; Palfi et al., 2014).   
The suitability of a shaken 24-well plate system for the suspension culture of HEK293T-derived 
producer  cells,  and  its  utility  when  combined  with  statistical  DoE  techniques  for  rapidly 
identifying key operating parameters impacting on lentiviral vector titre, was first established in 
Chapter 3.  Initial evaluative studies demonstrated that the microwell system, operating with a 
0.8 mL working volume, could support comparable cell growth, metabolite and pH kinetics as 
traditional shake flasks operating with a 50 mL working volume, when the HEK293T-derived 
dox-inducible ProSavin
® producer cell line, PS46.2, and a second HEK293T cell line not stably 
transfected  with  vector  DNA  were  examined  (Sections  3.2.1  and  3.2.3).    Lentiviral  vector 
(ProSavin
®) titres obtained from PS46.2 cultured in both vessel types were also comparable 
(Section  3.2.2).  The  data  indicated  that  subsequent  process  development  studies  could 
feasibly  be  performed  using  the  microwell  system,  yielding  a  62.5-fold  reduction  in  culture 
volume and substantially increasing the opportunity  for parallelisation and thus experimental 
throughput.    Six  24-well  plates  can  be  slotted  on  to  a  single  clamp  unit,  enabling  144 
experimental conditions to be investigated in parallel.  The area occupied on a shaking platform 268 
 
 
by the clamp unit is roughly equivalent to that of four conventional 250 mL shake flasks.  Thus, 
a 36-fold increase in experimental throughput is enabled while the equipment footprint remains 
the  same.    For  the  microwell  platform  to  be  a  truly  effective  bioprocess  development  tool, 
however, it was necessary to verify that any data generated was readily scalable.  Although 
scale-up from microwells to WAVE bioreactors has been previously achieved on the basis of a 
single criterion, mixing time (Gill et al., 2011), application of this approach to the ProSavin
® 
process was found to be impracticable.  The previous study by Gill et al. (2011) had focused on 
cell culture kinetics and antibody production using a CHO cell line, and the microwell mixing 
conditions used were more vigorous than those found to be optimal for PS46.2 cell culture and 
ProSavin
® production in the current work.  As a consequence of the gentle agitation conditions 
favoured by PS46.2, mixing times obtained in microwells were long and could not be replicated 
at large scale (Section 3.2.4), and alternative scaling criteria were consequently sought using 
DoE  methodology.    The  DoE  approach  employed  here  comprised  three  key  stages:  (i) 
screening,  (ii)  locating  the  optimal  region,  and  (iii)  optimisation  (Section  1.5.2,  Figure  1.4).  
During the screening stage, a fractional factorial experiment was undertaken in microwells to 
examine the relative influence of nine processing parameters on ProSavin
® titres obtained from 
PS46.2.    The  factors  examined  included  biological  variables  (induction  and  harvest  timings, 
serum  concentration  of  medium,  cell  seeding  density  and  inducer  [dox  and  NaBu] 
concentrations) in addition to variables pertaining to the cell culture engineering environment 
(shaking speed, shaking diameter and liquid fill volume).  Three parameters were identified as 
having a critical impact on titres.  These were post-induction period (time to harvest), liquid fill 
volume  and  concentration  of  dox  (Section  3.2.5).  These  parameters  were  therefore  taken 
forward  for  further  characterisation  studies  to  optimise  process  performance  and  inform  the 
design of a scale-up strategy. 
In Chapter 4, a series of DoE-guided experiments were undertaken in microwells to locate the 
optimum region and optimise the operating ranges for post-induction period, liquid fill volume 
and concentration of dox.   This approach was shown to be efficient for optimising the titre and 
P:I ratio of ProSavin
® preparations.  The investigations revealed that: (i) an optimal harvest time 
existed  between  approximately  26  and  46  hr  post-induction,  during  which  maximal  titres  of 
around 6 x 10
4 TU mL
-1 could be attained, (ii) 1 µg mL
-1 dox was sufficient for the full induction 269 
 
 
of PS46.2 producer cells over this timeframe, and (iii) liquid fill volume should be maintained at 
or below 1000 µL as higher volumes compromised titres and the P:I ratio (Sections 4.2.1 and 
4.2.3).  Post-induction period and concentration of dox were critical parameters as expression of 
ProSavin
® is tightly controlled by the TetR regulatory protein (Stewart et al., 2009; Stewart et al., 
2011).    ProSavin
®  production  is  initiated  upon  addition  of  dox  to  the  culture  medium.    Full 
cellular induction is achieved by the addition of dox to saturating levels.  Here, 1 µg mL
-1 dox 
was observed to be sufficient for the full induction of PS46.2 for culture durations of up to 70 hr, 
as further daily additions of 1 µg mL
-1, or a higher starting concentration of 3 or 5 µg mL
-1 did not 
enhance  titres  (Section  4.2.3).    ProSavin
®  production  is  terminated  likely  as  a  result  of  cell 
death, which is possibly a consequence of nutrient limitations, such as a lack of glutamine or an 
accumulation  of  ammonia  (Section  3.2.1.4),  or  due  to  an  accumulation  of  VSV-G,  as  the 
cytotoxic  properties  of  this  viral  envelope  protein  have  been  previously  noted  (Burns  et  al., 
1993; Yee et al., 1994; Yang et al., 1995; Ory et al., 1996).  ProSavin
® exists only transitorily in 
culture supernatants as it is continually inactivated over time (Chapter 6).  Consequently, the 
changing production kinetics and constant decay of ProSavin
® throughout the  culture period 
combine  to  make  the  post-induction  period  a  critical  parameter.    Liquid  fill  volume  was 
discovered to be an important parameter as it influenced the fluid mixing and oxygen transfer 
characteristics of the culture.  Cultures with liquid fill volumes exceeding 1000 µL (29 % of the 
total volume of the well) exhibited reduced titres and worse P:I ratios, in conjunction with lower 
pH and higher lactate values (Section 4.2.1.4).  It is probable that oxygen transfer was limited in 
these  cultures  and  this  triggered  PS46.2  to  increase  the  production  of  lactate,  which 
accumulated and forced a reduction in the pH.   Although the decrease in pH was relatively 
small - cultures with a fill volume above 1 mL yielded pH values of 6.7, while cultures with a fill 
volume less than or equal to 1 mL exhibited a pH of between 6.8 and 7.2 - this decrease was 
accompanied  by  a  four-  to  six-fold  reduction  in  ProSavin
®  titres  (Section  4.2.1.4).    This 
acidification may have compromised the productivity of PS46.2 cells and/or accelerated the rate 
of ProSavin
® inactivation.  The fluid hydrodynamics within microwells operating under optimised 
conditions were further characterised using the Re, Fr and Ph numbers, and this revealed that 
fluid flow was likely laminar and dominated by gravitational forces, leading to gentle mixing of 
the  culture  (Section  4.2.2).    Together,  the  data  indicated  that  mild  agitation  combined  with 
adequate aeration was optimal for ProSavin
® production in microwells.   270 
 
 
In Chapter 5, the insights obtained during the microwell experiments described in Chapters 3 
and  4  were  used  to  inform  scale-up  of  the  ProSavin
®  process  to  a  single-use  2  L  WAVE 
bioreactor.  Feasibility studies were first conducted to establish a basic operating protocol.  An 
initial run, conducted using a 1 L fill volume, produced acidic conditions and low titres (Section 
5.2.1.1).  The earlier understanding derived from microwell  data that  low pH  conditions can 
develop  when  fill  volumes  are  too  high,  presumably  as  the  supply  of  oxygen  to  cells  is 
restricted, directed a second study in which the fill volume was reduced to 0.5 L (25 % of the 
total volume of the culture chamber).  No culture acidification was observed during this run and 
titres were improved (Section 5.2.1.2).  The maximum titre observed was 2.5 x 10
4 TU mL
-1, 
thus  insights  obtained  at  the  microwell  scale  had  been  successfully  employed  to  design  a 
WAVE bioreactor process capable of delivering ProSavin
® titres within two to three-fold of those 
observed in microwells.  This represents a 585-fold scale translation of the process.  A series of 
experiments were next conducted in which different rocking rates (6, 12, 18 and 24 rocks min
-1) 
and post-induction periods (17, 23, 41, 47 and 65 hr) were examined, to verify whether the key 
conclusions  generated  using  the  microwell  system,  i.e.  that  gentle  agitation  while  ensuring 
adequate  oxygenation,  and  a  post-induction  period  of  around  26  -  46  hr  were  optimal  for 
ProSavin
® production, held true following scale-up of the process (Section 5.2.2).  As microwell 
experiments had demonstrated that a dox concentration of 1.0 to 3.0 μg mL
-1 was sufficient for 
full cell induction over production timescales of up to 70 hr, this parameter was given a fixed 
value within this range.  The experiments demonstrated that vigorous agitation (produced by a 
rocking rate of 24 rocks min
-1) or limited oxygen availability (produced by a rocking rate of 6 
rocks min
-1)  compromised  titres,  verifying  the  hypothesis  based  on  microwell  data  that  mild 
agitation while ensuring sufficient oxygenation is critical for ProSavin
® production.  Maximum 
titres were observed at 23 hr post induction during the 12 or 18 rocks min
-1 runs, which was 3 hr 
earlier than the optimum harvest window predicted  during the earlier microwell experiments; 
however this discrepancy was attributed to batch-to-batch variability in the cell stock.  Overall, 
the  microwell  data  correctly  predicted  the  important  parameters  affecting  ProSavin
®  titres  in 
WAVE bioreactor cultures, therefore the microwell platform may be viewed as an effective tool 
in the future development of lentiviral vector bioprocesses.  The hypothetical steps required to 
take the WAVE bioreactor process described in this chapter from research development stage 
to validated commercial application was considered in Appendix A.   271 
 
 
The microwell and WAVE bioreactor data consistently demonstrated that post-induction period 
was a critical factor impacting on ProSavin
® titres from suspension cultures of PS46.2 (Chapters 
3 - 5).  As titres declined during the latter stages of the culture, this indicated that functional 
particles were inactivated over time.    The half-life of EIAV-based lentiviral vectors was not 
known and, as this knowledge could be used to further improve bioprocess design, the half-life 
of ProSavin
® and other EIAV-based lentiviral vectors was assessed as described in Chapter 6, 
and several approaches to moderate the rate of decay were also trialled.  It was discovered that 
the half-life of ProSavin
® generated from suspension cultures of PS46.2 was 10.1 hr at 36.5 °C, 
and  during  a  30  hr  incubation  period  87  %  of  ProSavin
®  was  inactivated  (Section  6.2.1.1).  
Lowering the temperature to 4 °C preserved more than 50 % of functional vector over a period 
of up to 16 days (Section 6.2.2.1).  This suggests that a perfusion strategy, where supernatants 
are  continually  harvested  and  refrigerated,  could  improve  overall  yields  obtained  during 
upstream processing.   Attempts to improve ProSavin
® titres from batch cultivations of PS46.2, 
based on either a reduction in the culture temperature to 31.5 °C or adjustment of the medium 
osmolality by the addition of sugars, proved unsuccessful (Sections 6.2.2.2 and 6.2.2.3).  The 
stability of ProSavin
® produced from adherent cultures of PS46.2 or using transient transfection 
techniques was also compared, and the impact of substituting the ProSavin
® transgene for one 
expressing eGFP or an alternative therapeutic transgene examined.  ProSavin
® derived from 
adherent PS46.2 exhibited a half-life of 16.1 - 21.2 hr (depending on the titration method) at 
36.5 °C, while ProSavin
® obtained by transient transfection displayed a half-life of 18.0 - 21.5 hr 
during the first 8 hr incubation and a half-life of 2.4 - 3.2 hr thereafter.  The eGFP vector and 
Vector 13.1 (both generated by transient transfection) exhibited half-lives of 44.1 hr and 33.7 hr, 
respectively.  It was thus revealed that vector half-life is a function of the particular production 
method and transgene employed, highlighting the necessity for bioprocess development studies 
to  be  completed  using  individual  vector  systems  (Section  6.2.3).    Finally,  regardless  of  the 
choice of production method or transgene, it was observed throughout these investigations that 
the RNA and reverse transcriptase (RT) associated with vector particles declined at a slower 
rate  than  functional  particles  (Sections  6.2.1.1,  6.2.2.1  and  6.2.3),  which  is  consistent  with 
findings for retroviral (Carmo et al., 2008) and HIV-1 derived vectors (Carmo et al., 2009b), and 
supports the theory that degradation of these components is not the primary cause of lentiviral 
vector  inactivation.    It  has  been  hypothesised  that  a  loss  in  the  functionality  of  other  key 272 
 
 
components  of  the  pre-integration  complex  (PIC),  such  as  nucleocapsid  proteins  or  primer 
tRNA, may instead be responsible (Carmo et al., 2008; 2009b). 
The  microwell  system  used  throughout  this  thesis  delivered  data  that  was  fundamental  in 
informing the design of a WAVE bioreactor process for a single cell line (PS46.2).  This section 
concludes by considering (i) the overall predictive capabilities of the microwell system and (ii) 
the limitations of single cell line studies.  Microwell titres were two- to three-fold higher than 
those  obtained  from  optimised  WAVE  cultures,  and  this  discrepancy  likely  arose  as  the 
microwell  system  is  not  an  exact  replica  of  the  WAVE  bioreactor,  and  therefore  additional, 
unforeseen factors affected cell culture performance upon scale-up.  For example, titres may 
have been reduced as a consequence of the severe cellular aggregation observed during most 
WAVE runs (Section 5.2.2.1), where clumps were much larger than those previously observed 
in  microwells  operating  under  optimised  conditions  (Figure  4.9  insert).    The  increased 
aggregation  within  the  WAVE  cultures  may  have  been  due  to  the  unique  hydrodynamic 
environment,  caused  by  the  different  mode  of  mixing  (i.e.  rocking  not  rotating)  and  the 
increased volume of cells.  The vessel geometry, plastic type and air flow system also make the 
WAVE bioreactor distinct from the microwell.  The utility of the microwell system is therefore 
mostly limited to the early stages of process development, when it may be used efficiently to 
screen a large number of variables, and identify those which most affect titres and should be 
closely monitored during scale-up.  Here, application of this approach to the ProSavin
® process 
delivered important insights that enabled the fast development of a WAVE bioreactor process 
capable of delivering titres that were close to (within two- to three-fold of) those observed in 
microwells.  Thus while it is important to verify key conclusions and refine the process at scale, 
the microwell system may be viewed as an important early stage process development tool.   
This work identified fill volume, harvest timing and dox concentration as key factors affecting 
lentiviral vector production.  When developing processes for other dox-inducible stable producer 
cell lines, the importance of these factors is likely to be universal, however it is important to 
acknowledge that the optimum ranges for these factors will likely differ.  The development of 
stable producer cell lines typically involves multiple rounds of antibiotic selection and cloning by 
limiting dilution (e.g. Stewart et al., 2009).  Each cell line is therefore likely to possess unique 
cell growth characteristics and have a differing set of culture requirements.  For example, it was 273 
 
 
observed that the HEK293T-derived PS46.2 cell line consumed lactate after 73 hr cultivation, 
while a HEK293T cell line not stably transfected with DNA did not, which had implications for 
the culture pH (Sections 3.2.1.3 and 3.2.3.3).  The choice of product will also have an impact 
as, for example, lentiviral vectors expressing different transgenes were shown to have distinct 
stability  characteristics  (Section  6.2.3.2),  suggesting  that  the  optimal  harvest  time  for  each 
product will be unique.  Therefore, while this thesis has identified key factors affecting lentiviral 
vector  production,  the  optimal  ranges  for  these  factors  are  likely  to  be  cell  line  and  vector 
specific.  Furthermore, when developing lentiviral vector processes using alternative cell lines it 
may be prudent to re-examine those factors earlier dismissed as having a lesser impact (e.g. 
the  agitation  conditions).   This may  be  achieved  quickly  and  efficiently  using  the  microwell-
based process development approach presented in this thesis.   
7.2  Suggestions for future work 
Future  work  should  endeavour  to  develop  the  ProSavin
®  process  towards  commercial 
application.    Appendix  A  provides  general  discussion  of  the  possible  next  steps  required  to 
scale-up and validate the WAVE bioreactor process presented in Chapter 5, and covers aspects 
of  process  design,  qualification  and  the  continual  verification  of  commercial  batches.    In 
contrast, this section discusses in more detail the immediate next steps required to address 
specific concerns with the current process that were identified as a result of the investigations 
described in this thesis, and that must be dealt with before further scale-up of the process is 
considered.  First, as titres obtained using suspension-adapted PS46.2 fell short of those ideally 
required for clinical application, the adaption of HEK293T cells to serum-free suspension growth 
and  subsequent  creation  of  new  stable  producer  cell  lines  is  recommended  (note  that  it  is 
anticipated that ProSavin
® titres of at least 2 x 10
5 TU mL
-1 will be required for commercial 
application,  based  on  values  reported  for  clinical  trial  batches;  Section  1.4.1,  Table  1.7).  
Second, also with a view to improving crude titres, further investigations are recommended to 
better  understand  and  potentially  control  the  factors  leading  to  lentiviral  vector  inactivation.  
Third,  to  improve  process  understanding  and  facilitate  greater  process  control,  increased 
instrumentation of the WAVE bioreactor system is proposed.  Fourth, to improve total vector 
yields  from  individual  WAVE  bioreactor  runs,  the  evaluation  of  a  perfusion  strategy  is 
suggested.    Together  this  work  should  advance  the  design  of  a  commercially  viable 274 
 
 
manufacturing  process  for  ProSavin
®,  and  help  expedite  the  development  of  manufacturing 
processes for alternative lentiviral vectors.  
7.2.1  Cell line and media development  
ProSavin
® titres were reduced following adaption of the adherent PS46.2 cell line to suspension 
growth  (see  Section  1.4.5).    Subsequent  process  optimisation  studies  using  this  cell  line 
(Chapters 3 - 4) successfully informed the design of a scalable WAVE bioreactor process for 
ProSavin
®  production  (Chapter  5),  however  did  not  restore  ProSavin
®  titres  to  those  levels 
previously recorded for adherent PS46.2.  It is possible that titres had been diminished during 
the suspension adaption process due to changes in the morphology and membrane properties 
of cells (Ansorge  et al., 2010), or  vector production was inhibited by cellular  aggregation  in 
suspension cultures (Merten et al., 2001).  To address the first of these concerns, it may be 
necessary to derive new ProSavin
® stable producer cell lines using HEK293T cells that have 
already  undergone  suspension  adaption.    To  address  the  second  of  these  concerns, 
suspension adaption and subsequent cultivation of HEK293T cells should ideally be performed 
using serum-free media.  The viability of generating high-titre lentiviral vector producer clones 
from cells previously adapted to serum-free suspension growth has been earlier demonstrated 
(Broussau et al., 2008).   
7.2.1.1  Development of serum-free media  
The tendency of HEK293 cells and their derivatives to aggregate when cultured in suspension 
has been well documented (Wurm and Bernard, 1999; Liu et al., 2006; Zhao et al., 2007) and 
the PS46.2 cell line was found to be no exception (Sections 3.2.5.2, 4.2.1.5 [see Figure 4.9 
insert], and 5.2.2.1).  PS46.2 were cultivated in the WAVE bioreactor using FreeStyle 293
TM 
expression  medium  supplemented  with  5  %  tet-free  FCS  (Chapter  5).    The  tet-free  FCS 
contains calcium ions (Ca
+; Section 3.2.5.2), which are known to induce aggregative behaviour 
(Peshwa et al., 1993; Zhao et al., 2007).  Cellular aggregation is undesired as cells trapped in 
the  centre  of  clumps  can  become  non-viable  (Peshwa  et  al.,  1993),  reducing  the  overall 
productivity of the culture (Merten et al., 2001).  With regard to the PS46.2 cell line, titres may 
also be diminished as a consequence of dox not reaching cells in the centre of clumps, and/or 
due  to  ProSavin
®  being  unable  to  escape  into  the  supernatant.    Switching  to  a  serum-free 275 
 
 
medium  formulation  has  been  reported  to  reduce  cellular  aggregation  (Côté  et  al.,  1998).  
Furthermore, the complete removal of animal-derived components from the cell culture medium 
would  be  advantageous  from  a  regulatory  standpoint.    It  is  therefore  recommended  that 
elimination of FCS from the culture medium is trialled here.  In the event that ProSavin
® titres 
from PS46.2 are not improved as  a result  of these investigations, adaption of the adherent 
HEK293T  cell  line  to  FCS-free  media  is  also  recommended,  with  a  view  to  the  future 
development of new stable producer clones (Section 7.2.1.2).  Adaptation of cell lines to FCS-
free media should be completed using a process of gradual serum reduction, such as previously 
described  (Stevenson  et  al.,  2009;  Guy  et  al.,  2013).    FreeStyle  293
TM  expression  medium 
without serum or any form of serum-replacement has been previously used for lentiviral vector 
production (Segura et al., 2007; Witting et al., 2012).  However, if complete removal of serum 
proves difficult, the potential of chemically-defined animal origin-free substitutes, e.g. the lipid 
mixture L5146 (Sigma-Aldrich) previously used during lentiviral vector production by Ansorge et 
al.  (2009),  could  also  be  explored.    To  enable  the  rapid  characterisation  of  various  media 
formulations  and  cellular  responses  (e.g.  cell  growth,  viability,  metabolite  consumption  and 
production), this work should be undertaken using the microwell platform (described in Chapters 
3 and 4 of this thesis).  To ensure the timely identification of potential scale-up issues, such as 
medium-plastic interactions, WAVE bioreactor cultivations should be performed using the most 
promising formulations.   
7.2.1.2  Creation of ProSavin
® producer cell lines 
If adaption of the PS46.2 cell line to serum-free conditions is found not to increase titres to 
clinically relevant levels, the next step would be to take forward the best media formulations and 
HEK293T suspension clones and generate new ProSavin
® stable producer cell lines, adapting 
the  techniques  previously  described  for  adherent  cultures  (Stewart  et  al.,  2009).    Again, 
application of the microwell system would be crucial for this work, as this would facilitate the 
screening  of  large  numbers  of  clones,  maximising  the  likelihood  of  identifying  a  high-titre 
candidate.  Screening for vector production should be performed on the basis of biological titre, 
and use of the ProSavin
® flow cytometry assay (Section 2.11.2.1) is recommended, as higher 
throughput  may  be  achieved  using  this  assay  as  compared  to  the  DNA  integration  assay 
(Section 2.11.2.3).  RNA copy number or PERT predicted titre measurements (Section 2.11.3) 276 
 
 
should  not  be  used  as  a  substitute  for measurements  of  biological  titre,  as  the  relationship 
between  these  parameters  and  titre  was  shown  to  be  variable  (Chapters  4  -  6).    Vector 
production should be screened at several harvest points, as the critical impact of post-induction 
period on ProSavin
® titres was earlier demonstrated (Chapters 3 - 5).  The half-life of generated 
vectors  should  also  be  examined,  as  this  was  shown  to  differ  depending  on  the  specific 
production conditions employed (Chapter 6), and will impact on the design of batch/perfusion 
production  processes.  Again,  it should be  verified that the chosen clones are  amenable to 
growth in the WAVE bioreactor. 
7.2.1.3  Microcarrier culture of adherent ProSavin
® producer cells 
If neither of the above approaches is successful in yielding a suspension process that delivers 
commercially relevant titres, a third option may be to use microcarrier cultures of the adherent 
PS46.2 cell line.  This option is less ideal, as microcarriers increase process complexity and 
cost, and can generate contaminants that are difficult to eliminate downstream (Section 1.4.2).  
This approach is scalable, however, and the use of microcarrier cultures to generate lentiviral 
vectors in a WAVE bioreactor has been previously demonstrated (Throm et al., 2009; Greene et 
al.,  2012).  If  the  adherent  PS46.2  cell  line  were  to  be  used  however,  the  evaluation  of 
alternative culture systems, particularly fixed-bed technologies that support higher cell densities, 
would be worthwhile.  For example, the Integrity
® iCELLis
TM bioreactor by Pall Corporation uses 
a culture volume of just 25 L, yet reportedly provides the equivalent surface area of 3000 roller 
bottles (each 1700 cm
2) (Pall Corporation, 2014).  This is comparable to 807 of the 10-layer Cell 
Factory
TM systems (each 6320 cm
2) currently used for the production of clinical-grade lentiviral 
vectors  (Table  1.7;  Section  1.4.2).  A  fixed-bed  bioreactor  is  also  well-suited  to  perfusion 
culture, if such a strategy were to be pursued using the adherent PS46.2 cell line (the relevance 
of  a  perfusion  strategy  for  ProSavin
®  production  based  on  suspension-adapted  PS46.2  is 
discussed in Section 7.2.4). 
7.2.2  Further investigation into factors affecting lentiviral vector stability 
Lentiviral  vector  inactivation  during  upstream  processing  is  undesirable  as  it  reduces  crude 
titres.  Future studies should seek to build on the insights obtained during Chapter 6, to better 
understand  and  potentially  control  the  factors  affecting  lentiviral  vector  stability.    First,  it  is 277 
 
 
recommended that the impact of production method and transgene choice on lentiviral vector 
half-life (Section 6.2.3) is verified using additional batches of material.  Second, experiments 
should  be  conducted  to  elucidate  why  some  lentiviral  vectors  are  more  or  less  stable  than 
others, for example, is it the expressed proteins or the genome RNA sequence that affects the 
stability of lentiviral vectors containing different transgenes?  Third, based on the outcome of 
these investigations, methods to improve vector stability should be tested.  For example, if the 
ProSavin
® transgene proteins were found to negatively impact on vector stability, future studies 
may seek to develop methods to suppress their expression during upstream processing.  
7.2.3  Greater instrumentation for enhanced process monitoring and control   
The  purpose  of  the  process  development  work  suggested  in  Sections  7.2.1  and  7.2.2  is  to 
support the establishment of a cell culture process that can deliver commercially relevant titres.  
In parallel, it is recommended that the WAVE bioreactor system should be further developed to 
enable  greater  process  monitoring  and  control.    A  robust  control  strategy  is  a  fundamental 
requirement  of  bioprocess  validation  (see  Appendix  A).    At  present,  the  WAVE  bioreactor 
system described in Chapter 5 provides limited opportunity for online monitoring or feedback 
control.  Mixing parameters, such as the rocking rate, rocking angle, air flow rate and fill volume 
are set and altered manually if desired during a run.  Dissolved oxygen was the only response 
parameter measured using an in situ probe, and only the last 10 min of data could be stored on 
the WAVEPOD module - therefore to obtain insight into the oxygen profile during cell cultivation, 
it  was  necessary  to  note  down  readings  periodically.    It  is  worth  noting,  however,  that  the 
rocking  rate  may  be  automatically  adjusted,  or  automated  oxygen  blending  introduced,  to 
maintain dissolved oxygen levels within defined limits (General Electric Company, 2008c), and 
this  facility  may  prove  useful  once  the  relationship  between  oxygen  levels,  agitation  and 
ProSavin
® titres is better understood.   
Other pertinent culture parameters, such as pH, cell growth and vector titres were measured 
offline following manual sampling at various intervals, which were dictated in part by the length 
of the working day.  In situ pH probes are available for the WAVE bioreactor (General Electric 
Company, 2008c).  Use of an in situ pH probe (as compared to a pH indicator strip outside of 
the CO2 controlled culture environment) should improve the precision of pH readings and reduce 278 
 
 
the requirement for in-process sample collection (desirable as sample removal poses a risk of 
contamination).  Automatic acid-base addition or automatic CO2 adjustments to control the pH 
are also feasible (General Electric Company, 2008c), the utility of which should be explored.  To 
the best of my knowledge, the WAVE bioreactor does not currently support automated sample 
removal, therefore some innovation would be required if sample collection for the measurement 
of cell growth characteristics and vector titre is desired outside of conventional working hours 
(alternatively overnight staffing will be required).  The automated Cedex XS cell counter used in 
this work (Section 2.11.1.1) already enables rapid measurement of cell density and viability.  A 
similarly rapid measurement of vector titre would be advantageous, but is unfeasible due to the 
necessary inclusion of a cell transduction step.  It may be possible to rapidly estimate total 
particle numbers, however, using a virus counter such as the Virus Counter 3100 developed by 
virocyt, and this data could be useful if found to correlate well with functional titre values.  This 
information  could  assist  the  development  of  enhanced  process  control  strategies,  enabling 
harvest timing, for example, to be determined on a batch-by-batch basis.  Another option would 
be to investigate the utility of technologies such as permittivity measurements for the real-time 
detection of vector release, the potential of which has been recently demonstrated (Ansorge et 
al., 2011).   
Lastly, documentation is an essential element of process validation that supplies the evidence 
that robust process control has been, and continues to be, achieved (European Commission, 
2001; FDA, 2011).  To accomplish this, a system to capture and retain inline and online data 
throughout the cultivation period needs to be established.  The WAVEPOD has an Ethernet port 
which may be configured for external data collection (General Electric Company, 2008c), thus 
the utility of this  feature should be explored.   
7.2.4  Evaluation of a perfusion strategy   
The final recommendation for future work is the evaluation of a perfusion strategy for ProSavin
® 
production.    ProSavin
®  generated  using  suspension  cultures  of  PS46.2  was  continually 
inactivated at 36.5 °C with a half-life of around 10.1 hr (Section 6.2.1.1).   As the half-life of 
ProSavin
® was greatly extended when supernatants were stored at 4 °C (more than 50 % was 
preserved  for  up  to  16  days;  Section  6.2.2.1),  it  is  conceivable  that  overall  yields  may  be 279 
 
 
improved if a perfusion system were to be developed that enabled the continual harvest and 
refrigeration of culture supernatants.  The simultaneous dilution of cytotoxic vector proteins (e.g. 
VSV-G)  and  metabolic  by-products,  and  the  replenishment  of  limiting  nutrients,  could  also 
extend the productivity of the cell culture.  The first goal would be to determine the value of this 
approach, i.e. to compare the increase in overall yield (titre x total volume) with that obtained 
from a batch cultivation.  A perfused system will generate a bulk harvest that is larger but more 
dilute, and it should be ascertained whether the increase in overall yield is substantial enough to 
warrant  the  increased  pressures  imposed  on  the  downstream  processing  steps  as  a  result.  
Note  that  purification  of  ProSavin
®-containing  supernatants  is  currently  undertaken  prior  to 
concentration (Section 1.4.3, Table 1.10), thus the cost implications and overall feasibility of 
purifying larger volumes of more dilute material should be considered.  It is also worth noting 
that as culture duration increases, more of the cells will die, releasing DNA, host cell proteins 
and  waste  metabolites  that  also  need  to  be  removed  downstream,  which  may  add  to  the 
processing time and cost.  In order to make a judgement as to whether a perfusion strategy is 
likely  to  be  viable,  a  process  that  is  reasonably  optimal  needs  first  to  be  developed.    The 
microwell  platform  may  serve  as  a  rough  mimic  of  the  large  scale  process  and  assist  the 
development of such a strategy, although the addition of media and harvesting of supernatants 
(ideally through a filter to prevent the removal of cells) could not be performed continually, and 
would need to be performed manually at regular intervals.  The designed process should be 
refined using the laboratory scale WAVE bioreactor system.   
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Appendix A  Bioprocess scale-up and validation 
A.1  Introduction and aims 
“Process validation” is the term used to describe the documented evidence, obtained from the 
initial process design stage through to commercial application, that a process can consistently 
deliver  a  product  that  meets  predefined  specifications  (European  Commission,  2001;  FDA, 
2011).    Process  validation  is  a  prerequisite  for  regulatory  approval  for  the  commercial 
manufacture of biopharmaceuticals in Europe and the U.S. (European Commission, 2001; FDA, 
2011).  Chapters 3 to 5 of this thesis described the microwell characterisation and scale-up 
verification of an upstream processing route for ProSavin
®, an EIAV-derived lentiviral vector. 
This  appendix  considers,  hypothetically,  the  steps  required  to  take  the  WAVE  bioreactor 
process  described  in  Chapter  5  from  research  development  stage  to  validated  commercial 
application.  The specific objectives of this chapter are: 
  To propose a strategy for refinement of the process and scale-up to commercial scale 
  To review the procedures required for qualification of the commercial process 
  To consider how continual process verification may be accomplished  
A.2  Proposed approach to bioprocess scale-up and validation 
A successful validation programme essentially depends on the detection, understanding and 
control  of  sources  of  process  variability  so  that  consistent  product  quality  is  assured  (FDA, 
2011).    Process  validation  activities  may  be  broadly  divided  into  three  stages:  (1)  process 
design, (2) process qualification, and (3) continued process verification (FDA, 2011).  Below, 
each stage is briefly introduced and activities to support validation of the ProSavin
® process are 
suggested.  Throughout all stages, it is recommended that an enhanced, Quality by Design 
(QbD) approach is adopted.  A detailed comparison between a typical minimal approach, and a 
QbD approach to process validation is provided in Appendix I of ICH (2009).  Key aspects of a 
QbD approach include: (i) use of multivariate (rather than OFAT) experimental techniques to 
improve process knowledge, (ii) a manufacturing process that is not fixed, but is adjustable 
within  the  design  space  (iii)  incorporation  of  process  analytical  technologies  (PAT)  for 281 
 
 
responsive process control, and (iv) continual process improvement throughout the lifecycle of 
the product (ICH, 2009).       
A.2.1  Process design  
The goal of the process design stage is to use information obtained during small scale process 
development and scale translation studies to define a commercial manufacturing process (FDA, 
2011).    The  commercial  process  should  comply  with  current  Good  Manufacturing  Practice 
(GMP) regulations, i.e. be designed and controlled to ensure that raw materials and the final 
biopharmaceutical product consistently meet predefined quality specifications (FDA, 2011).   
As described earlier (Chapters 3 - 5), microscale bioprocess development studies led to the 
creation of a WAVE bioreactor process for ProSavin
® production based on suspension cultures 
of a stable producer cell line (PS46.2).  This process differs from that used to generate Phase 
I/II clinical material, and a comparison of the two approaches is provided in Table A.1.  When 
seeking regulatory approval, significant differences between the manufacturing process used to 
generate  material  for  clinical  trials,  and  the  process  proposed  for  commercial  application, 
require discussion, and the influence on the quality of the product understood (ICH, 2009).  It 
would therefore be desirable to demonstrate, by reference to historical data, that the quality of 
ProSavin
® was not affected by the changes to the upstream processing route proposed in this 
thesis.    Quality  is  assured  by  maintaining  key  characteristics  of  the  product,  termed  critical 
quality attributes (CQAs), within predefined specifications (ICH, 2009).  Examples of CQAs for 
ProSavin
® that may be assessed post-harvest (i.e. using crude supernatants) are listed in Table 
A.2.    Titre  is  arguably  the  most  important  CQA,  as  this  represents  the  concentration  of 
functional  vector  particles,  and  is  the  primary  indicator  of  quality  used  to  guide  bioprocess 
development  studies.    PERT  and  RNA  copy  number  measurements  are  also  important 
however,  as  this  information  may  be  used  in  conjunction  with  titre  data  to  estimate  the 
proportion  of  lentiviral  vector  particles  that  are  functional,  and  thus  provide  insight  into  the 
overall  quality  of  a  given  preparation.    ProSavin
®  titres  obtained  when  using  the  WAVE 
bioreactor process are approximately one to two orders of magnitude lower than those obtained 
from the current clinical GMP process (Table A.1).  This issue must be resolved before further 
scale-up of the WAVE bioreactor process is considered.   282 
 
 
As well as demonstrating that the post-harvest CQAs (Table A.2) are not affected by the change 
in the upstream manufacturing process, bridging studies may  also need to be performed to 
demonstrate that the safety and efficacy of the product remains unaffected.  This may include 
non-clinical  toxicology  and  biodistribution  studies  in  relevant  animal  models,  and  may  also 
include further clinical studies.  The scope and extent of this work should be decided following 
consultation with the appropriate regulatory authority. 
Table A.1  Comparison  of  the  current  clinical  GMP  upstream  process  for  ProSavin
® 
production with the WAVE bioreactor process described in Chapter 5 of this thesis.  Dox is an 
abbreviation  for  doxycycline,  DMEM  for  Dulbecco’s  Modified  Eagle’s  Medium,  and  FCS  for 
foetal calf serum.  *A 200 L vessel represents the proposed commercial scale, note that a 2 L 
WAVE bioreactor with 0.5 L fill volume was evaluated in this project.  **Different quantitation 
methods  were  used  to  assess  crude  titres  -  GMP  titres  were  determined  using  the  DNA 
integration assay (Section 2.11.2.3), while WAVE bioreactor titres were determined using flow 
cytometry (Section 2.11.2.1).  Earlier data (Section 6.2.3.1 of this thesis) indicated that titres 
quantified using flow cytometry may be around 40 % lower than those quantified using the DNA 
integration assay (compare corresponding starting concentration values in Table 6.5).   
  Current GMP process  Process evaluated in this thesis 
Reference  Schweizer and Merten (2010); 
Stewart et al. (2011) 
Section 5.2.2 of this thesis (18 
rock min
-1 condition) 
Expression system 
Triple plasmid transient 
transfection of HEK293T cells 
using Lipofectamine
TM 2000 CD 
reagent 
Dox inducible producer cell line 
(PS46.2) derived from HEK293T 
with all vector components stably 
integrated 
Cell growth mode  Adherent   Suspension 
Culture medium 
DMEM supplemented with 2 mM 
L-glutamine, 1 % non-essential 
amino acids and 10 % FCS 
FreeStyle
TM 293 expression 
medium supplemented with 5 % 
tetracycline-free FCS 
Vessel  10-layer Cell Factory
TM  200 L WAVE bioreactor* 
Production scale (L)  72 (24 per campaign)  50* 
Crude titre** (TU mL
-1)  0.2 - 2.0 x 10
6   2.4 - 4.1 x 10
4 
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Table A.2  Examples  of  critical  quality  attributes  (CQAs)  for  ProSavin
®  that  may  be 
monitored  post-harvest  (prior  to  downstream  processing  and  product  formulation  steps).  
Clarification  refers  to  the  low  speed  centrifugation  and  0.45  µm  filtration  of  supernatants  to 
remove cells and cellular debris.  The example specification for DNA integration titre is based 
on the lower limit of the reported range obtained for current clinical GMP batches (Table A.1).  
The  example  specification  for  ProSavin
®  titre  as  assessed  by  flow  cytometry  reflects  the 
observation that titres quantified using this method may be around 40 % lower (Table A.1).  
Tests  for  mycoplasma,  bioburden,  endotoxin  and  adventitious  agents  should  be  conducted 
according  to  procedures  outlined  by  the  European  Pharmacopoeia.    Replication  competent 
lentivirus (RCL) assays for EIAV-derived vectors have been described by Miskin et al. (2006) 
and Farley et al. (2012), while methods for quantifying functional titres, PERT predicted titres 
and RNA copy numbers were described in Sections 2.11.2.1, 2.11.2.3 and 2.11.3 of this thesis.   
Step  Test  Specification 
Crude supernatant 
(prior to clarification) 
Mycoplasma  ≤ x 
Bioburden  ≤ x 
Endotoxin  ≤ x 
Adventitious agents  ≤ x 
replication competent lentivirus (RCL)  Negative 
Crude supernatant 
(post-clarification) 
DNA integration titre  ≥ 2.0 x 10
5 TU mL
-1 
ProSavin
® titre assessed by flow cytometry  ≥ 1.2 x 10
5 TU mL
-1 
PERT predicted titre  None 
RNA copy number  None 
A recommended strategy for defining a commercial manufacturing process for ProSavin
®  is 
outlined in Table A.3.  The proposed strategy is based on the insights obtained during the early 
phase bioprocess development work described in this thesis (Chapters 3 - 6).  In brief, it is 
recommended that initial studies should use the microwell system described in Chapters 3 and 
4 to tackle the issue of low titres and cellular aggregation.  Towards this aim, the evaluation of 
serum-free media formulations and the screening and selection of new stable producer cell lines 
is suggested.  Following identification of a suitable medium formulation and cell line, it would be 
prudent to re-evaluate the relative impact of various processing parameters on ProSavin
® titres.  
This  work  should  incorporate  Design  of  Experiments  (DoE)  techniques  and  may  initially  be 
conducted  using  the  microwell  system,  although  it  is  recommended  that  operating  limits  for 
important parameters should be refined and ultimately defined using a laboratory scale WAVE 
bioreactor that better mimics the proposed commercial scale vessel (a 200 L WAVE bioreactor).  
This  work  should  inform  the  implementation  of  appropriate  control  strategies  to  assure 
consistent  product  quality.    Finally,  scalability  between  the  laboratory  and  commercial  scale 284 
 
 
vessels should be verified.  For the development of this strategy, it was assumed that the CQAs 
monitored post-harvest are those outlined in Table A.2, and that assays to quantitate these 
responses  are  validated.    As  the  focus  is  on  upstream  process  development  it  was  also 
assumed  that  downstream  processing  steps  are  such  as  those  currently  employed  for  the 
purification of clinical GMP batches (e.g. see Section 1.4.3, Table 1.10) and these have also 
been validated.  In reality, however, it is likely that certain changes, such as the removal of 
serum from the medium, will force modifications to be made to the downstream procedure, and 
this is something that should be investigated in parallel.  Note that if titres are not improved as a 
consequence of the cell line and media development work proposed here (Table A.3, Activities 
1 and 2), the feasibility of increasing the downstream concentration factor (which is currently 
2000-fold, see Section 1.4.3, Table 1.10) should be investigated.  It was noted in Section 1.4.5 
that compensating for low crude titres by altering the downstream process was undesirable, as 
the final product would comprise a greater proportion of impurities.   However, this approach 
may become viable if ProSavin
® is generated using a stable producer cell line cultured in FCS-
free media, as the starting material would contain fewer contaminants than that derived from the 
current  clinical  process  (Table  A.1),  and  the  co-concentration  of  plasmid  DNA,  transfection 
reagents and animal-derived components would no longer present a concern. 
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Table A.3  Suggested  strategy  for  defining  a  commercial  manufacturing  process  for 
ProSavin
®.    Activities  are  broadly  listed  chronologically,  although  in  practice  some  overlap 
between activities is expected.  Initial operating conditions for microwells and the laboratory 
scale (2 L) WAVE bioreactor should reflect those described in Sections 2.4.5 and 2.7.3.3 (18 
rocks min
-1 condition) of this thesis, respectively. 
Activity (scale)  Description 
1.  Adapt  
HEK293T cells to 
serum-free 
suspension 
culture 
(microwells) 
 
It  is  desirable  to  eliminate  FCS  from  the  cell  culture  medium  for  two 
reasons.    Firstly,  from  a  processing  perspective,  it  would  be 
advantageous  to  diminish  the  calcium  content  of  the  medium  so  that 
cellular  aggregation  is  reduced.    Note  that,  in  microwell  cultures  of 
PS46.2,  aggregation  was  found  to  be  exacerbated  when  higher 
concentrations of FCS (5 % versus 1 %) were used (Section 3.2.5.2), and 
in  WAVE  bioreactor  cultures  supplemented  with  5  %  FCS,  cellular 
aggregation was extensive (Section 5.2.2.1).  Eliminating FCS from the 
culture  medium  should  yield  a  more  homogenous  cell  population  and 
possibly improve titres.  The potential presence of extraneous agents in 
FCS provides a second reason why, from a regulatory perspective, it is 
preferable  to  eliminate  this  component  from  cell  culture  media  (EMA, 
2013).  
Lentiviral  vector  production  has  been  achieved  using  FreeStyle  293
TM 
expression medium without serum or any form of serum -replacement 
(Segura et al., 2007; Witting et al., 2012).  It is preferable to continue to 
using FreeStyle 293
TM expression medium for ProSavin
® production as 
this  medium  has  been  used  effectively  throughout  the  bioprocess 
development work described in this thesis.  This medium is chemically 
defined, free from animal -derived components and manufactured in a 
GMP compliant facility  (Thermo Fisher Sc ientific, 2014).  Although its 
formulation is proprietary, if the medium is to be used in a commercial 
manufacturing process it is possible to request access to the Drug Master 
File (which includes formulation information) that is lodged with the U.S. 
Food and Drug Administration (FDA).  
To adapt HEK293T cells to serum -free medium, a method of gradual 
serum  reduction  is  recommended,  such  as  previously  described 
(Stevenson et al., 2009; Guy et al., 2013).  If complete serum removal is 
unsuccessful, the use of animal origin-free substitutes could be explored.  
For example, the lipid mixture L5146 (Sigma-Aldrich) has previously been 
used successfully as a serum substitute during lentiviral vector production 
(Ansorge et al., 2009) and its potential could be evaluated here.  This 
work  should  be  conducted  using  the  microwell  system,  as  this  would 
enable multiple media formulations and cellular adaptation strategies to 
be  evaluated.    Promising  formulations  should  be  verified  using  a 
laboratory scale (2 L) WAVE bioreactor to facilitate the early identification 
of any potential scale-up issues, such as medium-Cellbag interactions.  286 
 
 
2.  Generate 
ProSavin
® 
producer cell 
lines (microwells) 
Titres  were  diminished  five-  to  twenty-fold  following  the  adaption  of 
adherent PS46.2 to growth in suspension (Section 1.4.5).  As subsequent 
process optimisation studies did not yield significant improvements in titre 
(Chapters  3  -  4),  it  is  hypothesised  that  cellular  aggregation  and/or 
changes  in  the  morphology  and  membrane  properties  of  cells  during 
adaption may have compromised titres (Section 1.4.5).  Broussau et al. 
(2008)  previously  described  the  generation  of  high-titre  lentiviral  vector 
producer  clones  from  cells  that  were  already  adapted  to  serum-free 
suspension growth. It is suggested that value of this approach is trialled 
here.  
ProSavin
® stable producer cell lines should be generated as described 
previously  (Stewart  et  al.,  2009),  except  that  HEK293T  cells  already 
adapted to serum-free suspension growth should be used (see Activity 
1.).    At  this  stage,  the  possibility  of  transgene  suppression  during 
ProSavin
® production could also be explored, as it is hypothesised that 
expression of the ProSavin
® transgene cassette may limit vector half-life 
during  upstream  processing  (Section  6.3.5).    The  microwell  system 
should be employed to facilitate the screening of large numbers of clones 
and  improve  the  chances  of  identifying  high-titre  candidates  (the  best 
candidates  should  be  verified  using  the  laboratory  scale  WAVE 
bioreactor).  The developed cell lines and associated ProSavin
® vector 
should  be  thoroughly  characterised  in  terms  of  identity  and  genetic 
stability using methods such as those previously described (Stewart et al., 
2011).  
Note that, if titres are not improved as a consequence of the media and 
cell line development work suggested here (Activities 1 and 2), studies to 
investigate  the  feasibility  of  increasing  the  downstream  concentration 
factor  should  be  instigated  and  conducted  in  parallel  to  the  further 
upstream process development work outlined below (Activities 3 to 6).   
3.  Establish 
critical 
processing 
parameters 
(CPPs) and their 
approximate 
optimal ranges 
(microwells) 
 
Having identified a suitable medium formation and candidate ProSavin
® 
producer cell line, it would be prudent to re-assess the impact of certain 
processing  parameters  on  titre.    This  work  should  incorporate  DoE 
techniques  and may initially  be conducted using the microwell system.  
Risk assessment tools, such as Ishikawa (fishbone) diagrams and failure 
mode  effects  analysis  (FMEA)  techniques,  can  be  used  to  identify 
parameters for inclusion in DoE studies (ICH, 2009;  FDA, 2011).  The 
microwell studies conducted using the PS46.2 cell line (Chapters 3 and 4) 
should provide the starting point for this work.  As well as identifying and 
establishing  approximate  ranges  for  critical  processing  parameters 
(CPPs),  i.e.  parameters  whose  variability  impacts  on  a  CQA  and  thus 
require monitoring and control to ensure consistent product quality (ICH, 
2009),  it  would  be  desirable  at  this  point  to  identify  raw  materials  or 
process stages that may be eliminated without compromising CQAs.  This 
would streamline the process, enable cost-savings, and ease regulatory 
approval.  An example of a raw material that could potentially be removed 
is sodium butyrate (NaBu), as this was found to have no significant impact 
of ProSavin
® titres obtained from PS46.2 over the range 0.2 - 1.8 µg mL
-1 
(Section 3.2.5.1).      287 
 
 
4.  Verify 
microwell 
findings and 
execute further 
studies to identify 
‘WAVE bioreactor 
specific’ CPPs 
(laboratory scale 
WAVE bioreactor) 
Operating ranges for CPPs should be verified using a laboratory scale 
WAVE  bioreactor,  which  better  mimics  the  commercial  vessel.    In 
addition,  some  processing  parameters  are  ‘WAVE  bioreactor  specific’, 
such  as  air  flow  rate,  and  cannot  be  evaluated  using  the  microscale 
system,  therefore  further  risk  assessment  activities  and  DoE-based 
experimentation  using  the  laboratory  scale  WAVE  bioreactor  will  be 
necessary to establish operating ranges for these factors.   
Additionally at this stage (if not before), it would be worthwhile confirming 
that  all  raw  materials  to  be  used  in  the  commercial  process  (including 
disposable plasticware, for example) conform to GMP specifications and 
are qualified for use in the generation of a medicinal product.  The long-
term supply of these materials should also be confirmed.  It may also be 
necessary to conduct studies to demonstrate that plastic leaching from 
the disposable culture chamber does not present a concern.   
5.  Define process 
control approach 
(laboratory scale 
WAVE bioreactor) 
Once the design space, i.e. the combination of raw material attributes and 
process  parameters  known  to  assure  product  quality  (ICH,  2009),  has 
been characterised, a control strategy to ensure that the process does not 
deviate  from  operation  within  the  design  space  should  be  defined.  
Process  control  strategies  may  be  designed  to  reduce  input  variation, 
adjust for input variation, or both (FDA, 2011).  For example, this may be 
achieved by specifying fixed ranges for CPPs in the former instance, or by 
employing process analytical technology (PAT) in the latter.  PAT affords 
increased  process  flexibility,  as  online  analysis  of  important  responses 
and the use of feedback loops can adjust the processing conditions to 
ensure  the  output  remains  constant  (FDA,  2011).    Harvest  timing  was 
demonstrated  to  be  a  critical  parameter  affecting  ProSavin
®  titres  from 
PS46.2,  and  the  optimal  time  to  harvest  varied  between  batches 
(Chapters 3 - 5).  To reduce titre variability as a consequence of shifts in 
the  optimal  harvest  time,  the  potential  of  technologies  such  as  in  situ 
permittivity  measurements  for  real-time  detection  of  lentiviral  vector 
release could be investigated (Ansorge et al., 2011).   
6.  Scale-up to 
commercial size 
vessel (laboratory 
to commercial 
scale WAVE 
bioreactor) 
 
It is acceptable for a design space to be developed at any scale, however 
the relevance of the design space should be justified, and potential risks 
in the scale-up operation understood (ICH, 2009).  Verification that the 
design space and control strategy developed using the laboratory scale 
WAVE bioreactor is predictive of commercial scale process performance 
is therefore vital.  As turbulence and oxygen availability were important 
factors affecting ProSavin
® titres obtained from WAVE bioreactor cultures 
of PS46.2 (Chapter 5), Remod (Eibl and Eibl, 2006; Eibl et al., 2010b) may 
be  an  appropriate  parameter  on  which  to  base  scale-up  studies.  
Predictive scale-up of cell culture processes to 200 L WAVE bioreactor 
scale has been previously performed using this criterion in conjunction 
with  knowledge  of  the  impact  of  aeration  rate,  rocking  conditions  and 
liquid fill volume on oxygen transfer efficiency (Eibl et al., 2010b).   
It  will  also  be  necessary  to  establish  effective  protocols  for  seed 
expansion, although this is not included in the design space and does not 
form  part  of  the  registered  detail  (Osborne,  2011),  and  procedures  for 
representative sampling of commercial batches (FDA, 2011).  Finally, the 
overall  compliance  of  the  commercial  process  design  with  GMP 
regulations should be demonstrated (European Commission, 2001). 
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A.2.2  Process qualification  
A.2.2.1 Overview of process qualification 
During the process qualification stage, the designed process is assessed to determine whether 
it is capable of reproducible commercial manufacture (FDA, 2011).  This stage comprises two 
key  elements:  (i)  facility  design  and  qualification  of  utilities  and  equipment  and  (ii)  process 
performance qualification (PPQ), which, if successful, should ultimately culminate in regulatory 
submission (FDA, 2011).   
Proper  design  of  the  manufacturing  facility  is  a  requirement  of  GMP  (FDA,  2011).    New  or 
modified  utilities  and  equipment  require  proper  qualification,  and  this  typically  includes  the 
following activities (European Commission, 2001; FDA, 2011): 
  Selecting construction materials,  operating methods, and  performance characteristics for 
utilities and equipment that are appropriate for their intended application 
  Verifying that installed utility systems and equipment conform to the design specifications 
  Verifying that utility systems and equipment operate in line with the requirements of the 
process over all expected operating ranges  
PPQ succeeds the successful qualification  of the facility, utilities and equipment.  This step 
combines  these  elements  with  the  trained  personnel  and  designed  process  to  produce 
commercial  batches  of  material  (FDA,  2011).    The  overall  goal  is  to  demonstrate  that  the 
commercial  manufacturing  process  performs  as  expected  (FDA,  2011),  and  typically  three 
successful  consecutive  batches  are  considered  sufficient  for  validation  of  the  process 
(European Commission, 2001). 
It is difficult to propose process qualification activities for ProSavin
® manufacture without the 
process design stage being near complete.  However, assuming the process design strategy 
proposed in Section A.2.1 (Table A.3) has been broadly followed and a 200 L WAVE bioreactor 
process developed, the following general considerations (Sections A.2.2.2 and A.2.2.3) may 
play a role in informing the preparation of a process qualification plan.   289 
 
 
A.2.2.2 Process qualification in relation to ProSavin
®: Facility design and qualification of utilities 
and equipment 
The size of the facility should be based on projections regarding the number of patients to be 
treated each year, the dosage required for each patient, the shelf-life of the final product, and 
economic constraints.  It may be desirable to conduct single runs consecutively using a small 
facility and a limited number of personnel, or it may be preferable to generate large volumes of 
material  quickly  using  several  bioreactors  operated  in  parallel,  although  this  would  require 
bigger  premises  and  more  operating  staff.    As  ProSavin
®  is  one  of  a  pipeline  of  products 
developed by Oxford BioMedica that are based on the EIAV lentiviral vector platform (Section 
1.3.3) the facility, utility systems and equipment may need to be designed with a view to their 
subsequent/simultaneous application for the manufacture of several products.  As well as the 
upstream processing area, the facility will need to include areas for cell expansion, downstream 
processing and product formulation.  The overall layout of the facility should take into account 
whether  one  or  more  discrete  processing  suites  are  required  for  concurrent  production  of 
multiple batches of ProSavin
® or other pipeline products. 
A.2.2.3 Process qualification in relation to ProSavin
®: PPQ 
Prior to performing PPQ it would be prudent to verify the robustness of the commercial process 
several  times  by  undertaking  runs  that  test  the  extreme  operating  limits  of  the  system 
(European  Commission,  2001).    PPQ  may  then  be  achieved  by  the  production  of  three 
consecutive  batches  of  ProSavin
®  material  using  the  commercial  process.    As  well  as  end-
product  testing,  relevant  CQAs  should  be  monitored  in-process  (e.g.  directly  after  vector 
harvests; Table  A.2).  Samples should be representative of the entire batch, and ideally an 
increased number of samples should be collected than would typically be during a commercial 
run.  Successful validation will depend on whether the process specifications (including cleaning 
procedures) and product specifications are met for all batches. 
A.2.3  Continued process verification 
The aim of continued process verification is to monitor the process during routine commercial 
production to assure a continual state of control (FDA, 2011).  Systems should be in place for 290 
 
 
the  collection  and  review  of  data  during  standard  commercial  runs,  to  enable  the  timely 
detection  and  resolution  of  undesired  process  variability  (FDA,  2011).    The  commercial 
upstream  process  for  ProSavin
®  may  be  continually  verified  by  monitoring  cell  culture 
performance parameters and CQAs during each run using in situ probes and by regular offline 
sampling.  Assuming a batch protocol were developed, the production timescale is likely to be 
short, around three or four days, thus to gain reasonable insight into the process performance 
samples for offline analysis would need to be taken and analysed throughout the day and night 
– necessitating staff to work in shifts.  Alert systems should  be in place in case immediate 
corrective action is needed to retain monitored parameters within set limits.  At the end of each 
run, all data should be passed on to a team of trained statisticians, who should trend and review 
the  data,  highlighting  areas  for  improvement.    Continual  improvement  is  as  important  as 
continual  verification,  and  process  failures  should  be  assessed  to  inform  the  design  and 
implementation  of  preventative  strategies.    Knowledge  obtained  through  the  analysis  of 
commercial batch data and from parallel small scale experiments should also inform process 
changes  that  increase  robustness  or  reduce  costs.    In  addition,  as  much  of  the  regulation 
pertaining  to  the  manufacture  of  viral  vectors  for  human  use  has  not  been  formalised,  the 
manufacturing process should have the capacity to incorporate changes driven by changing 
regulatory requirements.   
A.3  Summary 
The purpose of this section was to consider how the WAVE bioreactor process described in 
Chapter 5 may  be taken forward from research development stage to  validated commercial 
application.  Currently this process is in the relatively early stages of development.  A strategy 
for refinement and scale-up of the process was proposed (Section A.2.1).  It was suggested that 
the microwell platform described in Chapters 3 and 4 of this thesis could be usefully employed 
for initial media development and cell line selection studies, with a view to identifying a high-titre 
stable producer clone suited to growth in serum-free conditions.  Subsequent studies using the 
microwell platform in conjunction with DoE techniques should ascertain the critical processing 
parameters  (CPPs)  and  raw  material  attributes  that  impact  on  ProSavin
®  critical  quality 
attributes (CQAs), in particular titre.  The microwell findings should be verified using a laboratory 
scale 2 L WAVE bioreactor, and the impact of further WAVE bioreactor-specific parameters 291 
 
 
(e.g. air flow rate) examined.  Operating limits and raw material specifications should ultimately 
be defined using this system and appropriate control strategies put in place to ensure consistent 
product quality.  Knowledge of the effect of air flow rate, liquid fill volume, and rocking conditions 
on  the  turbulence  and  oxygen  transfer  capacity  within  different  sized  vessels  should  inform 
scale-up of the process to a 200 L vessel.  Following the successful development of a GMP-
compliant  commercial  process,  the  process  requires  qualification  (Section  A.2.2).    Initially 
facilities, utilities and equipment should be chosen, installed and demonstrated to be working 
correctly  and  in  line  with  design  specifications.    Subsequently  these  components  may  be 
combined with the personnel and manufacturing process, and process qualification completed 
by the successful demonstration that the process performs as expected during the production of 
three  consecutive  batches  of  material.    Following  the  attainment  of  regulatory  approval, 
continual  verification  of  the  commercial  process  should  be  performed  by  the  collection  and 
timely analysis of data obtained during commercial runs, leading to improvements in process 
control where necessary (Section A.2.3). 
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Appendix B  Establishment of a LOQ for the ProSavin
® titre 
assay  
This study relates to Chapter 6, Section 6.2.1.1 of this thesis.  In order to define an appropriate 
lower  limit  of  quantification  (LOQ) for  the  ProSavin
®  assay,  and  thus  determine  a  threshold 
above which titre values may be considered accurate and consequently suitable for inclusion in 
linear regression analyses, a simple dilution series of lentiviral vector samples was prepared 
and quantified (Figure B.1).  For 2 out of 3 test samples analysed, when a dilution factor of 128 
was  used  (corresponding  to  a  transduced  cell  population  0.12  -  0.19  %)  titres  markedly 
exceeded  those  recorded  for  lower  dilutions  (Figure  B.1  [a]  and  [b]).    The  data  indicates, 
therefore, that when a standard population size of 10,000 cells is analysed using flow cytometry, 
accurate quantitation may be expected only when the proportion of transduced cells equals or 
exceeds  around  0.2  %.    This  threshold  exceeds  background  fluorescence  levels  by 
approximately  8-fold,  and  was  subsequently  employed  as  the  LOQ  for  all  stability  studies 
described  in  Chapter  6  (note  that  the  upper  limit  of  accurate  quantitation  is  20  %;  Section 
2.11.2.1). 293 
 
 
 
Figure B.1  Analysis  of  lentiviral  vector  test  samples  that  had  undergone  two-fold  serial 
dilutions in order to ascertain a LOQ for the ProSavin
® titre assay (Section 2.11.2.1).  Test 
sample #1 (a)  was crude  supernatant supplied by Charlotte  Parker (Oxford BioMedica) and  
contained  ProSavin
®  generated  by  transient  transfection  of  adherent  HEK293T  cells.    Test 
samples #2 (b) and #3 (c) were from the same batch of ProSavin
® generated using standard 
shake flask cultures of PS46.2 (Section 2.4.1.3), but were exposed to different concentrations of 
polybrene at the transduction stage of the ProSavin
® assay (6 and 8 μg mL
-1, respectively).  
Each  sample  was  analysed  in  duplicate  and  mean  titre  values  are  presented  (error  bars 
represent the range).  The proportion of cells expressing ProSavin
® (following the analysis of 
10,000  events)  is  also  indicated  below  each  graph  (DF  denotes  the  dilution  factor,  and  the 
sample reference is indicated).  Note that duplicate negative controls (fluorescent-stained non-
transduced  HEK293T  cells)  included  in  the  assay  returned  values  of  0.02  and  0.03  % 
transduced cells.  
   
 
      
 
 
 
 
% transduced cells 
 DF  2  4  8  16  32  64  128 
#3.1  8.16  2.46  1.15  0.56  0.26  0.13  0.06 
#3.2  5.35  1.77  1.14  0.55  0.28  0.18  0.09 
 
 
 
% transduced cells 
 DF  2  4  8  16  32  64  128 
#1.1  6.33  3.19  1.07  0.62  0.26  0.06  0.12 
#1.2  5.58  2.45  1.41  0.59  0.33  0.17  0.13 
% transduced cells 
 DF  2  4  8  16  32  64  128 
#2.1  5.60  2.29  1.18  0.90  0.23  0.23  0.19 
#2.2  5.63  2.18  0.96  0.58  0.34  0.18  0.17 294 
 
 
Appendix C  Effect of medium osmolality on the growth of 
PS46.2 cells in shake flasks  
This data is supplementary to that presented in Chapter 6, Section 6.2.2.3 of this thesis, and 
discusses  the  concentration  and  viability  of  PS46.2  following  the  three  day  shake  flask 
acclimatisation period.  Following three days cultivation in shake flasks in the various media 
(Section 6.2.2.3, Table 6.4), large differences in cell growth and viability were observed (Table 
C.1).  Where the medium had not been supplemented with sugars but had been diluted to the 
same extent as all other runs where a sugar solution had been added (run 1), cells reached a 
concentration  of  35.4  x  10
5  viable  cells  mL
-1,  which  was  equivalent  to  that  attained  in  the 
reference culture (34.6 x 10
5 viable cells mL
-1; REF, in which neither the sugar or water content 
of the medium was adjusted).  The viability of these cultures was also high (96.3 %) and similar 
to that observed in the reference culture (95.2 %).  The viable cell concentration and viability of 
all other cultures was negatively correlated with the total sugar content of the medium.  Where 
the standard culture medium had been supplemented with 100 mM fructose, glucose or sorbitol 
(runs 2, 3 and 5), the viable cell concentration was reduced to 18.8 – 26.9 x 10
5 viable cells mL
-
1, although viabilities remained high (91.2 - 94.2 %).  Where all three sugar types had been 
added to a final concentration of 150 mM (centre point runs 9 - 12) the viable cell concentration 
was reduced further to 7.5 x 10
5 viable cells mL
-1 and cell viability was also reduced (81.7 %).  
Combinations of two sugar types added to a final concentration of 200 mM (runs 4, 6 and 7) 
yielded even lower viable cell concentrations (3.6 - 4.5 x 10
5 viable cells mL
-1) and cell viabilities 
(60.3 - 67.9 %), while the addition of all three sugar types to a final concentration of 300 mM 
(run 8) produced the poorest outcome of all (viable cell concentration 1.5 x 10
5 viable cells mL
-1 
and viability 20.7 %).  It was expected that the osmolality of the medium would increase in line 
with increasing sugar concentrations, and this trend was observed except in the case of run 8, 
where all sugar types had been added to a final concentration of 300 mM (Section 6.2.2.3, 
Table 6.4).  This medium had an osmolality of 0.456 osmol kg
-1, which was slightly lower than 
those media containing two sugar types added to a final concentration of 200 mM (runs 4, 6 and 
7; osmolality 0.470 - 0.473 osmol kg
-1).  Although all media were mixed by agitation following 
supplementation and prior to osmolality measurements, it is possible that this was insufficient to 
attain a homogenous solution in the case of the medium prepared for run 8, which contained the 295 
 
 
greatest concentration of sugars overall, and the osmolality was underestimated as a result.  It 
may be concluded that, overall, the viable cell concentration and viability of shake flask cultures 
was  negatively  correlated  to  increasing  sugar  concentrations  and,  broadly,  to  increasing 
medium osmolalities.   
Table C.1  Viable  cell  concentration  and  cell  viability  of  PS46.2  following  cultivation  in 
shake flasks in medium supplemented with varying concentrations of fructose, glucose and/or 
sorbitol.  The concentration of each sugar type was as indicated in Section 6.2.2.3, Table 6.4.  
Shake flasks were seeded with 4 x 10
5 viable cells mL
-1, and cell counts were performed three 
days  later.  Procedures  were  as  outlined  in  Section  2.9.3.    Duplicate  measurements  were 
performed and mean values are presented with the range (n = 1). 
Run  Viable cell concentration (x 10
5 cells mL
-1)  Cell viability (%) 
1  35.4 ± 2.0  96.3 ± 0.4 
2  24.9 ± 2.4  92.9 ± 0.9 
3  18.8 ± 0.5  91.2 ± 0.3 
4  3.6 ± 0.2  60.3 ± 0.9 
5  26.9 ± 1.4  94.2 ± 1.1 
6  4.5 ± 0.2  67.9 ± 0.2 
7  3.7 ± 0.2  61.7 ± 2.5 
8  1.5 ± 0.2  20.7 ± 1.9 
9 -12  7.5 ± 0.2  81.7 ± 0.5 
REF  34.6 ± 0.4  95.2 ± 0.1 
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Appendix D  Publication 
Publication derived from work presented in this thesis:  
Guy, H. M., McCloskey, L., Lye, G. J., Mitrophanous, K. A. and Mukhopadhyay, T. K.  (2013). 
Characterization  of  Lentiviral  Vector  Production  Using  Microwell  Suspension  Cultures  of 
HEK293T-Derived Producer Cells. Human Gene Therapy Methods 24(2):125-139. 
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